<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:cc="http://web.resource.org/cc/"
 xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:admin="http://webns.net/mvcb/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel rdf:about="https://www.mdpi.com/rss/journal/idr">
		<title>Infectious Disease Reports</title>
		<description>Latest open access articles published in Infect. Dis. Rep. at https://www.mdpi.com/journal/idr</description>
		<link>https://www.mdpi.com/journal/idr</link>
		<admin:generatorAgent rdf:resource="https://www.mdpi.com/journal/idr"/>
		<admin:errorReportsTo rdf:resource="mailto:support@mdpi.com"/>
		<dc:publisher>MDPI</dc:publisher>
		<dc:language>en</dc:language>
		<dc:rights>Creative Commons Attribution (CC-BY)</dc:rights>
						<prism:copyright>MDPI</prism:copyright>
		<prism:rightsAgent>support@mdpi.com</prism:rightsAgent>
		<image rdf:resource="https://pub.mdpi-res.com/img/design/mdpi-pub-logo.png?13cf3b5bd783e021?1785915150"/>
				<items>
			<rdf:Seq>
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/84" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/83" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/82" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/81" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/80" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/79" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/78" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/77" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/76" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/75" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/74" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/73" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/72" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/71" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/70" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/69" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/68" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/67" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/66" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/65" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/64" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/4/63" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/62" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/61" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/60" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/59" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/58" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/57" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/56" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/55" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/54" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/53" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/52" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/51" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/50" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/49" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/48" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/47" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/46" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/45" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/44" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/43" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/42" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/41" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/40" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/39" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/3/38" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/37" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/36" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/35" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/34" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/33" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/32" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/31" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/30" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/29" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/28" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/27" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/26" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/25" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/24" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/23" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/22" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/21" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/2/20" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/19" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/18" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/17" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/16" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/15" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/14" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/13" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/12" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/11" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/10" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/9" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/8" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/7" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/6" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/5" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/4" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/3" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/2" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/18/1/1" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/151" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/150" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/149" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/148" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/147" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/146" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/145" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/144" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/143" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/142" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/141" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/140" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/139" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/138" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/137" />
            				<rdf:li rdf:resource="https://www.mdpi.com/2036-7449/17/6/136" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="https://creativecommons.org/licenses/by/4.0/" />
	</channel>

        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/84">

	<title>Infectious Disease Reports, Vol. 18, Pages 84: Concomitant Borreliosis and Invasive Amoebiasis: A Rare Case with Suspected Sexual Acquisition</title>
	<link>https://www.mdpi.com/2036-7449/18/4/84</link>
	<description>Background: The movement of endemic diseases from tropical and disadvantaged areas is gradually spreading to developed countries as well. Amoebiasis, in particular, represents a significant threat to public health, amplified by globalization and increasing contact between humans and animals or vectors. In this way, atypical diseases may emerge in our country, also through an unusual mode of transmission&amp;amp;mdash;likely sexual, as &amp;amp;ldquo;sexually transmitted enteric (STE) diseases&amp;amp;rdquo;. Objective: We report and discuss the clinic approach to a rare case of dual human infestations by ecto- and endo-parasites with multiple liver abscesses presentation in a young truck driver residing in Northern Italy. Methods: The patient underwent a comprehensive screening with laboratory and microbiological tests, and CT images. Results: In July, the patient was admitted to our hepatology unit following the ultrasound identification of two hypoechoic lesions in the right lobe of the liver. In his medical history, in April, after a seemingly harmless infestation of body lice, effectively treated, he suffered from a prolonged and debilitating episode of acute diarrhea, lasting a month. This status was also accompanied by intestinal cramps, weight loss, and recurring fever episodes. Afterwards also appeared a Quincke&amp;amp;rsquo;s-like angioedema involving the lips and mouth mucosa, with evening time exacerbation. Conclusions: The differential diagnosis of this complex and unusual clinical picture, together with the temporal evolution of the patient&amp;amp;rsquo;s signs and symptoms, led us to hypothesize the presence of concomitant infections. These were most likely borreliosis and a STE disease, the latter ultimately diagnosed as amebiasis with hepatic invasion, allowing appropriate treatment and a favorable clinical outcome.</description>
	<pubDate>2026-08-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 84: Concomitant Borreliosis and Invasive Amoebiasis: A Rare Case with Suspected Sexual Acquisition</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/84">doi: 10.3390/idr18040084</a></p>
	<p>Authors:
		Luisa Cavalletto
		Sara Valpione
		Chiara Giraudo
		Claudia Mescoli
		Valeria M. Besutti
		Liliana Chemello
		</p>
	<p>Background: The movement of endemic diseases from tropical and disadvantaged areas is gradually spreading to developed countries as well. Amoebiasis, in particular, represents a significant threat to public health, amplified by globalization and increasing contact between humans and animals or vectors. In this way, atypical diseases may emerge in our country, also through an unusual mode of transmission&amp;amp;mdash;likely sexual, as &amp;amp;ldquo;sexually transmitted enteric (STE) diseases&amp;amp;rdquo;. Objective: We report and discuss the clinic approach to a rare case of dual human infestations by ecto- and endo-parasites with multiple liver abscesses presentation in a young truck driver residing in Northern Italy. Methods: The patient underwent a comprehensive screening with laboratory and microbiological tests, and CT images. Results: In July, the patient was admitted to our hepatology unit following the ultrasound identification of two hypoechoic lesions in the right lobe of the liver. In his medical history, in April, after a seemingly harmless infestation of body lice, effectively treated, he suffered from a prolonged and debilitating episode of acute diarrhea, lasting a month. This status was also accompanied by intestinal cramps, weight loss, and recurring fever episodes. Afterwards also appeared a Quincke&amp;amp;rsquo;s-like angioedema involving the lips and mouth mucosa, with evening time exacerbation. Conclusions: The differential diagnosis of this complex and unusual clinical picture, together with the temporal evolution of the patient&amp;amp;rsquo;s signs and symptoms, led us to hypothesize the presence of concomitant infections. These were most likely borreliosis and a STE disease, the latter ultimately diagnosed as amebiasis with hepatic invasion, allowing appropriate treatment and a favorable clinical outcome.</p>
	]]></content:encoded>

	<dc:title>Concomitant Borreliosis and Invasive Amoebiasis: A Rare Case with Suspected Sexual Acquisition</dc:title>
			<dc:creator>Luisa Cavalletto</dc:creator>
			<dc:creator>Sara Valpione</dc:creator>
			<dc:creator>Chiara Giraudo</dc:creator>
			<dc:creator>Claudia Mescoli</dc:creator>
			<dc:creator>Valeria M. Besutti</dc:creator>
			<dc:creator>Liliana Chemello</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040084</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-08-07</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-08-07</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>84</prism:startingPage>
		<prism:doi>10.3390/idr18040084</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/84</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/83">

	<title>Infectious Disease Reports, Vol. 18, Pages 83: First Report of Ignatzschineria indica Infection in Greece and Review of the Literature</title>
	<link>https://www.mdpi.com/2036-7449/18/4/83</link>
	<description>Background: Ignatzschineria species are rare emerging human pathogens that are typically associated with myiasis. Methods: We report the first case of Ignatzschineria indica bacteraemia in Greece in a male patient presenting with maggot-infested wounds of the thorax, shoulders, and arms. The isolate was identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and antimicrobial susceptibility testing was performed according to EUCAST guidance. A review of the published literature on I. indica bacteraemia was also conducted. Results: The patient was diagnosed with bacteraemia caused by a multisusceptible I. indica isolate and was successfully treated with antibiotic therapy, resulting in complete recovery. This represents the first reported case of I. indica infection in Greece. Review of the literature showed that most published I. indica isolates were susceptible to a broad range of antimicrobial agents, and all reported patients survived, although some required limb amputation because of severe underlying soft tissue disease. Conclusions: Ignatzschineria indica infection should be considered in patients with neglected, maggot-infested wounds. Increased awareness of this emerging pathogen, together with the use of modern microbiological identification methods, may improve recognition of these uncommon infections. Socio-economic inequalities and the changing distribution of insect vectors due to climate change may contribute to the occurrence of such infections.</description>
	<pubDate>2026-08-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 83: First Report of Ignatzschineria indica Infection in Greece and Review of the Literature</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/83">doi: 10.3390/idr18040083</a></p>
	<p>Authors:
		Alexandra Vasilakopoulou
		Evaggelia Oikonomoula
		Vasiliki Anagnosti
		Pavlos Siozos
		Ioannis Liakopoulos
		Eleni Kalogeropoulou
		Sofia Damianidou
		Polyxeni Karakosta
		Sophia Vourli
		Panagiota-Christina Georgiou
		Anastasios Ioannidis
		Spyros Pournaras
		</p>
	<p>Background: Ignatzschineria species are rare emerging human pathogens that are typically associated with myiasis. Methods: We report the first case of Ignatzschineria indica bacteraemia in Greece in a male patient presenting with maggot-infested wounds of the thorax, shoulders, and arms. The isolate was identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and antimicrobial susceptibility testing was performed according to EUCAST guidance. A review of the published literature on I. indica bacteraemia was also conducted. Results: The patient was diagnosed with bacteraemia caused by a multisusceptible I. indica isolate and was successfully treated with antibiotic therapy, resulting in complete recovery. This represents the first reported case of I. indica infection in Greece. Review of the literature showed that most published I. indica isolates were susceptible to a broad range of antimicrobial agents, and all reported patients survived, although some required limb amputation because of severe underlying soft tissue disease. Conclusions: Ignatzschineria indica infection should be considered in patients with neglected, maggot-infested wounds. Increased awareness of this emerging pathogen, together with the use of modern microbiological identification methods, may improve recognition of these uncommon infections. Socio-economic inequalities and the changing distribution of insect vectors due to climate change may contribute to the occurrence of such infections.</p>
	]]></content:encoded>

	<dc:title>First Report of Ignatzschineria indica Infection in Greece and Review of the Literature</dc:title>
			<dc:creator>Alexandra Vasilakopoulou</dc:creator>
			<dc:creator>Evaggelia Oikonomoula</dc:creator>
			<dc:creator>Vasiliki Anagnosti</dc:creator>
			<dc:creator>Pavlos Siozos</dc:creator>
			<dc:creator>Ioannis Liakopoulos</dc:creator>
			<dc:creator>Eleni Kalogeropoulou</dc:creator>
			<dc:creator>Sofia Damianidou</dc:creator>
			<dc:creator>Polyxeni Karakosta</dc:creator>
			<dc:creator>Sophia Vourli</dc:creator>
			<dc:creator>Panagiota-Christina Georgiou</dc:creator>
			<dc:creator>Anastasios Ioannidis</dc:creator>
			<dc:creator>Spyros Pournaras</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040083</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-08-07</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-08-07</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>83</prism:startingPage>
		<prism:doi>10.3390/idr18040083</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/83</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/82">

	<title>Infectious Disease Reports, Vol. 18, Pages 82: Associations of Influenza Illness During Pregnancy with Pregnancy Loss and Program-Defined Child Health Monitoring Indicator: A Matched Cohort Study</title>
	<link>https://www.mdpi.com/2036-7449/18/4/82</link>
	<description>Background/Objectives: This prospective cohort study assessed the impact of seasonal influenza during pregnancy on fetal and infant health outcomes. Methods: Pregnant women with laboratory-confirmed influenza were matched (1:4) by age and pregnancy loss history with women without influenza from annual cohorts in Suzhou, China, during 2015&amp;amp;ndash;2018. Participants underwent twice-weekly follow-up for influenza illness, and medical records were linked to ascertain outcomes. Multivariable regression models were used to estimate associations. Results: We included 441 pregnant women with influenza and 1764 without it. Four (0.9%) in the influenza group had late pregnancy loss, whereas one (0.1%) in the non-influenza group did. Influenza was associated with late pregnancy loss (adjusted hazard ratio [aHR] 31.1, 95% Confidence Interval [CI]: 1.3&amp;amp;ndash;756.8, p = 0.035). Four (0.9%) in the influenza group experienced early pregnancy loss, while five (0.3%) in the non-influenza group did. Influenza was not significantly associated with early pregnancy loss (aHR 2.1, 95% CI: 0.4&amp;amp;ndash;10.4, p = 0.374). By 8 months of age, infants born to 198 of the 441 mothers (44.9%) in the influenza group met the criteria for the program-defined child health monitoring indicator, compared with infants born to 650 of the 1764 mothers (36.8%) in the non-influenza group. Overweight/obesity was the largest contributor: 142 (32.2%) versus 470 (26.6%). Maternal influenza was associated with higher odds of meeting program-defined child health monitoring indicator in offspring (adjusted odds ratio [aOR] 1.4, 95% CI: 1.1&amp;amp;ndash;1.8, p = 0.006), with a significant contribution from overweight/obesity (aOR 1.3, 95% CI: 1.0&amp;amp;ndash;1.7, p = 0.045). Conclusions: In this cohort, influenza during pregnancy was associated with an increased risk of late pregnancy loss and program-defined child health monitoring indicator in offspring, particularly overweight/obesity. Because the observed association with pregnancy loss was based on a small number of events and had a wide confidence interval, it should be interpreted cautiously and confirmed in larger studies. These findings are consistent with current recommendations supporting influenza vaccination during pregnancy to protect maternal and infant health.</description>
	<pubDate>2026-08-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 82: Associations of Influenza Illness During Pregnancy with Pregnancy Loss and Program-Defined Child Health Monitoring Indicator: A Matched Cohort Study</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/82">doi: 10.3390/idr18040082</a></p>
	<p>Authors:
		Yuanyuan Zhang
		Yan Shao
		Suizan Zhou
		Qianlan Wu
		Ningning Du
		Mingzhi Zhang
		Qian Feng
		Lin Bao
		Yuanyuan Pang
		Yayun Tan
		Pengwei Cui
		Jun Zhang
		Haibing Yang
		Suping Zhang
		Liling Chen
		Ying Song
		W. William Schluter
		</p>
	<p>Background/Objectives: This prospective cohort study assessed the impact of seasonal influenza during pregnancy on fetal and infant health outcomes. Methods: Pregnant women with laboratory-confirmed influenza were matched (1:4) by age and pregnancy loss history with women without influenza from annual cohorts in Suzhou, China, during 2015&amp;amp;ndash;2018. Participants underwent twice-weekly follow-up for influenza illness, and medical records were linked to ascertain outcomes. Multivariable regression models were used to estimate associations. Results: We included 441 pregnant women with influenza and 1764 without it. Four (0.9%) in the influenza group had late pregnancy loss, whereas one (0.1%) in the non-influenza group did. Influenza was associated with late pregnancy loss (adjusted hazard ratio [aHR] 31.1, 95% Confidence Interval [CI]: 1.3&amp;amp;ndash;756.8, p = 0.035). Four (0.9%) in the influenza group experienced early pregnancy loss, while five (0.3%) in the non-influenza group did. Influenza was not significantly associated with early pregnancy loss (aHR 2.1, 95% CI: 0.4&amp;amp;ndash;10.4, p = 0.374). By 8 months of age, infants born to 198 of the 441 mothers (44.9%) in the influenza group met the criteria for the program-defined child health monitoring indicator, compared with infants born to 650 of the 1764 mothers (36.8%) in the non-influenza group. Overweight/obesity was the largest contributor: 142 (32.2%) versus 470 (26.6%). Maternal influenza was associated with higher odds of meeting program-defined child health monitoring indicator in offspring (adjusted odds ratio [aOR] 1.4, 95% CI: 1.1&amp;amp;ndash;1.8, p = 0.006), with a significant contribution from overweight/obesity (aOR 1.3, 95% CI: 1.0&amp;amp;ndash;1.7, p = 0.045). Conclusions: In this cohort, influenza during pregnancy was associated with an increased risk of late pregnancy loss and program-defined child health monitoring indicator in offspring, particularly overweight/obesity. Because the observed association with pregnancy loss was based on a small number of events and had a wide confidence interval, it should be interpreted cautiously and confirmed in larger studies. These findings are consistent with current recommendations supporting influenza vaccination during pregnancy to protect maternal and infant health.</p>
	]]></content:encoded>

	<dc:title>Associations of Influenza Illness During Pregnancy with Pregnancy Loss and Program-Defined Child Health Monitoring Indicator: A Matched Cohort Study</dc:title>
			<dc:creator>Yuanyuan Zhang</dc:creator>
			<dc:creator>Yan Shao</dc:creator>
			<dc:creator>Suizan Zhou</dc:creator>
			<dc:creator>Qianlan Wu</dc:creator>
			<dc:creator>Ningning Du</dc:creator>
			<dc:creator>Mingzhi Zhang</dc:creator>
			<dc:creator>Qian Feng</dc:creator>
			<dc:creator>Lin Bao</dc:creator>
			<dc:creator>Yuanyuan Pang</dc:creator>
			<dc:creator>Yayun Tan</dc:creator>
			<dc:creator>Pengwei Cui</dc:creator>
			<dc:creator>Jun Zhang</dc:creator>
			<dc:creator>Haibing Yang</dc:creator>
			<dc:creator>Suping Zhang</dc:creator>
			<dc:creator>Liling Chen</dc:creator>
			<dc:creator>Ying Song</dc:creator>
			<dc:creator>W. William Schluter</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040082</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-08-05</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-08-05</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>82</prism:startingPage>
		<prism:doi>10.3390/idr18040082</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/82</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/81">

	<title>Infectious Disease Reports, Vol. 18, Pages 81: Maternal and Perinatal Outcomes Associated with Maternal HIV Infection in a Tertiary Hospital in Eastern Cape Province, South Africa</title>
	<link>https://www.mdpi.com/2036-7449/18/4/81</link>
	<description>Background: Despite substantial progress in prevention of mother-to-child transmission (PMTCT) programmes and widespread access to antiretroviral therapy (ART), maternal HIV infection remains associated with adverse maternal and neonatal outcomes in many high HIV-burden settings. This study compared maternal and perinatal outcomes among women living with HIV and HIV-negative women delivering at a tertiary referral hospital in the Eastern Cape Province, South Africa. Methods: A retrospective comparative cohort study was conducted using routinely collected clinical records of 600 women (300 HIV-positive and 300 HIV-negative) who delivered at Nelson Mandela Academic Hospital between January and December 2019. Maternal, obstetric, and neonatal characteristics were compared according to maternal HIV status. Associations were evaluated using chi-square tests, multivariable logistic regression, Kaplan&amp;amp;ndash;Meier survival analysis, and Cox proportional hazards regression models. Results: Women living with HIV were older, had higher parity, and were more likely to have documented anaemia and delayed antenatal care attendance than HIV-negative women. HIV-exposed pregnancies had higher frequencies of preterm birth (26.3% vs. 20.3%) and low birthweight (LBW). In adjusted analyses, maternal HIV-positive status remained independently associated with increased odds of LBW (AOR = 1.88; 95% CI: 1.18&amp;amp;ndash;3.00; p = 0.008). LBW was independently associated with neonatal intensive care unit (NICU) admission (AOR = 2.45; 95% CI: 1.46&amp;amp;ndash;4.11; p &amp;amp;lt; 0.001) and an increased hazard of in-hospital neonatal mortality (HR = 2.40; 95% CI: 1.55&amp;amp;ndash;3.70; p &amp;amp;lt; 0.001). Maternal HIV-positive status (HR = 1.75; 95% CI: 1.12&amp;amp;ndash;2.71; p = 0.015) and unsuppressed maternal viral load (HR = 2.05; 95% CI: 1.13&amp;amp;ndash;3.73; p = 0.018) were also associated with increased hazards of neonatal mortality. However, these findings should be interpreted cautiously, given the limited number of neonatal mortality events (n = 32). Among HIV-exposed infants with documented HIV test results, the observed mother-to-child transmission rate was 1.7%. However, incomplete infant follow-up and HIV testing data limited the precision of this estimate. Among women living with HIV, birthweight did not differ significantly according to the timing of ART initiation. Conclusions: In this tertiary referral hospital cohort, maternal HIV infection was associated with adverse maternal and neonatal outcomes, particularly anemia, preterm birth, and LBW. LBW emerged as an important predictor of neonatal morbidity and mortality. These findings support continued efforts to strengthen integrated HIV and maternal healthcare services, promote early antenatal care engagement, maintain maternal viral suppression, and improve monitoring and care of high-risk neonates. Given the retrospective observational design, incomplete follow-up for selected outcomes, limited numbers of neonatal mortality events, and the tertiary referral setting, the findings should be interpreted as associations rather than evidence of causal relationships and may not be generalizable to lower-level healthcare facilities or community-based obstetric populations.</description>
	<pubDate>2026-07-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 81: Maternal and Perinatal Outcomes Associated with Maternal HIV Infection in a Tertiary Hospital in Eastern Cape Province, South Africa</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/81">doi: 10.3390/idr18040081</a></p>
	<p>Authors:
		Viwe Sodo-Mbotya
		Ntandazo Dlatu
		Geoffrey A. B. Buga
		</p>
	<p>Background: Despite substantial progress in prevention of mother-to-child transmission (PMTCT) programmes and widespread access to antiretroviral therapy (ART), maternal HIV infection remains associated with adverse maternal and neonatal outcomes in many high HIV-burden settings. This study compared maternal and perinatal outcomes among women living with HIV and HIV-negative women delivering at a tertiary referral hospital in the Eastern Cape Province, South Africa. Methods: A retrospective comparative cohort study was conducted using routinely collected clinical records of 600 women (300 HIV-positive and 300 HIV-negative) who delivered at Nelson Mandela Academic Hospital between January and December 2019. Maternal, obstetric, and neonatal characteristics were compared according to maternal HIV status. Associations were evaluated using chi-square tests, multivariable logistic regression, Kaplan&amp;amp;ndash;Meier survival analysis, and Cox proportional hazards regression models. Results: Women living with HIV were older, had higher parity, and were more likely to have documented anaemia and delayed antenatal care attendance than HIV-negative women. HIV-exposed pregnancies had higher frequencies of preterm birth (26.3% vs. 20.3%) and low birthweight (LBW). In adjusted analyses, maternal HIV-positive status remained independently associated with increased odds of LBW (AOR = 1.88; 95% CI: 1.18&amp;amp;ndash;3.00; p = 0.008). LBW was independently associated with neonatal intensive care unit (NICU) admission (AOR = 2.45; 95% CI: 1.46&amp;amp;ndash;4.11; p &amp;amp;lt; 0.001) and an increased hazard of in-hospital neonatal mortality (HR = 2.40; 95% CI: 1.55&amp;amp;ndash;3.70; p &amp;amp;lt; 0.001). Maternal HIV-positive status (HR = 1.75; 95% CI: 1.12&amp;amp;ndash;2.71; p = 0.015) and unsuppressed maternal viral load (HR = 2.05; 95% CI: 1.13&amp;amp;ndash;3.73; p = 0.018) were also associated with increased hazards of neonatal mortality. However, these findings should be interpreted cautiously, given the limited number of neonatal mortality events (n = 32). Among HIV-exposed infants with documented HIV test results, the observed mother-to-child transmission rate was 1.7%. However, incomplete infant follow-up and HIV testing data limited the precision of this estimate. Among women living with HIV, birthweight did not differ significantly according to the timing of ART initiation. Conclusions: In this tertiary referral hospital cohort, maternal HIV infection was associated with adverse maternal and neonatal outcomes, particularly anemia, preterm birth, and LBW. LBW emerged as an important predictor of neonatal morbidity and mortality. These findings support continued efforts to strengthen integrated HIV and maternal healthcare services, promote early antenatal care engagement, maintain maternal viral suppression, and improve monitoring and care of high-risk neonates. Given the retrospective observational design, incomplete follow-up for selected outcomes, limited numbers of neonatal mortality events, and the tertiary referral setting, the findings should be interpreted as associations rather than evidence of causal relationships and may not be generalizable to lower-level healthcare facilities or community-based obstetric populations.</p>
	]]></content:encoded>

	<dc:title>Maternal and Perinatal Outcomes Associated with Maternal HIV Infection in a Tertiary Hospital in Eastern Cape Province, South Africa</dc:title>
			<dc:creator>Viwe Sodo-Mbotya</dc:creator>
			<dc:creator>Ntandazo Dlatu</dc:creator>
			<dc:creator>Geoffrey A. B. Buga</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040081</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-30</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>81</prism:startingPage>
		<prism:doi>10.3390/idr18040081</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/81</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/80">

	<title>Infectious Disease Reports, Vol. 18, Pages 80: Human Infections Caused by Flavobacteriales: Clinical Characteristics and Antimicrobial Susceptibility Patterns</title>
	<link>https://www.mdpi.com/2036-7449/18/4/80</link>
	<description>Background/Objectives: Bacteria of the order Flavobacteriales are environmental Gram-negative bacilli. Several organisms within the order represent rare but clinically important causes of infection in human hosts, particularly in immunocompromised and hospitalized individuals. Eight genera have been implicated in human infections: Elizabethkingia, Capnocytophaga, Chryseobacterium, Myroides, Bergeyella, Flavobacterium, Empedobacter, and Weeksella. Despite their clinical relevance, there has been, as yet, no consolidated summary of clinical characteristics or resistance patterns across pathogens within the order. Methods: This narrative review examines the currently published data on human infections caused by organisms within Flavobacteriales. 63 sources, including 57 peer-reviewed articles, were included. Results: The clinical associations of infections caused by each of the above genera are discussed. In addition, available antimicrobial resistance data for the same organisms are summarized. Knowledge gaps are identified, including the lack of dedicated antimicrobial susceptibility breakpoints and limited data on rare categories of organisms. Conclusions: Human pathogens within Flavobacteriales display a number of commonalities, including a predilection for immunocompromised hosts, and frequently display resistance to carbapenems and aminoglycosides. Additional studies to better characterize these pathogens and optimize the approach to their treatment are strongly warranted.</description>
	<pubDate>2026-07-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 80: Human Infections Caused by Flavobacteriales: Clinical Characteristics and Antimicrobial Susceptibility Patterns</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/80">doi: 10.3390/idr18040080</a></p>
	<p>Authors:
		Grant Whitmer
		Maria Joyce
		</p>
	<p>Background/Objectives: Bacteria of the order Flavobacteriales are environmental Gram-negative bacilli. Several organisms within the order represent rare but clinically important causes of infection in human hosts, particularly in immunocompromised and hospitalized individuals. Eight genera have been implicated in human infections: Elizabethkingia, Capnocytophaga, Chryseobacterium, Myroides, Bergeyella, Flavobacterium, Empedobacter, and Weeksella. Despite their clinical relevance, there has been, as yet, no consolidated summary of clinical characteristics or resistance patterns across pathogens within the order. Methods: This narrative review examines the currently published data on human infections caused by organisms within Flavobacteriales. 63 sources, including 57 peer-reviewed articles, were included. Results: The clinical associations of infections caused by each of the above genera are discussed. In addition, available antimicrobial resistance data for the same organisms are summarized. Knowledge gaps are identified, including the lack of dedicated antimicrobial susceptibility breakpoints and limited data on rare categories of organisms. Conclusions: Human pathogens within Flavobacteriales display a number of commonalities, including a predilection for immunocompromised hosts, and frequently display resistance to carbapenems and aminoglycosides. Additional studies to better characterize these pathogens and optimize the approach to their treatment are strongly warranted.</p>
	]]></content:encoded>

	<dc:title>Human Infections Caused by Flavobacteriales: Clinical Characteristics and Antimicrobial Susceptibility Patterns</dc:title>
			<dc:creator>Grant Whitmer</dc:creator>
			<dc:creator>Maria Joyce</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040080</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-30</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>80</prism:startingPage>
		<prism:doi>10.3390/idr18040080</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/80</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/79">

	<title>Infectious Disease Reports, Vol. 18, Pages 79: A Rare Case of Acute Rheumatic Fever Diagnosed After Recent Travel Abroad</title>
	<link>https://www.mdpi.com/2036-7449/18/4/79</link>
	<description>Background: Acute rheumatic fever (ARF) is a clinical syndrome triggered by group A streptococcal (GAS) infections and characterized by fever, carditis, and arthritis as its main manifestations. Diagnosis relies on the revised Jones criteria. We report a rare case of ARF diagnosed in Switzerland. Case Presentation: An 18-year-old woman presented to the emergency department five days after returning from a one-week stay in Egypt with intermittent fever and a transient sore throat, followed by migratory joint pain. Laboratory testing revealed leukocytosis, elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Chest X-ray, urine analysis, and (travel-associated) pathogen-testing (Epstein&amp;amp;ndash;Barr virus, Cytomegalovirus, human immunodeficiency virus, Malaria, Dengue, Zika, Chikungunya) were unremarkable. Blood cultures remained negative. Initially, a viral respiratory infection was suspected and symptomatic treatment established. Days later the patient was re-evaluated due to persistent symptoms. Leukocyte count (Lc) and CRP further increased and subcutaneous nodules appeared. The antistreptolysin-O (ASO)-titer was elevated more than three times higher than the normal upper limit and proofed serological evidence of a preceding streptococcal infection (GAS throat culture had not been performed). ARF was diagnosed according to the Jones criteria. Treatment with amoxicillin and a high dose of acetylsalicylic acid (ASA) led to a rapid clinical improvement. Secondary prophylaxis with depot penicillin (benzathine penicillin G; 1.2 million units; once monthly) was initiated to prevent rheumatic heart disease. Conclusions: This case highlights a rare occurrence of ARF following travel to Egypt, with probable acquisition of group A streptococcal infection during the trip. It emphasizes consideration of ARF even in Western countries with low ARF-prevalence if clinical history is suggestive. Early recognition and initiation of antimicrobial and anti-inflammatory therapy is crucial to prevent cardiac involvement. To the best of our knowledge, this represents one of the first cases diagnosed in Switzerland in the past 20 years.</description>
	<pubDate>2026-07-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 79: A Rare Case of Acute Rheumatic Fever Diagnosed After Recent Travel Abroad</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/79">doi: 10.3390/idr18040079</a></p>
	<p>Authors:
		Debora Agreiter
		Stefan Fuchs
		Franziska Marti
		</p>
	<p>Background: Acute rheumatic fever (ARF) is a clinical syndrome triggered by group A streptococcal (GAS) infections and characterized by fever, carditis, and arthritis as its main manifestations. Diagnosis relies on the revised Jones criteria. We report a rare case of ARF diagnosed in Switzerland. Case Presentation: An 18-year-old woman presented to the emergency department five days after returning from a one-week stay in Egypt with intermittent fever and a transient sore throat, followed by migratory joint pain. Laboratory testing revealed leukocytosis, elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Chest X-ray, urine analysis, and (travel-associated) pathogen-testing (Epstein&amp;amp;ndash;Barr virus, Cytomegalovirus, human immunodeficiency virus, Malaria, Dengue, Zika, Chikungunya) were unremarkable. Blood cultures remained negative. Initially, a viral respiratory infection was suspected and symptomatic treatment established. Days later the patient was re-evaluated due to persistent symptoms. Leukocyte count (Lc) and CRP further increased and subcutaneous nodules appeared. The antistreptolysin-O (ASO)-titer was elevated more than three times higher than the normal upper limit and proofed serological evidence of a preceding streptococcal infection (GAS throat culture had not been performed). ARF was diagnosed according to the Jones criteria. Treatment with amoxicillin and a high dose of acetylsalicylic acid (ASA) led to a rapid clinical improvement. Secondary prophylaxis with depot penicillin (benzathine penicillin G; 1.2 million units; once monthly) was initiated to prevent rheumatic heart disease. Conclusions: This case highlights a rare occurrence of ARF following travel to Egypt, with probable acquisition of group A streptococcal infection during the trip. It emphasizes consideration of ARF even in Western countries with low ARF-prevalence if clinical history is suggestive. Early recognition and initiation of antimicrobial and anti-inflammatory therapy is crucial to prevent cardiac involvement. To the best of our knowledge, this represents one of the first cases diagnosed in Switzerland in the past 20 years.</p>
	]]></content:encoded>

	<dc:title>A Rare Case of Acute Rheumatic Fever Diagnosed After Recent Travel Abroad</dc:title>
			<dc:creator>Debora Agreiter</dc:creator>
			<dc:creator>Stefan Fuchs</dc:creator>
			<dc:creator>Franziska Marti</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040079</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-27</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>79</prism:startingPage>
		<prism:doi>10.3390/idr18040079</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/79</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/78">

	<title>Infectious Disease Reports, Vol. 18, Pages 78: Deep Learning-Based Malaria Parasite Image Classification on Real Microscopy Data</title>
	<link>https://www.mdpi.com/2036-7449/18/4/78</link>
	<description>Background: Accurate and timely malaria diagnosis with species-level identification of Plasmodium parasites is critical for guiding effective treatment and disease management. Although light microscopy remains the diagnostic gold standard, its dependence on highly trained personnel limits accessibility, particularly in resource-constrained settings. Recent advances in deep learning have enabled automated image-based diagnosis with promising performance; however, reliable differentiation among Plasmodium species continues to pose a major challenge. This study aims to evaluate and compare the effectiveness of different deep learning architectures for automated species identification from microscopy images. Methods: Three deep learning architectures were systematically assessed: a convolutional backbone (ResNet50), a Vision Transformer (ViT), and a hybrid ResNetViT model. All models were trained from scratch, without using pretrained weights, on a dataset comprising real-world thick blood smear images augmented with publicly available microscopy data from Kaggle. In the hybrid architecture, the ResNet module was used to extract robust local morphological features, while the ViT component captured long-range dependencies and contextual relationships within images. Results: In cross-validation experiments, all three architectures consistently achieved high diagnostic performance. ResNet50 attained the highest accuracy (96.9%), an F1-score of 96.3%, and an ROC-AUC of 0.997. The Vision Transformer achieved 93.1% accuracy, 91.7% F1-score, and an ROC-AUC of 0.989. The hybrid ResNetViT reached 95.2% accuracy, 94.2% F1-score, and an ROC-AUC of 0.995. These results confirm that all architectures can reliably distinguish among Plasmodium species. Although ResNet50 achieved the highest raw accuracy, the hybrid model showed the most stable calibration and the closest qualitative agreement between its attention maps and expert-annotated parasite locations. Conclusions: The findings demonstrate that convolutional, transformer-based, and hybrid deep learning architectures can be successfully trained on real microscopy data for species-level malaria diagnosis. These results support the feasibility of deploying scalable, automated diagnostic systems to improve both accuracy and accessibility of malaria detection, particularly in resource-limited healthcare settings.</description>
	<pubDate>2026-07-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 78: Deep Learning-Based Malaria Parasite Image Classification on Real Microscopy Data</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/78">doi: 10.3390/idr18040078</a></p>
	<p>Authors:
		Francesco Branda
		Lilia Andriani
		Riccardo Lucis
		Annamaria Defilippo
		Ugo Lomoio
		Barbara Puccio
		Giancarlo Ceccarelli
		Massimo Ciccozzi
		Fabio Scarpa
		Pierangelo Veltri
		Pietro Hiram Guzzi
		</p>
	<p>Background: Accurate and timely malaria diagnosis with species-level identification of Plasmodium parasites is critical for guiding effective treatment and disease management. Although light microscopy remains the diagnostic gold standard, its dependence on highly trained personnel limits accessibility, particularly in resource-constrained settings. Recent advances in deep learning have enabled automated image-based diagnosis with promising performance; however, reliable differentiation among Plasmodium species continues to pose a major challenge. This study aims to evaluate and compare the effectiveness of different deep learning architectures for automated species identification from microscopy images. Methods: Three deep learning architectures were systematically assessed: a convolutional backbone (ResNet50), a Vision Transformer (ViT), and a hybrid ResNetViT model. All models were trained from scratch, without using pretrained weights, on a dataset comprising real-world thick blood smear images augmented with publicly available microscopy data from Kaggle. In the hybrid architecture, the ResNet module was used to extract robust local morphological features, while the ViT component captured long-range dependencies and contextual relationships within images. Results: In cross-validation experiments, all three architectures consistently achieved high diagnostic performance. ResNet50 attained the highest accuracy (96.9%), an F1-score of 96.3%, and an ROC-AUC of 0.997. The Vision Transformer achieved 93.1% accuracy, 91.7% F1-score, and an ROC-AUC of 0.989. The hybrid ResNetViT reached 95.2% accuracy, 94.2% F1-score, and an ROC-AUC of 0.995. These results confirm that all architectures can reliably distinguish among Plasmodium species. Although ResNet50 achieved the highest raw accuracy, the hybrid model showed the most stable calibration and the closest qualitative agreement between its attention maps and expert-annotated parasite locations. Conclusions: The findings demonstrate that convolutional, transformer-based, and hybrid deep learning architectures can be successfully trained on real microscopy data for species-level malaria diagnosis. These results support the feasibility of deploying scalable, automated diagnostic systems to improve both accuracy and accessibility of malaria detection, particularly in resource-limited healthcare settings.</p>
	]]></content:encoded>

	<dc:title>Deep Learning-Based Malaria Parasite Image Classification on Real Microscopy Data</dc:title>
			<dc:creator>Francesco Branda</dc:creator>
			<dc:creator>Lilia Andriani</dc:creator>
			<dc:creator>Riccardo Lucis</dc:creator>
			<dc:creator>Annamaria Defilippo</dc:creator>
			<dc:creator>Ugo Lomoio</dc:creator>
			<dc:creator>Barbara Puccio</dc:creator>
			<dc:creator>Giancarlo Ceccarelli</dc:creator>
			<dc:creator>Massimo Ciccozzi</dc:creator>
			<dc:creator>Fabio Scarpa</dc:creator>
			<dc:creator>Pierangelo Veltri</dc:creator>
			<dc:creator>Pietro Hiram Guzzi</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040078</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-27</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>78</prism:startingPage>
		<prism:doi>10.3390/idr18040078</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/78</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/77">

	<title>Infectious Disease Reports, Vol. 18, Pages 77: Early Machine Learning-Based Identification of Hospitalized Patients at Low Risk of Respiratory Deterioration or Mortality in Community-Acquired Pneumonia: External Validation of a Multivariable Model</title>
	<link>https://www.mdpi.com/2036-7449/18/4/77</link>
	<description>Background/Objective: To externally validate our previously published machine learning model for identifying hospitalized patients with community-acquired pneumonia (CAP) at low risk of respiratory deterioration or death using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Methods: This is a retrospective cohort study of adult patients (&amp;amp;ge;18 years) who were admitted with CAP and acute hypoxemic respiratory failure using the publicly available MIMIC-IV critical care dataset (Beth Israel Deaconess Medical Center, Boston, MA). We conducted an external validation study of a previously developed gradient boosting machine (GBM) model without recalibration using data available within the first 6 h of hospital admission. Results: For the primary composite outcome (need for advanced respiratory support [high flow nasal cannula (HFNC), non-invasive mechanical ventilation (NIMV), invasive mechanical ventilation (IMV)] or in-hospital death), the gradient boosting model demonstrated comparable performance in the derivation and external validation cohorts. The area under the receiver operating characteristic curve (AUC) was 0.713 in the Mayo cohort (n = 4379) and 0.689 in the MIMIC-IV cohort. Accuracy was 0.612 (95% confidence interval [CI], 0.595&amp;amp;ndash;0.628) versus 0.606 (95% CI 0.600&amp;amp;ndash;0.611), specificity 0.574 versus 0.523, sensitivity 0.723 versus 0.754, NPV 0.860 versus 0.842, and PPV 0.364 versus 0.401, respectively. For secondary outcomes, model discrimination was comparable between cohorts. The AUC for in-hospital mortality was 0.727 in the Mayo Cohort versus 0.733 in MIMIC-IV; for IMV, 0.736 versus 0.724; and for NIMV, 0.732 versus 0.708. Conclusions: Our machine learning algorithm demonstrated good discrimination and a high negative predictive value for identifying low-risk hospitalized CAP patients for respiratory deterioration or death in the external MIMIC-IV dataset, supporting its potential utility for prognostic enrichment in pneumonia clinical trials.</description>
	<pubDate>2026-07-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 77: Early Machine Learning-Based Identification of Hospitalized Patients at Low Risk of Respiratory Deterioration or Mortality in Community-Acquired Pneumonia: External Validation of a Multivariable Model</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/77">doi: 10.3390/idr18040077</a></p>
	<p>Authors:
		Claudia Gyimah
		Prasamsa Pudasaini
		Allison LeMahieu
		Phillip Schulte
		Yewande E. Odeyemi
		</p>
	<p>Background/Objective: To externally validate our previously published machine learning model for identifying hospitalized patients with community-acquired pneumonia (CAP) at low risk of respiratory deterioration or death using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Methods: This is a retrospective cohort study of adult patients (&amp;amp;ge;18 years) who were admitted with CAP and acute hypoxemic respiratory failure using the publicly available MIMIC-IV critical care dataset (Beth Israel Deaconess Medical Center, Boston, MA). We conducted an external validation study of a previously developed gradient boosting machine (GBM) model without recalibration using data available within the first 6 h of hospital admission. Results: For the primary composite outcome (need for advanced respiratory support [high flow nasal cannula (HFNC), non-invasive mechanical ventilation (NIMV), invasive mechanical ventilation (IMV)] or in-hospital death), the gradient boosting model demonstrated comparable performance in the derivation and external validation cohorts. The area under the receiver operating characteristic curve (AUC) was 0.713 in the Mayo cohort (n = 4379) and 0.689 in the MIMIC-IV cohort. Accuracy was 0.612 (95% confidence interval [CI], 0.595&amp;amp;ndash;0.628) versus 0.606 (95% CI 0.600&amp;amp;ndash;0.611), specificity 0.574 versus 0.523, sensitivity 0.723 versus 0.754, NPV 0.860 versus 0.842, and PPV 0.364 versus 0.401, respectively. For secondary outcomes, model discrimination was comparable between cohorts. The AUC for in-hospital mortality was 0.727 in the Mayo Cohort versus 0.733 in MIMIC-IV; for IMV, 0.736 versus 0.724; and for NIMV, 0.732 versus 0.708. Conclusions: Our machine learning algorithm demonstrated good discrimination and a high negative predictive value for identifying low-risk hospitalized CAP patients for respiratory deterioration or death in the external MIMIC-IV dataset, supporting its potential utility for prognostic enrichment in pneumonia clinical trials.</p>
	]]></content:encoded>

	<dc:title>Early Machine Learning-Based Identification of Hospitalized Patients at Low Risk of Respiratory Deterioration or Mortality in Community-Acquired Pneumonia: External Validation of a Multivariable Model</dc:title>
			<dc:creator>Claudia Gyimah</dc:creator>
			<dc:creator>Prasamsa Pudasaini</dc:creator>
			<dc:creator>Allison LeMahieu</dc:creator>
			<dc:creator>Phillip Schulte</dc:creator>
			<dc:creator>Yewande E. Odeyemi</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040077</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-25</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-25</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>77</prism:startingPage>
		<prism:doi>10.3390/idr18040077</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/77</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/76">

	<title>Infectious Disease Reports, Vol. 18, Pages 76: Medication Patterns as a Lens on Health Needs Among Migrant Agricultural Workers in Informal Settlements in Apulia: A Descriptive Outreach Study</title>
	<link>https://www.mdpi.com/2036-7449/18/4/76</link>
	<description>Background: Migrant agricultural workers in Italy often experience social and health vulnerabilities, including unstable housing and limited access to primary care. In Southern Italy, many live in informal settlements and seek care through outreach services. This study describes patterns of pharmacological treatment in this population and examines how they relate to the clinical conditions managed in mobile clinics. Methods: We analyzed routinely collected data from 2928 unique patients (8547 clinical encounters; 8965 treatment occurrences) managed by Doctors with Africa CUAMM mobile clinics in 12 informal settlements in Apulia, Italy, between 2017 and 2026. Diagnoses were grouped into clinical categories, and pharmacological treatments were classified by therapeutic class. We conducted a descriptive analysis of the distribution of diagnostic categories and associated treatments. Results: The population was predominantly male (96.5%), young (81% &amp;amp;lt;45 years), and largely excluded from regular primary care (93.5% without a General Practitioner). Musculoskeletal disorders and fatigue were the leading diagnostic category (34.0%), followed by gastrointestinal (13.5%) and respiratory conditions (13.0%). Non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics were the most frequently recorded treatments (32.6% of treatment occurrences). Among musculoskeletal presentations, NSAIDs were used in 76% of cases. Gastroprotective agents were documented in 52% of encounters with gastrointestinal symptoms. Among cardiovascular presentations, 87.7% of treatment occurrences involved chronic management with antihypertensives or beta-blockers. Conclusions: In this outreach setting, medication use provides a descriptive picture of common health problems and treatment responses among migrant agricultural workers living in informal settlements. The prominent use of symptomatic pharmacological relief, particularly NSAIDs in musculoskeletal conditions, suggests that care is often focused on managing pain and acute complaints in a population facing barriers to continuous primary care. These findings support the need for stronger inclusion of migrant workers in the National Health Service and for policies that address underlying social and structural determinants of health.</description>
	<pubDate>2026-07-21</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 76: Medication Patterns as a Lens on Health Needs Among Migrant Agricultural Workers in Informal Settlements in Apulia: A Descriptive Outreach Study</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/76">doi: 10.3390/idr18040076</a></p>
	<p>Authors:
		Cesare De Virgilio Suglia
		Renato Laforgia
		Marcella Schiavone
		Anna Belfiore
		Giacomo Guido
		Rosa Buonamassa
		Alba Cuxart-Graell
		Martina Di Noto
		Valeria Mele
		Emanuele Costanza
		Venilia Cocco
		Alexandre Meduri
		Lucia Raho
		Nicole Laforgia
		Roberta Iatta
		Giovanni Putoto
		Francesco Di Gennaro
		</p>
	<p>Background: Migrant agricultural workers in Italy often experience social and health vulnerabilities, including unstable housing and limited access to primary care. In Southern Italy, many live in informal settlements and seek care through outreach services. This study describes patterns of pharmacological treatment in this population and examines how they relate to the clinical conditions managed in mobile clinics. Methods: We analyzed routinely collected data from 2928 unique patients (8547 clinical encounters; 8965 treatment occurrences) managed by Doctors with Africa CUAMM mobile clinics in 12 informal settlements in Apulia, Italy, between 2017 and 2026. Diagnoses were grouped into clinical categories, and pharmacological treatments were classified by therapeutic class. We conducted a descriptive analysis of the distribution of diagnostic categories and associated treatments. Results: The population was predominantly male (96.5%), young (81% &amp;amp;lt;45 years), and largely excluded from regular primary care (93.5% without a General Practitioner). Musculoskeletal disorders and fatigue were the leading diagnostic category (34.0%), followed by gastrointestinal (13.5%) and respiratory conditions (13.0%). Non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics were the most frequently recorded treatments (32.6% of treatment occurrences). Among musculoskeletal presentations, NSAIDs were used in 76% of cases. Gastroprotective agents were documented in 52% of encounters with gastrointestinal symptoms. Among cardiovascular presentations, 87.7% of treatment occurrences involved chronic management with antihypertensives or beta-blockers. Conclusions: In this outreach setting, medication use provides a descriptive picture of common health problems and treatment responses among migrant agricultural workers living in informal settlements. The prominent use of symptomatic pharmacological relief, particularly NSAIDs in musculoskeletal conditions, suggests that care is often focused on managing pain and acute complaints in a population facing barriers to continuous primary care. These findings support the need for stronger inclusion of migrant workers in the National Health Service and for policies that address underlying social and structural determinants of health.</p>
	]]></content:encoded>

	<dc:title>Medication Patterns as a Lens on Health Needs Among Migrant Agricultural Workers in Informal Settlements in Apulia: A Descriptive Outreach Study</dc:title>
			<dc:creator>Cesare De Virgilio Suglia</dc:creator>
			<dc:creator>Renato Laforgia</dc:creator>
			<dc:creator>Marcella Schiavone</dc:creator>
			<dc:creator>Anna Belfiore</dc:creator>
			<dc:creator>Giacomo Guido</dc:creator>
			<dc:creator>Rosa Buonamassa</dc:creator>
			<dc:creator>Alba Cuxart-Graell</dc:creator>
			<dc:creator>Martina Di Noto</dc:creator>
			<dc:creator>Valeria Mele</dc:creator>
			<dc:creator>Emanuele Costanza</dc:creator>
			<dc:creator>Venilia Cocco</dc:creator>
			<dc:creator>Alexandre Meduri</dc:creator>
			<dc:creator>Lucia Raho</dc:creator>
			<dc:creator>Nicole Laforgia</dc:creator>
			<dc:creator>Roberta Iatta</dc:creator>
			<dc:creator>Giovanni Putoto</dc:creator>
			<dc:creator>Francesco Di Gennaro</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040076</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-21</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-21</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>76</prism:startingPage>
		<prism:doi>10.3390/idr18040076</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/76</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/75">

	<title>Infectious Disease Reports, Vol. 18, Pages 75: Facial Cellulitis Mimicking Ludwig&amp;rsquo;s Angina in a Patient with Chronic Myelogenous Leukemia on Dasatinib Therapy</title>
	<link>https://www.mdpi.com/2036-7449/18/4/75</link>
	<description>Background: Immunosuppressed patients are at an increased risk for developing odontogenic and orofacial infections, which can present with atypical processes and features that may mimic rare but life-threatening infections such as Ludwig&amp;amp;rsquo;s angina. Differentiating cellulitis from a deep neck space infection is often challenging in this population in acute settings due to a broad differential diagnosis and blunted inflammatory responses. This diagnostic uncertainty complicates acute risk stratification and may delay recognition of conditions requiring early airway evaluation and intervention. Case Presentation: We present the case of a 28-year-old male with chronic myelogenous leukemia on immunosuppression with dasatinib who developed unilateral facial swelling and severe odontogenic pain that was refractory to empiric antibiotic therapy. The patient&amp;amp;rsquo;s presentation with rapid clinical progression, early trismus, submandibular involvement, and floor-of-mouth tenderness raised significant concern for evolving Ludwig&amp;amp;rsquo;s angina. Laboratory evaluation demonstrated elevated inflammatory markers, including erythrocyte sedimentation rate and C-reactive protein, further complicating early assessment. Imaging was promptly obtained to determine the nature of the infection, and the patient was admitted for intravenous antibiotic therapy and airway monitoring. Clinical improvement ensued. Conclusions: This case highlights the diagnostic overlap between facial cellulitis and Ludwig&amp;amp;rsquo;s angina and underscores the importance of prompt imaging, airway monitoring, and clinical vigilance for risk stratification of immunocompromised patients in the acute setting to prevent life-threatening complications.</description>
	<pubDate>2026-07-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 75: Facial Cellulitis Mimicking Ludwig&amp;rsquo;s Angina in a Patient with Chronic Myelogenous Leukemia on Dasatinib Therapy</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/75">doi: 10.3390/idr18040075</a></p>
	<p>Authors:
		Nicole Liang
		Jenna DeTemple
		Christopher E. Potts
		Usman Alizai
		Charles Meadows
		</p>
	<p>Background: Immunosuppressed patients are at an increased risk for developing odontogenic and orofacial infections, which can present with atypical processes and features that may mimic rare but life-threatening infections such as Ludwig&amp;amp;rsquo;s angina. Differentiating cellulitis from a deep neck space infection is often challenging in this population in acute settings due to a broad differential diagnosis and blunted inflammatory responses. This diagnostic uncertainty complicates acute risk stratification and may delay recognition of conditions requiring early airway evaluation and intervention. Case Presentation: We present the case of a 28-year-old male with chronic myelogenous leukemia on immunosuppression with dasatinib who developed unilateral facial swelling and severe odontogenic pain that was refractory to empiric antibiotic therapy. The patient&amp;amp;rsquo;s presentation with rapid clinical progression, early trismus, submandibular involvement, and floor-of-mouth tenderness raised significant concern for evolving Ludwig&amp;amp;rsquo;s angina. Laboratory evaluation demonstrated elevated inflammatory markers, including erythrocyte sedimentation rate and C-reactive protein, further complicating early assessment. Imaging was promptly obtained to determine the nature of the infection, and the patient was admitted for intravenous antibiotic therapy and airway monitoring. Clinical improvement ensued. Conclusions: This case highlights the diagnostic overlap between facial cellulitis and Ludwig&amp;amp;rsquo;s angina and underscores the importance of prompt imaging, airway monitoring, and clinical vigilance for risk stratification of immunocompromised patients in the acute setting to prevent life-threatening complications.</p>
	]]></content:encoded>

	<dc:title>Facial Cellulitis Mimicking Ludwig&amp;amp;rsquo;s Angina in a Patient with Chronic Myelogenous Leukemia on Dasatinib Therapy</dc:title>
			<dc:creator>Nicole Liang</dc:creator>
			<dc:creator>Jenna DeTemple</dc:creator>
			<dc:creator>Christopher E. Potts</dc:creator>
			<dc:creator>Usman Alizai</dc:creator>
			<dc:creator>Charles Meadows</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040075</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-15</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-15</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>75</prism:startingPage>
		<prism:doi>10.3390/idr18040075</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/75</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/74">

	<title>Infectious Disease Reports, Vol. 18, Pages 74: Typhus Group Rickettsiosis and the Dengue Diagnostic Paradox: Low Laboratory-Confirmed Dengue Amid the Americas&amp;rsquo; Largest Epidemic</title>
	<link>https://www.mdpi.com/2036-7449/18/4/74</link>
	<description>Background: Rickettsial diseases, particularly typhus group rickettsioses, remain underrecognized across the Americas despite ecological conditions favorable for transmission. Concurrently, Central America is experiencing one of its largest dengue epidemics, with an unexpectedly low proportion of laboratory-confirmed cases. Objective: We aimed to explore whether typhus group rickettsioses may contribute to dengue-like febrile illness in Central America in the context of low dengue diagnostic confirmation. Materials and Methods: An analytical narrative review was conducted integrating secondary epidemiological data from the Pan American Health Organization (PAHO) Arbovirus Surveillance Portal and the peer-reviewed literature. Data from seven Central American countries (2024) were analyzed to estimate the proportion of laboratory-confirmed dengue cases. A focused literature review examined epidemiological, clinical, and ecological evidence supporting rickettsial transmission. Results: Of 543,006 reported dengue cases in Central America in 2024, only 62,285 (11%) were laboratory-confirmed. Evidence from Costa Rica and regional serologic studies suggests ongoing rickettsial transmission. Ecological and socioeconomic conditions&amp;amp;mdash;including vector abundance, peridomestic reservoirs, and climate variability&amp;amp;mdash;mirror those of South Texas, where murine typhus is endemic. Conclusions: The discrepancy between reported and confirmed dengue cases suggests a potential diagnostic gap. Typhus group rickettsioses represent a plausible, underrecognized contributor to febrile illness in Central America. Strengthening surveillance, diagnostics, and clinical awareness is essential to address this hidden burden.</description>
	<pubDate>2026-07-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 74: Typhus Group Rickettsiosis and the Dengue Diagnostic Paradox: Low Laboratory-Confirmed Dengue Amid the Americas&amp;rsquo; Largest Epidemic</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/74">doi: 10.3390/idr18040074</a></p>
	<p>Authors:
		Manuel Sierra
		Elsa Palou
		Fernando Baires
		Helen Hoffman
		Heike Hesse
		Miguel Sierra-Hoffman
		Amy C. Madril
		</p>
	<p>Background: Rickettsial diseases, particularly typhus group rickettsioses, remain underrecognized across the Americas despite ecological conditions favorable for transmission. Concurrently, Central America is experiencing one of its largest dengue epidemics, with an unexpectedly low proportion of laboratory-confirmed cases. Objective: We aimed to explore whether typhus group rickettsioses may contribute to dengue-like febrile illness in Central America in the context of low dengue diagnostic confirmation. Materials and Methods: An analytical narrative review was conducted integrating secondary epidemiological data from the Pan American Health Organization (PAHO) Arbovirus Surveillance Portal and the peer-reviewed literature. Data from seven Central American countries (2024) were analyzed to estimate the proportion of laboratory-confirmed dengue cases. A focused literature review examined epidemiological, clinical, and ecological evidence supporting rickettsial transmission. Results: Of 543,006 reported dengue cases in Central America in 2024, only 62,285 (11%) were laboratory-confirmed. Evidence from Costa Rica and regional serologic studies suggests ongoing rickettsial transmission. Ecological and socioeconomic conditions&amp;amp;mdash;including vector abundance, peridomestic reservoirs, and climate variability&amp;amp;mdash;mirror those of South Texas, where murine typhus is endemic. Conclusions: The discrepancy between reported and confirmed dengue cases suggests a potential diagnostic gap. Typhus group rickettsioses represent a plausible, underrecognized contributor to febrile illness in Central America. Strengthening surveillance, diagnostics, and clinical awareness is essential to address this hidden burden.</p>
	]]></content:encoded>

	<dc:title>Typhus Group Rickettsiosis and the Dengue Diagnostic Paradox: Low Laboratory-Confirmed Dengue Amid the Americas&amp;amp;rsquo; Largest Epidemic</dc:title>
			<dc:creator>Manuel Sierra</dc:creator>
			<dc:creator>Elsa Palou</dc:creator>
			<dc:creator>Fernando Baires</dc:creator>
			<dc:creator>Helen Hoffman</dc:creator>
			<dc:creator>Heike Hesse</dc:creator>
			<dc:creator>Miguel Sierra-Hoffman</dc:creator>
			<dc:creator>Amy C. Madril</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040074</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-14</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Brief Report</prism:section>
	<prism:startingPage>74</prism:startingPage>
		<prism:doi>10.3390/idr18040074</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/74</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/73">

	<title>Infectious Disease Reports, Vol. 18, Pages 73: Subspecies Identification and Characterization of Drug Resistance and Virulence Factors in Clinical Strains of Mycobacterium abscessus Complex Isolated from South India</title>
	<link>https://www.mdpi.com/2036-7449/18/4/73</link>
	<description>Background: Mycobacterium abscessus complex (MABC), comprising Mycobacterium abscessus subsp. abscessus (MABa), Mycobacterium abscessus subsp. bolletii (MABb), and Mycobacterium abscessus subsp. massiliense (MABm), is an emerging group of non-tuberculous mycobacteria with clinically significant infections and challenging treatment outcomes due to extensive antimicrobial resistance. Accurate subspecies identification and characterization of resistance- and virulence-associated determinants are essential for effective disease management. This study aimed to determine the prevalence and subspecies distribution of MABC and to characterize resistance-associated mutations and virulence factors, including biofilm formation. Methods: A total of 1110 NTM-suspected clinical samples were screened during the study period, between January 2024 and October 2025. Samples negative by GeneXpert MTB/RIF were subjected to Mycobacteria Growth Indicator Tube (MGIT) culture, followed by Ziehl&amp;amp;ndash;Neelsen staining and MPT64 antigen testing. Acid-fast bacilli-positive, MPT64-negative isolates were identified as NTM and analyzed using GenoType CM and NTM-DR line probe assays (LPA) for species identification and detection of resistance-associated mutations. A polymerase chain reaction (PCR) assay was optimized to differentiate MABa and MABm. All MABC clinical strains were further characterized for colony morphology (smooth and rough) and biofilm formation. Three biofilm-producing MABa strains (2 rough and 1 smooth) that were detected as macrolide-resistant by NTM-DR were subjected to whole-genome sequencing (WGS). Results: Among 1110 clinical samples, MABC was identified in 2.25% (n = 25) of cases, while other NTM species accounted for 4.41% (n = 49). Among 25 MABC clinical strains, 14 (56%) were MABm, and 11 (44%) were MABa, as confirmed by both LPA and PCR. LPA-NTM DR detected erm(41) T28 sequevar (n = 9) and C28 mutation (n = 2) among MABa strains, with one strain exhibiting aminoglycoside resistance-associated rrs mutation. Nineteen isolates displayed a smooth morphotype (MABa = 8 and MABm = 11), and six were rough (MABa = 3 and MABm = 3). Biofilm formation was observed in both smooth (n = 5) and rough (n = 4) morphotypes. WGS analysis confirmed erm(41) T28 sequevar, identified a missense mutation (A238G), and revealed genes associated with glycopeptidolipid biosynthesis. Conclusions: Our findings provide important insights into subspecies identification and genetic determinants associated with drug resistance and virulence in MABC. The biofilm-forming ability observed in both smooth and rough morphotypes emphasizes its potential role in persistence and treatment challenges, emphasizing the need for comprehensive diagnostic strategies.</description>
	<pubDate>2026-07-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 73: Subspecies Identification and Characterization of Drug Resistance and Virulence Factors in Clinical Strains of Mycobacterium abscessus Complex Isolated from South India</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/73">doi: 10.3390/idr18040073</a></p>
	<p>Authors:
		Kumaran Oudhaya
		Ellappan Kalaiarasan
		Anoop Alex
		Kooleri Padinjare Veetil Hyma
		Harishni Padmanaban
		Sangitha Jayagandan
		Noyal Mariya Joseph
		</p>
	<p>Background: Mycobacterium abscessus complex (MABC), comprising Mycobacterium abscessus subsp. abscessus (MABa), Mycobacterium abscessus subsp. bolletii (MABb), and Mycobacterium abscessus subsp. massiliense (MABm), is an emerging group of non-tuberculous mycobacteria with clinically significant infections and challenging treatment outcomes due to extensive antimicrobial resistance. Accurate subspecies identification and characterization of resistance- and virulence-associated determinants are essential for effective disease management. This study aimed to determine the prevalence and subspecies distribution of MABC and to characterize resistance-associated mutations and virulence factors, including biofilm formation. Methods: A total of 1110 NTM-suspected clinical samples were screened during the study period, between January 2024 and October 2025. Samples negative by GeneXpert MTB/RIF were subjected to Mycobacteria Growth Indicator Tube (MGIT) culture, followed by Ziehl&amp;amp;ndash;Neelsen staining and MPT64 antigen testing. Acid-fast bacilli-positive, MPT64-negative isolates were identified as NTM and analyzed using GenoType CM and NTM-DR line probe assays (LPA) for species identification and detection of resistance-associated mutations. A polymerase chain reaction (PCR) assay was optimized to differentiate MABa and MABm. All MABC clinical strains were further characterized for colony morphology (smooth and rough) and biofilm formation. Three biofilm-producing MABa strains (2 rough and 1 smooth) that were detected as macrolide-resistant by NTM-DR were subjected to whole-genome sequencing (WGS). Results: Among 1110 clinical samples, MABC was identified in 2.25% (n = 25) of cases, while other NTM species accounted for 4.41% (n = 49). Among 25 MABC clinical strains, 14 (56%) were MABm, and 11 (44%) were MABa, as confirmed by both LPA and PCR. LPA-NTM DR detected erm(41) T28 sequevar (n = 9) and C28 mutation (n = 2) among MABa strains, with one strain exhibiting aminoglycoside resistance-associated rrs mutation. Nineteen isolates displayed a smooth morphotype (MABa = 8 and MABm = 11), and six were rough (MABa = 3 and MABm = 3). Biofilm formation was observed in both smooth (n = 5) and rough (n = 4) morphotypes. WGS analysis confirmed erm(41) T28 sequevar, identified a missense mutation (A238G), and revealed genes associated with glycopeptidolipid biosynthesis. Conclusions: Our findings provide important insights into subspecies identification and genetic determinants associated with drug resistance and virulence in MABC. The biofilm-forming ability observed in both smooth and rough morphotypes emphasizes its potential role in persistence and treatment challenges, emphasizing the need for comprehensive diagnostic strategies.</p>
	]]></content:encoded>

	<dc:title>Subspecies Identification and Characterization of Drug Resistance and Virulence Factors in Clinical Strains of Mycobacterium abscessus Complex Isolated from South India</dc:title>
			<dc:creator>Kumaran Oudhaya</dc:creator>
			<dc:creator>Ellappan Kalaiarasan</dc:creator>
			<dc:creator>Anoop Alex</dc:creator>
			<dc:creator>Kooleri Padinjare Veetil Hyma</dc:creator>
			<dc:creator>Harishni Padmanaban</dc:creator>
			<dc:creator>Sangitha Jayagandan</dc:creator>
			<dc:creator>Noyal Mariya Joseph</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040073</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>73</prism:startingPage>
		<prism:doi>10.3390/idr18040073</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/73</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/72">

	<title>Infectious Disease Reports, Vol. 18, Pages 72: Ensemble Machine Learning for Malaria Diagnosis in Resource-Limited Settings Using Clinical and Demographic Features</title>
	<link>https://www.mdpi.com/2036-7449/18/4/72</link>
	<description>Background: Sub-Saharan Africa suffers the greatest impact of malaria, with the 2024 Health Organization (WHO )report stating that the region represents 94% of global cases and 95% of deaths. Challenges in malaria elimination stem from weak health systems and limitations of traditional diagnostic methods like microscopy and malaria Rapid Diagnostic Tests (mRDTs), which result in missed diagnoses, delays in treatment, and preventable fatalities in resource-limited settings. This paper addresses these diagnostic limitations by developing and systematically evaluating a machine learning (ML) framework for malaria diagnosis that leverages routine clinical symptoms and demographic information tailored for these environments. Methods: Examining 637 patient records from Gutu Mission Hospital and Gweru Provincial Hospital in Zimbabwe, the research analyzed clinical symptoms (fever, chills, abdominal pain, headache, diarrhea) and demographic data (age, gender, residence, travel history). Data preprocessing involved addressing class imbalance with the Synthetic Minority Oversampling Technique (SMOTE) and employing Recursive Feature Elimination (RFE) for feature selection. Seven ML models were trained: Logistic Regression, Random Forest, Decision Trees, Gradient Boosting, K-Nearest Neighbor, Naive Bayes, and XGBoost. These individual models were used to construct ensemble models like Bagging, Stacking, Soft Voting, and AdaBoost. Performance metrics included accuracy, precision, confusion matrices, recall, F1 score, and AUC-ROC. Results: Statistically significant predictors for malaria included chills (p = 0.001), fever (p = 0.003), diarrhea (p = 0.01), and abdominal pain (p &amp;amp;lt; 0.001), with travel history showing significance among demographic factors (p = 0.02). The stacking ensemble model yielded superior performance, achieving an accuracy of 0.96, precision of 0.95, recall of 0.98, F1 score of 0.96, and AUC-ROC of 0.98. Conclusions: This study underscores the potential of ML, particularly ensemble techniques, to enhance malaria management in resource-limited settings, providing a scalable and cost-effective diagnostic alternative that utilizes accessible clinical and demographic data, thereby supporting healthcare workers and control programs in areas where traditional methods are inadequate.</description>
	<pubDate>2026-07-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 72: Ensemble Machine Learning for Malaria Diagnosis in Resource-Limited Settings Using Clinical and Demographic Features</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/72">doi: 10.3390/idr18040072</a></p>
	<p>Authors:
		Panashe Nyengera
		Hilary Takunda Takawira
		Farai Fredric Mlambo
		</p>
	<p>Background: Sub-Saharan Africa suffers the greatest impact of malaria, with the 2024 Health Organization (WHO )report stating that the region represents 94% of global cases and 95% of deaths. Challenges in malaria elimination stem from weak health systems and limitations of traditional diagnostic methods like microscopy and malaria Rapid Diagnostic Tests (mRDTs), which result in missed diagnoses, delays in treatment, and preventable fatalities in resource-limited settings. This paper addresses these diagnostic limitations by developing and systematically evaluating a machine learning (ML) framework for malaria diagnosis that leverages routine clinical symptoms and demographic information tailored for these environments. Methods: Examining 637 patient records from Gutu Mission Hospital and Gweru Provincial Hospital in Zimbabwe, the research analyzed clinical symptoms (fever, chills, abdominal pain, headache, diarrhea) and demographic data (age, gender, residence, travel history). Data preprocessing involved addressing class imbalance with the Synthetic Minority Oversampling Technique (SMOTE) and employing Recursive Feature Elimination (RFE) for feature selection. Seven ML models were trained: Logistic Regression, Random Forest, Decision Trees, Gradient Boosting, K-Nearest Neighbor, Naive Bayes, and XGBoost. These individual models were used to construct ensemble models like Bagging, Stacking, Soft Voting, and AdaBoost. Performance metrics included accuracy, precision, confusion matrices, recall, F1 score, and AUC-ROC. Results: Statistically significant predictors for malaria included chills (p = 0.001), fever (p = 0.003), diarrhea (p = 0.01), and abdominal pain (p &amp;amp;lt; 0.001), with travel history showing significance among demographic factors (p = 0.02). The stacking ensemble model yielded superior performance, achieving an accuracy of 0.96, precision of 0.95, recall of 0.98, F1 score of 0.96, and AUC-ROC of 0.98. Conclusions: This study underscores the potential of ML, particularly ensemble techniques, to enhance malaria management in resource-limited settings, providing a scalable and cost-effective diagnostic alternative that utilizes accessible clinical and demographic data, thereby supporting healthcare workers and control programs in areas where traditional methods are inadequate.</p>
	]]></content:encoded>

	<dc:title>Ensemble Machine Learning for Malaria Diagnosis in Resource-Limited Settings Using Clinical and Demographic Features</dc:title>
			<dc:creator>Panashe Nyengera</dc:creator>
			<dc:creator>Hilary Takunda Takawira</dc:creator>
			<dc:creator>Farai Fredric Mlambo</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040072</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>72</prism:startingPage>
		<prism:doi>10.3390/idr18040072</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/72</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/71">

	<title>Infectious Disease Reports, Vol. 18, Pages 71: Influenza Virus Isolation for Public Health Surveillance Before, During, and After the COVID-19 Pandemic: Experiences from the New York State National Influenza Reference Center Laboratory</title>
	<link>https://www.mdpi.com/2036-7449/18/4/71</link>
	<description>Background: Influenza viruses can cause mild to severe illnesses. The burden of disease varies widely depending on multiple factors, including the type and subtype of circulating viruses, timing of the season, flu vaccine efficacy and vaccination rates. Influenza viruses are also highly prone to genetic change and rapid spread due to modern human movement patterns, making influenza surveillance vital for public health awareness, guidance, policy, disease mitigation, and annual recommendations on vaccine composition. Methods: A network of three National Influenza Reference Centers (NIRCs) was established in the United States more than 10 years ago to support the Centers for Disease Control and Prevention&amp;amp;rsquo;s (CDC) Influenza Division with its national influenza surveillance efforts. Located in California, New York, and Wisconsin, they are funded by CDC via a collaborative agreement with the Association of Public Health Laboratories (APHL). The role of the NIRCs is critical to national and global influenza surveillance, providing rapid information on circulating influenza strains from three arms of laboratory testing: (1) the virus isolation project (VIP), (2) next-generation sequencing (NGS), and (3) anti-viral drug resistance testing. Results: Here, we review the data generated in the VIP lab of the New York State (NYS) NIRC before, during, and after the COVID-19 pandemic and discuss its utility in an understanding of disease dynamics and viral evolution, as well as public health policy and decision making during this historic period in health care. Conclusion: Continued preparedness and surveillance are critical to mitigating the impact of evolving influenza viruses.</description>
	<pubDate>2026-07-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 71: Influenza Virus Isolation for Public Health Surveillance Before, During, and After the COVID-19 Pandemic: Experiences from the New York State National Influenza Reference Center Laboratory</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/71">doi: 10.3390/idr18040071</a></p>
	<p>Authors:
		Amruta Pramod Moghe
		Emaly Starrett Leak
		Jennifer May Laplante
		Kirsten St. George
		</p>
	<p>Background: Influenza viruses can cause mild to severe illnesses. The burden of disease varies widely depending on multiple factors, including the type and subtype of circulating viruses, timing of the season, flu vaccine efficacy and vaccination rates. Influenza viruses are also highly prone to genetic change and rapid spread due to modern human movement patterns, making influenza surveillance vital for public health awareness, guidance, policy, disease mitigation, and annual recommendations on vaccine composition. Methods: A network of three National Influenza Reference Centers (NIRCs) was established in the United States more than 10 years ago to support the Centers for Disease Control and Prevention&amp;amp;rsquo;s (CDC) Influenza Division with its national influenza surveillance efforts. Located in California, New York, and Wisconsin, they are funded by CDC via a collaborative agreement with the Association of Public Health Laboratories (APHL). The role of the NIRCs is critical to national and global influenza surveillance, providing rapid information on circulating influenza strains from three arms of laboratory testing: (1) the virus isolation project (VIP), (2) next-generation sequencing (NGS), and (3) anti-viral drug resistance testing. Results: Here, we review the data generated in the VIP lab of the New York State (NYS) NIRC before, during, and after the COVID-19 pandemic and discuss its utility in an understanding of disease dynamics and viral evolution, as well as public health policy and decision making during this historic period in health care. Conclusion: Continued preparedness and surveillance are critical to mitigating the impact of evolving influenza viruses.</p>
	]]></content:encoded>

	<dc:title>Influenza Virus Isolation for Public Health Surveillance Before, During, and After the COVID-19 Pandemic: Experiences from the New York State National Influenza Reference Center Laboratory</dc:title>
			<dc:creator>Amruta Pramod Moghe</dc:creator>
			<dc:creator>Emaly Starrett Leak</dc:creator>
			<dc:creator>Jennifer May Laplante</dc:creator>
			<dc:creator>Kirsten St. George</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040071</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-10</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-10</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>71</prism:startingPage>
		<prism:doi>10.3390/idr18040071</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/71</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/70">

	<title>Infectious Disease Reports, Vol. 18, Pages 70: Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies</title>
	<link>https://www.mdpi.com/2036-7449/18/4/70</link>
	<description>Background/Objectives: Antimicrobial resistance (AMR) is a major global public health threat, compromising prevention and treatment of infectious diseases. This narrative review examines AMR as a multifactorial and transnational crisis through epidemiological, One Health, social and bioethical perspectives, and discusses emerging non-antibiotic preventive and therapeutic strategies. Methods: PubMed and Scopus were searched using terms related to AMR, epidemiology, public health, surveillance, One Health, bioethics, equity and alternative therapies. Peer-reviewed medical and public health articles were considered, together with selected reports from international organizations and public health agencies. Results: AMR is driven by inappropriate antibiotic use in human medicine, livestock, aquaculture and agriculture, combined with weaknesses in infection prevention, stewardship, environmental control and surveillance. Epidemiological evidence shows a substantial global burden, marked regional inequalities in resistance patterns, surveillance capacity and policy response, and major consequences, including increased mortality, prolonged hospitalization, rising healthcare costs and disproportionate effects on vulnerable populations. Key bioethical concerns include collective responsibility, equitable access to effective treatment, stewardship, global justice and intergenerational accountability. Emerging non-antibiotic strategies vary in translational maturity: vaccines and selected microbiome-based interventions have preventive or supportive roles in defined settings, bacteriophage therapy is used mainly in compassionate or specialized contexts, and many antimicrobial peptides and nanotechnology-based platforms remain experimental or early translational. Conclusions: AMR requires coordinated global action grounded in One Health, strong public health systems, integrated surveillance, responsible antimicrobial use and sustained innovation. Effective containment must also address social inequalities, ethical stewardship, equitable access to diagnostics and treatment, and responsibility toward future generations.</description>
	<pubDate>2026-07-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 70: Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/70">doi: 10.3390/idr18040070</a></p>
	<p>Authors:
		Christos Ntais
		Ioanna P. Chatziprodromidou
		</p>
	<p>Background/Objectives: Antimicrobial resistance (AMR) is a major global public health threat, compromising prevention and treatment of infectious diseases. This narrative review examines AMR as a multifactorial and transnational crisis through epidemiological, One Health, social and bioethical perspectives, and discusses emerging non-antibiotic preventive and therapeutic strategies. Methods: PubMed and Scopus were searched using terms related to AMR, epidemiology, public health, surveillance, One Health, bioethics, equity and alternative therapies. Peer-reviewed medical and public health articles were considered, together with selected reports from international organizations and public health agencies. Results: AMR is driven by inappropriate antibiotic use in human medicine, livestock, aquaculture and agriculture, combined with weaknesses in infection prevention, stewardship, environmental control and surveillance. Epidemiological evidence shows a substantial global burden, marked regional inequalities in resistance patterns, surveillance capacity and policy response, and major consequences, including increased mortality, prolonged hospitalization, rising healthcare costs and disproportionate effects on vulnerable populations. Key bioethical concerns include collective responsibility, equitable access to effective treatment, stewardship, global justice and intergenerational accountability. Emerging non-antibiotic strategies vary in translational maturity: vaccines and selected microbiome-based interventions have preventive or supportive roles in defined settings, bacteriophage therapy is used mainly in compassionate or specialized contexts, and many antimicrobial peptides and nanotechnology-based platforms remain experimental or early translational. Conclusions: AMR requires coordinated global action grounded in One Health, strong public health systems, integrated surveillance, responsible antimicrobial use and sustained innovation. Effective containment must also address social inequalities, ethical stewardship, equitable access to diagnostics and treatment, and responsibility toward future generations.</p>
	]]></content:encoded>

	<dc:title>Antimicrobial Resistance as a Global Public Health Challenge: Epidemiological Burden, Bioethical Dimensions and Emerging Therapeutic Strategies</dc:title>
			<dc:creator>Christos Ntais</dc:creator>
			<dc:creator>Ioanna P. Chatziprodromidou</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040070</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>70</prism:startingPage>
		<prism:doi>10.3390/idr18040070</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/70</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/69">

	<title>Infectious Disease Reports, Vol. 18, Pages 69: Infection-Associated Pediatric Acute-Onset Neuropsychiatric Syndrome: A Review of Immunological Mechanisms, Clinical Phenotypes, and Therapeutic Strategies</title>
	<link>https://www.mdpi.com/2036-7449/18/4/69</link>
	<description>Background/Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) describes the rapid onset of obsessive&amp;amp;ndash;compulsive symptoms or severe food restriction, accompanied by neuropsychiatric or somatic features that are not better explained by another disorder. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) is a related, more narrowly defined construct in which symptoms are temporally associated with group A Streptococcus infection. This review examines clinical symptoms, infectious associations, proposed immune mechanisms, biomarker limitations, and treatment strategies for infection-associated PANS/PANDAS. Methods: A structured narrative search of PubMed/MEDLINE, Embase, the Cochrane Library, Google Scholar/publisher-indexed literature, ClinicalTrials.gov, and reference lists was performed up to 16 June 2026. Original cohorts, case series, systematic reviews, narrative reviews, consensus guidance, mechanistic studies, and registered prospective studies were prioritized. The review was not designed as a PRISMA-ScR scoping review; however, the methods were expanded to improve transparency and align with SANRA principles. Results: Group A Streptococcus remains the best characterized infectious association, although prospective studies have not uniformly demonstrated a consistent temporal relationship between streptococcal infection and neuropsychiatric exacerbations. Parent-reported surveys and case-based literature also describe temporal associations with Mycoplasma pneumoniae, influenza-like illnesses, upper respiratory infections, Borrelia burgdorferi, Epstein&amp;amp;ndash;Barr virus, and SARS-CoV-2. Proposed mechanisms include molecular mimicry, anti-D1R and anti-D2R antibodies, other antineuronal antibodies, calcium/calmodulin-dependent protein kinase II signaling, blood&amp;amp;ndash;brain barrier vulnerability, cytokine and Th17 effects, neuroinflammatory amplification, basal ganglia/CSTC circuit dysfunction, and gut&amp;amp;ndash;oral&amp;amp;ndash;brain immune interactions. None currently provides a definitive diagnostic biomarker. Conclusions: Infection-associated PANS is best approached as a clinically defined, heterogeneous neuroimmune presentation that requires rigorous differential diagnosis, multidisciplinary care, cautious treatment escalation, prospective biomarker validation, and large, multicenter treatment trials.</description>
	<pubDate>2026-07-07</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 69: Infection-Associated Pediatric Acute-Onset Neuropsychiatric Syndrome: A Review of Immunological Mechanisms, Clinical Phenotypes, and Therapeutic Strategies</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/69">doi: 10.3390/idr18040069</a></p>
	<p>Authors:
		Enoch Chi Ngai Lim
		Nga Chong Lisa Cheng
		Chi Eung Danforn Lim
		</p>
	<p>Background/Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) describes the rapid onset of obsessive&amp;amp;ndash;compulsive symptoms or severe food restriction, accompanied by neuropsychiatric or somatic features that are not better explained by another disorder. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) is a related, more narrowly defined construct in which symptoms are temporally associated with group A Streptococcus infection. This review examines clinical symptoms, infectious associations, proposed immune mechanisms, biomarker limitations, and treatment strategies for infection-associated PANS/PANDAS. Methods: A structured narrative search of PubMed/MEDLINE, Embase, the Cochrane Library, Google Scholar/publisher-indexed literature, ClinicalTrials.gov, and reference lists was performed up to 16 June 2026. Original cohorts, case series, systematic reviews, narrative reviews, consensus guidance, mechanistic studies, and registered prospective studies were prioritized. The review was not designed as a PRISMA-ScR scoping review; however, the methods were expanded to improve transparency and align with SANRA principles. Results: Group A Streptococcus remains the best characterized infectious association, although prospective studies have not uniformly demonstrated a consistent temporal relationship between streptococcal infection and neuropsychiatric exacerbations. Parent-reported surveys and case-based literature also describe temporal associations with Mycoplasma pneumoniae, influenza-like illnesses, upper respiratory infections, Borrelia burgdorferi, Epstein&amp;amp;ndash;Barr virus, and SARS-CoV-2. Proposed mechanisms include molecular mimicry, anti-D1R and anti-D2R antibodies, other antineuronal antibodies, calcium/calmodulin-dependent protein kinase II signaling, blood&amp;amp;ndash;brain barrier vulnerability, cytokine and Th17 effects, neuroinflammatory amplification, basal ganglia/CSTC circuit dysfunction, and gut&amp;amp;ndash;oral&amp;amp;ndash;brain immune interactions. None currently provides a definitive diagnostic biomarker. Conclusions: Infection-associated PANS is best approached as a clinically defined, heterogeneous neuroimmune presentation that requires rigorous differential diagnosis, multidisciplinary care, cautious treatment escalation, prospective biomarker validation, and large, multicenter treatment trials.</p>
	]]></content:encoded>

	<dc:title>Infection-Associated Pediatric Acute-Onset Neuropsychiatric Syndrome: A Review of Immunological Mechanisms, Clinical Phenotypes, and Therapeutic Strategies</dc:title>
			<dc:creator>Enoch Chi Ngai Lim</dc:creator>
			<dc:creator>Nga Chong Lisa Cheng</dc:creator>
			<dc:creator>Chi Eung Danforn Lim</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040069</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-07</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-07</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>69</prism:startingPage>
		<prism:doi>10.3390/idr18040069</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/69</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/68">

	<title>Infectious Disease Reports, Vol. 18, Pages 68: A Case of Spinal Epidural Abscess and Paraplegia After Group A Streptococcal Pharyngitis</title>
	<link>https://www.mdpi.com/2036-7449/18/4/68</link>
	<description>Background: Spinal epidural abscesses (SEA) are rare, occurring 2.5&amp;amp;ndash;3 times per 10,000 hospital admissions. While streptococcus species comprise 7% of reported SEAs, Group A Streptococcus (GAS) has been described only once in the medical literature to our knowledge. Case presentation: We present a case of GAS pharyngitis with subsequent paraplegia from a GAS SEA. A 33-year-old female presented to the emergency department (ED) and was initially diagnosed with GAS pharyngitis and a suspected strained lower back. Following treatment with amoxicillin, she returned with worsened back pain, radiculopathy, and leukocytosis, for which she was treated with cyclobenzaprine. On her third presentation, she had new bilateral lower extremity weakness with decreased sensation, bilateral ankle clonus, and hyperreflexia. MRI of the thoracic and lumbar spine revealed a multiloculated SEA at T5-T10 requiring laminectomy and abscess evacuation. Intraoperative cultures grew Streptococcus pyogenes. Despite surgery, medical management, and physical therapy, she remained paraplegic. Conclusions: To our knowledge, this is the first report of SEA preceded by GAS pharyngitis. This case exposes the critical association between a recent infection, progression of back pain, eventual neurologic symptoms, and inflammatory markers that should trigger concern for SEA and early evaluation with MRI.</description>
	<pubDate>2026-07-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 68: A Case of Spinal Epidural Abscess and Paraplegia After Group A Streptococcal Pharyngitis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/68">doi: 10.3390/idr18040068</a></p>
	<p>Authors:
		Blake J. McKinley
		Rob M. Seby
		Robert C. Chase
		Tatjana Gavrancic
		Jeremy Collado
		Libardo Rueda Prada
		</p>
	<p>Background: Spinal epidural abscesses (SEA) are rare, occurring 2.5&amp;amp;ndash;3 times per 10,000 hospital admissions. While streptococcus species comprise 7% of reported SEAs, Group A Streptococcus (GAS) has been described only once in the medical literature to our knowledge. Case presentation: We present a case of GAS pharyngitis with subsequent paraplegia from a GAS SEA. A 33-year-old female presented to the emergency department (ED) and was initially diagnosed with GAS pharyngitis and a suspected strained lower back. Following treatment with amoxicillin, she returned with worsened back pain, radiculopathy, and leukocytosis, for which she was treated with cyclobenzaprine. On her third presentation, she had new bilateral lower extremity weakness with decreased sensation, bilateral ankle clonus, and hyperreflexia. MRI of the thoracic and lumbar spine revealed a multiloculated SEA at T5-T10 requiring laminectomy and abscess evacuation. Intraoperative cultures grew Streptococcus pyogenes. Despite surgery, medical management, and physical therapy, she remained paraplegic. Conclusions: To our knowledge, this is the first report of SEA preceded by GAS pharyngitis. This case exposes the critical association between a recent infection, progression of back pain, eventual neurologic symptoms, and inflammatory markers that should trigger concern for SEA and early evaluation with MRI.</p>
	]]></content:encoded>

	<dc:title>A Case of Spinal Epidural Abscess and Paraplegia After Group A Streptococcal Pharyngitis</dc:title>
			<dc:creator>Blake J. McKinley</dc:creator>
			<dc:creator>Rob M. Seby</dc:creator>
			<dc:creator>Robert C. Chase</dc:creator>
			<dc:creator>Tatjana Gavrancic</dc:creator>
			<dc:creator>Jeremy Collado</dc:creator>
			<dc:creator>Libardo Rueda Prada</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040068</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-04</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-04</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>68</prism:startingPage>
		<prism:doi>10.3390/idr18040068</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/68</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/67">

	<title>Infectious Disease Reports, Vol. 18, Pages 67: Clostridioides difficile Infection (CDI) Disease Burden (Cases, Hospitalizations, and Deaths) in China: A Systematic Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/4/67</link>
	<description>Background/Objectives: Although Clostridioides difficile infection (CDI) is a key cause of global morbidity and mortality, the burden of CDI in mainland China is not well-defined. The objective of this systematic literature review was to summarize the available epidemiologic evidence on the CDI disease burden (cases, hospitalizations, and deaths) in mainland China. Methods: Six databases (three global [PubMed, Embase, Cochrane] and three Chinese [Chinese National Knowledge Infrastructure, Chinese Science Citation, Wanfang]) were searched on 5 August 2025 using CDI-related and epidemiological search terms. No date or language limits were applied. Real-world epidemiologic studies of adults and/or children with laboratory-confirmed CDI in mainland China reporting population-based CDI incidence, hospital-based CDI incidence, and/or CDI admission rates were included. All studies not meeting these criteria were excluded. Risk-of-bias (RoB) assessment was performed using the Newcastle&amp;amp;ndash;Ottawa Scale. Results were summarized descriptively. Results: In total, 11 articles formed the evidence base for this review; each was a single-center, hospital-based study conducted in one of six cities in mainland China and published between 2014 and 2023. RoB assessment indicated that the evidence base was appropriate for this study. No study reported population-based CDI incidence. In total, 10 studies reported hospital-based CDI incidence (0 to 82.0/10,000 patient-days), and four reported CDI admission rates (0 to 23.1/1000 admissions). Eight studies reported mortality rates, which varied across studies. Conclusions: Several single-center, hospital-based studies demonstrate that CDI is present in hospitals in mainland China, but there are no published population-based CDI incidence estimates. These results should be interpreted considering this study&amp;amp;rsquo;s limitations, including potential publication and selection bias, heterogeneity, and limited generalizability. Overall, the burden of CDI is poorly understood in mainland China. Thus, prospective epidemiological studies, including those with sensitive detection methods, are needed to examine CDI burden across multiple cities in mainland China. These efforts would help illuminate the CDI burden and guide prevention efforts. (PROSPERO ID 1140152; registered 17 March 2026; funding by Pfizer Inc.).</description>
	<pubDate>2026-07-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 67: Clostridioides difficile Infection (CDI) Disease Burden (Cases, Hospitalizations, and Deaths) in China: A Systematic Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/67">doi: 10.3390/idr18040067</a></p>
	<p>Authors:
		Frederick J. Angulo
		Genming Zhao
		Yuan Wu
		Zundong Yin
		Jin Yang
		Shahnaz Khan
		Daniel Khuong Tran
		Elisa N. Gonzalez
		Anli Sun
		Steven Shen
		Jamie Findlow
		</p>
	<p>Background/Objectives: Although Clostridioides difficile infection (CDI) is a key cause of global morbidity and mortality, the burden of CDI in mainland China is not well-defined. The objective of this systematic literature review was to summarize the available epidemiologic evidence on the CDI disease burden (cases, hospitalizations, and deaths) in mainland China. Methods: Six databases (three global [PubMed, Embase, Cochrane] and three Chinese [Chinese National Knowledge Infrastructure, Chinese Science Citation, Wanfang]) were searched on 5 August 2025 using CDI-related and epidemiological search terms. No date or language limits were applied. Real-world epidemiologic studies of adults and/or children with laboratory-confirmed CDI in mainland China reporting population-based CDI incidence, hospital-based CDI incidence, and/or CDI admission rates were included. All studies not meeting these criteria were excluded. Risk-of-bias (RoB) assessment was performed using the Newcastle&amp;amp;ndash;Ottawa Scale. Results were summarized descriptively. Results: In total, 11 articles formed the evidence base for this review; each was a single-center, hospital-based study conducted in one of six cities in mainland China and published between 2014 and 2023. RoB assessment indicated that the evidence base was appropriate for this study. No study reported population-based CDI incidence. In total, 10 studies reported hospital-based CDI incidence (0 to 82.0/10,000 patient-days), and four reported CDI admission rates (0 to 23.1/1000 admissions). Eight studies reported mortality rates, which varied across studies. Conclusions: Several single-center, hospital-based studies demonstrate that CDI is present in hospitals in mainland China, but there are no published population-based CDI incidence estimates. These results should be interpreted considering this study&amp;amp;rsquo;s limitations, including potential publication and selection bias, heterogeneity, and limited generalizability. Overall, the burden of CDI is poorly understood in mainland China. Thus, prospective epidemiological studies, including those with sensitive detection methods, are needed to examine CDI burden across multiple cities in mainland China. These efforts would help illuminate the CDI burden and guide prevention efforts. (PROSPERO ID 1140152; registered 17 March 2026; funding by Pfizer Inc.).</p>
	]]></content:encoded>

	<dc:title>Clostridioides difficile Infection (CDI) Disease Burden (Cases, Hospitalizations, and Deaths) in China: A Systematic Literature Review</dc:title>
			<dc:creator>Frederick J. Angulo</dc:creator>
			<dc:creator>Genming Zhao</dc:creator>
			<dc:creator>Yuan Wu</dc:creator>
			<dc:creator>Zundong Yin</dc:creator>
			<dc:creator>Jin Yang</dc:creator>
			<dc:creator>Shahnaz Khan</dc:creator>
			<dc:creator>Daniel Khuong Tran</dc:creator>
			<dc:creator>Elisa N. Gonzalez</dc:creator>
			<dc:creator>Anli Sun</dc:creator>
			<dc:creator>Steven Shen</dc:creator>
			<dc:creator>Jamie Findlow</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040067</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-07-03</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-07-03</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>67</prism:startingPage>
		<prism:doi>10.3390/idr18040067</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/67</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/66">

	<title>Infectious Disease Reports, Vol. 18, Pages 66: Cytomegalovirus Retinitis in Newly Diagnosed Advanced HIV Infection: A Three-Case Series Emphasizing Multidisciplinary Infection Screening</title>
	<link>https://www.mdpi.com/2036-7449/18/4/66</link>
	<description>Background/Objectives: Cytomegalovirus (CMV) retinitis remains a significant opportunistic infection in patients with advanced human immunodeficiency virus (HIV) infection, particularly with late HIV diagnoses. This three-case series aimed to describe HIV-associated CMV retinitis in newly diagnosed advanced HIV infection with documented concurrent and/or prior infectious conditions, and to highlight the importance of bord systemic screening and multidisciplinary management. Methods: We retrospectively reviewed three male patients diagnosed with HIV-associated CMV retinitis at a tertiary ophthalmology referral center. Clinical findings, CD4-positive T-cell counts, HIV-RNA levels, aqueous humor CMV-DNA results, systemic infectious conditions, treatment and ocular outcomes were summarized. Results: All patients had marked cellular immunodeficiency, with CD4-positive T-cell counts ranging from 46 to 141 cells/&amp;amp;micro;L, and CMV-DNA was detected in aqueous humor in all cases. The infectious burden was substantial: all three patients had syphilis and hepatitis B virus infection, two had oral candidiasis, and individual patients had chlamydia infection, tuberculosis, amebic colitis, or a history of herpes zoster. One patient was initially suspected of having syphilitic uveitis, which illustrates how coinfections may obscure the diagnosis of CMV retinitis. Retinal detachment occurred in two cases and was surgically repaired with anatomical recovery. Conclusions: These cases emphasize that CMV retinitis in newly diagnosed advanced HIV infection should prompt broad infection screening and multidisciplinary evaluation, particularly in the setting of delayed HIV diagnosis and severe immunosuppression. Comprehensive screening for opportunistic and sexually transmitted infections, prompt ocular virological confirmation, and multidisciplinary management are essential in patients with HIV-associated CMV retinitis.</description>
	<pubDate>2026-06-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 66: Cytomegalovirus Retinitis in Newly Diagnosed Advanced HIV Infection: A Three-Case Series Emphasizing Multidisciplinary Infection Screening</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/66">doi: 10.3390/idr18040066</a></p>
	<p>Authors:
		Shintaro Yataka
		Kinya Tsubota
		Kei Wakatsuki
		Risa Sugawara
		Masaki Asakage
		Yoshihiko Usui
		</p>
	<p>Background/Objectives: Cytomegalovirus (CMV) retinitis remains a significant opportunistic infection in patients with advanced human immunodeficiency virus (HIV) infection, particularly with late HIV diagnoses. This three-case series aimed to describe HIV-associated CMV retinitis in newly diagnosed advanced HIV infection with documented concurrent and/or prior infectious conditions, and to highlight the importance of bord systemic screening and multidisciplinary management. Methods: We retrospectively reviewed three male patients diagnosed with HIV-associated CMV retinitis at a tertiary ophthalmology referral center. Clinical findings, CD4-positive T-cell counts, HIV-RNA levels, aqueous humor CMV-DNA results, systemic infectious conditions, treatment and ocular outcomes were summarized. Results: All patients had marked cellular immunodeficiency, with CD4-positive T-cell counts ranging from 46 to 141 cells/&amp;amp;micro;L, and CMV-DNA was detected in aqueous humor in all cases. The infectious burden was substantial: all three patients had syphilis and hepatitis B virus infection, two had oral candidiasis, and individual patients had chlamydia infection, tuberculosis, amebic colitis, or a history of herpes zoster. One patient was initially suspected of having syphilitic uveitis, which illustrates how coinfections may obscure the diagnosis of CMV retinitis. Retinal detachment occurred in two cases and was surgically repaired with anatomical recovery. Conclusions: These cases emphasize that CMV retinitis in newly diagnosed advanced HIV infection should prompt broad infection screening and multidisciplinary evaluation, particularly in the setting of delayed HIV diagnosis and severe immunosuppression. Comprehensive screening for opportunistic and sexually transmitted infections, prompt ocular virological confirmation, and multidisciplinary management are essential in patients with HIV-associated CMV retinitis.</p>
	]]></content:encoded>

	<dc:title>Cytomegalovirus Retinitis in Newly Diagnosed Advanced HIV Infection: A Three-Case Series Emphasizing Multidisciplinary Infection Screening</dc:title>
			<dc:creator>Shintaro Yataka</dc:creator>
			<dc:creator>Kinya Tsubota</dc:creator>
			<dc:creator>Kei Wakatsuki</dc:creator>
			<dc:creator>Risa Sugawara</dc:creator>
			<dc:creator>Masaki Asakage</dc:creator>
			<dc:creator>Yoshihiko Usui</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040066</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-30</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>66</prism:startingPage>
		<prism:doi>10.3390/idr18040066</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/66</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/65">

	<title>Infectious Disease Reports, Vol. 18, Pages 65: Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation</title>
	<link>https://www.mdpi.com/2036-7449/18/4/65</link>
	<description>Chagas disease, caused by Trypanosoma cruzi, remains a major public health problem in Latin America and an emerging global health concern due to population mobility. Although benznidazole and nifurtimox remain the only approved antiparasitic drugs, their limited efficacy in chronic infection, prolonged treatment regimens, frequent adverse effects, and variable activity across parasite strains highlight the need for new therapeutic strategies. In addition, the pathogenesis of chronic Chagas disease is driven not only by parasite persistence but also by immune-mediated tissue damage, particularly in chronic Chagas cardiomyopathy. In this review, we examine emerging therapeutic approaches that extend beyond conventional trypanocidal chemotherapy, with emphasis on natural products, antimicrobial peptides, and cell-based immunomodulatory strategies. Plant compounds and essential oils have shown antiparasitic activity through mechanisms including oxidative stress induction, membrane disruption, interference with sterol biosynthesis, and mitochondrial dysfunction, while some extracts also modulate host immune responses. Antimicrobial peptides display dual potential by directly damaging parasite membranes and organelles or by reshaping infection-associated inflammatory responses. In parallel, cell-based therapies such as mesenchymal stromal cells, tolerogenic dendritic cells, and bone marrow-derived cells have demonstrated promising cardioprotective and immunoregulatory effects in experimental chronic Chagas disease. Collectively, these approaches support a multitarget therapeutic framework in which parasite-directed and host-directed interventions may complement each other. Further mechanistic studies, standardization, and translational validation will be essential to advance these candidates toward clinically useful therapies for Chagas disease.</description>
	<pubDate>2026-06-30</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 65: Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/65">doi: 10.3390/idr18040065</a></p>
	<p>Authors:
		Ana María Fernández-Presas
		Katia Jarquín-Yáñez
		Adolfo Cruz-Reséndiz
		Oscar Rodríguez-Lima
		Jaime Zamora-Chimal
		Blanca Esther Blancas-Luciano
		</p>
	<p>Chagas disease, caused by Trypanosoma cruzi, remains a major public health problem in Latin America and an emerging global health concern due to population mobility. Although benznidazole and nifurtimox remain the only approved antiparasitic drugs, their limited efficacy in chronic infection, prolonged treatment regimens, frequent adverse effects, and variable activity across parasite strains highlight the need for new therapeutic strategies. In addition, the pathogenesis of chronic Chagas disease is driven not only by parasite persistence but also by immune-mediated tissue damage, particularly in chronic Chagas cardiomyopathy. In this review, we examine emerging therapeutic approaches that extend beyond conventional trypanocidal chemotherapy, with emphasis on natural products, antimicrobial peptides, and cell-based immunomodulatory strategies. Plant compounds and essential oils have shown antiparasitic activity through mechanisms including oxidative stress induction, membrane disruption, interference with sterol biosynthesis, and mitochondrial dysfunction, while some extracts also modulate host immune responses. Antimicrobial peptides display dual potential by directly damaging parasite membranes and organelles or by reshaping infection-associated inflammatory responses. In parallel, cell-based therapies such as mesenchymal stromal cells, tolerogenic dendritic cells, and bone marrow-derived cells have demonstrated promising cardioprotective and immunoregulatory effects in experimental chronic Chagas disease. Collectively, these approaches support a multitarget therapeutic framework in which parasite-directed and host-directed interventions may complement each other. Further mechanistic studies, standardization, and translational validation will be essential to advance these candidates toward clinically useful therapies for Chagas disease.</p>
	]]></content:encoded>

	<dc:title>Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation</dc:title>
			<dc:creator>Ana María Fernández-Presas</dc:creator>
			<dc:creator>Katia Jarquín-Yáñez</dc:creator>
			<dc:creator>Adolfo Cruz-Reséndiz</dc:creator>
			<dc:creator>Oscar Rodríguez-Lima</dc:creator>
			<dc:creator>Jaime Zamora-Chimal</dc:creator>
			<dc:creator>Blanca Esther Blancas-Luciano</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040065</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-30</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-30</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>65</prism:startingPage>
		<prism:doi>10.3390/idr18040065</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/65</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/64">

	<title>Infectious Disease Reports, Vol. 18, Pages 64: Multiple Brain Microabscesses and a Lung Abscess Caused by Streptococcus intermedius Following COVID-19: A Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/4/64</link>
	<description>Background: Secondary bacterial infections are increasingly recognized after coronavirus disease 2019 (COVID-19); however, bacterial abscess formation remains uncommon, and the simultaneous occurrence of brain and lung abscesses has not been previously reported. We report a rare case of Streptococcus intermedius infection presenting with multiple brain microabscesses and a lung abscess following COVID-19. Case Presentation: A 75-year-old man with no significant medical history except cholelithiasis experienced persistent fever following a diagnosis of COVID-19 and subsequently developed impaired consciousness 17 days later. Because bacterial meningitis was suspected, he was admitted to a neurology-specialized hospital on the same day. Brain MRI revealed more than 80 small enhancing lesions scattered throughout the brain parenchyma, consistent with multiple microabscesses. Chest CT demonstrated a mass-like lesion in the left lower lobe. Although cerebrospinal fluid cultures were negative, blood cultures obtained on admission yielded S. intermedius. Further investigation of the source of infection revealed moderate periodontitis, suggesting the oral cavity as the probable portal of entry. The patient was treated with intravenous antibiotics for eight weeks based on antimicrobial susceptibility testing, resulting in near-complete resolution of the lesions. Conclusions: Although a causal relationship between COVID-19 and abscess formation cannot be established, COVID-19-associated immune and mucosal barrier dysfunction may have contributed to the progression and dissemination of infection in this patient. Clinicians should be aware of the possibility of severe bacterial superinfection when fever or respiratory symptoms related to COVID-19 persist, even in patients without overt immunocompromise, particularly in those with pre-existing oral infections.</description>
	<pubDate>2026-06-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 64: Multiple Brain Microabscesses and a Lung Abscess Caused by Streptococcus intermedius Following COVID-19: A Case Report and Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/64">doi: 10.3390/idr18040064</a></p>
	<p>Authors:
		Ryoma Takeda
		Kazunori Yamada
		Takenori Abe
		Tomoyuki Ishigo
		Hirohiko Nakamura
		</p>
	<p>Background: Secondary bacterial infections are increasingly recognized after coronavirus disease 2019 (COVID-19); however, bacterial abscess formation remains uncommon, and the simultaneous occurrence of brain and lung abscesses has not been previously reported. We report a rare case of Streptococcus intermedius infection presenting with multiple brain microabscesses and a lung abscess following COVID-19. Case Presentation: A 75-year-old man with no significant medical history except cholelithiasis experienced persistent fever following a diagnosis of COVID-19 and subsequently developed impaired consciousness 17 days later. Because bacterial meningitis was suspected, he was admitted to a neurology-specialized hospital on the same day. Brain MRI revealed more than 80 small enhancing lesions scattered throughout the brain parenchyma, consistent with multiple microabscesses. Chest CT demonstrated a mass-like lesion in the left lower lobe. Although cerebrospinal fluid cultures were negative, blood cultures obtained on admission yielded S. intermedius. Further investigation of the source of infection revealed moderate periodontitis, suggesting the oral cavity as the probable portal of entry. The patient was treated with intravenous antibiotics for eight weeks based on antimicrobial susceptibility testing, resulting in near-complete resolution of the lesions. Conclusions: Although a causal relationship between COVID-19 and abscess formation cannot be established, COVID-19-associated immune and mucosal barrier dysfunction may have contributed to the progression and dissemination of infection in this patient. Clinicians should be aware of the possibility of severe bacterial superinfection when fever or respiratory symptoms related to COVID-19 persist, even in patients without overt immunocompromise, particularly in those with pre-existing oral infections.</p>
	]]></content:encoded>

	<dc:title>Multiple Brain Microabscesses and a Lung Abscess Caused by Streptococcus intermedius Following COVID-19: A Case Report and Literature Review</dc:title>
			<dc:creator>Ryoma Takeda</dc:creator>
			<dc:creator>Kazunori Yamada</dc:creator>
			<dc:creator>Takenori Abe</dc:creator>
			<dc:creator>Tomoyuki Ishigo</dc:creator>
			<dc:creator>Hirohiko Nakamura</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040064</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-24</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>64</prism:startingPage>
		<prism:doi>10.3390/idr18040064</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/64</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/4/63">

	<title>Infectious Disease Reports, Vol. 18, Pages 63: Is Virulence Gene papGII a Predictor of Urosepsis in Uropathogenic E. coli?</title>
	<link>https://www.mdpi.com/2036-7449/18/4/63</link>
	<description>Background: Urosepsis is a life-threatening condition accounting for approximately 20&amp;amp;ndash;30% of all sepsis cases and typically arises from ascending infection by uropathogenic Escherichia coli (UPEC). Disease progression is mediated by virulence factors, including adhesins, iron acquisition systems, and toxins. Among these, P fimbriae, particularly papGII adhesin subunit, have been implicated in the transition from uncomplicated urinary tract infection (UTI) to severe urosepsis. This study aimed to evaluate whether papGII carriage, alone or in combination with other UPEC virulence determinants and clinical risk factors, can predict urosepsis. Methods: A total of 60 paired Escherichia coli isolates from concurrent blood and urine samples of adults with clinical sepsis were collected between January and June 2024. Control isolates were obtained from patients with cystitis (n = 28) and pyelonephritis (n = 32). Polymerase chain reaction (PCR) assays were used to detect fifteen virulence-associated genes, including the pap operon (with papG allelic variants), the type 1 fimbriae (fimH), S fimbriae (sfaS), curli fimbriae (csgA), afa/Dr adhesin operon genes, cytotoxic necrotizing factor 1 (cnf1), and the aerobactin biosynthesis (iucD) and receptor (iutA) genes. Associations between gene carriage and clinical groups were analyzed using chi-square tests. Results: The incidence of urosepsis increased with age, peaking in the 60&amp;amp;ndash;69-year age group. Renal disease and catheterization were identified as significant risk factors (p &amp;amp;lt; 0.05). More than 95% of UPEC isolates carried the csgA gene associated with biofilm formation and the iucD gene. The &amp;amp;alpha;- hemolysin toxin (hlyA) was significantly associated with urosepsis [X2(1, N = 120) = 6.62, p = 0.03]. No significant differences were observed in the carriage of papA, papC, or fimH. Although papGII was present in 65% of urosepsis-associated UPEC isolates, it did not demonstrate a statistically significant independent association with urosepsis [p = 0.1]. Conclusion: This study demonstrates that while papGII may contribute to the pathogenic potential of UPEC and facilitate systemic infection, it is not a reliable independent predictor of urosepsis.</description>
	<pubDate>2026-06-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 63: Is Virulence Gene papGII a Predictor of Urosepsis in Uropathogenic E. coli?</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/4/63">doi: 10.3390/idr18040063</a></p>
	<p>Authors:
		Nihitta Hanna
		Suji Thangamani
		Rosemol Varghese
		Jiji Smila Arockiasamy
		Balaji Veeraraghavan
		Rani Diana Sahni
		</p>
	<p>Background: Urosepsis is a life-threatening condition accounting for approximately 20&amp;amp;ndash;30% of all sepsis cases and typically arises from ascending infection by uropathogenic Escherichia coli (UPEC). Disease progression is mediated by virulence factors, including adhesins, iron acquisition systems, and toxins. Among these, P fimbriae, particularly papGII adhesin subunit, have been implicated in the transition from uncomplicated urinary tract infection (UTI) to severe urosepsis. This study aimed to evaluate whether papGII carriage, alone or in combination with other UPEC virulence determinants and clinical risk factors, can predict urosepsis. Methods: A total of 60 paired Escherichia coli isolates from concurrent blood and urine samples of adults with clinical sepsis were collected between January and June 2024. Control isolates were obtained from patients with cystitis (n = 28) and pyelonephritis (n = 32). Polymerase chain reaction (PCR) assays were used to detect fifteen virulence-associated genes, including the pap operon (with papG allelic variants), the type 1 fimbriae (fimH), S fimbriae (sfaS), curli fimbriae (csgA), afa/Dr adhesin operon genes, cytotoxic necrotizing factor 1 (cnf1), and the aerobactin biosynthesis (iucD) and receptor (iutA) genes. Associations between gene carriage and clinical groups were analyzed using chi-square tests. Results: The incidence of urosepsis increased with age, peaking in the 60&amp;amp;ndash;69-year age group. Renal disease and catheterization were identified as significant risk factors (p &amp;amp;lt; 0.05). More than 95% of UPEC isolates carried the csgA gene associated with biofilm formation and the iucD gene. The &amp;amp;alpha;- hemolysin toxin (hlyA) was significantly associated with urosepsis [X2(1, N = 120) = 6.62, p = 0.03]. No significant differences were observed in the carriage of papA, papC, or fimH. Although papGII was present in 65% of urosepsis-associated UPEC isolates, it did not demonstrate a statistically significant independent association with urosepsis [p = 0.1]. Conclusion: This study demonstrates that while papGII may contribute to the pathogenic potential of UPEC and facilitate systemic infection, it is not a reliable independent predictor of urosepsis.</p>
	]]></content:encoded>

	<dc:title>Is Virulence Gene papGII a Predictor of Urosepsis in Uropathogenic E. coli?</dc:title>
			<dc:creator>Nihitta Hanna</dc:creator>
			<dc:creator>Suji Thangamani</dc:creator>
			<dc:creator>Rosemol Varghese</dc:creator>
			<dc:creator>Jiji Smila Arockiasamy</dc:creator>
			<dc:creator>Balaji Veeraraghavan</dc:creator>
			<dc:creator>Rani Diana Sahni</dc:creator>
		<dc:identifier>doi: 10.3390/idr18040063</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-24</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>63</prism:startingPage>
		<prism:doi>10.3390/idr18040063</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/4/63</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/62">

	<title>Infectious Disease Reports, Vol. 18, Pages 62: Cardiovascular Complications of Anaplasmosis: A Case of Acute Pulmonary Embolism and Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/3/62</link>
	<description>Background: Anaplasmosis is an emerging tick-borne infection that typically presents as a non-specific febrile illness, with variable degrees of cytopenias and liver tests abnormalities. Severe complications remain atypical and uncommon. Case Report: We report a case of acute pulmonary embolism (PE) occurring during confirmed anaplasmosis in a 73-year-old male with no traditional thromboembolic risk factors. The patient presented with fever, constitutional symptoms, thrombocytopenia, leukopenia, and abnormal liver tests, raising suspicion for a tick-borne illness. Despite early clinical improvement on doxycycline, persistent tachycardia triggered further evaluation and uncovered an acute PE. Comprehensive workup at admission and repeated 14 months later excluded inherited and acquired thrombophilias, malignancies, autoimmune diseases, and alternative infectious etiologies. The patient was treated with doxycycline 100 mg orally twice daily for 10 days and anticoagulation with unfractionated heparin followed by 6 months of apixaban for a first episode of provoked PE. He attained complete clinical recovery without recurrence of thrombosis at the two-year follow-up. Discussion: Infectious diseases are increasingly recognized as contributors to thrombosis through inflammation-mediated hypercoagulability and endothelial dysfunction. Pulmonary involvement in anaplasmosis typically manifests as pneumonitis, pneumonia or acute respiratory distress syndrome, but thrombotic complications such as PE are exceedingly rare. This case highlights a rare but clinically significant vascular complication of anaplasmosis and underscores the importance of considering thromboembolic events in patients with persistent or unexplained tachycardia. Conclusions: As the incidence of anaplasmosis continues to rise, greater awareness of its potential cardiovascular manifestations is essential. Early recognition and prompt treatment with doxycycline remain critical, while further studies are needed to better define the thrombotic risk associated with this infection.</description>
	<pubDate>2026-06-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 62: Cardiovascular Complications of Anaplasmosis: A Case of Acute Pulmonary Embolism and Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/62">doi: 10.3390/idr18030062</a></p>
	<p>Authors:
		Aleksandar Gavrancic
		Christian M. Jacobson
		Veljko Rabasovic
		Erik Sviggum
		Jelena Stojsavljevic
		Nestor G. Tarragona
		Peter J. Mattingly
		Igor Dumic
		</p>
	<p>Background: Anaplasmosis is an emerging tick-borne infection that typically presents as a non-specific febrile illness, with variable degrees of cytopenias and liver tests abnormalities. Severe complications remain atypical and uncommon. Case Report: We report a case of acute pulmonary embolism (PE) occurring during confirmed anaplasmosis in a 73-year-old male with no traditional thromboembolic risk factors. The patient presented with fever, constitutional symptoms, thrombocytopenia, leukopenia, and abnormal liver tests, raising suspicion for a tick-borne illness. Despite early clinical improvement on doxycycline, persistent tachycardia triggered further evaluation and uncovered an acute PE. Comprehensive workup at admission and repeated 14 months later excluded inherited and acquired thrombophilias, malignancies, autoimmune diseases, and alternative infectious etiologies. The patient was treated with doxycycline 100 mg orally twice daily for 10 days and anticoagulation with unfractionated heparin followed by 6 months of apixaban for a first episode of provoked PE. He attained complete clinical recovery without recurrence of thrombosis at the two-year follow-up. Discussion: Infectious diseases are increasingly recognized as contributors to thrombosis through inflammation-mediated hypercoagulability and endothelial dysfunction. Pulmonary involvement in anaplasmosis typically manifests as pneumonitis, pneumonia or acute respiratory distress syndrome, but thrombotic complications such as PE are exceedingly rare. This case highlights a rare but clinically significant vascular complication of anaplasmosis and underscores the importance of considering thromboembolic events in patients with persistent or unexplained tachycardia. Conclusions: As the incidence of anaplasmosis continues to rise, greater awareness of its potential cardiovascular manifestations is essential. Early recognition and prompt treatment with doxycycline remain critical, while further studies are needed to better define the thrombotic risk associated with this infection.</p>
	]]></content:encoded>

	<dc:title>Cardiovascular Complications of Anaplasmosis: A Case of Acute Pulmonary Embolism and Literature Review</dc:title>
			<dc:creator>Aleksandar Gavrancic</dc:creator>
			<dc:creator>Christian M. Jacobson</dc:creator>
			<dc:creator>Veljko Rabasovic</dc:creator>
			<dc:creator>Erik Sviggum</dc:creator>
			<dc:creator>Jelena Stojsavljevic</dc:creator>
			<dc:creator>Nestor G. Tarragona</dc:creator>
			<dc:creator>Peter J. Mattingly</dc:creator>
			<dc:creator>Igor Dumic</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030062</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-20</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-20</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>62</prism:startingPage>
		<prism:doi>10.3390/idr18030062</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/62</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/61">

	<title>Infectious Disease Reports, Vol. 18, Pages 61: Game Over for the Baseline: Influenza Hospitalization Patterns Before, During, and After the COVID-19 Pandemic (FluSurv-NET, 2009&amp;ndash;2025)</title>
	<link>https://www.mdpi.com/2036-7449/18/3/61</link>
	<description>Background/Objectives: The trajectory of influenza hospitalization burden from pre-COVID-19 pandemic baseline through post-pandemic recovery remains poorly characterized at the national level. This study characterized phase-stratified burden and seasonal structure, quantified racial and ethnic disparities, and assessed whether post-pandemic seasons represent anomalous departures from pre-pandemic expectations. Methods: Sixteen complete seasons of FluSurv-NET surveillance data (2009&amp;amp;ndash;2010 through 2024&amp;amp;ndash;2025; 509 observation weeks) were analyzed across pre-pandemic, disruption, and recovery phases using OLS regression with effect-size estimation, bootstrapped age-adjusted rate ratios, seasonal-trend decomposition (STL), Prophet time-series forecasting, and Isolation Forest anomaly detection. Results: Mean peak weekly hospitalization rate nearly doubled from pre-pandemic to recovery (5.1 to 11.1 per 100,000), cumulative seasonal burden increased from 46.3 to 87.0 per 100,000, and median peak timing advanced from MMWR week 9 to week 50. STL decomposition revealed a marked shift from weak pre-pandemic seasonality (Fs = 0.14) to substantially stronger annual regularity (Fs = 0.98) across three recovery seasons, with threefold amplitude increase. Non-Hispanic Black persons had rate ratios of 1.72, 2.16, and 1.99 relative to White persons across phases; American Indian and Alaska Native persons showed the highest disruption-phase ratio (2.24, 95% CI 1.90&amp;amp;ndash;3.53), based on two contributing seasons. A flat-growth Prophet model detected first exceedance in February 2020, outperforming a linear-growth specification on held-out validation. Isolation Forest identified 2017&amp;amp;ndash;2018, 2023&amp;amp;ndash;2024, and 2024&amp;amp;ndash;2025 as robust anomalies across all contamination thresholds. Conclusions: Post-COVID-19 pandemic influenza recovery is characterized by intensified and restructured seasonality, persistent racial and ethnic disparities, and anomalous burden exceeding pre-pandemic projections, identified independently by time-series forecasting and unsupervised anomaly detection.</description>
	<pubDate>2026-06-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 61: Game Over for the Baseline: Influenza Hospitalization Patterns Before, During, and After the COVID-19 Pandemic (FluSurv-NET, 2009&amp;ndash;2025)</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/61">doi: 10.3390/idr18030061</a></p>
	<p>Authors:
		Hayden D. Hedman
		</p>
	<p>Background/Objectives: The trajectory of influenza hospitalization burden from pre-COVID-19 pandemic baseline through post-pandemic recovery remains poorly characterized at the national level. This study characterized phase-stratified burden and seasonal structure, quantified racial and ethnic disparities, and assessed whether post-pandemic seasons represent anomalous departures from pre-pandemic expectations. Methods: Sixteen complete seasons of FluSurv-NET surveillance data (2009&amp;amp;ndash;2010 through 2024&amp;amp;ndash;2025; 509 observation weeks) were analyzed across pre-pandemic, disruption, and recovery phases using OLS regression with effect-size estimation, bootstrapped age-adjusted rate ratios, seasonal-trend decomposition (STL), Prophet time-series forecasting, and Isolation Forest anomaly detection. Results: Mean peak weekly hospitalization rate nearly doubled from pre-pandemic to recovery (5.1 to 11.1 per 100,000), cumulative seasonal burden increased from 46.3 to 87.0 per 100,000, and median peak timing advanced from MMWR week 9 to week 50. STL decomposition revealed a marked shift from weak pre-pandemic seasonality (Fs = 0.14) to substantially stronger annual regularity (Fs = 0.98) across three recovery seasons, with threefold amplitude increase. Non-Hispanic Black persons had rate ratios of 1.72, 2.16, and 1.99 relative to White persons across phases; American Indian and Alaska Native persons showed the highest disruption-phase ratio (2.24, 95% CI 1.90&amp;amp;ndash;3.53), based on two contributing seasons. A flat-growth Prophet model detected first exceedance in February 2020, outperforming a linear-growth specification on held-out validation. Isolation Forest identified 2017&amp;amp;ndash;2018, 2023&amp;amp;ndash;2024, and 2024&amp;amp;ndash;2025 as robust anomalies across all contamination thresholds. Conclusions: Post-COVID-19 pandemic influenza recovery is characterized by intensified and restructured seasonality, persistent racial and ethnic disparities, and anomalous burden exceeding pre-pandemic projections, identified independently by time-series forecasting and unsupervised anomaly detection.</p>
	]]></content:encoded>

	<dc:title>Game Over for the Baseline: Influenza Hospitalization Patterns Before, During, and After the COVID-19 Pandemic (FluSurv-NET, 2009&amp;amp;ndash;2025)</dc:title>
			<dc:creator>Hayden D. Hedman</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030061</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-19</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-19</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>61</prism:startingPage>
		<prism:doi>10.3390/idr18030061</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/61</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/60">

	<title>Infectious Disease Reports, Vol. 18, Pages 60: Five Hot Topics in Tropical Medicine: 2025</title>
	<link>https://www.mdpi.com/2036-7449/18/3/60</link>
	<description>In 2025, tropical medicine was shaped by advances in diagnostic technology, expanding arboviral epidemics, rapid progress in filovirus vaccine development, evolving regulatory responses to newly licensed vaccines, and translational breakthroughs addressing neglected tropical diseases. This review discusses five select developments that significantly influenced clinical practice and global health policy over the past year, highlighting the implications of each for clinicians, researchers, and public health systems.</description>
	<pubDate>2026-06-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 60: Five Hot Topics in Tropical Medicine: 2025</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/60">doi: 10.3390/idr18030060</a></p>
	<p>Authors:
		Amanda Hempel
		Gregory D. Hawley
		Jahmar Hewitt
		Maxime Billick
		Adrienne J. Showler
		Kevin C. Kain
		Andrea K. Boggild
		</p>
	<p>In 2025, tropical medicine was shaped by advances in diagnostic technology, expanding arboviral epidemics, rapid progress in filovirus vaccine development, evolving regulatory responses to newly licensed vaccines, and translational breakthroughs addressing neglected tropical diseases. This review discusses five select developments that significantly influenced clinical practice and global health policy over the past year, highlighting the implications of each for clinicians, researchers, and public health systems.</p>
	]]></content:encoded>

	<dc:title>Five Hot Topics in Tropical Medicine: 2025</dc:title>
			<dc:creator>Amanda Hempel</dc:creator>
			<dc:creator>Gregory D. Hawley</dc:creator>
			<dc:creator>Jahmar Hewitt</dc:creator>
			<dc:creator>Maxime Billick</dc:creator>
			<dc:creator>Adrienne J. Showler</dc:creator>
			<dc:creator>Kevin C. Kain</dc:creator>
			<dc:creator>Andrea K. Boggild</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030060</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-19</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-19</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>60</prism:startingPage>
		<prism:doi>10.3390/idr18030060</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/60</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/59">

	<title>Infectious Disease Reports, Vol. 18, Pages 59: Ecotourism and the Hidden Ecology of Infection: The Andes Virus Cruise Outbreak</title>
	<link>https://www.mdpi.com/2036-7449/18/3/59</link>
	<description>Over the past decade, outdoor recreational activities&amp;amp;mdash;including ecotourism, wildlife observation, adventure travel, and expedition cruising&amp;amp;mdash;have expanded at an unprecedented pace [...]</description>
	<pubDate>2026-06-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 59: Ecotourism and the Hidden Ecology of Infection: The Andes Virus Cruise Outbreak</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/59">doi: 10.3390/idr18030059</a></p>
	<p>Authors:
		Laura Scorzolini
		Alessandra D’Abramo
		Enrico Girardi
		Emanuele Nicastri
		</p>
	<p>Over the past decade, outdoor recreational activities&amp;amp;mdash;including ecotourism, wildlife observation, adventure travel, and expedition cruising&amp;amp;mdash;have expanded at an unprecedented pace [...]</p>
	]]></content:encoded>

	<dc:title>Ecotourism and the Hidden Ecology of Infection: The Andes Virus Cruise Outbreak</dc:title>
			<dc:creator>Laura Scorzolini</dc:creator>
			<dc:creator>Alessandra D’Abramo</dc:creator>
			<dc:creator>Enrico Girardi</dc:creator>
			<dc:creator>Emanuele Nicastri</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030059</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-16</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-16</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>59</prism:startingPage>
		<prism:doi>10.3390/idr18030059</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/59</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/58">

	<title>Infectious Disease Reports, Vol. 18, Pages 58: Concurrent Central and Autonomic Nervous System Involvement in Varicella-Zoster Virus Infection in an Immunocompetent Patient: A Case-Based Mechanistic Analysis</title>
	<link>https://www.mdpi.com/2036-7449/18/3/58</link>
	<description>Background: Varicella-zoster virus (VZV) is a neurotropic alphaherpesvirus capable of causing a broad spectrum of neurologic complications beyond classic dermatomal herpes zoster. Although meningitis and encephalitis are well recognized manifestations of neuroinvasive VZV infection, associated autonomic dysfunction remains comparatively underreported, particularly in immunocompetent individuals. Case Presentation: We describe a 66-year-old immunocompetent man who developed VZV meningoencephalitis associated with sacral dermatomal herpes zoster, urinary retention, and bowel dysmotility. Initial symptoms included fever, severe headache, photophobia, and low back pain, with delayed recognition of the characteristic sacral vesicular eruption. The patient subsequently developed encephalopathy and meningeal signs requiring intensive care unit admission. Cerebrospinal fluid analysis demonstrated lymphocytic pleocytosis and markedly elevated protein concentration, and VZV DNA was detected by polymerase chain reaction testing. During hospitalization, the patient developed severe urinary retention and gastrointestinal dysmotility without evidence of mechanical obstruction, raising concern for concurrent autonomic nervous system involvement. Following intravenous acyclovir therapy and supportive management, the patient experienced gradual neurologic and autonomic recovery. Conclusions: This case highlights the potential for multifocal neuroinvasive VZV disease involving both central and autonomic nervous system structures in immunocompetent hosts. Clinicians should maintain awareness that urinary retention and bowel dysmotility may represent clinically significant autonomic manifestations of VZV reactivation, particularly in the setting of sacral dermatomal involvement.</description>
	<pubDate>2026-06-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 58: Concurrent Central and Autonomic Nervous System Involvement in Varicella-Zoster Virus Infection in an Immunocompetent Patient: A Case-Based Mechanistic Analysis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/58">doi: 10.3390/idr18030058</a></p>
	<p>Authors:
		Jordan Pyatt
		Carlos A. Umaña Mejía
		Justice Cruz
		Fernando Baires
		Helen Hoffman
		Joanne Cordero Guerra
		Miguel Sierra-Hoffman
		Heike Hesse
		Amy C. Madril
		</p>
	<p>Background: Varicella-zoster virus (VZV) is a neurotropic alphaherpesvirus capable of causing a broad spectrum of neurologic complications beyond classic dermatomal herpes zoster. Although meningitis and encephalitis are well recognized manifestations of neuroinvasive VZV infection, associated autonomic dysfunction remains comparatively underreported, particularly in immunocompetent individuals. Case Presentation: We describe a 66-year-old immunocompetent man who developed VZV meningoencephalitis associated with sacral dermatomal herpes zoster, urinary retention, and bowel dysmotility. Initial symptoms included fever, severe headache, photophobia, and low back pain, with delayed recognition of the characteristic sacral vesicular eruption. The patient subsequently developed encephalopathy and meningeal signs requiring intensive care unit admission. Cerebrospinal fluid analysis demonstrated lymphocytic pleocytosis and markedly elevated protein concentration, and VZV DNA was detected by polymerase chain reaction testing. During hospitalization, the patient developed severe urinary retention and gastrointestinal dysmotility without evidence of mechanical obstruction, raising concern for concurrent autonomic nervous system involvement. Following intravenous acyclovir therapy and supportive management, the patient experienced gradual neurologic and autonomic recovery. Conclusions: This case highlights the potential for multifocal neuroinvasive VZV disease involving both central and autonomic nervous system structures in immunocompetent hosts. Clinicians should maintain awareness that urinary retention and bowel dysmotility may represent clinically significant autonomic manifestations of VZV reactivation, particularly in the setting of sacral dermatomal involvement.</p>
	]]></content:encoded>

	<dc:title>Concurrent Central and Autonomic Nervous System Involvement in Varicella-Zoster Virus Infection in an Immunocompetent Patient: A Case-Based Mechanistic Analysis</dc:title>
			<dc:creator>Jordan Pyatt</dc:creator>
			<dc:creator>Carlos A. Umaña Mejía</dc:creator>
			<dc:creator>Justice Cruz</dc:creator>
			<dc:creator>Fernando Baires</dc:creator>
			<dc:creator>Helen Hoffman</dc:creator>
			<dc:creator>Joanne Cordero Guerra</dc:creator>
			<dc:creator>Miguel Sierra-Hoffman</dc:creator>
			<dc:creator>Heike Hesse</dc:creator>
			<dc:creator>Amy C. Madril</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030058</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-15</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-15</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>58</prism:startingPage>
		<prism:doi>10.3390/idr18030058</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/58</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/57">

	<title>Infectious Disease Reports, Vol. 18, Pages 57: Climate Change and Emerging Arboviral Threats in Saudi Arabia: Epidemiology, Vector Ecology, and One Health Preparedness</title>
	<link>https://www.mdpi.com/2036-7449/18/3/57</link>
	<description>Arboviral diseases are emerging as important public health threats in Saudi Arabia, driven by rapid urbanization, climate variability, the expansion of Aedes aegypti populations, international travel, and large-scale religious mass gatherings. Dengue virus remains the most established arboviral infection in the Kingdom, particularly in the southwestern regions such as Jazan and the western urban centers of Makkah and Jeddah, where ecological and climatic conditions are conducive to sustained vector survival and transmission. This review synthesizes current evidence on the epidemiology, vector ecology, climatic determinants, diagnostics, and prevention strategies of arboviral diseases in Saudi Arabia. Particular attention is paid to the impacts of rising temperatures, changes in rainfall patterns, urban heat island effects, population mobility, and cross-border movement on vector expansion and disease emergence. The review also identifies gaps in surveillance, diagnostics, insecticide resistance monitoring, and integrated vector management programs. Emerging preparedness strategies include climate-informed early warning systems, Geographic Information System-based risk mapping, multiplex molecular diagnostics, genomic surveillance, and community-based vector control. The review emphasizes the importance of implementing a One Health approach that combines data on humans, the environment, entomology, and climate. Currently, sustained endemic transmission of chikungunya and Zika viruses has not been conclusively demonstrated in Saudi Arabia, but increased environmental suitability and connectivity with other areas highlight the need for proactive surveillance and preparedness.</description>
	<pubDate>2026-06-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 57: Climate Change and Emerging Arboviral Threats in Saudi Arabia: Epidemiology, Vector Ecology, and One Health Preparedness</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/57">doi: 10.3390/idr18030057</a></p>
	<p>Authors:
		Shuaibu Abdullahi Hudu
		Emad A. Morad
		Ghusun M. Alhazimi
		Abdulgafar Olayiwola Jimoh
		</p>
	<p>Arboviral diseases are emerging as important public health threats in Saudi Arabia, driven by rapid urbanization, climate variability, the expansion of Aedes aegypti populations, international travel, and large-scale religious mass gatherings. Dengue virus remains the most established arboviral infection in the Kingdom, particularly in the southwestern regions such as Jazan and the western urban centers of Makkah and Jeddah, where ecological and climatic conditions are conducive to sustained vector survival and transmission. This review synthesizes current evidence on the epidemiology, vector ecology, climatic determinants, diagnostics, and prevention strategies of arboviral diseases in Saudi Arabia. Particular attention is paid to the impacts of rising temperatures, changes in rainfall patterns, urban heat island effects, population mobility, and cross-border movement on vector expansion and disease emergence. The review also identifies gaps in surveillance, diagnostics, insecticide resistance monitoring, and integrated vector management programs. Emerging preparedness strategies include climate-informed early warning systems, Geographic Information System-based risk mapping, multiplex molecular diagnostics, genomic surveillance, and community-based vector control. The review emphasizes the importance of implementing a One Health approach that combines data on humans, the environment, entomology, and climate. Currently, sustained endemic transmission of chikungunya and Zika viruses has not been conclusively demonstrated in Saudi Arabia, but increased environmental suitability and connectivity with other areas highlight the need for proactive surveillance and preparedness.</p>
	]]></content:encoded>

	<dc:title>Climate Change and Emerging Arboviral Threats in Saudi Arabia: Epidemiology, Vector Ecology, and One Health Preparedness</dc:title>
			<dc:creator>Shuaibu Abdullahi Hudu</dc:creator>
			<dc:creator>Emad A. Morad</dc:creator>
			<dc:creator>Ghusun M. Alhazimi</dc:creator>
			<dc:creator>Abdulgafar Olayiwola Jimoh</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030057</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>57</prism:startingPage>
		<prism:doi>10.3390/idr18030057</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/57</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/56">

	<title>Infectious Disease Reports, Vol. 18, Pages 56: Correlation of Age and Laboratory Parameters with Urine Flow Cytometry and Culture Results in Patients with Urinary Tract Infections</title>
	<link>https://www.mdpi.com/2036-7449/18/3/56</link>
	<description>Background: The diagnosis of urinary tract infection (UTI) remains a clinical challenge, with urine culture as the gold standard. In developing countries like Bosnia and Herzegovina, a high prevalence of antimicrobial resistance and frequent empirical treatment pose significant clinical challenges. Automated urine flow cytometry has emerged as a rapid tool to optimize diagnostic processes. Objectives: To determine the correlation of age, gender, and laboratory parameters&amp;amp;mdash;such as white blood cell (WBC) count, neutrophil count, and C-reactive protein (CRP)&amp;amp;mdash;with both urinary bacterial counts and urine culture results. Methods: This retrospective study analyzed 200 adult patients (&amp;amp;ge;18 years) with symptoms suggestive of UTI at the University Clinical Center Tuzla. Data on age, gender, WBC, neutrophils, CRP, and urine flow cytometry (Sysmex UF-4000) were collected. Statistical analysis was performed using R software (version 4.5.1), utilizing logistic regression models via the &amp;amp;lsquo;glm&amp;amp;rsquo; function to identify independent predictors, with statistical significance set at p &amp;amp;lt; 0.05. Results: The mean age of the population was 68.61 &amp;amp;plusmn; 15.19 years. Logistic regression demonstrated that WBC count (OR = 1.06, p = 0.004), neutrophil count (OR = 1.04, p = 0.014), and patient age (OR = 1.03, p = 0.001) were significant independent predictors of UTI. Furthermore, patients with a urinary bacterial count &amp;amp;gt; 1200/&amp;amp;mu;L had 83 times higher odds of a positive urine culture (OR = 83, 95% CI 32.25&amp;amp;ndash;200, p &amp;amp;lt; 0.001). Conversely, CRP levels and gender were not significant predictors (p &amp;amp;gt; 0.05). Conclusions: Patient age, WBC, and neutrophil counts are key factors for predicting UTIs. Integrating these parameters with urine flow cytometry bacterial counts can significantly enhance diagnostic accuracy and rapid screening in clinical practice.</description>
	<pubDate>2026-06-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 56: Correlation of Age and Laboratory Parameters with Urine Flow Cytometry and Culture Results in Patients with Urinary Tract Infections</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/56">doi: 10.3390/idr18030056</a></p>
	<p>Authors:
		Alma Trnacevic
		Emir Trnacevic
		Merjema Mahmutovic
		Amra Serak
		Humera Porobic Jahic
		Jasminka Petrovic
		Dilista Piljic
		Rahima Jahic
		Danijel Bijedic
		Amela Becirovic
		</p>
	<p>Background: The diagnosis of urinary tract infection (UTI) remains a clinical challenge, with urine culture as the gold standard. In developing countries like Bosnia and Herzegovina, a high prevalence of antimicrobial resistance and frequent empirical treatment pose significant clinical challenges. Automated urine flow cytometry has emerged as a rapid tool to optimize diagnostic processes. Objectives: To determine the correlation of age, gender, and laboratory parameters&amp;amp;mdash;such as white blood cell (WBC) count, neutrophil count, and C-reactive protein (CRP)&amp;amp;mdash;with both urinary bacterial counts and urine culture results. Methods: This retrospective study analyzed 200 adult patients (&amp;amp;ge;18 years) with symptoms suggestive of UTI at the University Clinical Center Tuzla. Data on age, gender, WBC, neutrophils, CRP, and urine flow cytometry (Sysmex UF-4000) were collected. Statistical analysis was performed using R software (version 4.5.1), utilizing logistic regression models via the &amp;amp;lsquo;glm&amp;amp;rsquo; function to identify independent predictors, with statistical significance set at p &amp;amp;lt; 0.05. Results: The mean age of the population was 68.61 &amp;amp;plusmn; 15.19 years. Logistic regression demonstrated that WBC count (OR = 1.06, p = 0.004), neutrophil count (OR = 1.04, p = 0.014), and patient age (OR = 1.03, p = 0.001) were significant independent predictors of UTI. Furthermore, patients with a urinary bacterial count &amp;amp;gt; 1200/&amp;amp;mu;L had 83 times higher odds of a positive urine culture (OR = 83, 95% CI 32.25&amp;amp;ndash;200, p &amp;amp;lt; 0.001). Conversely, CRP levels and gender were not significant predictors (p &amp;amp;gt; 0.05). Conclusions: Patient age, WBC, and neutrophil counts are key factors for predicting UTIs. Integrating these parameters with urine flow cytometry bacterial counts can significantly enhance diagnostic accuracy and rapid screening in clinical practice.</p>
	]]></content:encoded>

	<dc:title>Correlation of Age and Laboratory Parameters with Urine Flow Cytometry and Culture Results in Patients with Urinary Tract Infections</dc:title>
			<dc:creator>Alma Trnacevic</dc:creator>
			<dc:creator>Emir Trnacevic</dc:creator>
			<dc:creator>Merjema Mahmutovic</dc:creator>
			<dc:creator>Amra Serak</dc:creator>
			<dc:creator>Humera Porobic Jahic</dc:creator>
			<dc:creator>Jasminka Petrovic</dc:creator>
			<dc:creator>Dilista Piljic</dc:creator>
			<dc:creator>Rahima Jahic</dc:creator>
			<dc:creator>Danijel Bijedic</dc:creator>
			<dc:creator>Amela Becirovic</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030056</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>56</prism:startingPage>
		<prism:doi>10.3390/idr18030056</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/56</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/55">

	<title>Infectious Disease Reports, Vol. 18, Pages 55: Climate Variability Drives Dengue Transmission in Bangladesh</title>
	<link>https://www.mdpi.com/2036-7449/18/3/55</link>
	<description>Background: Dengue fever has emerged as a major public health concern in Bangladesh, with increasing incidence and geographic spread of outbreaks in recent years. This study aimed to investigate the lagged and non-linear associations between climatic factors and dengue incidence across all eight administrative divisions of Bangladesh from 2014 to 2025. Materials and Methods: An ecological time-series design was employed using monthly dengue case data (n = 741,338) and meteorological variables. A generalized additive model (GAM) with a negative binomial distribution was applied to account for overdispersion and capture complex relationships. Descriptive analysis was conducted to assess spatial heterogeneity, and choropleth maps were constructed to visualize the spatial distribution and regional variation in dengue burden across the country. Cross-correlation analysis was performed to identify significant lagged associations between climatic variables and dengue incidence. Results: Descriptive analysis showed substantial spatial heterogeneity, with the highest incidence observed in Dhaka (6.53 per 100,000) and the lowest in Sylhet (0.21 per 100,000). Choropleth maps illustrated distinct spatial distribution and regional variation in dengue burden across the country. Cross-correlation analysis identified significant lagged associations for temperature and rainfall (lag 1&amp;amp;ndash;3 months), humidity (lag 1&amp;amp;ndash;2 months), and wind speed (lag 2&amp;amp;ndash;3 months). The final GAM explained 88.6% of the deviance in dengue incidence (AIC = 7404.15; dispersion = 0.767). The approximate significance of smooth terms revealed that temperature at a lag of 1 month (p &amp;amp;lt; 0.001, edf = 12.28), rainfall at a lag of 3 months (p &amp;amp;lt; 0.001, edf = 2.85), and wind speed at a lag of 2 months (p &amp;amp;lt; 0.001, edf = 2.25) were highly significant non-linear predictors of dengue transmission. Relative humidity was not significantly associated with dengue incidence. Non-linear effects revealed peak dengue risk at temperatures between 25 and 30 &amp;amp;deg;C and moderate rainfall (~10 mm), particularly during monsoon months (June&amp;amp;ndash;October). A strong autoregressive effect indicated that prior dengue incidence significantly influenced current transmission. Conclusions: Overall, dengue transmission in Bangladesh is driven by complex, lagged, and non-linear interactions between climatic variables, seasonality, and regional factors. These findings provide critical evidence for climate-based early warning systems, enhance outbreak prediction, and inform evidence-based vector control strategies.</description>
	<pubDate>2026-06-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 55: Climate Variability Drives Dengue Transmission in Bangladesh</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/55">doi: 10.3390/idr18030055</a></p>
	<p>Authors:
		Ayesha Siddiqa
		Prosenjit Choudhury
		Nabil Jahan Mahim
		Suman Paul
		Syed Sayeem Uddin Ahmed
		Md Bashir Uddin
		</p>
	<p>Background: Dengue fever has emerged as a major public health concern in Bangladesh, with increasing incidence and geographic spread of outbreaks in recent years. This study aimed to investigate the lagged and non-linear associations between climatic factors and dengue incidence across all eight administrative divisions of Bangladesh from 2014 to 2025. Materials and Methods: An ecological time-series design was employed using monthly dengue case data (n = 741,338) and meteorological variables. A generalized additive model (GAM) with a negative binomial distribution was applied to account for overdispersion and capture complex relationships. Descriptive analysis was conducted to assess spatial heterogeneity, and choropleth maps were constructed to visualize the spatial distribution and regional variation in dengue burden across the country. Cross-correlation analysis was performed to identify significant lagged associations between climatic variables and dengue incidence. Results: Descriptive analysis showed substantial spatial heterogeneity, with the highest incidence observed in Dhaka (6.53 per 100,000) and the lowest in Sylhet (0.21 per 100,000). Choropleth maps illustrated distinct spatial distribution and regional variation in dengue burden across the country. Cross-correlation analysis identified significant lagged associations for temperature and rainfall (lag 1&amp;amp;ndash;3 months), humidity (lag 1&amp;amp;ndash;2 months), and wind speed (lag 2&amp;amp;ndash;3 months). The final GAM explained 88.6% of the deviance in dengue incidence (AIC = 7404.15; dispersion = 0.767). The approximate significance of smooth terms revealed that temperature at a lag of 1 month (p &amp;amp;lt; 0.001, edf = 12.28), rainfall at a lag of 3 months (p &amp;amp;lt; 0.001, edf = 2.85), and wind speed at a lag of 2 months (p &amp;amp;lt; 0.001, edf = 2.25) were highly significant non-linear predictors of dengue transmission. Relative humidity was not significantly associated with dengue incidence. Non-linear effects revealed peak dengue risk at temperatures between 25 and 30 &amp;amp;deg;C and moderate rainfall (~10 mm), particularly during monsoon months (June&amp;amp;ndash;October). A strong autoregressive effect indicated that prior dengue incidence significantly influenced current transmission. Conclusions: Overall, dengue transmission in Bangladesh is driven by complex, lagged, and non-linear interactions between climatic variables, seasonality, and regional factors. These findings provide critical evidence for climate-based early warning systems, enhance outbreak prediction, and inform evidence-based vector control strategies.</p>
	]]></content:encoded>

	<dc:title>Climate Variability Drives Dengue Transmission in Bangladesh</dc:title>
			<dc:creator>Ayesha Siddiqa</dc:creator>
			<dc:creator>Prosenjit Choudhury</dc:creator>
			<dc:creator>Nabil Jahan Mahim</dc:creator>
			<dc:creator>Suman Paul</dc:creator>
			<dc:creator>Syed Sayeem Uddin Ahmed</dc:creator>
			<dc:creator>Md Bashir Uddin</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030055</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>55</prism:startingPage>
		<prism:doi>10.3390/idr18030055</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/55</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/54">

	<title>Infectious Disease Reports, Vol. 18, Pages 54: Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam&amp;ndash;Durlobactam in a Preterm Neonate: A Case Report</title>
	<link>https://www.mdpi.com/2036-7449/18/3/54</link>
	<description>Background: Ventilator-associated pneumonia (VAP) is a leading cause of nosocomial infections in neonatal intensive care units (NICUs) and is associated with significant morbidity, mortality, and prolonged hospitalization, particularly in preterm neonates. Management is complicated by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, with very limited evidence supporting the use of reserve antibiotics in this population. Case Presentation: We report a male neonate born at 25 weeks of gestation (birth weight 740 g) who developed severe VAP caused by XDR Acinetobacter calcoaceticus-baumannii complex and Pseudomonas aeruginosa. After failure of multiple antibiotic regimens, including ampicillin, amikacin, meropenem, vancomycin, cefepime with inhaled colistin, tigecycline, and ceftazidime-avibactam combined with fosfomycin, the infant was treated with sulbactam&amp;amp;ndash;durlobactam (25 mg/kg/dose every 6 h) in combination with ceftazidime-avibactam. After 12 days of this regimen, the neonate was successfully extubated. Conclusions: This case highlights the therapeutic challenges of XDR infections in extremely preterm neonates and suggests that sulbactam&amp;amp;ndash;durlobactam may represent a viable salvage treatment option. Further pharmacokinetic and clinical studies are needed to establish optimal dosing and safety in the neonatal population.</description>
	<pubDate>2026-06-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 54: Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam&amp;ndash;Durlobactam in a Preterm Neonate: A Case Report</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/54">doi: 10.3390/idr18030054</a></p>
	<p>Authors:
		Suzana Zivojinovic
		Tijana Prodanovic
		Nikola Prodanovic
		Rasa Medovic
		Milica Cekerevac
		Dragana Savic
		Bojana Markovic
		Slobodan Jankovic
		</p>
	<p>Background: Ventilator-associated pneumonia (VAP) is a leading cause of nosocomial infections in neonatal intensive care units (NICUs) and is associated with significant morbidity, mortality, and prolonged hospitalization, particularly in preterm neonates. Management is complicated by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, with very limited evidence supporting the use of reserve antibiotics in this population. Case Presentation: We report a male neonate born at 25 weeks of gestation (birth weight 740 g) who developed severe VAP caused by XDR Acinetobacter calcoaceticus-baumannii complex and Pseudomonas aeruginosa. After failure of multiple antibiotic regimens, including ampicillin, amikacin, meropenem, vancomycin, cefepime with inhaled colistin, tigecycline, and ceftazidime-avibactam combined with fosfomycin, the infant was treated with sulbactam&amp;amp;ndash;durlobactam (25 mg/kg/dose every 6 h) in combination with ceftazidime-avibactam. After 12 days of this regimen, the neonate was successfully extubated. Conclusions: This case highlights the therapeutic challenges of XDR infections in extremely preterm neonates and suggests that sulbactam&amp;amp;ndash;durlobactam may represent a viable salvage treatment option. Further pharmacokinetic and clinical studies are needed to establish optimal dosing and safety in the neonatal population.</p>
	]]></content:encoded>

	<dc:title>Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam&amp;amp;ndash;Durlobactam in a Preterm Neonate: A Case Report</dc:title>
			<dc:creator>Suzana Zivojinovic</dc:creator>
			<dc:creator>Tijana Prodanovic</dc:creator>
			<dc:creator>Nikola Prodanovic</dc:creator>
			<dc:creator>Rasa Medovic</dc:creator>
			<dc:creator>Milica Cekerevac</dc:creator>
			<dc:creator>Dragana Savic</dc:creator>
			<dc:creator>Bojana Markovic</dc:creator>
			<dc:creator>Slobodan Jankovic</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030054</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-06-01</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-06-01</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>54</prism:startingPage>
		<prism:doi>10.3390/idr18030054</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/54</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/53">

	<title>Infectious Disease Reports, Vol. 18, Pages 53: Bacterial Granulomatous Lung Diseases: Radiological Findings and Differential Diagnosis</title>
	<link>https://www.mdpi.com/2036-7449/18/3/53</link>
	<description>Background Granulomatous lung diseases include a spectrum of disorders, both infectious and noninfectious, unified by the presence of granulomas in the lung parenchyma. Granulomas are microscopic, organized collections of immune cells that arise as a response to persistent antigenic stimulation. Infectious granulomatous lung diseases arise from a variety of microbial agents, that include most frequently Mycobacterium tuberculosis, non-tuberculous mycobacteria, Nocardia, and Borrelia, as well as a wide range of fungal pathogens including Histoplasma, Cryptococcus, Pneumocystis, and Aspergillus species. Methods and Results: Definitive diagnosis is achieved through direct identification and subsequent culture of the causative pathogen in appropriate clinical specimens, including sputum, bronchoscopic samples, gastric aspirates, or pleural fluid. Imaging is fundamental for the detection and characterization of pulmonary granulomas. HRCT allows precise assessment of the number, size, and distribution of granulomatous lesions, can suggest an infectious etiology based on specific imaging patterns, and is essential for monitoring response to therapy over time. Differential diagnosis is challenging due to the numerous different imaging appearances with whom granulomatous lung diseases may manifest. Conclusions: The purpose of our review is to describe the spectrum of infectious granulomatous lung diseases caused by bacterial pathogens, highlighting their diverse radiologic presentations in order to assist radiologists in recognizing these entities and improving diagnostic accuracy.</description>
	<pubDate>2026-05-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 53: Bacterial Granulomatous Lung Diseases: Radiological Findings and Differential Diagnosis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/53">doi: 10.3390/idr18030053</a></p>
	<p>Authors:
		Stefano Picchi
		Augusto Minieri
		Francesco Lassandro
		Giuseppe Russo
		Giulia Lassandro
		</p>
	<p>Background Granulomatous lung diseases include a spectrum of disorders, both infectious and noninfectious, unified by the presence of granulomas in the lung parenchyma. Granulomas are microscopic, organized collections of immune cells that arise as a response to persistent antigenic stimulation. Infectious granulomatous lung diseases arise from a variety of microbial agents, that include most frequently Mycobacterium tuberculosis, non-tuberculous mycobacteria, Nocardia, and Borrelia, as well as a wide range of fungal pathogens including Histoplasma, Cryptococcus, Pneumocystis, and Aspergillus species. Methods and Results: Definitive diagnosis is achieved through direct identification and subsequent culture of the causative pathogen in appropriate clinical specimens, including sputum, bronchoscopic samples, gastric aspirates, or pleural fluid. Imaging is fundamental for the detection and characterization of pulmonary granulomas. HRCT allows precise assessment of the number, size, and distribution of granulomatous lesions, can suggest an infectious etiology based on specific imaging patterns, and is essential for monitoring response to therapy over time. Differential diagnosis is challenging due to the numerous different imaging appearances with whom granulomatous lung diseases may manifest. Conclusions: The purpose of our review is to describe the spectrum of infectious granulomatous lung diseases caused by bacterial pathogens, highlighting their diverse radiologic presentations in order to assist radiologists in recognizing these entities and improving diagnostic accuracy.</p>
	]]></content:encoded>

	<dc:title>Bacterial Granulomatous Lung Diseases: Radiological Findings and Differential Diagnosis</dc:title>
			<dc:creator>Stefano Picchi</dc:creator>
			<dc:creator>Augusto Minieri</dc:creator>
			<dc:creator>Francesco Lassandro</dc:creator>
			<dc:creator>Giuseppe Russo</dc:creator>
			<dc:creator>Giulia Lassandro</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030053</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-28</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-28</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>53</prism:startingPage>
		<prism:doi>10.3390/idr18030053</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/53</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/52">

	<title>Infectious Disease Reports, Vol. 18, Pages 52: Dirofilaria spp. Detection in Dog Blood Samples from Southern Poland&amp;mdash;A Retrospective Data Analysis</title>
	<link>https://www.mdpi.com/2036-7449/18/3/52</link>
	<description>Background: Dirofilaria spp. is an etiological agent of dirofilariasis, a mosquito-borne parasitic disease of increasing zoonotic concern in Europe. The aim of this study was to assess the occurrence of Dirofilaria spp. in dogs from Southern Poland using retrospective data from a commercial veterinary diagnostic laboratory (Vetlab, Katowice, Poland). Methods: Blood tests from 2060 dogs were analyzed between 1 August 2018 and 31 December 2022. All samples were collected by the clinicians during routine veterinary activity and examined by a specific test&amp;amp;mdash;microscopic (blood smear/blood smear and Knott&amp;amp;rsquo;s test), molecular or both&amp;amp;mdash;from the Vetlab laboratory offer (test selected by clinician). Results: Out of all examined dogs, 19 (0.92%) tested positive for Dirofilaria. Positive samples originated from the &amp;amp;#346;l&amp;amp;#261;skie (n = 13), Opolskie (n = 3), and Ma&amp;amp;#322;opolskie (n = 3) voivodeships. Co-infections with Babesia spp. and Anaplasma spp. were identified in two blood samples. Conclusions: This study demonstrates the presence of Dirofilaria spp. in dogs from Southern Poland, a region where data about dirofilariasis cases remain limited. Its overall occurrence was low in comparison to endemic areas in Central Poland. However, the presence of confirmed cases highlights the need for increased veterinary awareness, implementation of preventive measures, and further molecular epidemiological studies to better evaluate the risk of exposure to Dirofilaria in this region.</description>
	<pubDate>2026-05-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 52: Dirofilaria spp. Detection in Dog Blood Samples from Southern Poland&amp;mdash;A Retrospective Data Analysis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/52">doi: 10.3390/idr18030052</a></p>
	<p>Authors:
		Olga Pawełczyk
		Paulina Iwase
		Bartosz Wierzba
		Jolanta Szłapka-Kosarzewska
		</p>
	<p>Background: Dirofilaria spp. is an etiological agent of dirofilariasis, a mosquito-borne parasitic disease of increasing zoonotic concern in Europe. The aim of this study was to assess the occurrence of Dirofilaria spp. in dogs from Southern Poland using retrospective data from a commercial veterinary diagnostic laboratory (Vetlab, Katowice, Poland). Methods: Blood tests from 2060 dogs were analyzed between 1 August 2018 and 31 December 2022. All samples were collected by the clinicians during routine veterinary activity and examined by a specific test&amp;amp;mdash;microscopic (blood smear/blood smear and Knott&amp;amp;rsquo;s test), molecular or both&amp;amp;mdash;from the Vetlab laboratory offer (test selected by clinician). Results: Out of all examined dogs, 19 (0.92%) tested positive for Dirofilaria. Positive samples originated from the &amp;amp;#346;l&amp;amp;#261;skie (n = 13), Opolskie (n = 3), and Ma&amp;amp;#322;opolskie (n = 3) voivodeships. Co-infections with Babesia spp. and Anaplasma spp. were identified in two blood samples. Conclusions: This study demonstrates the presence of Dirofilaria spp. in dogs from Southern Poland, a region where data about dirofilariasis cases remain limited. Its overall occurrence was low in comparison to endemic areas in Central Poland. However, the presence of confirmed cases highlights the need for increased veterinary awareness, implementation of preventive measures, and further molecular epidemiological studies to better evaluate the risk of exposure to Dirofilaria in this region.</p>
	]]></content:encoded>

	<dc:title>Dirofilaria spp. Detection in Dog Blood Samples from Southern Poland&amp;amp;mdash;A Retrospective Data Analysis</dc:title>
			<dc:creator>Olga Pawełczyk</dc:creator>
			<dc:creator>Paulina Iwase</dc:creator>
			<dc:creator>Bartosz Wierzba</dc:creator>
			<dc:creator>Jolanta Szłapka-Kosarzewska</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030052</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-27</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>52</prism:startingPage>
		<prism:doi>10.3390/idr18030052</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/52</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/51">

	<title>Infectious Disease Reports, Vol. 18, Pages 51: Meningococcal Outbreaks in Tertiary Education Settings in the United Kingdom: Lessons from the 2026 Kent Cluster for Surveillance, Vaccination Policy, and Institutional Preparedness in Sub-Saharan Africa&amp;mdash;A Narrative Review</title>
	<link>https://www.mdpi.com/2036-7449/18/3/51</link>
	<description>Background: In March 2026, a meningococcal cluster centred on the University of Kent, England, caused two deaths and resulted in over 20 reported cases within the first week, including confirmed and suspected invasive cases. Subsequent UKHSA updates in early April 2026 reported 21 laboratory-confirmed MenB cases (18 linked to the outbreak strain) and two deaths, with the outbreak subsequently spreading to a second Canterbury university, Canterbury Christ Church University, and confirmed as Neisseria meningitidis serogroup B (MenB). Sub-Saharan Africa (SSA) bears a disproportionate global burden of meningococcal disease, yet university settings remain a critically understudied outbreak amplifier. This narrative review extracts epidemiological and policy lessons from the Kent event and applies them to the SSA context. Methods: We conducted a narrative review following the SANRA criteria, searching PubMed, Embase, Scopus, Google Scholar, and African Journals Online (2000&amp;amp;ndash;2026), with supplementary grey literature retrieved from World Health Organisation (WHO), Africa Centre for Disease Control, and United Kingdom Health Security Agency (UKHSA). Outbreak data were drawn from official UKHSA public-health statements (grey literature, archived), the University of Kent communications, and peer-reviewed expert commentary. Results: The Canterbury outbreak exposed six reproducible vulnerabilities: unprotected serogroup circulation (confirmed MenB, not covered for the current university-age cohort), nightlife-linked transmission amplification, delayed serogroup identification, poor student symptom-recognition, inadequate institutional response capacity, and, critically, multi-institutional spread via shared nightlife venues (confirmed extension to Canterbury Christ Church University within five days). Each vulnerability is demonstrably more severe in SSA universities, which face a broader multi-serogroup threat environment (NmA, B, C, W, X), virtually no university-entry vaccination requirement, and critical evidence gap of campus-specific meningococcal evidence in the published literature. Conclusions: This review proposes a five-pillar preparedness framework for SSA tertiary institutions, derived from a synthesis of the Kent outbreak and broader epidemiological evidence, intended to inform policy discussion and future research. Moreover, these should be embedded within a broader age-linked prevention strategy that begins before university entry, particularly during the transition into secondary school in high-risk settings. Priority measures include meningococcal vaccination at key educational transition points, prophylactic antibiotic pre-positioning, serogroup-capable surveillance, symptom-recognition training, and pan-continental alert A predominantly reactive response may carry substantial risk in SSA settings.</description>
	<pubDate>2026-05-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 51: Meningococcal Outbreaks in Tertiary Education Settings in the United Kingdom: Lessons from the 2026 Kent Cluster for Surveillance, Vaccination Policy, and Institutional Preparedness in Sub-Saharan Africa&amp;mdash;A Narrative Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/51">doi: 10.3390/idr18030051</a></p>
	<p>Authors:
		Malizgani Mhango
		Enos Moyo
		Nigel Tungwarara
		Knowledge Denhere
		Moses Chirimbana
		Tafadzwa Dzinamarira
		</p>
	<p>Background: In March 2026, a meningococcal cluster centred on the University of Kent, England, caused two deaths and resulted in over 20 reported cases within the first week, including confirmed and suspected invasive cases. Subsequent UKHSA updates in early April 2026 reported 21 laboratory-confirmed MenB cases (18 linked to the outbreak strain) and two deaths, with the outbreak subsequently spreading to a second Canterbury university, Canterbury Christ Church University, and confirmed as Neisseria meningitidis serogroup B (MenB). Sub-Saharan Africa (SSA) bears a disproportionate global burden of meningococcal disease, yet university settings remain a critically understudied outbreak amplifier. This narrative review extracts epidemiological and policy lessons from the Kent event and applies them to the SSA context. Methods: We conducted a narrative review following the SANRA criteria, searching PubMed, Embase, Scopus, Google Scholar, and African Journals Online (2000&amp;amp;ndash;2026), with supplementary grey literature retrieved from World Health Organisation (WHO), Africa Centre for Disease Control, and United Kingdom Health Security Agency (UKHSA). Outbreak data were drawn from official UKHSA public-health statements (grey literature, archived), the University of Kent communications, and peer-reviewed expert commentary. Results: The Canterbury outbreak exposed six reproducible vulnerabilities: unprotected serogroup circulation (confirmed MenB, not covered for the current university-age cohort), nightlife-linked transmission amplification, delayed serogroup identification, poor student symptom-recognition, inadequate institutional response capacity, and, critically, multi-institutional spread via shared nightlife venues (confirmed extension to Canterbury Christ Church University within five days). Each vulnerability is demonstrably more severe in SSA universities, which face a broader multi-serogroup threat environment (NmA, B, C, W, X), virtually no university-entry vaccination requirement, and critical evidence gap of campus-specific meningococcal evidence in the published literature. Conclusions: This review proposes a five-pillar preparedness framework for SSA tertiary institutions, derived from a synthesis of the Kent outbreak and broader epidemiological evidence, intended to inform policy discussion and future research. Moreover, these should be embedded within a broader age-linked prevention strategy that begins before university entry, particularly during the transition into secondary school in high-risk settings. Priority measures include meningococcal vaccination at key educational transition points, prophylactic antibiotic pre-positioning, serogroup-capable surveillance, symptom-recognition training, and pan-continental alert A predominantly reactive response may carry substantial risk in SSA settings.</p>
	]]></content:encoded>

	<dc:title>Meningococcal Outbreaks in Tertiary Education Settings in the United Kingdom: Lessons from the 2026 Kent Cluster for Surveillance, Vaccination Policy, and Institutional Preparedness in Sub-Saharan Africa&amp;amp;mdash;A Narrative Review</dc:title>
			<dc:creator>Malizgani Mhango</dc:creator>
			<dc:creator>Enos Moyo</dc:creator>
			<dc:creator>Nigel Tungwarara</dc:creator>
			<dc:creator>Knowledge Denhere</dc:creator>
			<dc:creator>Moses Chirimbana</dc:creator>
			<dc:creator>Tafadzwa Dzinamarira</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030051</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-26</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-26</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>51</prism:startingPage>
		<prism:doi>10.3390/idr18030051</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/51</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/50">

	<title>Infectious Disease Reports, Vol. 18, Pages 50: Cellular Metabolic Signatures of Long COVID-19</title>
	<link>https://www.mdpi.com/2036-7449/18/3/50</link>
	<description>Background/Objectives: Long COVID-19 (LC-19), also known as Post-Acute COVID-19 Syndrome (PACS), is a chronic condition some people experience after an initial SARS-CoV-2 infection. The etiology of this complex, multifactorial disease remains largely unknown, although various theories have been propounded. This study aims to profile and compare the metabolic activity of cells of normal and LC-19 patients. Methods: A cohort of 20 individuals, 10 with LC-19 and 10 without LC-19, was selected based on their post-COVID-19 symptomatology. Saliva was tested for opportunistic viruses like Epstein&amp;amp;ndash;Barr virus (EBV) and Human Herpesvirus 6 (HHV-6). Lymphoblastoid cell lines derived from blood were analyzed using the Biolog Phenotype Mammalian Microarrays (PM-M1, PM-M6, and PM-M7) to assess metabolic activity across a wide array of growth substrates and effector molecules. Results: Unique metabolic profiles emerged across the controls and LC-19 groups. The SARS-CoV-2 infection causes an over two-fold enhanced utilization of glycolytic and anaerobic substrates and a reduced response to growth factors and effectors. The increased energy source utilization assessed in PM-M1 is unsustainable, and the LC-19 groups demonstrate this with a clear correlation with the number of LC-19 symptoms, demonstrating a trend consistent with metabolic reprogramming. The infection also results in a reduced response to growth factors and effectors, assessed in PM-M6 and PM-M7, with the level of reduction commensurate with the symptom burden. Conclusions: The data from the patient groups were analyzed and compared to construct a metabolic profile unique to individuals who developed LC-19, which could, in the future, be used for diagnosis and to identify targets for therapeutic intervention. Our study identified an LC-19-specific metabolic profile indicative of adaptive responses to stress, cellular dysfunction, and prolonged inflammation, leading to the reprogramming of bioenergetic pathways.</description>
	<pubDate>2026-05-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 50: Cellular Metabolic Signatures of Long COVID-19</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/50">doi: 10.3390/idr18030050</a></p>
	<p>Authors:
		Sujata Srikanth
		Diana Ivankovic
		Lucia Gonzales
		Delphine Dean
		Luigi Boccuto
		</p>
	<p>Background/Objectives: Long COVID-19 (LC-19), also known as Post-Acute COVID-19 Syndrome (PACS), is a chronic condition some people experience after an initial SARS-CoV-2 infection. The etiology of this complex, multifactorial disease remains largely unknown, although various theories have been propounded. This study aims to profile and compare the metabolic activity of cells of normal and LC-19 patients. Methods: A cohort of 20 individuals, 10 with LC-19 and 10 without LC-19, was selected based on their post-COVID-19 symptomatology. Saliva was tested for opportunistic viruses like Epstein&amp;amp;ndash;Barr virus (EBV) and Human Herpesvirus 6 (HHV-6). Lymphoblastoid cell lines derived from blood were analyzed using the Biolog Phenotype Mammalian Microarrays (PM-M1, PM-M6, and PM-M7) to assess metabolic activity across a wide array of growth substrates and effector molecules. Results: Unique metabolic profiles emerged across the controls and LC-19 groups. The SARS-CoV-2 infection causes an over two-fold enhanced utilization of glycolytic and anaerobic substrates and a reduced response to growth factors and effectors. The increased energy source utilization assessed in PM-M1 is unsustainable, and the LC-19 groups demonstrate this with a clear correlation with the number of LC-19 symptoms, demonstrating a trend consistent with metabolic reprogramming. The infection also results in a reduced response to growth factors and effectors, assessed in PM-M6 and PM-M7, with the level of reduction commensurate with the symptom burden. Conclusions: The data from the patient groups were analyzed and compared to construct a metabolic profile unique to individuals who developed LC-19, which could, in the future, be used for diagnosis and to identify targets for therapeutic intervention. Our study identified an LC-19-specific metabolic profile indicative of adaptive responses to stress, cellular dysfunction, and prolonged inflammation, leading to the reprogramming of bioenergetic pathways.</p>
	]]></content:encoded>

	<dc:title>Cellular Metabolic Signatures of Long COVID-19</dc:title>
			<dc:creator>Sujata Srikanth</dc:creator>
			<dc:creator>Diana Ivankovic</dc:creator>
			<dc:creator>Lucia Gonzales</dc:creator>
			<dc:creator>Delphine Dean</dc:creator>
			<dc:creator>Luigi Boccuto</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030050</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-26</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-26</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>50</prism:startingPage>
		<prism:doi>10.3390/idr18030050</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/50</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/49">

	<title>Infectious Disease Reports, Vol. 18, Pages 49: Clinical Characteristics, Risk Factors, and Predictors of Fatal Outcomes and Prolonged Hospitalization of Crimean&amp;ndash;Congo Hemorrhagic Fever Cases in Basrah, Iraq</title>
	<link>https://www.mdpi.com/2036-7449/18/3/49</link>
	<description>Background: The impact of climate change on birds&amp;amp;rsquo; migration and ticks&amp;amp;rsquo; reservoir habits is contributing to the spread of Crimean&amp;amp;ndash;Congo hemorrhagic fever (CCHF), caused by CCHF virus (CCHFV), to new continents and countries. CCHF is endemic to the Eastern Mediterranean Region, including Iraq, and is witnessing a substantial surge in confirmed cases with considerable disparity and gaps in managing CCHF cases. The increasing CCHF spread across Asia, Africa, and Europe, including Spain and Turkey, highlights the danger of its expansion. Developing high-confidence diagnostic criteria, identifying risk factors, and accurate predictors of CCHF outcomes are critical to managing suspected and confirmed cases of CCHF and to reducing the current case fatality rate of CCHF, which is the goal of this study. Methods: We completed a retrospective evaluation of 61 confirmed cases of CCHF in Basrah (Iraq). The cases were screened according to the clinical presentation, and CCHF cases were identified by ELISA and validated by PCR. Data was analyzed using SPSS version 22. T-tests, chi-square/Fisher exact tests, and Pearson&amp;amp;rsquo;s correlation were used, with significance set at p &amp;amp;lt; 0.05 and high significance at p &amp;amp;lt; 0.01. Results: We found that repeated exposure to animals during animal slaughtering was a significant risk factor. In addition, 5% of the patients with confirmed CCHF, mainly from rural areas, reported exposure to rats. Clinical presentations included fever, headache, gastrointestinal problems, eye and orbital symptoms, and hemorrhagic complications. Predictors of death included advanced age, decreased platelet counts, and neuropsychiatric symptoms such as delusions and confusion. Conclusions: Our findings identify clinical and laboratory features of CCHF cases in Iraq, which will help to implement the most effective interventions to manage CCHF cases and protect the public in all Iraqi governorates. In summary, this study highlights a recent and significant rise in CCHF cases in Basrah Governorate, Iraq. Notably, 5% of confirmed cases reported contact with rats. The paper also proposes diagnostic criteria and identifies key predictors of mortality to support improved clinical management of CCHF. These findings underscore the urgent need for strengthened public health interventions, including enhanced infection prevention and control measures, increased awareness, and improved surveillance systems. The findings have important implications for improving control procedures, guiding therapeutic development, informing vaccine strategies, and supporting evidence-based policy alongside future research efforts.</description>
	<pubDate>2026-05-19</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 49: Clinical Characteristics, Risk Factors, and Predictors of Fatal Outcomes and Prolonged Hospitalization of Crimean&amp;ndash;Congo Hemorrhagic Fever Cases in Basrah, Iraq</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/49">doi: 10.3390/idr18030049</a></p>
	<p>Authors:
		Mohammed H. Al-Maliki
		Celine Tabche
		Alaa K. Mousa
		Ali R. Hashim
		Zeenah Atwan
		Hassan A. Farid
		Maitham G. Yousif
		David Rawaf
		Nazik Haikaz Hasrat
		Murtadha Almusafer
		Anees K. Nile
		Riyadh Al-Hilfi
		Azeem Majeed
		Alessandra Scagliarini
		Salman Rawaf
		Roaa Khafaji
		Juan Carlos de la Torre
		Haydar Witwit
		</p>
	<p>Background: The impact of climate change on birds&amp;amp;rsquo; migration and ticks&amp;amp;rsquo; reservoir habits is contributing to the spread of Crimean&amp;amp;ndash;Congo hemorrhagic fever (CCHF), caused by CCHF virus (CCHFV), to new continents and countries. CCHF is endemic to the Eastern Mediterranean Region, including Iraq, and is witnessing a substantial surge in confirmed cases with considerable disparity and gaps in managing CCHF cases. The increasing CCHF spread across Asia, Africa, and Europe, including Spain and Turkey, highlights the danger of its expansion. Developing high-confidence diagnostic criteria, identifying risk factors, and accurate predictors of CCHF outcomes are critical to managing suspected and confirmed cases of CCHF and to reducing the current case fatality rate of CCHF, which is the goal of this study. Methods: We completed a retrospective evaluation of 61 confirmed cases of CCHF in Basrah (Iraq). The cases were screened according to the clinical presentation, and CCHF cases were identified by ELISA and validated by PCR. Data was analyzed using SPSS version 22. T-tests, chi-square/Fisher exact tests, and Pearson&amp;amp;rsquo;s correlation were used, with significance set at p &amp;amp;lt; 0.05 and high significance at p &amp;amp;lt; 0.01. Results: We found that repeated exposure to animals during animal slaughtering was a significant risk factor. In addition, 5% of the patients with confirmed CCHF, mainly from rural areas, reported exposure to rats. Clinical presentations included fever, headache, gastrointestinal problems, eye and orbital symptoms, and hemorrhagic complications. Predictors of death included advanced age, decreased platelet counts, and neuropsychiatric symptoms such as delusions and confusion. Conclusions: Our findings identify clinical and laboratory features of CCHF cases in Iraq, which will help to implement the most effective interventions to manage CCHF cases and protect the public in all Iraqi governorates. In summary, this study highlights a recent and significant rise in CCHF cases in Basrah Governorate, Iraq. Notably, 5% of confirmed cases reported contact with rats. The paper also proposes diagnostic criteria and identifies key predictors of mortality to support improved clinical management of CCHF. These findings underscore the urgent need for strengthened public health interventions, including enhanced infection prevention and control measures, increased awareness, and improved surveillance systems. The findings have important implications for improving control procedures, guiding therapeutic development, informing vaccine strategies, and supporting evidence-based policy alongside future research efforts.</p>
	]]></content:encoded>

	<dc:title>Clinical Characteristics, Risk Factors, and Predictors of Fatal Outcomes and Prolonged Hospitalization of Crimean&amp;amp;ndash;Congo Hemorrhagic Fever Cases in Basrah, Iraq</dc:title>
			<dc:creator>Mohammed H. Al-Maliki</dc:creator>
			<dc:creator>Celine Tabche</dc:creator>
			<dc:creator>Alaa K. Mousa</dc:creator>
			<dc:creator>Ali R. Hashim</dc:creator>
			<dc:creator>Zeenah Atwan</dc:creator>
			<dc:creator>Hassan A. Farid</dc:creator>
			<dc:creator>Maitham G. Yousif</dc:creator>
			<dc:creator>David Rawaf</dc:creator>
			<dc:creator>Nazik Haikaz Hasrat</dc:creator>
			<dc:creator>Murtadha Almusafer</dc:creator>
			<dc:creator>Anees K. Nile</dc:creator>
			<dc:creator>Riyadh Al-Hilfi</dc:creator>
			<dc:creator>Azeem Majeed</dc:creator>
			<dc:creator>Alessandra Scagliarini</dc:creator>
			<dc:creator>Salman Rawaf</dc:creator>
			<dc:creator>Roaa Khafaji</dc:creator>
			<dc:creator>Juan Carlos de la Torre</dc:creator>
			<dc:creator>Haydar Witwit</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030049</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-19</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-19</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>49</prism:startingPage>
		<prism:doi>10.3390/idr18030049</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/49</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/48">

	<title>Infectious Disease Reports, Vol. 18, Pages 48: Necrotizing Fasciitis in Northern Italy: Clinical Characteristics, Risk Factors, and Prognostic Value of the LRINEC Score&amp;mdash;A Single-Center Retrospective Case Series</title>
	<link>https://www.mdpi.com/2036-7449/18/3/48</link>
	<description>Background: Necrotizing fasciitis (NF) is a rapidly progressive, life-threatening soft tissue infection characterized by fascial necrosis, with mortality rates of 20&amp;amp;ndash;30%. Despite its rarity, NF is increasingly encountered due to the rising prevalence of predisposing factors. Data from Southern European tertiary centers remain scarce. Methods: We retrospectively reviewed all patients &amp;amp;ge;18 years with radiological and/or surgical diagnosis of NF managed at IRCCS Policlinico San Matteo, Pavia, Italy, between November 2018 and August 2023. Clinical, microbiological, and treatment data were extracted from electronic medical records. The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score was calculated retrospectively. The Charlson Comorbidity Index was computed for each patient. Given the small sample size, we adopted a purely descriptive analytical approach without inferential testing. Results: Thirteen patients met inclusion criteria (median age 58 years, IQR 44.5&amp;amp;ndash;79.5; 69.2% male). The most common comorbidities were diabetes mellitus (6/13, 46.2%), renal failure (4/13, 30.8%), and chronic liver disease (4/13, 30.8%). The age-adjusted Charlson Index ranged from 0 to 11 (median 4). Lower limbs were the most frequently affected anatomic site (5/13, 38.5%), followed by the perineal/genital region (Fournier gangrene, 4/13, 30.8%). Type II (monomicrobial) NF predominated (9/13, 69.2%). Microbiological cultures were positive in 8/13 patients (61.5%): Gram-positive cocci were isolated in 5/8 (62.5%) and mixed aerobic/anaerobic flora in 3/8 (37.5%). Empirical antibiotic regimens included a piperacillin&amp;amp;ndash;tazobactam backbone in 6/12 (50.0%) patients and a meropenem-based combination in 5/12 (41.7%); 6/12 patients underwent targeted de-escalation after culture results. Two patients (15.4%) died in hospital, both with Fournier gangrene and Type I infection (mortality 2/4, 50.0% in Type I vs. 0/9 in Type II). The median length of stay was 26 days (IQR 17&amp;amp;ndash;28.5). All patients had LRINEC &amp;amp;ge;6 at admission, with 9/13 (69.2%) classified as high risk (&amp;amp;ge;8). Conclusions: In this small retrospective Italian cohort, NF was most frequently associated with diabetes and high comorbidity burden. Type I (polymicrobial) infections, predominantly involving the perineal region, showed worse outcomes than Type II infections. The clinical experience accumulated during this study period subsequently informed the development of an institutional empirical antimicrobial protocol for skin and soft tissue infections at our hospital.</description>
	<pubDate>2026-05-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 48: Necrotizing Fasciitis in Northern Italy: Clinical Characteristics, Risk Factors, and Prognostic Value of the LRINEC Score&amp;mdash;A Single-Center Retrospective Case Series</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/48">doi: 10.3390/idr18030048</a></p>
	<p>Authors:
		Aurelia Sangani
		Flavia Puci
		Davide Tirro
		Simona Villani
		Camilla Torriani
		Enrico Brunetti
		Raffaele Bruno
		Elisabetta Pagani
		</p>
	<p>Background: Necrotizing fasciitis (NF) is a rapidly progressive, life-threatening soft tissue infection characterized by fascial necrosis, with mortality rates of 20&amp;amp;ndash;30%. Despite its rarity, NF is increasingly encountered due to the rising prevalence of predisposing factors. Data from Southern European tertiary centers remain scarce. Methods: We retrospectively reviewed all patients &amp;amp;ge;18 years with radiological and/or surgical diagnosis of NF managed at IRCCS Policlinico San Matteo, Pavia, Italy, between November 2018 and August 2023. Clinical, microbiological, and treatment data were extracted from electronic medical records. The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score was calculated retrospectively. The Charlson Comorbidity Index was computed for each patient. Given the small sample size, we adopted a purely descriptive analytical approach without inferential testing. Results: Thirteen patients met inclusion criteria (median age 58 years, IQR 44.5&amp;amp;ndash;79.5; 69.2% male). The most common comorbidities were diabetes mellitus (6/13, 46.2%), renal failure (4/13, 30.8%), and chronic liver disease (4/13, 30.8%). The age-adjusted Charlson Index ranged from 0 to 11 (median 4). Lower limbs were the most frequently affected anatomic site (5/13, 38.5%), followed by the perineal/genital region (Fournier gangrene, 4/13, 30.8%). Type II (monomicrobial) NF predominated (9/13, 69.2%). Microbiological cultures were positive in 8/13 patients (61.5%): Gram-positive cocci were isolated in 5/8 (62.5%) and mixed aerobic/anaerobic flora in 3/8 (37.5%). Empirical antibiotic regimens included a piperacillin&amp;amp;ndash;tazobactam backbone in 6/12 (50.0%) patients and a meropenem-based combination in 5/12 (41.7%); 6/12 patients underwent targeted de-escalation after culture results. Two patients (15.4%) died in hospital, both with Fournier gangrene and Type I infection (mortality 2/4, 50.0% in Type I vs. 0/9 in Type II). The median length of stay was 26 days (IQR 17&amp;amp;ndash;28.5). All patients had LRINEC &amp;amp;ge;6 at admission, with 9/13 (69.2%) classified as high risk (&amp;amp;ge;8). Conclusions: In this small retrospective Italian cohort, NF was most frequently associated with diabetes and high comorbidity burden. Type I (polymicrobial) infections, predominantly involving the perineal region, showed worse outcomes than Type II infections. The clinical experience accumulated during this study period subsequently informed the development of an institutional empirical antimicrobial protocol for skin and soft tissue infections at our hospital.</p>
	]]></content:encoded>

	<dc:title>Necrotizing Fasciitis in Northern Italy: Clinical Characteristics, Risk Factors, and Prognostic Value of the LRINEC Score&amp;amp;mdash;A Single-Center Retrospective Case Series</dc:title>
			<dc:creator>Aurelia Sangani</dc:creator>
			<dc:creator>Flavia Puci</dc:creator>
			<dc:creator>Davide Tirro</dc:creator>
			<dc:creator>Simona Villani</dc:creator>
			<dc:creator>Camilla Torriani</dc:creator>
			<dc:creator>Enrico Brunetti</dc:creator>
			<dc:creator>Raffaele Bruno</dc:creator>
			<dc:creator>Elisabetta Pagani</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030048</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-18</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-18</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>48</prism:startingPage>
		<prism:doi>10.3390/idr18030048</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/48</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/47">

	<title>Infectious Disease Reports, Vol. 18, Pages 47: Association of Climatic Factors with Frequency of Dengue</title>
	<link>https://www.mdpi.com/2036-7449/18/3/47</link>
	<description>Background: Climate change has contributed to the global resurgence of dengue, with a spike of more than 14.4 million dengue cases. This study aimed to analyze the association between dengue frequency with climatic factors, circulating serotypes, and disease severity in northwestern Mexico. Methods: A retrospective time-series study was conducted using dengue molecular diagnostic data reported between September 2017 and January 2025 by the Laboratorio de Apoyo a la Vigilancia e Investigaci&amp;amp;oacute;n Epidemiol&amp;amp;oacute;gica del Centro de Investigaci&amp;amp;oacute;n Biom&amp;amp;eacute;dica de Occidente, Mexico. Data included dengue frequency, serotype distribution, and clinical severity across seven states in northwestern Mexico (Colima, Guanajuato, Jalisco, Michoac&amp;amp;aacute;n, Nayarit, Sinaloa, and Sonora). Meteorological data were obtained from the Automatic Meteorological Stations of the National Water Commission. Associations between dengue frequency and climatic variables were evaluated using linear regression models. Statistical analyses were performed using SPSS v24 and R v3.5. Results: In Jalisco, minimum, mean and maximum temperatures, as well as precipitation, were significant predictors of dengue cases, explaining approximately 21.7% of the variance (adjusted R2 = 0.217, p &amp;amp;lt; 0.001). In Colima and Michoac&amp;amp;aacute;n, precipitation showed no predictive value. In Guanajuato, the maximum temperature was excluded from the model (adjusted R2 = 0.226). Models for Nayarit, Sinaloa, and Sonora excluded two or more climatic variables, with adjusted R2 values of 0.111, 0.151, and 0.049, respectively. Conclusions: Climatic conditions and epidemiological time trends explain a modest proportion of dengue cases in northwestern Mexico, with the strongest association observed in Jalisco. Additional determinants, including vector ecology, host immunity, circulating serotypes, population mobility, and public health interventions, should be considered to better understand dengue dynamics.</description>
	<pubDate>2026-05-16</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 47: Association of Climatic Factors with Frequency of Dengue</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/47">doi: 10.3390/idr18030047</a></p>
	<p>Authors:
		Gracia Viviana González-Enríquez
		Blanca Miriam Torres-Mendoza
		Martha Escoto-Delgadillo
		Efrain Chavarria-Avila
		Sagrario Karina Esparza-Avila
		Clara Esperanza Santacruz-Tinoco
		Bernardo Martínez-Miguel
		Magally Farah Diva Arenas-Sevilla
		David Israel Javalera Castro
		</p>
	<p>Background: Climate change has contributed to the global resurgence of dengue, with a spike of more than 14.4 million dengue cases. This study aimed to analyze the association between dengue frequency with climatic factors, circulating serotypes, and disease severity in northwestern Mexico. Methods: A retrospective time-series study was conducted using dengue molecular diagnostic data reported between September 2017 and January 2025 by the Laboratorio de Apoyo a la Vigilancia e Investigaci&amp;amp;oacute;n Epidemiol&amp;amp;oacute;gica del Centro de Investigaci&amp;amp;oacute;n Biom&amp;amp;eacute;dica de Occidente, Mexico. Data included dengue frequency, serotype distribution, and clinical severity across seven states in northwestern Mexico (Colima, Guanajuato, Jalisco, Michoac&amp;amp;aacute;n, Nayarit, Sinaloa, and Sonora). Meteorological data were obtained from the Automatic Meteorological Stations of the National Water Commission. Associations between dengue frequency and climatic variables were evaluated using linear regression models. Statistical analyses were performed using SPSS v24 and R v3.5. Results: In Jalisco, minimum, mean and maximum temperatures, as well as precipitation, were significant predictors of dengue cases, explaining approximately 21.7% of the variance (adjusted R2 = 0.217, p &amp;amp;lt; 0.001). In Colima and Michoac&amp;amp;aacute;n, precipitation showed no predictive value. In Guanajuato, the maximum temperature was excluded from the model (adjusted R2 = 0.226). Models for Nayarit, Sinaloa, and Sonora excluded two or more climatic variables, with adjusted R2 values of 0.111, 0.151, and 0.049, respectively. Conclusions: Climatic conditions and epidemiological time trends explain a modest proportion of dengue cases in northwestern Mexico, with the strongest association observed in Jalisco. Additional determinants, including vector ecology, host immunity, circulating serotypes, population mobility, and public health interventions, should be considered to better understand dengue dynamics.</p>
	]]></content:encoded>

	<dc:title>Association of Climatic Factors with Frequency of Dengue</dc:title>
			<dc:creator>Gracia Viviana González-Enríquez</dc:creator>
			<dc:creator>Blanca Miriam Torres-Mendoza</dc:creator>
			<dc:creator>Martha Escoto-Delgadillo</dc:creator>
			<dc:creator>Efrain Chavarria-Avila</dc:creator>
			<dc:creator>Sagrario Karina Esparza-Avila</dc:creator>
			<dc:creator>Clara Esperanza Santacruz-Tinoco</dc:creator>
			<dc:creator>Bernardo Martínez-Miguel</dc:creator>
			<dc:creator>Magally Farah Diva Arenas-Sevilla</dc:creator>
			<dc:creator>David Israel Javalera Castro</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030047</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-16</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-16</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>47</prism:startingPage>
		<prism:doi>10.3390/idr18030047</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/47</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/46">

	<title>Infectious Disease Reports, Vol. 18, Pages 46: Superficial Fungal Infection Associations with Comorbid Diseases and Risk Factors: An Analysis of Global Burden of Disease 2023</title>
	<link>https://www.mdpi.com/2036-7449/18/3/46</link>
	<description>Background: Superficial fungal infections caused by dermatophyte and non-dermatophyte species are increasing globally. While several comorbid diseases and risk factors have been associated with fungal infections at the individual level, their epidemiological relationships at the population level remains poorly characterized. Objective: We aimed to examine population-level associations between the burden of superficial fungal infections and selected comorbid conditions and risk factors, stratified by age, sex and country. Methods: We obtained years lived with disability (YLDs) for superficial fungal infections, diabetes, psoriasis, and atopic dermatitis and summary exposure values (SEVs) for high body mass index (BMI) and high alcohol intake from Global Burden of Disease Study 2023. Data were obtained for Australia, Brazil, the United Kingdom and the United States for males and females younger than 20 years, 20 to 54 years and 55+ years old. Pearson correlation coefficients were calculated between fungal infection YLDs and each comorbid condition (YLDs) and risk factor (SEVs). Results: Significant positive correlations were observed between superficial fungal infection burden and diabetes (R = 0.6&amp;amp;ndash;0.98), high BMI (R = 0.75&amp;amp;ndash;0.95), psoriasis (R = 0.59&amp;amp;ndash;0.96), and atopic dermatitis (R = 0.51&amp;amp;ndash;0.93) in older adults (55 years+). Correlations with high alcohol consumption were more variable across regions and sex. In young&amp;amp;ndash;middle-aged adults (20&amp;amp;ndash;54 years), moderate-to-strong correlations (R ~ 0.8&amp;amp;ndash;0.9) were observed, although patterns were less consistent across countries. In individuals &amp;amp;lt; 20 years, associations were generally weaker, with some positive correlations observed for atopic dermatitis (R = 0.4&amp;amp;ndash;0.7) in select countries. Conclusions: The findings demonstrate population-level associations between superficial fungal infections and metabolic, inflammatory, and behavioural risk factors, with stronger correlations observed in older age groups. These patterns may reflect shared demographic, epidemiologic, and clinical patterns across conditions.</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 46: Superficial Fungal Infection Associations with Comorbid Diseases and Risk Factors: An Analysis of Global Burden of Disease 2023</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/46">doi: 10.3390/idr18030046</a></p>
	<p>Authors:
		Aditya K. Gupta
		Elizabeth Teasell
		Vasiliki Economopoulos
		</p>
	<p>Background: Superficial fungal infections caused by dermatophyte and non-dermatophyte species are increasing globally. While several comorbid diseases and risk factors have been associated with fungal infections at the individual level, their epidemiological relationships at the population level remains poorly characterized. Objective: We aimed to examine population-level associations between the burden of superficial fungal infections and selected comorbid conditions and risk factors, stratified by age, sex and country. Methods: We obtained years lived with disability (YLDs) for superficial fungal infections, diabetes, psoriasis, and atopic dermatitis and summary exposure values (SEVs) for high body mass index (BMI) and high alcohol intake from Global Burden of Disease Study 2023. Data were obtained for Australia, Brazil, the United Kingdom and the United States for males and females younger than 20 years, 20 to 54 years and 55+ years old. Pearson correlation coefficients were calculated between fungal infection YLDs and each comorbid condition (YLDs) and risk factor (SEVs). Results: Significant positive correlations were observed between superficial fungal infection burden and diabetes (R = 0.6&amp;amp;ndash;0.98), high BMI (R = 0.75&amp;amp;ndash;0.95), psoriasis (R = 0.59&amp;amp;ndash;0.96), and atopic dermatitis (R = 0.51&amp;amp;ndash;0.93) in older adults (55 years+). Correlations with high alcohol consumption were more variable across regions and sex. In young&amp;amp;ndash;middle-aged adults (20&amp;amp;ndash;54 years), moderate-to-strong correlations (R ~ 0.8&amp;amp;ndash;0.9) were observed, although patterns were less consistent across countries. In individuals &amp;amp;lt; 20 years, associations were generally weaker, with some positive correlations observed for atopic dermatitis (R = 0.4&amp;amp;ndash;0.7) in select countries. Conclusions: The findings demonstrate population-level associations between superficial fungal infections and metabolic, inflammatory, and behavioural risk factors, with stronger correlations observed in older age groups. These patterns may reflect shared demographic, epidemiologic, and clinical patterns across conditions.</p>
	]]></content:encoded>

	<dc:title>Superficial Fungal Infection Associations with Comorbid Diseases and Risk Factors: An Analysis of Global Burden of Disease 2023</dc:title>
			<dc:creator>Aditya K. Gupta</dc:creator>
			<dc:creator>Elizabeth Teasell</dc:creator>
			<dc:creator>Vasiliki Economopoulos</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030046</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>46</prism:startingPage>
		<prism:doi>10.3390/idr18030046</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/46</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/45">

	<title>Infectious Disease Reports, Vol. 18, Pages 45: Facility-Level Access Drives Disparities in Influenza and Pneumococcal Vaccination in Long-Term Care Facilities in Southern Poland</title>
	<link>https://www.mdpi.com/2036-7449/18/3/45</link>
	<description>Background: Vaccinations prevent severe respiratory infections in older adults, yet uptake in Polish long-term care facilities (LTCFs) remains poorly characterized. We assessed influenza and pneumococcal vaccination coverage and factors associated with uptake, including the influence of local government financing. Methods: In this prospective observational study (January&amp;amp;ndash;June 2022), residents aged &amp;amp;ge;65 years from eight LTCFs in southern Poland (four public, four private) were evaluated. Clinical data and geriatric assessments (Barthel Index, ADL, FRAIL-NH) were obtained from medical records and questionnaires. Comparative analyses were limited to residents living in facilities where vaccination activities were implemented and for whom complete data were available. Results: Overall, 429 residents were assessed: 136 (31.7%) received influenza vaccination and 77 (17.9%) received pneumococcal vaccination. Three of the eight LTCFs administered neither influenza nor pneumococcal vaccines, highlighting a facility-level access gap. For individual-level comparisons, 260 residents with complete data from LTCFs offering vaccination were analyzed (245 for pneumococcal outcomes). Influenza vaccination was not associated with most comorbidities or functional measures, but was more common among residents with dementia. Pneumococcal vaccine recipients were younger, had better functional status, and exhibited a lower burden of comorbidities than unvaccinated residents, suggesting preferential vaccination of fitter individuals. Municipality-level data showed low uptake of publicly funded pneumococcal programs (6.1% in Krak&amp;amp;oacute;w; 3.6% in Wilkowice). Conclusions: Vaccination coverage among LTCF residents was low and strongly influenced by structural access at the facility level. Simplifying costs, reducing out-of-pocket costs and addressing potential age-related biases are essential to improving equitable immunization in Polish LTCFs.</description>
	<pubDate>2026-05-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 45: Facility-Level Access Drives Disparities in Influenza and Pneumococcal Vaccination in Long-Term Care Facilities in Southern Poland</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/45">doi: 10.3390/idr18030045</a></p>
	<p>Authors:
		Zofia Gniadek
		Estera Jachowicz-Matczak
		Cezary Kapturkiewicz
		Izabella Bylica
		Dorota Romaniszyn
		Jadwiga Wójkowska-Mach
		</p>
	<p>Background: Vaccinations prevent severe respiratory infections in older adults, yet uptake in Polish long-term care facilities (LTCFs) remains poorly characterized. We assessed influenza and pneumococcal vaccination coverage and factors associated with uptake, including the influence of local government financing. Methods: In this prospective observational study (January&amp;amp;ndash;June 2022), residents aged &amp;amp;ge;65 years from eight LTCFs in southern Poland (four public, four private) were evaluated. Clinical data and geriatric assessments (Barthel Index, ADL, FRAIL-NH) were obtained from medical records and questionnaires. Comparative analyses were limited to residents living in facilities where vaccination activities were implemented and for whom complete data were available. Results: Overall, 429 residents were assessed: 136 (31.7%) received influenza vaccination and 77 (17.9%) received pneumococcal vaccination. Three of the eight LTCFs administered neither influenza nor pneumococcal vaccines, highlighting a facility-level access gap. For individual-level comparisons, 260 residents with complete data from LTCFs offering vaccination were analyzed (245 for pneumococcal outcomes). Influenza vaccination was not associated with most comorbidities or functional measures, but was more common among residents with dementia. Pneumococcal vaccine recipients were younger, had better functional status, and exhibited a lower burden of comorbidities than unvaccinated residents, suggesting preferential vaccination of fitter individuals. Municipality-level data showed low uptake of publicly funded pneumococcal programs (6.1% in Krak&amp;amp;oacute;w; 3.6% in Wilkowice). Conclusions: Vaccination coverage among LTCF residents was low and strongly influenced by structural access at the facility level. Simplifying costs, reducing out-of-pocket costs and addressing potential age-related biases are essential to improving equitable immunization in Polish LTCFs.</p>
	]]></content:encoded>

	<dc:title>Facility-Level Access Drives Disparities in Influenza and Pneumococcal Vaccination in Long-Term Care Facilities in Southern Poland</dc:title>
			<dc:creator>Zofia Gniadek</dc:creator>
			<dc:creator>Estera Jachowicz-Matczak</dc:creator>
			<dc:creator>Cezary Kapturkiewicz</dc:creator>
			<dc:creator>Izabella Bylica</dc:creator>
			<dc:creator>Dorota Romaniszyn</dc:creator>
			<dc:creator>Jadwiga Wójkowska-Mach</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030045</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>45</prism:startingPage>
		<prism:doi>10.3390/idr18030045</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/45</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/44">

	<title>Infectious Disease Reports, Vol. 18, Pages 44: A Risk-Based Isolation Strategy for MDR-Endemic Facilities with Limited Resources</title>
	<link>https://www.mdpi.com/2036-7449/18/3/44</link>
	<description>Background/Objectives: The increasing burden of multidrug-resistant (MDR) microorganisms and limited resources in healthcare settings are making traditional strategies based on routine isolation of all carriers unsustainable. Methods: A clinical narrative review was conducted by searching PubMed, Web of Science, and Google Scholar for studies published between 2011 and 2025. International guidelines were analyzed to synthesize a sustainable infection control strategy. Results: High-quality evidence, including cluster-randomized trials, indicates that routine contact isolation for endemic ESBL-producing Enterobacterales (IRR: 0.99) and VRE (RR: 0.93) provides no additional benefit over standard precautions. In contrast, strict isolation remains vital for high-threat pathogens such as Carbapenem-Resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), and Candidozyma auris due to their high environmental resilience and limited treatment options. Prioritization should be guided by pathogen biology, patient-specific transmission traits (e.g., diarrhea), and facility infrastructure. Conclusions: Traditional one-size-fits-all infection control is increasingly unsustainable under resource constraints. A risk-based approach prioritizing horizontal measures for low-risk pathogens enables a more balanced allocation of limited resources toward high-threat containment.</description>
	<pubDate>2026-05-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 44: A Risk-Based Isolation Strategy for MDR-Endemic Facilities with Limited Resources</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/44">doi: 10.3390/idr18030044</a></p>
	<p>Authors:
		Zeynep Ture
		Emine Alp
		</p>
	<p>Background/Objectives: The increasing burden of multidrug-resistant (MDR) microorganisms and limited resources in healthcare settings are making traditional strategies based on routine isolation of all carriers unsustainable. Methods: A clinical narrative review was conducted by searching PubMed, Web of Science, and Google Scholar for studies published between 2011 and 2025. International guidelines were analyzed to synthesize a sustainable infection control strategy. Results: High-quality evidence, including cluster-randomized trials, indicates that routine contact isolation for endemic ESBL-producing Enterobacterales (IRR: 0.99) and VRE (RR: 0.93) provides no additional benefit over standard precautions. In contrast, strict isolation remains vital for high-threat pathogens such as Carbapenem-Resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), and Candidozyma auris due to their high environmental resilience and limited treatment options. Prioritization should be guided by pathogen biology, patient-specific transmission traits (e.g., diarrhea), and facility infrastructure. Conclusions: Traditional one-size-fits-all infection control is increasingly unsustainable under resource constraints. A risk-based approach prioritizing horizontal measures for low-risk pathogens enables a more balanced allocation of limited resources toward high-threat containment.</p>
	]]></content:encoded>

	<dc:title>A Risk-Based Isolation Strategy for MDR-Endemic Facilities with Limited Resources</dc:title>
			<dc:creator>Zeynep Ture</dc:creator>
			<dc:creator>Emine Alp</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030044</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>44</prism:startingPage>
		<prism:doi>10.3390/idr18030044</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/44</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/43">

	<title>Infectious Disease Reports, Vol. 18, Pages 43: A Real-World Pharmacovigilance Analysis of the Safety Profiles Associated with Anti-MRSA Agents Using the Japanese Adverse Drug Event Report (JADER) Database</title>
	<link>https://www.mdpi.com/2036-7449/18/3/43</link>
	<description>Background: Anti-MRSA agents are essential for treating severe infections, yet their use is constrained by distinct toxicity profiles. However, comparative real-world data remain scarce. Methods: This nationwide pharmacovigilance study used the Japanese Adverse Drug Event Report (JADER) database (2004&amp;amp;ndash;2025). Disproportionality analyses (proportional reporting ratio [PRR]) were performed at the Standardized MedDRA Query and Preferred Term levels, complemented by Weibull-based time-to-onset modeling, to characterize AE patterns associated with vancomycin (VCM), teicoplanin (TEIC), arbekacin (ABK), daptomycin (DAP), linezolid (LZD), and tedizolid (TZD). Results: Distinct agent-specific AE profiles were observed. VCM showed disproportionate reporting of acute renal failure (PRR 6.66) and severe cutaneous reactions. TEIC displayed fewer renal signals but relatively higher reporting of hematologic events (PRR 3.51). ABK demonstrated high disproportionality in acute and chronic renal failure, reflecting aminoglycoside nephrotoxicity. DAP showed a high reporting signal for eosinophilic pneumonia (PRR 23.30), interstitial lung disease, and creatine kinase elevation/rhabdomyolysis, with wear-out hazard patterns suggesting a possible time-dependent reporting tendency. LZD exhibited hematopoietic signals (PRR 6.13) and additional associations with hyponatremia, lactic acidosis, and optic neuropathy, consistent with marrow suppression and mitochondrial toxicity. Weibull analysis indicated cumulative &amp;amp;ldquo;wear-out&amp;amp;rdquo; risks for renal, hepatic, and hematologic events, whereas hypersensitivity and many pulmonary events followed random-failure patterns. Conclusions: This large-scale JADER analysis delineated the distinct safety profiles of the six anti-MRSA agents. The key findings included DAP pulmonary and muscle toxicities, LZD hematological events, and VCM nephrotoxicity. Time-to-onset modeling indicates potential cumulative versus random risk patterns, suggesting the need for individualized monitoring and cross-validation.</description>
	<pubDate>2026-05-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 43: A Real-World Pharmacovigilance Analysis of the Safety Profiles Associated with Anti-MRSA Agents Using the Japanese Adverse Drug Event Report (JADER) Database</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/43">doi: 10.3390/idr18030043</a></p>
	<p>Authors:
		Yuki Hanai
		Shusuke Uekusa
		Mizuki Mori
		Kohei Shimoyama
		Hayato Ohashi
		Koji Nishimura
		Sachiko Yanagino
		Takahiro Matsumoto
		Kazuhiro Matsuo
		</p>
	<p>Background: Anti-MRSA agents are essential for treating severe infections, yet their use is constrained by distinct toxicity profiles. However, comparative real-world data remain scarce. Methods: This nationwide pharmacovigilance study used the Japanese Adverse Drug Event Report (JADER) database (2004&amp;amp;ndash;2025). Disproportionality analyses (proportional reporting ratio [PRR]) were performed at the Standardized MedDRA Query and Preferred Term levels, complemented by Weibull-based time-to-onset modeling, to characterize AE patterns associated with vancomycin (VCM), teicoplanin (TEIC), arbekacin (ABK), daptomycin (DAP), linezolid (LZD), and tedizolid (TZD). Results: Distinct agent-specific AE profiles were observed. VCM showed disproportionate reporting of acute renal failure (PRR 6.66) and severe cutaneous reactions. TEIC displayed fewer renal signals but relatively higher reporting of hematologic events (PRR 3.51). ABK demonstrated high disproportionality in acute and chronic renal failure, reflecting aminoglycoside nephrotoxicity. DAP showed a high reporting signal for eosinophilic pneumonia (PRR 23.30), interstitial lung disease, and creatine kinase elevation/rhabdomyolysis, with wear-out hazard patterns suggesting a possible time-dependent reporting tendency. LZD exhibited hematopoietic signals (PRR 6.13) and additional associations with hyponatremia, lactic acidosis, and optic neuropathy, consistent with marrow suppression and mitochondrial toxicity. Weibull analysis indicated cumulative &amp;amp;ldquo;wear-out&amp;amp;rdquo; risks for renal, hepatic, and hematologic events, whereas hypersensitivity and many pulmonary events followed random-failure patterns. Conclusions: This large-scale JADER analysis delineated the distinct safety profiles of the six anti-MRSA agents. The key findings included DAP pulmonary and muscle toxicities, LZD hematological events, and VCM nephrotoxicity. Time-to-onset modeling indicates potential cumulative versus random risk patterns, suggesting the need for individualized monitoring and cross-validation.</p>
	]]></content:encoded>

	<dc:title>A Real-World Pharmacovigilance Analysis of the Safety Profiles Associated with Anti-MRSA Agents Using the Japanese Adverse Drug Event Report (JADER) Database</dc:title>
			<dc:creator>Yuki Hanai</dc:creator>
			<dc:creator>Shusuke Uekusa</dc:creator>
			<dc:creator>Mizuki Mori</dc:creator>
			<dc:creator>Kohei Shimoyama</dc:creator>
			<dc:creator>Hayato Ohashi</dc:creator>
			<dc:creator>Koji Nishimura</dc:creator>
			<dc:creator>Sachiko Yanagino</dc:creator>
			<dc:creator>Takahiro Matsumoto</dc:creator>
			<dc:creator>Kazuhiro Matsuo</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030043</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-02</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-02</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>43</prism:startingPage>
		<prism:doi>10.3390/idr18030043</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/43</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/42">

	<title>Infectious Disease Reports, Vol. 18, Pages 42: Chromosomal Mechanisms of Colistin Resistance in Clinical Isolates of Carbapenem-Resistant Klebsiella pneumoniae from a Tunisian Tertiary-Care Hospital</title>
	<link>https://www.mdpi.com/2036-7449/18/3/42</link>
	<description>Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major nosocomial pathogen. Although newer agents have reduced colistin use in high-income countries, this polymyxin remains important in many low- and middle-income settings. Colistin resistance in K. pneumoniae is most commonly associated with chromosomal alterations affecting the MgrB&amp;amp;ndash;PhoPQ pathway, or with plasmid-mediated mcr genes. This study aimed to investigate chromosomally mediated colistin resistance in CRKP clinical isolates from a Tunisian tertiary hospital. Methods: Between 2010 and 2015, 317 non-duplicate CRKP isolates were collected at Charles Nicolle Hospital, Tunis. Colistin MICs were determined by broth microdilution. Phenotypic tests and PCR characterized carbapenemases, extended-spectrum &amp;amp;beta;-lactamases, AmpC, plasmid-mediated quinolone resistance, mcr and virulence genes. Porins (OmpK35/OmpK36) and the mgrB, phoP and phoQ loci were analyzed by SDS-PAGE and sequencing. Clonal relatedness was assessed by ERIC-PCR and multilocus sequence typing. We additionally compared colistin-resistant isolates with a panel of colistin-susceptible CRKP controls and assessed phenotypic stability after serial passages without colistin. Results: Five isolates (1.6%) were colistin-resistant. All were multidrug-resistant, produced OXA-48, and two also carried NDM-1. The isolates belonged to five distinct sequence types, including high-risk clones (ST11, ST101, ST147). No mcr genes were detected. Four isolates carried disruptive mutations in mgrB, and the remaining strain harbored inactivating mutations in both phoP and phoQ with an intact mgrB. Truncating alterations in PhoP/PhoQ and frequent loss or truncation of OmpK35/OmpK36 were observed. No mgrB/phoP/phoQ alterations were detected among colistin-susceptible controls, and colistin MICs remained stable after 7 days of drug-free passaging. Conclusions: In Tunisian CRKP, colistin resistance was associated with chromosomal alterations, predominantly involving disruption of the MgrB&amp;amp;ndash;PhoPQ pathway, in the absence of mcr genes. These mechanisms in both high-risk and emerging sequence types underscore the adaptability of CRKP and the need for surveillance where colistin remains an important therapeutic option.</description>
	<pubDate>2026-05-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 42: Chromosomal Mechanisms of Colistin Resistance in Clinical Isolates of Carbapenem-Resistant Klebsiella pneumoniae from a Tunisian Tertiary-Care Hospital</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/42">doi: 10.3390/idr18030042</a></p>
	<p>Authors:
		Zaineb Hamzaoui
		Hajer Kilani
		Alain Ocampo-Sosa
		Sana Ferjani
		Elaa Maamar
		Lamia Kanzari
		Ahmed Fakhfakh
		Amel Rehaiem
		Luis Martínez-Martínez
		Ilhem Boutiba Ben Boubaker
		</p>
	<p>Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major nosocomial pathogen. Although newer agents have reduced colistin use in high-income countries, this polymyxin remains important in many low- and middle-income settings. Colistin resistance in K. pneumoniae is most commonly associated with chromosomal alterations affecting the MgrB&amp;amp;ndash;PhoPQ pathway, or with plasmid-mediated mcr genes. This study aimed to investigate chromosomally mediated colistin resistance in CRKP clinical isolates from a Tunisian tertiary hospital. Methods: Between 2010 and 2015, 317 non-duplicate CRKP isolates were collected at Charles Nicolle Hospital, Tunis. Colistin MICs were determined by broth microdilution. Phenotypic tests and PCR characterized carbapenemases, extended-spectrum &amp;amp;beta;-lactamases, AmpC, plasmid-mediated quinolone resistance, mcr and virulence genes. Porins (OmpK35/OmpK36) and the mgrB, phoP and phoQ loci were analyzed by SDS-PAGE and sequencing. Clonal relatedness was assessed by ERIC-PCR and multilocus sequence typing. We additionally compared colistin-resistant isolates with a panel of colistin-susceptible CRKP controls and assessed phenotypic stability after serial passages without colistin. Results: Five isolates (1.6%) were colistin-resistant. All were multidrug-resistant, produced OXA-48, and two also carried NDM-1. The isolates belonged to five distinct sequence types, including high-risk clones (ST11, ST101, ST147). No mcr genes were detected. Four isolates carried disruptive mutations in mgrB, and the remaining strain harbored inactivating mutations in both phoP and phoQ with an intact mgrB. Truncating alterations in PhoP/PhoQ and frequent loss or truncation of OmpK35/OmpK36 were observed. No mgrB/phoP/phoQ alterations were detected among colistin-susceptible controls, and colistin MICs remained stable after 7 days of drug-free passaging. Conclusions: In Tunisian CRKP, colistin resistance was associated with chromosomal alterations, predominantly involving disruption of the MgrB&amp;amp;ndash;PhoPQ pathway, in the absence of mcr genes. These mechanisms in both high-risk and emerging sequence types underscore the adaptability of CRKP and the need for surveillance where colistin remains an important therapeutic option.</p>
	]]></content:encoded>

	<dc:title>Chromosomal Mechanisms of Colistin Resistance in Clinical Isolates of Carbapenem-Resistant Klebsiella pneumoniae from a Tunisian Tertiary-Care Hospital</dc:title>
			<dc:creator>Zaineb Hamzaoui</dc:creator>
			<dc:creator>Hajer Kilani</dc:creator>
			<dc:creator>Alain Ocampo-Sosa</dc:creator>
			<dc:creator>Sana Ferjani</dc:creator>
			<dc:creator>Elaa Maamar</dc:creator>
			<dc:creator>Lamia Kanzari</dc:creator>
			<dc:creator>Ahmed Fakhfakh</dc:creator>
			<dc:creator>Amel Rehaiem</dc:creator>
			<dc:creator>Luis Martínez-Martínez</dc:creator>
			<dc:creator>Ilhem Boutiba Ben Boubaker</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030042</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-05-01</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-05-01</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>42</prism:startingPage>
		<prism:doi>10.3390/idr18030042</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/42</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/41">

	<title>Infectious Disease Reports, Vol. 18, Pages 41: Non-Albicans Candida Peritonitis in Peritoneal Dialysis: Species Distribution, Management, and Outcomes&amp;mdash;A Systematic Case-Based Review</title>
	<link>https://www.mdpi.com/2036-7449/18/3/41</link>
	<description>Background/Objectives: Fungal peritonitis is a severe complication of peritoneal dialysis (PD) associated with catheter removal, technique failure, and increased mortality. Although Candida albicans was traditionally the predominant pathogen, non-albicans Candida (NAC) species are increasingly reported. This review summarizes the epidemiology and outcomes of PD-associated NAC peritonitis. Methods: A systematic review was performed following PRISMA guidelines. PubMed/MEDLINE, Scopus, and Google Scholar were searched (January 1990&amp;amp;ndash;March 2026) for NAC peritonitis studies. Case reports and series with species-level identification were included. Results: 31 studies met the inclusion criteria, comprising 25 individual case reports and 6 case series, totaling 89 NAC isolates. Candida parapsilosis was the most frequently reported species (n = 50), followed by Candida tropicalis (n = 15). Other pathogens included Candida glabrata, Candida guilliermondii, and several rare NAC species. Fluconazole was the most commonly used initial antifungal therapy. Catheter removal was performed in most cases, with the majority of patients requiring transition to hemodialysis. Overall mortality was 20% among individual case reports vs. 24% across case series. Species-specific differences were observed: C. parapsilosis and C. guilliermondii were generally associated with favorable outcomes, whereas infections involving C. glabrata and other emerging NAC species more frequently required treatment escalation and were linked to poorer outcomes. Conclusions: NAC species are an important cause of fungal peritonitis in PD patients and show considerable heterogeneity in clinical outcomes and antifungal susceptibility. Early species-level identification and prompt catheter removal remain essential for optimal management.</description>
	<pubDate>2026-04-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 41: Non-Albicans Candida Peritonitis in Peritoneal Dialysis: Species Distribution, Management, and Outcomes&amp;mdash;A Systematic Case-Based Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/41">doi: 10.3390/idr18030041</a></p>
	<p>Authors:
		John Dotis
		Athina Papadopoulou
		Maria Fourikou
		Marianna Papakonstantinou
		Ioustini Kalaitzopoulou
		Charalampos Antachopoulos
		</p>
	<p>Background/Objectives: Fungal peritonitis is a severe complication of peritoneal dialysis (PD) associated with catheter removal, technique failure, and increased mortality. Although Candida albicans was traditionally the predominant pathogen, non-albicans Candida (NAC) species are increasingly reported. This review summarizes the epidemiology and outcomes of PD-associated NAC peritonitis. Methods: A systematic review was performed following PRISMA guidelines. PubMed/MEDLINE, Scopus, and Google Scholar were searched (January 1990&amp;amp;ndash;March 2026) for NAC peritonitis studies. Case reports and series with species-level identification were included. Results: 31 studies met the inclusion criteria, comprising 25 individual case reports and 6 case series, totaling 89 NAC isolates. Candida parapsilosis was the most frequently reported species (n = 50), followed by Candida tropicalis (n = 15). Other pathogens included Candida glabrata, Candida guilliermondii, and several rare NAC species. Fluconazole was the most commonly used initial antifungal therapy. Catheter removal was performed in most cases, with the majority of patients requiring transition to hemodialysis. Overall mortality was 20% among individual case reports vs. 24% across case series. Species-specific differences were observed: C. parapsilosis and C. guilliermondii were generally associated with favorable outcomes, whereas infections involving C. glabrata and other emerging NAC species more frequently required treatment escalation and were linked to poorer outcomes. Conclusions: NAC species are an important cause of fungal peritonitis in PD patients and show considerable heterogeneity in clinical outcomes and antifungal susceptibility. Early species-level identification and prompt catheter removal remain essential for optimal management.</p>
	]]></content:encoded>

	<dc:title>Non-Albicans Candida Peritonitis in Peritoneal Dialysis: Species Distribution, Management, and Outcomes&amp;amp;mdash;A Systematic Case-Based Review</dc:title>
			<dc:creator>John Dotis</dc:creator>
			<dc:creator>Athina Papadopoulou</dc:creator>
			<dc:creator>Maria Fourikou</dc:creator>
			<dc:creator>Marianna Papakonstantinou</dc:creator>
			<dc:creator>Ioustini Kalaitzopoulou</dc:creator>
			<dc:creator>Charalampos Antachopoulos</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030041</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-27</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>41</prism:startingPage>
		<prism:doi>10.3390/idr18030041</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/41</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/40">

	<title>Infectious Disease Reports, Vol. 18, Pages 40: Cardiovascular Manifestations Documented in Patients with Lyme Disease: Clinical Presentation, Management Strategies, and Outcomes</title>
	<link>https://www.mdpi.com/2036-7449/18/3/40</link>
	<description>Background/Objectives: Lyme disease is a tick-borne zoonosis caused by Borrelia burgdorferi that can affect multiple organ systems. Although cardiovascular involvement is considered uncommon, it may lead to severe and potentially life-threatening complications, particularly conduction disturbances and inflammatory cardiac conditions. This review aims to describe the spectrum of cardiovascular manifestations documented in patients with Lyme disease, focusing on clinical presentation, diagnostic approaches, management strategies, and reported outcomes. Methods: A narrative literature review was performed using PubMed, MEDLINE, and Google Scholar. Articles published between January 2000 and July 2025 in English or Spanish were screened. Eligible studies included original research articles, systematic and narrative reviews, case series, and case reports describing confirmed Lyme disease with cardiovascular involvement. A total of 30 studies were included. The available evidence was predominantly based on case reports and small case series, with considerable heterogeneity in study design, patient populations, and reported outcomes. Data on clinical manifestations, diagnostic methods, treatment strategies, and outcomes were extracted and synthesized. Results: Atrioventricular conduction disturbances were the most frequently reported cardiovascular manifestation, ranging from first-degree block to complete heart block, often presenting abruptly with syncope or bradycardia. Other reported manifestations included atrial and ventricular arrhythmias, myocarditis, pericarditis, myopericarditis, valvular endocarditis, aortitis, and vasculitis. Diagnosis relied on a combination of clinical suspicion, epidemiologic exposure, serologic testing, electrocardiographic monitoring, and cardiac imaging. Most patients were treated with antimicrobial therapy, commonly intravenous ceftriaxone followed by oral doxycycline, with temporary pacemaker support required in selected cases. Overall, clinical outcomes were favorable when treatment was initiated promptly. Conclusions: Cardiovascular involvement in Lyme disease, although infrequent, encompasses a broad clinical spectrum with potentially serious consequences. Early recognition, appropriate diagnostic evaluation, and timely antimicrobial therapy are essential to ensure reversibility of cardiac manifestations and favorable outcomes. However, the available evidence is limited by heterogeneity and the predominance of low-level-evidence studies.</description>
	<pubDate>2026-04-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 40: Cardiovascular Manifestations Documented in Patients with Lyme Disease: Clinical Presentation, Management Strategies, and Outcomes</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/40">doi: 10.3390/idr18030040</a></p>
	<p>Authors:
		Luis Antonio Cortes Islas
		Priscila Mishelle Bartolo Gomez
		Nora Denice Cuevas Obispo
		Ayelen Xicohtencatl Muñoz
		Lao Yuling Lopez Lucero
		Juan Pablo Ramirez Hinojosa
		</p>
	<p>Background/Objectives: Lyme disease is a tick-borne zoonosis caused by Borrelia burgdorferi that can affect multiple organ systems. Although cardiovascular involvement is considered uncommon, it may lead to severe and potentially life-threatening complications, particularly conduction disturbances and inflammatory cardiac conditions. This review aims to describe the spectrum of cardiovascular manifestations documented in patients with Lyme disease, focusing on clinical presentation, diagnostic approaches, management strategies, and reported outcomes. Methods: A narrative literature review was performed using PubMed, MEDLINE, and Google Scholar. Articles published between January 2000 and July 2025 in English or Spanish were screened. Eligible studies included original research articles, systematic and narrative reviews, case series, and case reports describing confirmed Lyme disease with cardiovascular involvement. A total of 30 studies were included. The available evidence was predominantly based on case reports and small case series, with considerable heterogeneity in study design, patient populations, and reported outcomes. Data on clinical manifestations, diagnostic methods, treatment strategies, and outcomes were extracted and synthesized. Results: Atrioventricular conduction disturbances were the most frequently reported cardiovascular manifestation, ranging from first-degree block to complete heart block, often presenting abruptly with syncope or bradycardia. Other reported manifestations included atrial and ventricular arrhythmias, myocarditis, pericarditis, myopericarditis, valvular endocarditis, aortitis, and vasculitis. Diagnosis relied on a combination of clinical suspicion, epidemiologic exposure, serologic testing, electrocardiographic monitoring, and cardiac imaging. Most patients were treated with antimicrobial therapy, commonly intravenous ceftriaxone followed by oral doxycycline, with temporary pacemaker support required in selected cases. Overall, clinical outcomes were favorable when treatment was initiated promptly. Conclusions: Cardiovascular involvement in Lyme disease, although infrequent, encompasses a broad clinical spectrum with potentially serious consequences. Early recognition, appropriate diagnostic evaluation, and timely antimicrobial therapy are essential to ensure reversibility of cardiac manifestations and favorable outcomes. However, the available evidence is limited by heterogeneity and the predominance of low-level-evidence studies.</p>
	]]></content:encoded>

	<dc:title>Cardiovascular Manifestations Documented in Patients with Lyme Disease: Clinical Presentation, Management Strategies, and Outcomes</dc:title>
			<dc:creator>Luis Antonio Cortes Islas</dc:creator>
			<dc:creator>Priscila Mishelle Bartolo Gomez</dc:creator>
			<dc:creator>Nora Denice Cuevas Obispo</dc:creator>
			<dc:creator>Ayelen Xicohtencatl Muñoz</dc:creator>
			<dc:creator>Lao Yuling Lopez Lucero</dc:creator>
			<dc:creator>Juan Pablo Ramirez Hinojosa</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030040</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-27</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>40</prism:startingPage>
		<prism:doi>10.3390/idr18030040</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/40</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/39">

	<title>Infectious Disease Reports, Vol. 18, Pages 39: Spontaneous Pneumomediastinum, Subcutaneous Emphysema, and Pneumoperitoneum in RT-PCR-Confirmed Measles: A Pediatric Case Report</title>
	<link>https://www.mdpi.com/2036-7449/18/3/39</link>
	<description>Measles remains a major global public health challenge as declining vaccination coverage fuels outbreaks worldwide. Although pneumonia is the most recognized respiratory complication, spontaneous air leak syndrome&amp;amp;mdash;including pneumomediastinum, subcutaneous emphysema, and pneumoperitoneum&amp;amp;mdash;is rarely documented. We report the case of a 9-year-old previously healthy girl with no documented measles&amp;amp;ndash;rubella vaccination who presented with fever, maculopapular exanthem, Koplik spots, and persistent cough. Measles was confirmed by both immunoglobulin M enzyme-linked immunosorbent assay and real-time reverse transcription polymerase chain reaction. She developed sudden cervicothoracic swelling and chest pain. Chest radiography revealed pneumomediastinum and subcutaneous emphysema; computed tomography confirmed extensive air leak including pneumoperitoneum. Flexible bronchoscopy and upper gastrointestinal endoscopy excluded structural airway and esophageal injury. Laboratory evaluation revealed elevated hepatic transaminases, gamma-glutamyl transferase, lactate dehydrogenase, and D-dimer. Conservative management with high-flow supplemental oxygen and clinical surveillance led to progressive resolution. The patient was discharged on hospital day three, asymptomatic and breathing room air. This case highlights the spectrum of air leak complications in measles and supports conservative management in hemodynamically stable pediatric patients when structural injury has been excluded.</description>
	<pubDate>2026-04-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 39: Spontaneous Pneumomediastinum, Subcutaneous Emphysema, and Pneumoperitoneum in RT-PCR-Confirmed Measles: A Pediatric Case Report</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/39">doi: 10.3390/idr18030039</a></p>
	<p>Authors:
		Roberto Miguel Damián-Negrete
		Alondra Denisse Hernández-Luna
		Rocío Guadalupe Cano-Arias
		Antonio Durán-Plaza
		Judith Carolina De Arcos-Jiménez
		Kathya Analí Rodríguez-González
		Braulio Dazahel González-Flores
		Pedro Iván Navarro-González
		Jaime Briseno-Ramírez
		</p>
	<p>Measles remains a major global public health challenge as declining vaccination coverage fuels outbreaks worldwide. Although pneumonia is the most recognized respiratory complication, spontaneous air leak syndrome&amp;amp;mdash;including pneumomediastinum, subcutaneous emphysema, and pneumoperitoneum&amp;amp;mdash;is rarely documented. We report the case of a 9-year-old previously healthy girl with no documented measles&amp;amp;ndash;rubella vaccination who presented with fever, maculopapular exanthem, Koplik spots, and persistent cough. Measles was confirmed by both immunoglobulin M enzyme-linked immunosorbent assay and real-time reverse transcription polymerase chain reaction. She developed sudden cervicothoracic swelling and chest pain. Chest radiography revealed pneumomediastinum and subcutaneous emphysema; computed tomography confirmed extensive air leak including pneumoperitoneum. Flexible bronchoscopy and upper gastrointestinal endoscopy excluded structural airway and esophageal injury. Laboratory evaluation revealed elevated hepatic transaminases, gamma-glutamyl transferase, lactate dehydrogenase, and D-dimer. Conservative management with high-flow supplemental oxygen and clinical surveillance led to progressive resolution. The patient was discharged on hospital day three, asymptomatic and breathing room air. This case highlights the spectrum of air leak complications in measles and supports conservative management in hemodynamically stable pediatric patients when structural injury has been excluded.</p>
	]]></content:encoded>

	<dc:title>Spontaneous Pneumomediastinum, Subcutaneous Emphysema, and Pneumoperitoneum in RT-PCR-Confirmed Measles: A Pediatric Case Report</dc:title>
			<dc:creator>Roberto Miguel Damián-Negrete</dc:creator>
			<dc:creator>Alondra Denisse Hernández-Luna</dc:creator>
			<dc:creator>Rocío Guadalupe Cano-Arias</dc:creator>
			<dc:creator>Antonio Durán-Plaza</dc:creator>
			<dc:creator>Judith Carolina De Arcos-Jiménez</dc:creator>
			<dc:creator>Kathya Analí Rodríguez-González</dc:creator>
			<dc:creator>Braulio Dazahel González-Flores</dc:creator>
			<dc:creator>Pedro Iván Navarro-González</dc:creator>
			<dc:creator>Jaime Briseno-Ramírez</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030039</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-24</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>39</prism:startingPage>
		<prism:doi>10.3390/idr18030039</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/39</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/3/38">

	<title>Infectious Disease Reports, Vol. 18, Pages 38: HBV and the Microbiome&amp;mdash;PubMed Database Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/3/38</link>
	<description>Objective: Hepatitis B virus (HBV) is a globally distributed infectious disease affecting the liver. This literature review aims to summarize all available relevant information on the PubMed database about HBV&amp;amp;rsquo;s connection to the microbiome and to consider possible treatment adjuncts. Materials and methods: Database used: PubMed. Keywords used: &amp;amp;ldquo;HBV&amp;amp;rdquo;, &amp;amp;ldquo;Hepatitis B&amp;amp;rdquo;, &amp;amp;ldquo;microbiome&amp;amp;rdquo;. In the PubMed database, 179 research publications were identified using these keywords; 69 studies were excluded as they were irrelevant or retracted. Of the remaining, 110 were analyzed in this literature review, and four additional literature sources were used to supply background information and context. Information was summarized. The analysed studies in total included 14,814 participants (excluding animal studies), of whom 8564 were HBV-infected individuals. Results: Results characterizing abundance or decrease in specific bacterial, viral, and fungal species are heterogeneous; multiple studies support that the HBV patient oral and fecal microbiome is different from that in healthy controls (HCs) and varies throughout disease progression. The HBV seems to transform the microbiome negatively, leading to dysbiosis and decreased microbial diversity in most studies. Evidence links HBV microbiome changes with influence on HbeAg seroconversion, HBV-DNA load, metabolic pathways, liver cirrhosis, and hepatocellular carcinoma. The research proposes that members of microbiota could potentially promote or protect against liver injury in HBV. Four studies proposed that the plasma virome in HBV patients was primarily composed of members of the Anelloviridae. One study researched a parasite (Entamoeba gingivalis) in HBV patients. Two studies analyzed HBV patients&amp;amp;rsquo; fungal profiles. Conclusions: Microbiota research, although promising, at the present moment is heterogeneous. HBV patients&amp;amp;rsquo; microbiota is distinguishable from HCs, and multiple studies have tried to identify the HBV characteristic microbiome; however, more precise information is needed to draw conclusions. Fecal microbiota transplantation and probiotics have the potential to be therapy adjuncts for HBV patients, but more research is needed.</description>
	<pubDate>2026-04-22</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 38: HBV and the Microbiome&amp;mdash;PubMed Database Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/3/38">doi: 10.3390/idr18030038</a></p>
	<p>Authors:
		Anna Marija Prince
		Indra Zeltiņa
		Aigars Reinis
		Olga Valciņa
		Angelika Krūmiņa
		</p>
	<p>Objective: Hepatitis B virus (HBV) is a globally distributed infectious disease affecting the liver. This literature review aims to summarize all available relevant information on the PubMed database about HBV&amp;amp;rsquo;s connection to the microbiome and to consider possible treatment adjuncts. Materials and methods: Database used: PubMed. Keywords used: &amp;amp;ldquo;HBV&amp;amp;rdquo;, &amp;amp;ldquo;Hepatitis B&amp;amp;rdquo;, &amp;amp;ldquo;microbiome&amp;amp;rdquo;. In the PubMed database, 179 research publications were identified using these keywords; 69 studies were excluded as they were irrelevant or retracted. Of the remaining, 110 were analyzed in this literature review, and four additional literature sources were used to supply background information and context. Information was summarized. The analysed studies in total included 14,814 participants (excluding animal studies), of whom 8564 were HBV-infected individuals. Results: Results characterizing abundance or decrease in specific bacterial, viral, and fungal species are heterogeneous; multiple studies support that the HBV patient oral and fecal microbiome is different from that in healthy controls (HCs) and varies throughout disease progression. The HBV seems to transform the microbiome negatively, leading to dysbiosis and decreased microbial diversity in most studies. Evidence links HBV microbiome changes with influence on HbeAg seroconversion, HBV-DNA load, metabolic pathways, liver cirrhosis, and hepatocellular carcinoma. The research proposes that members of microbiota could potentially promote or protect against liver injury in HBV. Four studies proposed that the plasma virome in HBV patients was primarily composed of members of the Anelloviridae. One study researched a parasite (Entamoeba gingivalis) in HBV patients. Two studies analyzed HBV patients&amp;amp;rsquo; fungal profiles. Conclusions: Microbiota research, although promising, at the present moment is heterogeneous. HBV patients&amp;amp;rsquo; microbiota is distinguishable from HCs, and multiple studies have tried to identify the HBV characteristic microbiome; however, more precise information is needed to draw conclusions. Fecal microbiota transplantation and probiotics have the potential to be therapy adjuncts for HBV patients, but more research is needed.</p>
	]]></content:encoded>

	<dc:title>HBV and the Microbiome&amp;amp;mdash;PubMed Database Literature Review</dc:title>
			<dc:creator>Anna Marija Prince</dc:creator>
			<dc:creator>Indra Zeltiņa</dc:creator>
			<dc:creator>Aigars Reinis</dc:creator>
			<dc:creator>Olga Valciņa</dc:creator>
			<dc:creator>Angelika Krūmiņa</dc:creator>
		<dc:identifier>doi: 10.3390/idr18030038</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-22</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-22</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>38</prism:startingPage>
		<prism:doi>10.3390/idr18030038</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/3/38</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/37">

	<title>Infectious Disease Reports, Vol. 18, Pages 37: Influenza A(H3N2) Subclade K (J.2.4.1): Molecular Characterization, Antigenic Divergence, and Global Spread During the 2025/26 Season</title>
	<link>https://www.mdpi.com/2036-7449/18/2/37</link>
	<description>Background: Influenza A(H3N2) continues to evolve rapidly, frequently eroding population immunity and challenging seasonal vaccine strain selection. During the 2025/26 season, the A(H3N2) subclade K (J.2.4.1) expanded quickly across multiple regions and showed evidence of antigenic divergence in standard assays. Methods: In this study, we combined phylogenetic analyses of hemagglutinin (HA) and neuraminidase (NA) sequences with a systematic synthesis of recent peer-reviewed studies and official surveillance reports to comprehensively define the molecular profile and early epidemiological dynamics of subclade K. Results: Our phylogenetic reconstructions of HA and NA genes confirmed the emergence of a coherent and recently diversified lineage characterized by coordinated evolution of surface glycoproteins and broad geographic representation during 2025. Integration of molecular, temporal, and surveillance evidence further supported rapid expansion with limited early regional structuring. Antigenic analyses reported in peer-reviewed studies described reduced haemagglutination inhibition reactivity to vaccine reference antisera for many subclade K viruses, whereas vaccine effectiveness (VE) estimates from multiple settings remained moderate. Conclusions: Overall, the available genetic, antigenic, and epidemiological evidence indicates that subclade K represents a recently diversified A(H3N2) lineage associated with rapid international spread during the 2025/26 season, highlighting the importance of integrated HA/NA genomic surveillance and timely antigenic characterization to support evidence-based vaccine strain selection.</description>
	<pubDate>2026-04-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 37: Influenza A(H3N2) Subclade K (J.2.4.1): Molecular Characterization, Antigenic Divergence, and Global Spread During the 2025/26 Season</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/37">doi: 10.3390/idr18020037</a></p>
	<p>Authors:
		Francesco Branda
		Nicola Petrosillo
		Giancarlo Ceccarelli
		Fabio Scarpa
		Marta Giovanetti
		Massimo Ciccozzi
		</p>
	<p>Background: Influenza A(H3N2) continues to evolve rapidly, frequently eroding population immunity and challenging seasonal vaccine strain selection. During the 2025/26 season, the A(H3N2) subclade K (J.2.4.1) expanded quickly across multiple regions and showed evidence of antigenic divergence in standard assays. Methods: In this study, we combined phylogenetic analyses of hemagglutinin (HA) and neuraminidase (NA) sequences with a systematic synthesis of recent peer-reviewed studies and official surveillance reports to comprehensively define the molecular profile and early epidemiological dynamics of subclade K. Results: Our phylogenetic reconstructions of HA and NA genes confirmed the emergence of a coherent and recently diversified lineage characterized by coordinated evolution of surface glycoproteins and broad geographic representation during 2025. Integration of molecular, temporal, and surveillance evidence further supported rapid expansion with limited early regional structuring. Antigenic analyses reported in peer-reviewed studies described reduced haemagglutination inhibition reactivity to vaccine reference antisera for many subclade K viruses, whereas vaccine effectiveness (VE) estimates from multiple settings remained moderate. Conclusions: Overall, the available genetic, antigenic, and epidemiological evidence indicates that subclade K represents a recently diversified A(H3N2) lineage associated with rapid international spread during the 2025/26 season, highlighting the importance of integrated HA/NA genomic surveillance and timely antigenic characterization to support evidence-based vaccine strain selection.</p>
	]]></content:encoded>

	<dc:title>Influenza A(H3N2) Subclade K (J.2.4.1): Molecular Characterization, Antigenic Divergence, and Global Spread During the 2025/26 Season</dc:title>
			<dc:creator>Francesco Branda</dc:creator>
			<dc:creator>Nicola Petrosillo</dc:creator>
			<dc:creator>Giancarlo Ceccarelli</dc:creator>
			<dc:creator>Fabio Scarpa</dc:creator>
			<dc:creator>Marta Giovanetti</dc:creator>
			<dc:creator>Massimo Ciccozzi</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020037</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-14</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>37</prism:startingPage>
		<prism:doi>10.3390/idr18020037</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/37</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/36">

	<title>Infectious Disease Reports, Vol. 18, Pages 36: Trends in Outpatient Antibiotic Prescriptions Issued in Croatian Primary Healthcare, 2015&amp;ndash;2024</title>
	<link>https://www.mdpi.com/2036-7449/18/2/36</link>
	<description>Objectives: Outpatient antibiotic prescribing is a major driver of antimicrobial resistance, yet detailed long-term analyses of prescribing patterns in Croatia remain limited. This study aimed to analyze trends in outpatient antibiotic prescriptions issued in Croatian primary healthcare from 2015 to 2024, stratified by antibiotic class, substance, and the WHO AWaRe classification. Methods: A retrospective analysis of nationwide data on antibiotic prescriptions issued in primary care outpatient settings was conducted using the data from the Central Health Information System of the Republic of Croatia. All prescriptions for ATC group J01 antibiotics issued between 1 January 2015 and 31 December 2024 were included. The primary outcome was the annual number of issued outpatient antibiotic prescriptions, described overall and by substance. Annual counts were additionally expressed as a percentage of the 2015 baseline (index year = 100%) to enable the comparison across substances with different prescribing volumes. The prescriptions were classified according to the WHO AWaRe framework. Results: A total of 31,048,414 outpatient antibiotic prescriptions were issued between 2015 and 2024. Overall prescribing declined by 5.6% from 2015 to 2019, followed by a marked decrease of 21.0% in 2020, and subsequently rebounded to 3,338,235 prescriptions by 2024, a number virtually identical to pre-pandemic levels. Co-amoxiclav and azithromycin together accounted for 49.5% of all prescriptions. By 2024, prescribing third-generation cephalosporins increased by 281.9% compared to the 2015 levels, while prescribing amoxicillin decreased by 43.6% over the same period. The proportion of Access antibiotics declined from 64.7% in 2015 to 57.9% in 2024. Conclusions: The main challenge for antimicrobial stewardship in Croatia lies not only in overall prescribing volume but in prescribing composition. Targeted interventions are needed to reduce reliance on broad-spectrum agents and promote the use of narrower-spectrum first-line alternatives.</description>
	<pubDate>2026-04-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 36: Trends in Outpatient Antibiotic Prescriptions Issued in Croatian Primary Healthcare, 2015&amp;ndash;2024</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/36">doi: 10.3390/idr18020036</a></p>
	<p>Authors:
		Anamaria Jurčević
		Jelena Dimnjaković
		Rok Čivljak
		</p>
	<p>Objectives: Outpatient antibiotic prescribing is a major driver of antimicrobial resistance, yet detailed long-term analyses of prescribing patterns in Croatia remain limited. This study aimed to analyze trends in outpatient antibiotic prescriptions issued in Croatian primary healthcare from 2015 to 2024, stratified by antibiotic class, substance, and the WHO AWaRe classification. Methods: A retrospective analysis of nationwide data on antibiotic prescriptions issued in primary care outpatient settings was conducted using the data from the Central Health Information System of the Republic of Croatia. All prescriptions for ATC group J01 antibiotics issued between 1 January 2015 and 31 December 2024 were included. The primary outcome was the annual number of issued outpatient antibiotic prescriptions, described overall and by substance. Annual counts were additionally expressed as a percentage of the 2015 baseline (index year = 100%) to enable the comparison across substances with different prescribing volumes. The prescriptions were classified according to the WHO AWaRe framework. Results: A total of 31,048,414 outpatient antibiotic prescriptions were issued between 2015 and 2024. Overall prescribing declined by 5.6% from 2015 to 2019, followed by a marked decrease of 21.0% in 2020, and subsequently rebounded to 3,338,235 prescriptions by 2024, a number virtually identical to pre-pandemic levels. Co-amoxiclav and azithromycin together accounted for 49.5% of all prescriptions. By 2024, prescribing third-generation cephalosporins increased by 281.9% compared to the 2015 levels, while prescribing amoxicillin decreased by 43.6% over the same period. The proportion of Access antibiotics declined from 64.7% in 2015 to 57.9% in 2024. Conclusions: The main challenge for antimicrobial stewardship in Croatia lies not only in overall prescribing volume but in prescribing composition. Targeted interventions are needed to reduce reliance on broad-spectrum agents and promote the use of narrower-spectrum first-line alternatives.</p>
	]]></content:encoded>

	<dc:title>Trends in Outpatient Antibiotic Prescriptions Issued in Croatian Primary Healthcare, 2015&amp;amp;ndash;2024</dc:title>
			<dc:creator>Anamaria Jurčević</dc:creator>
			<dc:creator>Jelena Dimnjaković</dc:creator>
			<dc:creator>Rok Čivljak</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020036</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-14</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>36</prism:startingPage>
		<prism:doi>10.3390/idr18020036</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/36</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/35">

	<title>Infectious Disease Reports, Vol. 18, Pages 35: Prevalence of Mycoplasma genitalium and Co-Infections with Chlamydia trachomatis and Neisseria gonorrhoeae Among Japanese Women: A Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2036-7449/18/2/35</link>
	<description>Background/Objectives: Mycoplasma genitalium is an emerging cause of sexually transmitted infections (STIs) and is increasingly recognized for its association with cervicitis and pelvic inflammatory disease. However, prevalence data in specific Japanese subpopulations, particularly comparing pregnant and non-pregnant women, remains limited. This study aimed to determine the prevalence of M. genitalium and its co-infection rates with Chlamydia trachomatis and Neisseria gonorrhoeae among Japanese women. Methods: A cross-sectional study was conducted using vaginal swab specimens collected between April 2021 and November 2022 from patients visiting two clinics in Gifu, Japan. The study population comprised 2138 non-pregnant women presenting with urogenital symptoms or sexual contact history, and 236 pregnant women undergoing routine antenatal screening. Detection was performed using real-time polymerase chain reaction assays on the cobas&amp;amp;reg; 8800 system (Roche Diagnostics). Results: Among non-pregnant women, the overall prevalence was 3.8% (82/2138) for M. genitalium, 3.4% (72/2138) for C. trachomatis, and 0.4% (9/2138) for N. gonorrhoeae. Co-infection rates were low; M. genitalium and C. trachomatis co-infection was observed in 0.2% of cases. Among pregnant women, the prevalence was 3.8% (9/236) for both M. genitalium and C. trachomatis, and 0.4% (1/236) for N. gonorrhoeae. No statistically significant differences in prevalence were observed between pregnant and non-pregnant women for any pathogen. Conclusions: The prevalence of M. genitalium in this Japanese cohort was comparable to that of C. trachomatis in both pregnant and non-pregnant women, highlighting its significance as a major STI pathogen. These findings underscore the importance of including M. genitalium in routine STI screening panels for symptomatic women and antenatal care to prevent reproductive health complications. Given the high rates of antimicrobial resistance documented in Japanese M. genitalium strains, specific diagnostic testing is essential to enable targeted, resistance-guided therapy.</description>
	<pubDate>2026-04-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 35: Prevalence of Mycoplasma genitalium and Co-Infections with Chlamydia trachomatis and Neisseria gonorrhoeae Among Japanese Women: A Cross-Sectional Study</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/35">doi: 10.3390/idr18020035</a></p>
	<p>Authors:
		Hiroshige Mikamo
		Yuka Yamagishi
		Daisuke Sakanashi
		</p>
	<p>Background/Objectives: Mycoplasma genitalium is an emerging cause of sexually transmitted infections (STIs) and is increasingly recognized for its association with cervicitis and pelvic inflammatory disease. However, prevalence data in specific Japanese subpopulations, particularly comparing pregnant and non-pregnant women, remains limited. This study aimed to determine the prevalence of M. genitalium and its co-infection rates with Chlamydia trachomatis and Neisseria gonorrhoeae among Japanese women. Methods: A cross-sectional study was conducted using vaginal swab specimens collected between April 2021 and November 2022 from patients visiting two clinics in Gifu, Japan. The study population comprised 2138 non-pregnant women presenting with urogenital symptoms or sexual contact history, and 236 pregnant women undergoing routine antenatal screening. Detection was performed using real-time polymerase chain reaction assays on the cobas&amp;amp;reg; 8800 system (Roche Diagnostics). Results: Among non-pregnant women, the overall prevalence was 3.8% (82/2138) for M. genitalium, 3.4% (72/2138) for C. trachomatis, and 0.4% (9/2138) for N. gonorrhoeae. Co-infection rates were low; M. genitalium and C. trachomatis co-infection was observed in 0.2% of cases. Among pregnant women, the prevalence was 3.8% (9/236) for both M. genitalium and C. trachomatis, and 0.4% (1/236) for N. gonorrhoeae. No statistically significant differences in prevalence were observed between pregnant and non-pregnant women for any pathogen. Conclusions: The prevalence of M. genitalium in this Japanese cohort was comparable to that of C. trachomatis in both pregnant and non-pregnant women, highlighting its significance as a major STI pathogen. These findings underscore the importance of including M. genitalium in routine STI screening panels for symptomatic women and antenatal care to prevent reproductive health complications. Given the high rates of antimicrobial resistance documented in Japanese M. genitalium strains, specific diagnostic testing is essential to enable targeted, resistance-guided therapy.</p>
	]]></content:encoded>

	<dc:title>Prevalence of Mycoplasma genitalium and Co-Infections with Chlamydia trachomatis and Neisseria gonorrhoeae Among Japanese Women: A Cross-Sectional Study</dc:title>
			<dc:creator>Hiroshige Mikamo</dc:creator>
			<dc:creator>Yuka Yamagishi</dc:creator>
			<dc:creator>Daisuke Sakanashi</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020035</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>35</prism:startingPage>
		<prism:doi>10.3390/idr18020035</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/35</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/34">

	<title>Infectious Disease Reports, Vol. 18, Pages 34: Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome</title>
	<link>https://www.mdpi.com/2036-7449/18/2/34</link>
	<description>Background: The antibiotic ibezapolstat and the live biotherapeutic product live-JSLM are promising future approaches for treating Clostridioides difficile infection. Ibezapostat is a highly specific antibiotic for Clostridioides difficile, with minimal impact on the intestinal flora. Live-JSLM is designed to restore healthy intestinal microbiota, thus preventing recurrence of Clostridioides difficile infection. In this narrative review, we reviewed available data on ibezapostat and live-JSLM, considering that they are prototypes of two distinct, unique mechanisms of action against Clostridioides difficile. Methods: Data sources: PubMed and SCOPUS databases were searched from 1 January 2012 to 15 November 2025. Original articles reporting data on ibezapolstat and live-JSLM were included. Results: 31 studies were included. When compared to conventional anti-Clostridioides difficile antibiotics, ibezapolstat had a similar level of effectiveness and minimal impact on the gut microbiota. The available data confirm live-JSLM safety and efficacy in restoring the gut microbiota following the conclusion of the standard anti-Clostridioides difficile antibiotic regimen. Conclusions: The results on ibezapolstat efficacy are promising, but require confirmation in larger patient populations through double-blind, randomised phase III trials. In the near future, an integrated approach may enhance the management of Clostridioides difficile infection: starting with highly specific antibiotics, i.e., ibezapolstat, followed by microbiome-based therapies such as live-JSLM.</description>
	<pubDate>2026-04-11</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 34: Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/34">doi: 10.3390/idr18020034</a></p>
	<p>Authors:
		Guido Granata
		Nicola Petrosillo
		</p>
	<p>Background: The antibiotic ibezapolstat and the live biotherapeutic product live-JSLM are promising future approaches for treating Clostridioides difficile infection. Ibezapostat is a highly specific antibiotic for Clostridioides difficile, with minimal impact on the intestinal flora. Live-JSLM is designed to restore healthy intestinal microbiota, thus preventing recurrence of Clostridioides difficile infection. In this narrative review, we reviewed available data on ibezapostat and live-JSLM, considering that they are prototypes of two distinct, unique mechanisms of action against Clostridioides difficile. Methods: Data sources: PubMed and SCOPUS databases were searched from 1 January 2012 to 15 November 2025. Original articles reporting data on ibezapolstat and live-JSLM were included. Results: 31 studies were included. When compared to conventional anti-Clostridioides difficile antibiotics, ibezapolstat had a similar level of effectiveness and minimal impact on the gut microbiota. The available data confirm live-JSLM safety and efficacy in restoring the gut microbiota following the conclusion of the standard anti-Clostridioides difficile antibiotic regimen. Conclusions: The results on ibezapolstat efficacy are promising, but require confirmation in larger patient populations through double-blind, randomised phase III trials. In the near future, an integrated approach may enhance the management of Clostridioides difficile infection: starting with highly specific antibiotics, i.e., ibezapolstat, followed by microbiome-based therapies such as live-JSLM.</p>
	]]></content:encoded>

	<dc:title>Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome</dc:title>
			<dc:creator>Guido Granata</dc:creator>
			<dc:creator>Nicola Petrosillo</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020034</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-11</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-11</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>34</prism:startingPage>
		<prism:doi>10.3390/idr18020034</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/34</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/33">

	<title>Infectious Disease Reports, Vol. 18, Pages 33: Progressive Multifocal Leukoencephalopathy in AIDS: The Diagnostic Role of PET Imaging</title>
	<link>https://www.mdpi.com/2036-7449/18/2/33</link>
	<description>Introduction: The majority of progressive multifocal leukoencephalopathy (PML) cases is still represented by patients affected by acquired immunodeficiency syndrome (AIDS). Diagnosis of PML relies on histopathological findings or by the combination of clinical signs, radiological evidence, and molecular positivity of the JC virus in cerebrospinal fluid. However, AIDS status predisposes to various diseases involving the brain, testing the diagnostic ability of the clinician. Case description: We describe a PML case in a patient with AIDS, in whom lumbar puncture was initially impossible for severe thrombocytopenia and magnetic resonance showed an hyperintense lesion and was unable to distinguish between PML and lymphoma. In this case, [18F]-fluorodeoxyglucose (FDG)-PET imaging showing a hypometabolism of the lesion helped to initially orient toward PML, as diagnosis was later confirmed by lumbar puncture. We collected 21 cases in the literature in which [18F]-FDG-PET was helpful in cases of PML. Discussion and Conclusions: PET imaging is not considered a standard diagnostic tool for PML. However, in selected cases, it may provide valuable information to direct the diagnosis towards PML.</description>
	<pubDate>2026-04-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 33: Progressive Multifocal Leukoencephalopathy in AIDS: The Diagnostic Role of PET Imaging</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/33">doi: 10.3390/idr18020033</a></p>
	<p>Authors:
		Virginia Donini
		Riccardo Paggi
		Alberto Farese
		Costanza Malcontenti
		Enrico Tagliaferri
		Claudio Caroselli
		Spartaco Sani
		Maria Matteini
		Alessandro Bartoloni
		Lorenzo Zammarchi
		</p>
	<p>Introduction: The majority of progressive multifocal leukoencephalopathy (PML) cases is still represented by patients affected by acquired immunodeficiency syndrome (AIDS). Diagnosis of PML relies on histopathological findings or by the combination of clinical signs, radiological evidence, and molecular positivity of the JC virus in cerebrospinal fluid. However, AIDS status predisposes to various diseases involving the brain, testing the diagnostic ability of the clinician. Case description: We describe a PML case in a patient with AIDS, in whom lumbar puncture was initially impossible for severe thrombocytopenia and magnetic resonance showed an hyperintense lesion and was unable to distinguish between PML and lymphoma. In this case, [18F]-fluorodeoxyglucose (FDG)-PET imaging showing a hypometabolism of the lesion helped to initially orient toward PML, as diagnosis was later confirmed by lumbar puncture. We collected 21 cases in the literature in which [18F]-FDG-PET was helpful in cases of PML. Discussion and Conclusions: PET imaging is not considered a standard diagnostic tool for PML. However, in selected cases, it may provide valuable information to direct the diagnosis towards PML.</p>
	]]></content:encoded>

	<dc:title>Progressive Multifocal Leukoencephalopathy in AIDS: The Diagnostic Role of PET Imaging</dc:title>
			<dc:creator>Virginia Donini</dc:creator>
			<dc:creator>Riccardo Paggi</dc:creator>
			<dc:creator>Alberto Farese</dc:creator>
			<dc:creator>Costanza Malcontenti</dc:creator>
			<dc:creator>Enrico Tagliaferri</dc:creator>
			<dc:creator>Claudio Caroselli</dc:creator>
			<dc:creator>Spartaco Sani</dc:creator>
			<dc:creator>Maria Matteini</dc:creator>
			<dc:creator>Alessandro Bartoloni</dc:creator>
			<dc:creator>Lorenzo Zammarchi</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020033</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-08</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>33</prism:startingPage>
		<prism:doi>10.3390/idr18020033</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/33</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/32">

	<title>Infectious Disease Reports, Vol. 18, Pages 32: Brucella anthropi Endocarditis: An Unusual Pathogen</title>
	<link>https://www.mdpi.com/2036-7449/18/2/32</link>
	<description>Background: The genus Brucella has expanded considerably in the 21st century. With the advent of advanced phylogenetic analyses, a close genetic relationship between Brucella and Ochrobactrum has been identified, leading to reclassification of Ochrobactrum species within the genus Brucella. Among these, Brucella anthropi (formerly Ochrobactrum anthropi) is increasingly recognized as a rare cause of invasive human infection. We report a clinically significant case of B. anthropi infective endocarditis and review the available literature. Methods: We report a case of B. anthropi infective endocarditis and conducted a narrative review of the English-language medical literature through 2025. Cases were analyzed for demographics, clinical presentation, antimicrobial susceptibility, and outcomes. Results: A 75-year-old man with a prosthetic aortic valve and prior endocarditis presented with fever of unknown origin, weight loss, and prior transient ischemic attacks. Blood cultures grew B. anthropi after prolonged incubation. Transesophageal echocardiography demonstrated vegetations involving both the aortic and tricuspid valves, and the patient required targeted combination antimicrobial therapy due to persistent bacteremia. Seven additional cases of B. anthropi infective endocarditis were identified on review of the literature. Most patients had underlying valvular disease or prosthetic material. Reported lethality approached 25%. Antimicrobial susceptibility patterns were variable, underscoring the importance of targeted individualized therapy. Conclusion: Consistent with other Gram-negative bacilli, B. anthropi is a rare but established cause of acute bacterial endocarditis. Despite its rarity, it may represent an under-recognized cause of invasive disease. This case highlights the importance of prolonged culture incubation, careful microbiologic interpretation, and susceptibility-guided therapy.</description>
	<pubDate>2026-04-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 32: Brucella anthropi Endocarditis: An Unusual Pathogen</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/32">doi: 10.3390/idr18020032</a></p>
	<p>Authors:
		Fernando Baires
		Erin Arias
		María José Díaz
		Cesar Burgos
		Carlos A. Umaña Mejia
		Justice Cruz
		Joanne Cordero Guerra
		Helen Hoffman
		Jack Bordovsky
		Jana Radwanski
		Miguel Sierra-Hoffman
		Amy C. Madril
		</p>
	<p>Background: The genus Brucella has expanded considerably in the 21st century. With the advent of advanced phylogenetic analyses, a close genetic relationship between Brucella and Ochrobactrum has been identified, leading to reclassification of Ochrobactrum species within the genus Brucella. Among these, Brucella anthropi (formerly Ochrobactrum anthropi) is increasingly recognized as a rare cause of invasive human infection. We report a clinically significant case of B. anthropi infective endocarditis and review the available literature. Methods: We report a case of B. anthropi infective endocarditis and conducted a narrative review of the English-language medical literature through 2025. Cases were analyzed for demographics, clinical presentation, antimicrobial susceptibility, and outcomes. Results: A 75-year-old man with a prosthetic aortic valve and prior endocarditis presented with fever of unknown origin, weight loss, and prior transient ischemic attacks. Blood cultures grew B. anthropi after prolonged incubation. Transesophageal echocardiography demonstrated vegetations involving both the aortic and tricuspid valves, and the patient required targeted combination antimicrobial therapy due to persistent bacteremia. Seven additional cases of B. anthropi infective endocarditis were identified on review of the literature. Most patients had underlying valvular disease or prosthetic material. Reported lethality approached 25%. Antimicrobial susceptibility patterns were variable, underscoring the importance of targeted individualized therapy. Conclusion: Consistent with other Gram-negative bacilli, B. anthropi is a rare but established cause of acute bacterial endocarditis. Despite its rarity, it may represent an under-recognized cause of invasive disease. This case highlights the importance of prolonged culture incubation, careful microbiologic interpretation, and susceptibility-guided therapy.</p>
	]]></content:encoded>

	<dc:title>Brucella anthropi Endocarditis: An Unusual Pathogen</dc:title>
			<dc:creator>Fernando Baires</dc:creator>
			<dc:creator>Erin Arias</dc:creator>
			<dc:creator>María José Díaz</dc:creator>
			<dc:creator>Cesar Burgos</dc:creator>
			<dc:creator>Carlos A. Umaña Mejia</dc:creator>
			<dc:creator>Justice Cruz</dc:creator>
			<dc:creator>Joanne Cordero Guerra</dc:creator>
			<dc:creator>Helen Hoffman</dc:creator>
			<dc:creator>Jack Bordovsky</dc:creator>
			<dc:creator>Jana Radwanski</dc:creator>
			<dc:creator>Miguel Sierra-Hoffman</dc:creator>
			<dc:creator>Amy C. Madril</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020032</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-08</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-08</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>32</prism:startingPage>
		<prism:doi>10.3390/idr18020032</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/32</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/31">

	<title>Infectious Disease Reports, Vol. 18, Pages 31: Therapeutic Management of Septic Venous Thrombosis: A Narrative Review</title>
	<link>https://www.mdpi.com/2036-7449/18/2/31</link>
	<description>Background/Objectives: Septic venous thrombosis is an uncommon complication but clinically significant due to its high morbidity and mortality and the complexity of therapeutic decision-making. The lack of standardized guidelines and the scarcity of high-quality studies complicate clinical management, as most available evidence derives from highly heterogeneous case series and retrospective studies. In this context, a comprehensive overview is essential to guide real-world practice. Methods: This manuscritp provides an in-depth review of the treatment of septic venous thrombosis at its most frequent sites, including the portal vein and its branches, the pelvic veins, catheter-associated events, the internal jugular vein, and dural venous sinus thrombosis. Results: Across all scenarios, early initiation of appropriate antibiotic therapy is the cornerstone of treatment and must be tailored to the suspected source of infection and the patient&amp;amp;rsquo;s clinical course. In parallel, although the role of anticoagulation remains debated, several observational studies suggest potential benefits in terms of recanalization and complication prevention, particularly in selected patients. Conclusions: However, the decision to anticoagulate should be carefully individualized within a multidisciplinary framework. Despite the recent progress, many clinical uncertainties remain. Therefore, well-designed clinical trials are needed to define optimal therapeutic strategies for this condition.</description>
	<pubDate>2026-04-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 31: Therapeutic Management of Septic Venous Thrombosis: A Narrative Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/31">doi: 10.3390/idr18020031</a></p>
	<p>Authors:
		Anabel Franco-Moreno
		Ana Bustamante-Fermosel
		Juan Torres-Macho
		Belén Comeche-Fernández
		</p>
	<p>Background/Objectives: Septic venous thrombosis is an uncommon complication but clinically significant due to its high morbidity and mortality and the complexity of therapeutic decision-making. The lack of standardized guidelines and the scarcity of high-quality studies complicate clinical management, as most available evidence derives from highly heterogeneous case series and retrospective studies. In this context, a comprehensive overview is essential to guide real-world practice. Methods: This manuscritp provides an in-depth review of the treatment of septic venous thrombosis at its most frequent sites, including the portal vein and its branches, the pelvic veins, catheter-associated events, the internal jugular vein, and dural venous sinus thrombosis. Results: Across all scenarios, early initiation of appropriate antibiotic therapy is the cornerstone of treatment and must be tailored to the suspected source of infection and the patient&amp;amp;rsquo;s clinical course. In parallel, although the role of anticoagulation remains debated, several observational studies suggest potential benefits in terms of recanalization and complication prevention, particularly in selected patients. Conclusions: However, the decision to anticoagulate should be carefully individualized within a multidisciplinary framework. Despite the recent progress, many clinical uncertainties remain. Therefore, well-designed clinical trials are needed to define optimal therapeutic strategies for this condition.</p>
	]]></content:encoded>

	<dc:title>Therapeutic Management of Septic Venous Thrombosis: A Narrative Review</dc:title>
			<dc:creator>Anabel Franco-Moreno</dc:creator>
			<dc:creator>Ana Bustamante-Fermosel</dc:creator>
			<dc:creator>Juan Torres-Macho</dc:creator>
			<dc:creator>Belén Comeche-Fernández</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020031</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-03</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-03</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>31</prism:startingPage>
		<prism:doi>10.3390/idr18020031</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/31</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/30">

	<title>Infectious Disease Reports, Vol. 18, Pages 30: Non-Typhoidal Salmonella enterica Bacteremia Complicated by Native Shoulder Septic Arthritis in a Patient with Sickle Cell Disease Following Foodborne Exposure: A Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/2/30</link>
	<description>Background/Objectives: Non-typhoidal Salmonella (NTS) species are well-recognized causes of invasive infection in patients with sickle cell disease (SCD), with a particular predilection for the musculoskeletal system. Although Salmonella osteomyelitis is well described in this population, septic arthritis is uncommon, especially involving the shoulder joint. We describe a case of NTS bacteremia complicated by native shoulder septic arthritis in a patient with SCD and review its clinical implications. Methods: We report the clinical course, diagnostic evaluation, microbiologic findings, imaging studies, and management of a 22-year-old man with homozygous SCD who presented with a vaso-occlusive pain crisis and subsequently developed severe sepsis with persistent Salmonella enterica bacteremia following ingestion of undercooked poultry. Persistent bacteremia prompted further evaluation for metastatic infection using advanced imaging and diagnostic arthrocentesis. Results: Whole-body imaging identified septic arthritis of the native right shoulder, which was confirmed by synovial fluid cultures growing Salmonella species. The patient underwent arthroscopic irrigation and debridement for source control. Antimicrobial therapy was narrowed to intravenous ceftriaxone based on susceptibility data and continued for six weeks. The patient demonstrated clinical improvement with resolution of bacteremia and was discharged to rehabilitation to complete therapy. Conclusions: This case highlights the importance of a careful exposure history, including foodborne sources, in patients with SCD presenting with invasive Salmonella infection. Persistent bacteremia should prompt early investigation for metastatic foci, and timely surgical source control combined with targeted antimicrobial therapy is essential for optimal outcomes in this population.</description>
	<pubDate>2026-04-02</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 30: Non-Typhoidal Salmonella enterica Bacteremia Complicated by Native Shoulder Septic Arthritis in a Patient with Sickle Cell Disease Following Foodborne Exposure: A Case Report and Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/30">doi: 10.3390/idr18020030</a></p>
	<p>Authors:
		Gabriel A. Godart
		Vidit Yadav
		Joseph M. Bestic
		Bradley S. Schoch
		Bryan D. Springer
		Ravi V. Durvasula
		Sammer M. Elwasila
		Justin M. Oring
		</p>
	<p>Background/Objectives: Non-typhoidal Salmonella (NTS) species are well-recognized causes of invasive infection in patients with sickle cell disease (SCD), with a particular predilection for the musculoskeletal system. Although Salmonella osteomyelitis is well described in this population, septic arthritis is uncommon, especially involving the shoulder joint. We describe a case of NTS bacteremia complicated by native shoulder septic arthritis in a patient with SCD and review its clinical implications. Methods: We report the clinical course, diagnostic evaluation, microbiologic findings, imaging studies, and management of a 22-year-old man with homozygous SCD who presented with a vaso-occlusive pain crisis and subsequently developed severe sepsis with persistent Salmonella enterica bacteremia following ingestion of undercooked poultry. Persistent bacteremia prompted further evaluation for metastatic infection using advanced imaging and diagnostic arthrocentesis. Results: Whole-body imaging identified septic arthritis of the native right shoulder, which was confirmed by synovial fluid cultures growing Salmonella species. The patient underwent arthroscopic irrigation and debridement for source control. Antimicrobial therapy was narrowed to intravenous ceftriaxone based on susceptibility data and continued for six weeks. The patient demonstrated clinical improvement with resolution of bacteremia and was discharged to rehabilitation to complete therapy. Conclusions: This case highlights the importance of a careful exposure history, including foodborne sources, in patients with SCD presenting with invasive Salmonella infection. Persistent bacteremia should prompt early investigation for metastatic foci, and timely surgical source control combined with targeted antimicrobial therapy is essential for optimal outcomes in this population.</p>
	]]></content:encoded>

	<dc:title>Non-Typhoidal Salmonella enterica Bacteremia Complicated by Native Shoulder Septic Arthritis in a Patient with Sickle Cell Disease Following Foodborne Exposure: A Case Report and Literature Review</dc:title>
			<dc:creator>Gabriel A. Godart</dc:creator>
			<dc:creator>Vidit Yadav</dc:creator>
			<dc:creator>Joseph M. Bestic</dc:creator>
			<dc:creator>Bradley S. Schoch</dc:creator>
			<dc:creator>Bryan D. Springer</dc:creator>
			<dc:creator>Ravi V. Durvasula</dc:creator>
			<dc:creator>Sammer M. Elwasila</dc:creator>
			<dc:creator>Justin M. Oring</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020030</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-02</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-02</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>30</prism:startingPage>
		<prism:doi>10.3390/idr18020030</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/30</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/29">

	<title>Infectious Disease Reports, Vol. 18, Pages 29: A Blood-Based Interferon Viral Score Defines Acute RSV Bronchiolitis in Infants</title>
	<link>https://www.mdpi.com/2036-7449/18/2/29</link>
	<description>Background: Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infancy. Reliable biomarkers reflecting host antiviral responses and disease dynamics are still lacking. Methods: We evaluated the expression of the interferon-stimulated genes IFI44L, IFI27, and RSAD2 in peripheral blood of infants hospitalized with RSV bronchiolitis at admission and discharge, and in healthy controls, using multiplex RT-qPCR. A composite interferon-based Viral Score was derived from coordinated ISG expression. Results: All three ISGs and the Viral Score were markedly elevated during acute RSV infection at hospital admission compared with discharge and healthy controls. Following clinical recovery, ISG expression and Viral Score declined significantly and approached baseline levels. The Viral Score clearly discriminated acute infection from recovery and healthy states, reflecting dynamic systemic interferon activation. Conclusions: A Viral Score based on IFI44L, IFI27, and RSAD2 captures systemic antiviral immune responses in infants with RSV bronchiolitis and declines with disease resolution. This interferon-based host-response signature represents a promising biomarker for defining viral infection status and monitoring disease dynamics in pediatric respiratory infections.</description>
	<pubDate>2026-04-01</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 29: A Blood-Based Interferon Viral Score Defines Acute RSV Bronchiolitis in Infants</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/29">doi: 10.3390/idr18020029</a></p>
	<p>Authors:
		Ilaria Galliano
		Stefania Alfonsina Liguori
		Anna Pau
		Paola Montanari
		Cristina Calvi
		Anna Clemente
		Anna Massobrio
		Claudia Linari
		Stefano Gambarino
		Alessandra Conio
		Massimiliano Bergallo
		</p>
	<p>Background: Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infancy. Reliable biomarkers reflecting host antiviral responses and disease dynamics are still lacking. Methods: We evaluated the expression of the interferon-stimulated genes IFI44L, IFI27, and RSAD2 in peripheral blood of infants hospitalized with RSV bronchiolitis at admission and discharge, and in healthy controls, using multiplex RT-qPCR. A composite interferon-based Viral Score was derived from coordinated ISG expression. Results: All three ISGs and the Viral Score were markedly elevated during acute RSV infection at hospital admission compared with discharge and healthy controls. Following clinical recovery, ISG expression and Viral Score declined significantly and approached baseline levels. The Viral Score clearly discriminated acute infection from recovery and healthy states, reflecting dynamic systemic interferon activation. Conclusions: A Viral Score based on IFI44L, IFI27, and RSAD2 captures systemic antiviral immune responses in infants with RSV bronchiolitis and declines with disease resolution. This interferon-based host-response signature represents a promising biomarker for defining viral infection status and monitoring disease dynamics in pediatric respiratory infections.</p>
	]]></content:encoded>

	<dc:title>A Blood-Based Interferon Viral Score Defines Acute RSV Bronchiolitis in Infants</dc:title>
			<dc:creator>Ilaria Galliano</dc:creator>
			<dc:creator>Stefania Alfonsina Liguori</dc:creator>
			<dc:creator>Anna Pau</dc:creator>
			<dc:creator>Paola Montanari</dc:creator>
			<dc:creator>Cristina Calvi</dc:creator>
			<dc:creator>Anna Clemente</dc:creator>
			<dc:creator>Anna Massobrio</dc:creator>
			<dc:creator>Claudia Linari</dc:creator>
			<dc:creator>Stefano Gambarino</dc:creator>
			<dc:creator>Alessandra Conio</dc:creator>
			<dc:creator>Massimiliano Bergallo</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020029</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-04-01</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-04-01</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>29</prism:startingPage>
		<prism:doi>10.3390/idr18020029</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/29</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/28">

	<title>Infectious Disease Reports, Vol. 18, Pages 28: Heart Failure Incidence and Risk Factors in U.S. Adults Receiving Bezlotoxumab: A Large Database Analysis</title>
	<link>https://www.mdpi.com/2036-7449/18/2/28</link>
	<description>Background: Bezlotoxumab is used to prevent recurrent Clostridioides difficile infection. Although well tolerated, heart failure (HF) exacerbations have been reported as adverse events in clinical trials. This study evaluates the incidence and predictors of HF exacerbation following bezlotoxumab. Methods: We used the TriNetX research database to identify U.S. adults who received bezlotoxumab and stratified them into three groups based on HF history: no HF, HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The 90-day cumulative incidence of HF events and mortality were assessed. Cox proportional hazard models identified predictors of HF events. Results: Among 2515 patients, 89% had no HF history, 4% had HFpEF, and 7% had HFrEF. The 90-day HF event rates were 1%, 29%, and 52% for the no HF, HFpEF, and HFrEF groups, respectively (p &amp;amp;lt; 0.001). The 90-day all-cause mortality was 0.9%. Corresponding 90-day all-cause mortality rates were 0.04%, 4%, and 11%, respectively (p &amp;amp;lt; 0.001). Independent positive predictors of HF events included HFrEF (aHR 19.400), HFpEF (adjusted hazard ratio [aHR] 8.632), heart transplant (aHR 7.485), hyperlipidemia (aHR 3.184), valvular heart disease (aHR 2.267), chronic kidney disease stage &amp;amp;ge; 3 (aHR 1.715), and ischemic heart disease (aHR 1.987). Protective factors included non-cardiac solid organ transplant (aHR 0.333). Conclusions: Bezlotoxumab appears safe in patients without HF history but is associated with a significantly increased risk of HF exacerbation in those with pre-existing HF, especially HFrEF.</description>
	<pubDate>2026-03-31</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 28: Heart Failure Incidence and Risk Factors in U.S. Adults Receiving Bezlotoxumab: A Large Database Analysis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/28">doi: 10.3390/idr18020028</a></p>
	<p>Authors:
		Chia-Yu Chiu
		Daniel B. Chastain
		Joseph Sassine
		Andrés F. Henao-Martínez
		</p>
	<p>Background: Bezlotoxumab is used to prevent recurrent Clostridioides difficile infection. Although well tolerated, heart failure (HF) exacerbations have been reported as adverse events in clinical trials. This study evaluates the incidence and predictors of HF exacerbation following bezlotoxumab. Methods: We used the TriNetX research database to identify U.S. adults who received bezlotoxumab and stratified them into three groups based on HF history: no HF, HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The 90-day cumulative incidence of HF events and mortality were assessed. Cox proportional hazard models identified predictors of HF events. Results: Among 2515 patients, 89% had no HF history, 4% had HFpEF, and 7% had HFrEF. The 90-day HF event rates were 1%, 29%, and 52% for the no HF, HFpEF, and HFrEF groups, respectively (p &amp;amp;lt; 0.001). The 90-day all-cause mortality was 0.9%. Corresponding 90-day all-cause mortality rates were 0.04%, 4%, and 11%, respectively (p &amp;amp;lt; 0.001). Independent positive predictors of HF events included HFrEF (aHR 19.400), HFpEF (adjusted hazard ratio [aHR] 8.632), heart transplant (aHR 7.485), hyperlipidemia (aHR 3.184), valvular heart disease (aHR 2.267), chronic kidney disease stage &amp;amp;ge; 3 (aHR 1.715), and ischemic heart disease (aHR 1.987). Protective factors included non-cardiac solid organ transplant (aHR 0.333). Conclusions: Bezlotoxumab appears safe in patients without HF history but is associated with a significantly increased risk of HF exacerbation in those with pre-existing HF, especially HFrEF.</p>
	]]></content:encoded>

	<dc:title>Heart Failure Incidence and Risk Factors in U.S. Adults Receiving Bezlotoxumab: A Large Database Analysis</dc:title>
			<dc:creator>Chia-Yu Chiu</dc:creator>
			<dc:creator>Daniel B. Chastain</dc:creator>
			<dc:creator>Joseph Sassine</dc:creator>
			<dc:creator>Andrés F. Henao-Martínez</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020028</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-31</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-31</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>28</prism:startingPage>
		<prism:doi>10.3390/idr18020028</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/28</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/27">

	<title>Infectious Disease Reports, Vol. 18, Pages 27: Matrix-Dependent Sensitivity of Two Pan-Trematode PCR Assays for Detecting Schistosoma spp. in Clinical Human Samples</title>
	<link>https://www.mdpi.com/2036-7449/18/2/27</link>
	<description>Background: Schistosoma spp. are trematodes occurring in tropical endemic areas but can be imported to non-endemic regions as causes of travel-associated infections. In this study, two pan-trematode-specific real-time PCR assays were evaluated for their diagnostic sensitivity in detecting Schistosoma spp. DNA in diagnostic human samples. Methods: Two previously described pan-trematode-specific real-time PCR assays were comparatively assessed using diagnostic samples containing DNA of either the S. haematobium complex or the S. mansoni complex, as confirmed by Schistosoma species complex-specific real-time PCR. Results: Out of a total of 655 samples containing Schistosoma spp. DNA, positive signals in at least one of the two pan-trematode real-time PCR assays were recorded for 17 (2.6%) nucleic acid extractions. Although sensitivity was in the &amp;amp;gt;90% range for stool samples, only a few individual blood plasma and serum samples, and none of the Schistosoma spp. DNA-containing tissue or urine samples, tested positive by pan-trematode PCR. The lower sensitivity of pan-trematode PCR compared with Schistosoma spp.-specific PCR was semi-quantitatively confirmed by higher cycle threshold (Ct) values in the former. When comparing samples with concordant versus discordant positive results for Schistosoma spp.-specific and pan-trematode PCR, Ct values of the Schistosoma spp.-specific PCR were lower in concordantly positive samples than in discordantly positive samples. Conclusions: While the assessed pan-trematode PCR assays showed insufficient sensitivity as screening tools for blood plasma, blood serum, tissue, and urine samples from individuals with suspected schistosomiasis, they were sufficiently sensitive when applied to stool samples, in which substantial amounts of target DNA, as indicated by low Ct values in the Schistosoma species complex-specific real-time PCR assays, can be expected. For screening for Schistosoma spp. DNA in sample materials other than stool, the use of highly sensitive target-specific PCR remains necessary.</description>
	<pubDate>2026-03-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 27: Matrix-Dependent Sensitivity of Two Pan-Trematode PCR Assays for Detecting Schistosoma spp. in Clinical Human Samples</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/27">doi: 10.3390/idr18020027</a></p>
	<p>Authors:
		Hagen Frickmann
		Andreas Hahn
		Kirsten Alexandra Eberhardt
		Ulrike Loderstädt
		Norbert Georg Schwarz
		Ralf Matthias Hagen
		</p>
	<p>Background: Schistosoma spp. are trematodes occurring in tropical endemic areas but can be imported to non-endemic regions as causes of travel-associated infections. In this study, two pan-trematode-specific real-time PCR assays were evaluated for their diagnostic sensitivity in detecting Schistosoma spp. DNA in diagnostic human samples. Methods: Two previously described pan-trematode-specific real-time PCR assays were comparatively assessed using diagnostic samples containing DNA of either the S. haematobium complex or the S. mansoni complex, as confirmed by Schistosoma species complex-specific real-time PCR. Results: Out of a total of 655 samples containing Schistosoma spp. DNA, positive signals in at least one of the two pan-trematode real-time PCR assays were recorded for 17 (2.6%) nucleic acid extractions. Although sensitivity was in the &amp;amp;gt;90% range for stool samples, only a few individual blood plasma and serum samples, and none of the Schistosoma spp. DNA-containing tissue or urine samples, tested positive by pan-trematode PCR. The lower sensitivity of pan-trematode PCR compared with Schistosoma spp.-specific PCR was semi-quantitatively confirmed by higher cycle threshold (Ct) values in the former. When comparing samples with concordant versus discordant positive results for Schistosoma spp.-specific and pan-trematode PCR, Ct values of the Schistosoma spp.-specific PCR were lower in concordantly positive samples than in discordantly positive samples. Conclusions: While the assessed pan-trematode PCR assays showed insufficient sensitivity as screening tools for blood plasma, blood serum, tissue, and urine samples from individuals with suspected schistosomiasis, they were sufficiently sensitive when applied to stool samples, in which substantial amounts of target DNA, as indicated by low Ct values in the Schistosoma species complex-specific real-time PCR assays, can be expected. For screening for Schistosoma spp. DNA in sample materials other than stool, the use of highly sensitive target-specific PCR remains necessary.</p>
	]]></content:encoded>

	<dc:title>Matrix-Dependent Sensitivity of Two Pan-Trematode PCR Assays for Detecting Schistosoma spp. in Clinical Human Samples</dc:title>
			<dc:creator>Hagen Frickmann</dc:creator>
			<dc:creator>Andreas Hahn</dc:creator>
			<dc:creator>Kirsten Alexandra Eberhardt</dc:creator>
			<dc:creator>Ulrike Loderstädt</dc:creator>
			<dc:creator>Norbert Georg Schwarz</dc:creator>
			<dc:creator>Ralf Matthias Hagen</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020027</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-27</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>27</prism:startingPage>
		<prism:doi>10.3390/idr18020027</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/27</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/26">

	<title>Infectious Disease Reports, Vol. 18, Pages 26: Comparative Molecular Docking and Pharmacokinetic Profiling of Cinnamic Acid and Oleic Acid from Cinnamomum verum as Potential Inhibitors of Dengue Virus Proteins</title>
	<link>https://www.mdpi.com/2036-7449/18/2/26</link>
	<description>Background: Dengue virus (DENV) does not have any effective antiviral therapy. The Cinnamomum verum has cinnamic acid and oleic acid that could inhibit important viral proteins. Aim: To compare their inhibitory capacity with the key DENV proteins through molecular docking, molecular dynamics and in silico ADMET. Methods: Phytochemical profiling of the ethanolic extract of the bark was done by GCMS. AutoDock Vina (version 1.2.0) was used to dock cinnamic acid and oleic acid to key proteins of DENV (NS5, NS3, and envelope) in the presence of ribavirin as the reference. The best complexes were then subjected to 50 ns of molecular dynamics simulation and stability measured by RMSD, RMSF, Rg, SASA, hydrogen bonding and RDF. Validated in silico tools were used to predict the ADMET properties. Results: Analysis of GC&amp;amp;ndash;MS revealed cinnamic acid (85.92%) and oleic acid (5.33%). The outcome of docking was that the cinnamic acid had the greatest affinity with NS5 (&amp;amp;minus;5.970 kcal/mol) and the capsid protein (&amp;amp;minus;5.755 kcal/mol), and oleic acid showed the highest affinity with the capsid (&amp;amp;minus;6.150 kcal/mol) and then with NS5 (&amp;amp;minus;5.209 kcal/mol). Both ligands had a relatively weak interaction with NS3. Simulation of the molecular dynamics showed the stability of the top complexes, especially the cinnamic acid&amp;amp;ndash;NS5 complex, that retained low RMSD (1.6&amp;amp;ndash;1.9 A), stable Rg and SASA profiles, and continued hydrogen bonding during the 50 ns period. The use of cinnamic acid in ADMET projections was more preferable, as it was more soluble, orally bioavailable (0.91), and drug-like (QED 0.65), but oleic acid revealed higher lipophilicity and lower drug-like properties (QED 0.29). Conclusions: Cinnamic acid showed specificity towards the NS5 proteins with the help of stable dynamics and good predicted pharmacokinetics, which are features that make it a promising multi-target anti-DENV scaffold. Oleic acid exhibited poor affinity and poor pharmacokinetic properties. The findings are predictive and must be validated using biochemical, cellular, and toxicological means to prove the antiviral efficacy and safety.</description>
	<pubDate>2026-03-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 26: Comparative Molecular Docking and Pharmacokinetic Profiling of Cinnamic Acid and Oleic Acid from Cinnamomum verum as Potential Inhibitors of Dengue Virus Proteins</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/26">doi: 10.3390/idr18020026</a></p>
	<p>Authors:
		Wafaa Hussien Habeeb
		Noor Hameed Hanoush
		Meena Thaar Alani
		Ali Hazim Abdulkareem
		Mohammed Obaid Ibrahim
		Mohammed Salih Al-Janaby
		Mohammed Mukhles Ahmed
		Saja Saadallah Abduljaleel
		Zaid Mustafa Khaleel
		</p>
	<p>Background: Dengue virus (DENV) does not have any effective antiviral therapy. The Cinnamomum verum has cinnamic acid and oleic acid that could inhibit important viral proteins. Aim: To compare their inhibitory capacity with the key DENV proteins through molecular docking, molecular dynamics and in silico ADMET. Methods: Phytochemical profiling of the ethanolic extract of the bark was done by GCMS. AutoDock Vina (version 1.2.0) was used to dock cinnamic acid and oleic acid to key proteins of DENV (NS5, NS3, and envelope) in the presence of ribavirin as the reference. The best complexes were then subjected to 50 ns of molecular dynamics simulation and stability measured by RMSD, RMSF, Rg, SASA, hydrogen bonding and RDF. Validated in silico tools were used to predict the ADMET properties. Results: Analysis of GC&amp;amp;ndash;MS revealed cinnamic acid (85.92%) and oleic acid (5.33%). The outcome of docking was that the cinnamic acid had the greatest affinity with NS5 (&amp;amp;minus;5.970 kcal/mol) and the capsid protein (&amp;amp;minus;5.755 kcal/mol), and oleic acid showed the highest affinity with the capsid (&amp;amp;minus;6.150 kcal/mol) and then with NS5 (&amp;amp;minus;5.209 kcal/mol). Both ligands had a relatively weak interaction with NS3. Simulation of the molecular dynamics showed the stability of the top complexes, especially the cinnamic acid&amp;amp;ndash;NS5 complex, that retained low RMSD (1.6&amp;amp;ndash;1.9 A), stable Rg and SASA profiles, and continued hydrogen bonding during the 50 ns period. The use of cinnamic acid in ADMET projections was more preferable, as it was more soluble, orally bioavailable (0.91), and drug-like (QED 0.65), but oleic acid revealed higher lipophilicity and lower drug-like properties (QED 0.29). Conclusions: Cinnamic acid showed specificity towards the NS5 proteins with the help of stable dynamics and good predicted pharmacokinetics, which are features that make it a promising multi-target anti-DENV scaffold. Oleic acid exhibited poor affinity and poor pharmacokinetic properties. The findings are predictive and must be validated using biochemical, cellular, and toxicological means to prove the antiviral efficacy and safety.</p>
	]]></content:encoded>

	<dc:title>Comparative Molecular Docking and Pharmacokinetic Profiling of Cinnamic Acid and Oleic Acid from Cinnamomum verum as Potential Inhibitors of Dengue Virus Proteins</dc:title>
			<dc:creator>Wafaa Hussien Habeeb</dc:creator>
			<dc:creator>Noor Hameed Hanoush</dc:creator>
			<dc:creator>Meena Thaar Alani</dc:creator>
			<dc:creator>Ali Hazim Abdulkareem</dc:creator>
			<dc:creator>Mohammed Obaid Ibrahim</dc:creator>
			<dc:creator>Mohammed Salih Al-Janaby</dc:creator>
			<dc:creator>Mohammed Mukhles Ahmed</dc:creator>
			<dc:creator>Saja Saadallah Abduljaleel</dc:creator>
			<dc:creator>Zaid Mustafa Khaleel</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020026</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-26</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-26</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>26</prism:startingPage>
		<prism:doi>10.3390/idr18020026</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/26</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/25">

	<title>Infectious Disease Reports, Vol. 18, Pages 25: Global Review on Naegleria fowleri Cases: Contemporary Epidemiology, Diagnosis, Treatment and Outcomes</title>
	<link>https://www.mdpi.com/2036-7449/18/2/25</link>
	<description>Background/Objectives: Primary amoebic meningoencephalitis (PAM) is a rare, fulminant, and often fatal central nervous system infection caused by the opportunistic free-living amoeba Naegleria fowleri. Although Naegleria species are widely present in freshwater and soil worldwide, human disease is associated specifically with pathogenic N. fowleri rather than the many nonpathogenic environmental species, and virulence may vary across N. fowleri isolates. This systematic review aimed to synthesize contemporary global data from 2000 to 2024 to identify recent trends in epidemiology, clinical presentation, diagnosis, treatment, and outcomes. Methods: A systematic literature search was conducted across PubMed, Scopus, and the Cochrane Library, identifying 58 eligible publications encompassing 66 individual cases. Results: Most reports originated from the United States, India, and China. The median patient age was 14 years, with 78% of cases occurring in males. Annual case reports increased from one per year (2000&amp;amp;ndash;2005) to over four per year (2020&amp;amp;ndash;2024), reflecting either a true rise in incidence or improved detection. Common presenting symptoms included fever, headache, and altered mental status. Diagnosis was confirmed via polymerase chain reaction (PCR) testing or post-mortem biopsy in nearly one-third of cases. Treatment regimens varied, with amphotericin B and miltefosine being the most frequently used agents. Overall mortality was 83%, with survival strongly associated with early initiation of combination therapy. Pediatric patients had a higher survival rate (22%) compared to adults (7.1%). Conclusions: The findings highlight the need for heightened clinical awareness, especially in the context of climate-driven ecological changes that may expand N. fowleri&amp;amp;rsquo;s geographic range. This review underscores critical gaps in surveillance and diagnostics and emphasizes the importance of a One Health approach to addressing emerging threats like PAM. Further research into novel therapeutics, rapid diagnostics, and global case reporting systems is urgently needed.</description>
	<pubDate>2026-03-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 25: Global Review on Naegleria fowleri Cases: Contemporary Epidemiology, Diagnosis, Treatment and Outcomes</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/25">doi: 10.3390/idr18020025</a></p>
	<p>Authors:
		Andreas Sarantopoulos
		Annalisa Quattrocchi
		Ioannis Kopsidas
		Oliver A. Cornely
		Danila Seidel
		Itamar Grotto
		Zoi Dorothea Pana
		</p>
	<p>Background/Objectives: Primary amoebic meningoencephalitis (PAM) is a rare, fulminant, and often fatal central nervous system infection caused by the opportunistic free-living amoeba Naegleria fowleri. Although Naegleria species are widely present in freshwater and soil worldwide, human disease is associated specifically with pathogenic N. fowleri rather than the many nonpathogenic environmental species, and virulence may vary across N. fowleri isolates. This systematic review aimed to synthesize contemporary global data from 2000 to 2024 to identify recent trends in epidemiology, clinical presentation, diagnosis, treatment, and outcomes. Methods: A systematic literature search was conducted across PubMed, Scopus, and the Cochrane Library, identifying 58 eligible publications encompassing 66 individual cases. Results: Most reports originated from the United States, India, and China. The median patient age was 14 years, with 78% of cases occurring in males. Annual case reports increased from one per year (2000&amp;amp;ndash;2005) to over four per year (2020&amp;amp;ndash;2024), reflecting either a true rise in incidence or improved detection. Common presenting symptoms included fever, headache, and altered mental status. Diagnosis was confirmed via polymerase chain reaction (PCR) testing or post-mortem biopsy in nearly one-third of cases. Treatment regimens varied, with amphotericin B and miltefosine being the most frequently used agents. Overall mortality was 83%, with survival strongly associated with early initiation of combination therapy. Pediatric patients had a higher survival rate (22%) compared to adults (7.1%). Conclusions: The findings highlight the need for heightened clinical awareness, especially in the context of climate-driven ecological changes that may expand N. fowleri&amp;amp;rsquo;s geographic range. This review underscores critical gaps in surveillance and diagnostics and emphasizes the importance of a One Health approach to addressing emerging threats like PAM. Further research into novel therapeutics, rapid diagnostics, and global case reporting systems is urgently needed.</p>
	]]></content:encoded>

	<dc:title>Global Review on Naegleria fowleri Cases: Contemporary Epidemiology, Diagnosis, Treatment and Outcomes</dc:title>
			<dc:creator>Andreas Sarantopoulos</dc:creator>
			<dc:creator>Annalisa Quattrocchi</dc:creator>
			<dc:creator>Ioannis Kopsidas</dc:creator>
			<dc:creator>Oliver A. Cornely</dc:creator>
			<dc:creator>Danila Seidel</dc:creator>
			<dc:creator>Itamar Grotto</dc:creator>
			<dc:creator>Zoi Dorothea Pana</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020025</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-24</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>25</prism:startingPage>
		<prism:doi>10.3390/idr18020025</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/25</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/24">

	<title>Infectious Disease Reports, Vol. 18, Pages 24: Clinical Management of Severe Cupriavidus gilardii Superinfection After Influenza a Virus Pneumonia: A Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/2/24</link>
	<description>Background: Cupriavidus is an aerobic Gram-negative bacterium and a rare conditional pathogen that mainly infects immunocompromised patients or those undergoing invasive procedures. Methods: We present the case of a 70-year-old male with diabetes mellitus who developed septic shock following influenza A virus (IAV) pneumonia. Cupriavidus gilardii (C. gilardii) was identified in his blood and sputum samples. Through a literature review, we identified 31 reported cases of Cupriavidus infections. Clinical data, including demographic information, clinical characteristics, comorbidities, laboratory results, Cupriavidus species, treatment, and clinical outcomes, were collected. Results: Among these 32 patients (including our patient), 23 were male (71.9%) and 9 were female (28.1%). The median patient age was 32.5 (2.12&amp;amp;ndash;70) years. Most patients had relevant risk factors or comorbidities before Cupriavidus infection, including exposure to polluted environments and recent invasive procedures (68.9%). Among these cases, Cupriavidus pauculus was the most common strain, accounting for 56.3% of cases. The mortality rate was the highest for Cupriavidus pauculus infections. Conclusions: Cupriavidus is a rare opportunistic pathogen in patients with compromised immune function. Early identification of pathogen and timely treatment are crucial. When traditional microbiological detection methods encounter difficulties, gene sequencing can be used as an auxiliary diagnostic tool and can further predict drug resistance. Targeted anti-infection treatment is effective in most cases, but some severe infection cases may lead to death due to serious complications.</description>
	<pubDate>2026-03-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 24: Clinical Management of Severe Cupriavidus gilardii Superinfection After Influenza a Virus Pneumonia: A Case Report and Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/24">doi: 10.3390/idr18020024</a></p>
	<p>Authors:
		Chenxia Guo
		Cuihong Sun
		Jiajia Zheng
		Qingtao Zhou
		Ying Liang
		</p>
	<p>Background: Cupriavidus is an aerobic Gram-negative bacterium and a rare conditional pathogen that mainly infects immunocompromised patients or those undergoing invasive procedures. Methods: We present the case of a 70-year-old male with diabetes mellitus who developed septic shock following influenza A virus (IAV) pneumonia. Cupriavidus gilardii (C. gilardii) was identified in his blood and sputum samples. Through a literature review, we identified 31 reported cases of Cupriavidus infections. Clinical data, including demographic information, clinical characteristics, comorbidities, laboratory results, Cupriavidus species, treatment, and clinical outcomes, were collected. Results: Among these 32 patients (including our patient), 23 were male (71.9%) and 9 were female (28.1%). The median patient age was 32.5 (2.12&amp;amp;ndash;70) years. Most patients had relevant risk factors or comorbidities before Cupriavidus infection, including exposure to polluted environments and recent invasive procedures (68.9%). Among these cases, Cupriavidus pauculus was the most common strain, accounting for 56.3% of cases. The mortality rate was the highest for Cupriavidus pauculus infections. Conclusions: Cupriavidus is a rare opportunistic pathogen in patients with compromised immune function. Early identification of pathogen and timely treatment are crucial. When traditional microbiological detection methods encounter difficulties, gene sequencing can be used as an auxiliary diagnostic tool and can further predict drug resistance. Targeted anti-infection treatment is effective in most cases, but some severe infection cases may lead to death due to serious complications.</p>
	]]></content:encoded>

	<dc:title>Clinical Management of Severe Cupriavidus gilardii Superinfection After Influenza a Virus Pneumonia: A Case Report and Literature Review</dc:title>
			<dc:creator>Chenxia Guo</dc:creator>
			<dc:creator>Cuihong Sun</dc:creator>
			<dc:creator>Jiajia Zheng</dc:creator>
			<dc:creator>Qingtao Zhou</dc:creator>
			<dc:creator>Ying Liang</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020024</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>24</prism:startingPage>
		<prism:doi>10.3390/idr18020024</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/24</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/23">

	<title>Infectious Disease Reports, Vol. 18, Pages 23: Mycobacterium fortuitum: A Neglected Cause of Culture-Negative Prosthetic Valve Endocarditis and a Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/2/23</link>
	<description>Background/Objectives: Prosthetic valve endocarditis caused by non-tuberculous mycobacteria is a rare but serious condition and is often associated with delayed diagnosis due to initially negative routine blood cultures with late positivity after prolonged incubation. Mycobacterium fortuitum, a rapidly growing mycobacterium, is an uncommon cause of endocarditis but may result in significant morbidity if not promptly identified. Methods: We report a 67-year-old man with prior cardiac surgery who presented 18 months later with recurrent fever, weight loss, and renal dysfunction. Initial blood cultures, echocardiography, and standard imaging were non-diagnostic. Ongoing clinical suspicion prompted extended mycobacterial cultures with prolonged incubation and molecular identification performed at a reference laboratory, which revealed M. fortuitum. Results: Antimicrobial susceptibility testing demonstrated susceptibility to amikacin, ciprofloxacin, and clarithromycin, and treatment was initiated with an amikacin-based combination regimen. The patient showed marked clinical and laboratory improvement, including resolution of fever and stabilization of renal function. Conclusions: This case highlights the diagnostic and therapeutic challenges of M. fortuitum prosthetic valve endocarditis and underscores the limitations of routine diagnostic methods in culture-negative endocarditis. It also emphasizes the importance of prolonged incubation and targeted microbiological workflows in suspected cases.</description>
	<pubDate>2026-03-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 23: Mycobacterium fortuitum: A Neglected Cause of Culture-Negative Prosthetic Valve Endocarditis and a Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/23">doi: 10.3390/idr18020023</a></p>
	<p>Authors:
		Selen Şahin
		İrem Tümkaya Kılınç
		Eda Yüksel
		Çağla Mehmet
		Bedia Dinç
		Emine Alp Meşe
		</p>
	<p>Background/Objectives: Prosthetic valve endocarditis caused by non-tuberculous mycobacteria is a rare but serious condition and is often associated with delayed diagnosis due to initially negative routine blood cultures with late positivity after prolonged incubation. Mycobacterium fortuitum, a rapidly growing mycobacterium, is an uncommon cause of endocarditis but may result in significant morbidity if not promptly identified. Methods: We report a 67-year-old man with prior cardiac surgery who presented 18 months later with recurrent fever, weight loss, and renal dysfunction. Initial blood cultures, echocardiography, and standard imaging were non-diagnostic. Ongoing clinical suspicion prompted extended mycobacterial cultures with prolonged incubation and molecular identification performed at a reference laboratory, which revealed M. fortuitum. Results: Antimicrobial susceptibility testing demonstrated susceptibility to amikacin, ciprofloxacin, and clarithromycin, and treatment was initiated with an amikacin-based combination regimen. The patient showed marked clinical and laboratory improvement, including resolution of fever and stabilization of renal function. Conclusions: This case highlights the diagnostic and therapeutic challenges of M. fortuitum prosthetic valve endocarditis and underscores the limitations of routine diagnostic methods in culture-negative endocarditis. It also emphasizes the importance of prolonged incubation and targeted microbiological workflows in suspected cases.</p>
	]]></content:encoded>

	<dc:title>Mycobacterium fortuitum: A Neglected Cause of Culture-Negative Prosthetic Valve Endocarditis and a Literature Review</dc:title>
			<dc:creator>Selen Şahin</dc:creator>
			<dc:creator>İrem Tümkaya Kılınç</dc:creator>
			<dc:creator>Eda Yüksel</dc:creator>
			<dc:creator>Çağla Mehmet</dc:creator>
			<dc:creator>Bedia Dinç</dc:creator>
			<dc:creator>Emine Alp Meşe</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020023</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>23</prism:startingPage>
		<prism:doi>10.3390/idr18020023</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/23</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/22">

	<title>Infectious Disease Reports, Vol. 18, Pages 22: Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity</title>
	<link>https://www.mdpi.com/2036-7449/18/2/22</link>
	<description>Introduction: Trace elements such as zinc, selenium, iron, copper, and manganese play a vital role in human health&amp;amp;mdash;especially in how the immune system responds and how the body handles viral infections. These trace elements have complex and sometimes context-dependent effects: while they can strengthen the body&amp;amp;rsquo;s defenses, imbalances may promote viral replication and worsen tissue damage. Methods: Relevant articles discussed in this narrative review were identified through searches in major databases, including PubMed, Scopus, and Web of Science, primarily those published from 2020 onwards. Discussion: In this review, we examine key findings on how trace elements influence antioxidant defense, modulate viral replication, and regulate cytokine signaling, considering the context of innate immunity and the pathology of viral diseases. We discuss their impact on major infections such as HIV, viral hepatitis, and coronaviruses, highlighting how deficiencies or excesses of certain minerals can affect disease severity, immune responses, and clinical outcomes. The therapeutic use of trace element supplementation is also examined, emphasizing the importance of maintaining proper balance to avoid harmful effects. Conclusions: These findings contribute to a deeper understanding of the complex relationship between micronutrients and viral infections, which can inform the development of more effective prevention and treatment strategies. This review underscores the need for further clinical and experimental studies to define optimal levels of these elements in different health and disease scenarios.</description>
	<pubDate>2026-03-10</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 22: Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/22">doi: 10.3390/idr18020022</a></p>
	<p>Authors:
		Carla Mariana da Silva Medeiros
		Michely da Silva Sousa
		Lucas Hestevan Malta Alfredo
		Jemmyson Romário de Jesus
		Cícero Alves Lopes Júnior
		</p>
	<p>Introduction: Trace elements such as zinc, selenium, iron, copper, and manganese play a vital role in human health&amp;amp;mdash;especially in how the immune system responds and how the body handles viral infections. These trace elements have complex and sometimes context-dependent effects: while they can strengthen the body&amp;amp;rsquo;s defenses, imbalances may promote viral replication and worsen tissue damage. Methods: Relevant articles discussed in this narrative review were identified through searches in major databases, including PubMed, Scopus, and Web of Science, primarily those published from 2020 onwards. Discussion: In this review, we examine key findings on how trace elements influence antioxidant defense, modulate viral replication, and regulate cytokine signaling, considering the context of innate immunity and the pathology of viral diseases. We discuss their impact on major infections such as HIV, viral hepatitis, and coronaviruses, highlighting how deficiencies or excesses of certain minerals can affect disease severity, immune responses, and clinical outcomes. The therapeutic use of trace element supplementation is also examined, emphasizing the importance of maintaining proper balance to avoid harmful effects. Conclusions: These findings contribute to a deeper understanding of the complex relationship between micronutrients and viral infections, which can inform the development of more effective prevention and treatment strategies. This review underscores the need for further clinical and experimental studies to define optimal levels of these elements in different health and disease scenarios.</p>
	]]></content:encoded>

	<dc:title>Trace Elements and Viral Infectious Diseases: Dual Roles in Pathogenesis and Immunity</dc:title>
			<dc:creator>Carla Mariana da Silva Medeiros</dc:creator>
			<dc:creator>Michely da Silva Sousa</dc:creator>
			<dc:creator>Lucas Hestevan Malta Alfredo</dc:creator>
			<dc:creator>Jemmyson Romário de Jesus</dc:creator>
			<dc:creator>Cícero Alves Lopes Júnior</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020022</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-03-10</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-03-10</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>22</prism:startingPage>
		<prism:doi>10.3390/idr18020022</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/22</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/21">

	<title>Infectious Disease Reports, Vol. 18, Pages 21: Streptococcus intermedius Septic Arthritis of the Acromioclavicular Joint with Periarticular Abscesses in an Elderly Man with Diabetes and Recent Canine Exposure: A Case Report and Literature Review</title>
	<link>https://www.mdpi.com/2036-7449/18/2/21</link>
	<description>Background/Objectives: Streptococcus intermedius, a member of the Streptococcus anginosus group, is characterized by a marked propensity for abscess formation but only rarely causes native-joint septic arthritis. Involvement of the acromioclavicular (AC) joint is particularly uncommon. We describe a case of native AC joint septic arthritis due to S. intermedius in a patient with multiple predisposing factors and highlight diagnostic and management considerations. Methods: We report the clinical course of a 72-year-old man with poorly controlled type 2 diabetes mellitus who presented with progressive right shoulder pain, erythema, and swelling following recurrent minor skin abrasions from a newly adopted dog. Initial management for presumed inflammatory shoulder pathology included brief systemic corticosteroids and an ultrasound-guided intra-articular ketorolac injection. Magnetic resonance imaging (MRI) was performed after symptom progression. The patient underwent operative irrigation and debridement with collection of synovial fluid and deep tissue cultures. Blood cultures and transthoracic echocardiography were obtained to evaluate for systemic involvement. Results: MRI demonstrated multiloculated periarticular abscesses and osteolysis centered on the AC joint. Operative cultures yielded high colony counts of S. intermedius from synovial fluid and deep tissues. Blood cultures and echocardiography were negative. The patient required multiple operative debridements with irrigation, adjunctive local antibiotic therapy, and prolonged targeted &amp;amp;beta;-lactam treatment. Clinical and radiographic improvement was achieved following surgical source control and antimicrobial therapy. Conclusions: Native AC joint septic arthritis due to S. intermedius is rare. Older age, uncontrolled diabetes, recent intra-articular intervention, and possible zoonotic inoculation from canine wound licking may represent contributory risk factors. Early imaging, prompt surgical source control, and guideline-concordant antimicrobial therapy are essential when bone and soft tissue involvement is present.</description>
	<pubDate>2026-02-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 21: Streptococcus intermedius Septic Arthritis of the Acromioclavicular Joint with Periarticular Abscesses in an Elderly Man with Diabetes and Recent Canine Exposure: A Case Report and Literature Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/21">doi: 10.3390/idr18020021</a></p>
	<p>Authors:
		Gabriel A. Godart
		Vidit Yadav
		Elizabeth P. Wellings
		Rupert O. Stanborough
		Vincent C. Zummo
		Bryan D. Springer
		Ravi V. Durvasula
		Sammer M. Elwasila
		</p>
	<p>Background/Objectives: Streptococcus intermedius, a member of the Streptococcus anginosus group, is characterized by a marked propensity for abscess formation but only rarely causes native-joint septic arthritis. Involvement of the acromioclavicular (AC) joint is particularly uncommon. We describe a case of native AC joint septic arthritis due to S. intermedius in a patient with multiple predisposing factors and highlight diagnostic and management considerations. Methods: We report the clinical course of a 72-year-old man with poorly controlled type 2 diabetes mellitus who presented with progressive right shoulder pain, erythema, and swelling following recurrent minor skin abrasions from a newly adopted dog. Initial management for presumed inflammatory shoulder pathology included brief systemic corticosteroids and an ultrasound-guided intra-articular ketorolac injection. Magnetic resonance imaging (MRI) was performed after symptom progression. The patient underwent operative irrigation and debridement with collection of synovial fluid and deep tissue cultures. Blood cultures and transthoracic echocardiography were obtained to evaluate for systemic involvement. Results: MRI demonstrated multiloculated periarticular abscesses and osteolysis centered on the AC joint. Operative cultures yielded high colony counts of S. intermedius from synovial fluid and deep tissues. Blood cultures and echocardiography were negative. The patient required multiple operative debridements with irrigation, adjunctive local antibiotic therapy, and prolonged targeted &amp;amp;beta;-lactam treatment. Clinical and radiographic improvement was achieved following surgical source control and antimicrobial therapy. Conclusions: Native AC joint septic arthritis due to S. intermedius is rare. Older age, uncontrolled diabetes, recent intra-articular intervention, and possible zoonotic inoculation from canine wound licking may represent contributory risk factors. Early imaging, prompt surgical source control, and guideline-concordant antimicrobial therapy are essential when bone and soft tissue involvement is present.</p>
	]]></content:encoded>

	<dc:title>Streptococcus intermedius Septic Arthritis of the Acromioclavicular Joint with Periarticular Abscesses in an Elderly Man with Diabetes and Recent Canine Exposure: A Case Report and Literature Review</dc:title>
			<dc:creator>Gabriel A. Godart</dc:creator>
			<dc:creator>Vidit Yadav</dc:creator>
			<dc:creator>Elizabeth P. Wellings</dc:creator>
			<dc:creator>Rupert O. Stanborough</dc:creator>
			<dc:creator>Vincent C. Zummo</dc:creator>
			<dc:creator>Bryan D. Springer</dc:creator>
			<dc:creator>Ravi V. Durvasula</dc:creator>
			<dc:creator>Sammer M. Elwasila</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020021</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-26</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-26</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>21</prism:startingPage>
		<prism:doi>10.3390/idr18020021</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/21</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/2/20">

	<title>Infectious Disease Reports, Vol. 18, Pages 20: Post-COVID-19 Rabies Surveillance and Risk Factors in Rural Eastern Cape, South Africa: A One Health Perspective</title>
	<link>https://www.mdpi.com/2036-7449/18/2/20</link>
	<description>Background: Rabies remains a neglected zoonotic disease in South Africa, particularly in rural areas where surveillance weaknesses, behavioral gaps, and limited One Health coordination persist. Objectives: This study assessed rabies surveillance, behavioral risk factors, and system responsiveness in two rural Eastern Cape communities, with a focus on post-pandemic resilience within a One Health framework. Methods: A cross-sectional, community-based pilot study was conducted among 109 residents using structured questionnaires to collect data on demographics, rabies awareness, vaccination practices, and service disruptions. Descriptive, bivariate, and multivariate analyses identified predictors of dog-bite exposure and pet vaccination. Machine learning models (Decision Tree and Random Forest) were applied to explore risk hierarchies. A composite Surveillance Gap Index (SGI) was developed to integrate behavioral and systemic indicators. Results: While 88% of participants were aware of rabies, only 35% attended awareness campaigns. Dog-bite exposure affected 51% of households, with significantly higher risk among males (aOR = 4.33; p = 0.003). Education was positively associated with pet vaccination (aOR = 1.78). Despite 45% reporting COVID-19 disruptions, communities maintained high post-pandemic vaccination coverage (85.7%). Predictive models (AUC = 0.82&amp;amp;ndash;0.86) identified education, gender, awareness, and distance as key risk drivers. Conclusions: Integrating behavioral insights and predictive analytics into One Health strategies can strengthen rabies surveillance and support progress toward eliminating human rabies by 2030.</description>
	<pubDate>2026-02-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 20: Post-COVID-19 Rabies Surveillance and Risk Factors in Rural Eastern Cape, South Africa: A One Health Perspective</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/2/20">doi: 10.3390/idr18020020</a></p>
	<p>Authors:
		Sithabile Moso
		Laston Gonah
		Mojisola Clara Hosu
		Ntandazo Dlatu
		Teke Apalata
		Lindiwe Modest Faye
		</p>
	<p>Background: Rabies remains a neglected zoonotic disease in South Africa, particularly in rural areas where surveillance weaknesses, behavioral gaps, and limited One Health coordination persist. Objectives: This study assessed rabies surveillance, behavioral risk factors, and system responsiveness in two rural Eastern Cape communities, with a focus on post-pandemic resilience within a One Health framework. Methods: A cross-sectional, community-based pilot study was conducted among 109 residents using structured questionnaires to collect data on demographics, rabies awareness, vaccination practices, and service disruptions. Descriptive, bivariate, and multivariate analyses identified predictors of dog-bite exposure and pet vaccination. Machine learning models (Decision Tree and Random Forest) were applied to explore risk hierarchies. A composite Surveillance Gap Index (SGI) was developed to integrate behavioral and systemic indicators. Results: While 88% of participants were aware of rabies, only 35% attended awareness campaigns. Dog-bite exposure affected 51% of households, with significantly higher risk among males (aOR = 4.33; p = 0.003). Education was positively associated with pet vaccination (aOR = 1.78). Despite 45% reporting COVID-19 disruptions, communities maintained high post-pandemic vaccination coverage (85.7%). Predictive models (AUC = 0.82&amp;amp;ndash;0.86) identified education, gender, awareness, and distance as key risk drivers. Conclusions: Integrating behavioral insights and predictive analytics into One Health strategies can strengthen rabies surveillance and support progress toward eliminating human rabies by 2030.</p>
	]]></content:encoded>

	<dc:title>Post-COVID-19 Rabies Surveillance and Risk Factors in Rural Eastern Cape, South Africa: A One Health Perspective</dc:title>
			<dc:creator>Sithabile Moso</dc:creator>
			<dc:creator>Laston Gonah</dc:creator>
			<dc:creator>Mojisola Clara Hosu</dc:creator>
			<dc:creator>Ntandazo Dlatu</dc:creator>
			<dc:creator>Teke Apalata</dc:creator>
			<dc:creator>Lindiwe Modest Faye</dc:creator>
		<dc:identifier>doi: 10.3390/idr18020020</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-24</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-24</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>20</prism:startingPage>
		<prism:doi>10.3390/idr18020020</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/2/20</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/19">

	<title>Infectious Disease Reports, Vol. 18, Pages 19: Post-Exposure Prophylaxis Prescribing Practices in a Lyme Disease-Endemic Area</title>
	<link>https://www.mdpi.com/2036-7449/18/1/19</link>
	<description>Background/Objectives: The 2020 Infectious Diseases Society of America (IDSA) guidelines recommend a single 200 mg dose of doxycycline within 72 h of tick removal after a high-risk bite for Lyme disease prophylaxis. However, limited data are available on prescribing practices related to this recommendation in highly endemic Lyme disease areas. Methods: We conducted a retrospective chart review on adult patients (aged &amp;amp;ge; 18 years) who received a single dose of oral doxycycline for Lyme disease prevention for the period 2022&amp;amp;ndash;2024 within a rural Wisconsin health system. Patient and provider prescribing characteristics were evaluated. Manual data abstraction was performed on a random sample of 155 prescribing events to assess adherence to IDSA guidelines. Results: A total of 2404 prophylaxis prescriptions were identified; 44% were prescribed to older adults between 65 and 79 years of age, 54% were prescribed to males, and 66% were prescribed to patients living in rural areas. Prescriptions peaked in spring and summer months, consistent with the known seasonal trends in tick activity. Prescribing was distributed relatively evenly across provider types, with the majority (77%) of cases occurring in outpatient and urgent care settings. Upon manual abstraction, doxycycline was indicated in 12% with the remainder either classified as possibly indicated or not indicated due to suboptimal documentation and nonadherence. Conclusions: Our study identified high rates of incomplete documentation and uncertainty in guideline concordance in a Lyme-endemic health system, highlighting the opportunities to support evidence-based prescribing and to improve documentation practices.</description>
	<pubDate>2026-02-14</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 19: Post-Exposure Prophylaxis Prescribing Practices in a Lyme Disease-Endemic Area</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/19">doi: 10.3390/idr18010019</a></p>
	<p>Authors:
		Eun Bin Lee
		Anna Schotthoefer
		Philip Whitfield
		</p>
	<p>Background/Objectives: The 2020 Infectious Diseases Society of America (IDSA) guidelines recommend a single 200 mg dose of doxycycline within 72 h of tick removal after a high-risk bite for Lyme disease prophylaxis. However, limited data are available on prescribing practices related to this recommendation in highly endemic Lyme disease areas. Methods: We conducted a retrospective chart review on adult patients (aged &amp;amp;ge; 18 years) who received a single dose of oral doxycycline for Lyme disease prevention for the period 2022&amp;amp;ndash;2024 within a rural Wisconsin health system. Patient and provider prescribing characteristics were evaluated. Manual data abstraction was performed on a random sample of 155 prescribing events to assess adherence to IDSA guidelines. Results: A total of 2404 prophylaxis prescriptions were identified; 44% were prescribed to older adults between 65 and 79 years of age, 54% were prescribed to males, and 66% were prescribed to patients living in rural areas. Prescriptions peaked in spring and summer months, consistent with the known seasonal trends in tick activity. Prescribing was distributed relatively evenly across provider types, with the majority (77%) of cases occurring in outpatient and urgent care settings. Upon manual abstraction, doxycycline was indicated in 12% with the remainder either classified as possibly indicated or not indicated due to suboptimal documentation and nonadherence. Conclusions: Our study identified high rates of incomplete documentation and uncertainty in guideline concordance in a Lyme-endemic health system, highlighting the opportunities to support evidence-based prescribing and to improve documentation practices.</p>
	]]></content:encoded>

	<dc:title>Post-Exposure Prophylaxis Prescribing Practices in a Lyme Disease-Endemic Area</dc:title>
			<dc:creator>Eun Bin Lee</dc:creator>
			<dc:creator>Anna Schotthoefer</dc:creator>
			<dc:creator>Philip Whitfield</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010019</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-14</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-14</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>19</prism:startingPage>
		<prism:doi>10.3390/idr18010019</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/19</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/18">

	<title>Infectious Disease Reports, Vol. 18, Pages 18: Sickened by the Weather: Exploring the Climatic Impact on West Nile Virus (WNV) and Legionella pneumophila in Piedmont&amp;mdash;A Retrospective Observational Study (2021&amp;ndash;2024)</title>
	<link>https://www.mdpi.com/2036-7449/18/1/18</link>
	<description>Background: Climate change represents a major global health challenge, with rising temperatures and altered precipitation patterns influencing the spread of infectious diseases. This study investigated the association between climatic factors (average temperature and precipitation) and the monthly proportion of laboratory-confirmed Legionella pneumophila serogroup 1 and West Nile Virus infections among clinically suspected patients in a large teaching hospital in Northern Italy. Methods: We retrospectively analyzed data from 2021 to 2024. The primary outcome was the monthly proportion of positive tests (standardized per 1000 clinically suspected patients) for Legionella pneumophila serogroup 1 (urinary antigen) and West Nile Virus (serology). Associations with climatic variables were assessed using linear and multivariate regression models, as well as Generalized Additive Models (GAMs). Seasonal effects were evaluated through ANOVA. Results: For Legionella pneumophila, precipitation was not significantly associated with the proportion of positive tests (p = 0.1438; R2 = 0.049). In contrast, average temperature was a significant predictor: each 1 &amp;amp;deg;C increase was associated with +0.52 positive cases per 1000 tested patients (p = 0.000283; R2 = 0.267). Multivariate models confirmed temperature as the dominant factor. For West Nile Virus, precipitation showed no meaningful effect (p = 0.914). However, average temperature demonstrated a significant positive association with the proportion of positive cases (p = 0.00293; coefficient = 9.33), with seasonal analysis highlighting a marked summer peak (mean = 399.68 positive cases per 1000 tested; p = 0.00653). Conclusions: Our findings underline the predominant role of temperature over precipitation in driving the burden of both Legionella pneumophila and West Nile Virus infections among hospitalized patients. These results strengthen the evidence that the life cycles of these pathogens are tightly climate-dependent. Developing effective adaptation strategies is essential to mitigate climate-related health risks.</description>
	<pubDate>2026-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 18: Sickened by the Weather: Exploring the Climatic Impact on West Nile Virus (WNV) and Legionella pneumophila in Piedmont&amp;mdash;A Retrospective Observational Study (2021&amp;ndash;2024)</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/18">doi: 10.3390/idr18010018</a></p>
	<p>Authors:
		Paolo Valesella
		Antonio Curtoni
		Alessio Leone
		Marco Iannaccone
		Fabrizia Pittaluga
		Elisa Zanotto
		Alessandro Bondi
		Rocco Francesco Rinaldo
		Nour Shbaklo
		Silvia Corcione
		Simone Baldovino
		Irene Cecchi
		Elisa Menegatti
		Paolo Solidoro
		Cristina Costa
		</p>
	<p>Background: Climate change represents a major global health challenge, with rising temperatures and altered precipitation patterns influencing the spread of infectious diseases. This study investigated the association between climatic factors (average temperature and precipitation) and the monthly proportion of laboratory-confirmed Legionella pneumophila serogroup 1 and West Nile Virus infections among clinically suspected patients in a large teaching hospital in Northern Italy. Methods: We retrospectively analyzed data from 2021 to 2024. The primary outcome was the monthly proportion of positive tests (standardized per 1000 clinically suspected patients) for Legionella pneumophila serogroup 1 (urinary antigen) and West Nile Virus (serology). Associations with climatic variables were assessed using linear and multivariate regression models, as well as Generalized Additive Models (GAMs). Seasonal effects were evaluated through ANOVA. Results: For Legionella pneumophila, precipitation was not significantly associated with the proportion of positive tests (p = 0.1438; R2 = 0.049). In contrast, average temperature was a significant predictor: each 1 &amp;amp;deg;C increase was associated with +0.52 positive cases per 1000 tested patients (p = 0.000283; R2 = 0.267). Multivariate models confirmed temperature as the dominant factor. For West Nile Virus, precipitation showed no meaningful effect (p = 0.914). However, average temperature demonstrated a significant positive association with the proportion of positive cases (p = 0.00293; coefficient = 9.33), with seasonal analysis highlighting a marked summer peak (mean = 399.68 positive cases per 1000 tested; p = 0.00653). Conclusions: Our findings underline the predominant role of temperature over precipitation in driving the burden of both Legionella pneumophila and West Nile Virus infections among hospitalized patients. These results strengthen the evidence that the life cycles of these pathogens are tightly climate-dependent. Developing effective adaptation strategies is essential to mitigate climate-related health risks.</p>
	]]></content:encoded>

	<dc:title>Sickened by the Weather: Exploring the Climatic Impact on West Nile Virus (WNV) and Legionella pneumophila in Piedmont&amp;amp;mdash;A Retrospective Observational Study (2021&amp;amp;ndash;2024)</dc:title>
			<dc:creator>Paolo Valesella</dc:creator>
			<dc:creator>Antonio Curtoni</dc:creator>
			<dc:creator>Alessio Leone</dc:creator>
			<dc:creator>Marco Iannaccone</dc:creator>
			<dc:creator>Fabrizia Pittaluga</dc:creator>
			<dc:creator>Elisa Zanotto</dc:creator>
			<dc:creator>Alessandro Bondi</dc:creator>
			<dc:creator>Rocco Francesco Rinaldo</dc:creator>
			<dc:creator>Nour Shbaklo</dc:creator>
			<dc:creator>Silvia Corcione</dc:creator>
			<dc:creator>Simone Baldovino</dc:creator>
			<dc:creator>Irene Cecchi</dc:creator>
			<dc:creator>Elisa Menegatti</dc:creator>
			<dc:creator>Paolo Solidoro</dc:creator>
			<dc:creator>Cristina Costa</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010018</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>18</prism:startingPage>
		<prism:doi>10.3390/idr18010018</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/18</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/17">

	<title>Infectious Disease Reports, Vol. 18, Pages 17: Prosthetic-Valve Endocarditis with Discordant Isolates: A Case Report and a Review of the Literature</title>
	<link>https://www.mdpi.com/2036-7449/18/1/17</link>
	<description>Prosthetic-valve endocarditis (PVE) represents one of the most serious forms of infective endocarditis, marked by high mortality and considerable management complexity. The 2023 European Society of Cardiology (ESC) Guidelines emphasise the diagnostic centrality of repeatedly positive blood cultures. Nonetheless, a significant area of uncertainty remains regarding the diagnostic and prognostic value of cultures from explanted prosthetic valves&amp;amp;mdash;particularly in centres lacking access to molecular diagnostics. Case Presentation: We report a case of prosthetic-valve endocarditis on a bioprosthesis, in which repeated blood-culture sets yielded Streptococcus acidominimus, whereas culture of the explanted valve revealed Staphylococcus warnerii. The patient received six weeks of intravenous vancomycin, with treatment tailored according to the patient&amp;amp;rsquo;s clinical and laboratory parameters and in alignment with international endocarditis guidelines, obtaining a clear clinical and laboratory improvement. Discussion: The literature reports that discordance between blood-culture and valve-culture results in infective endocarditis may range from approximately 10% to 29%, attributable to contamination, biofilm formation or polymicrobial infection. In our case, management guided by the microorganism repeatedly isolated from blood cultures proved effective and aligned with the 2023 European Society of Cardiology (ESC) guidelines. The case underlines the importance of a multidisciplinary team and an integrated interpretation of microbiological, clinical and surgical data. Conclusions: Infective endocarditis with discordant isolates presents a complex diagnostic challenge. The etiological diagnosis must rely primarily on the results of blood cultures, whereas valve culture plays a complementary role&amp;amp;mdash;useful more for prognostic stratification than for initial diagnostic purposes. A multidisciplinary approach and a critical interpretation of microbiological findings are essential to optimise therapeutic management and improve patient outcomes.</description>
	<pubDate>2026-02-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 17: Prosthetic-Valve Endocarditis with Discordant Isolates: A Case Report and a Review of the Literature</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/17">doi: 10.3390/idr18010017</a></p>
	<p>Authors:
		Raffaele Ferri
		Francesco Mucedola
		Marcella Conserva
		Jacopo Vecchiet
		Katia Falasca
		</p>
	<p>Prosthetic-valve endocarditis (PVE) represents one of the most serious forms of infective endocarditis, marked by high mortality and considerable management complexity. The 2023 European Society of Cardiology (ESC) Guidelines emphasise the diagnostic centrality of repeatedly positive blood cultures. Nonetheless, a significant area of uncertainty remains regarding the diagnostic and prognostic value of cultures from explanted prosthetic valves&amp;amp;mdash;particularly in centres lacking access to molecular diagnostics. Case Presentation: We report a case of prosthetic-valve endocarditis on a bioprosthesis, in which repeated blood-culture sets yielded Streptococcus acidominimus, whereas culture of the explanted valve revealed Staphylococcus warnerii. The patient received six weeks of intravenous vancomycin, with treatment tailored according to the patient&amp;amp;rsquo;s clinical and laboratory parameters and in alignment with international endocarditis guidelines, obtaining a clear clinical and laboratory improvement. Discussion: The literature reports that discordance between blood-culture and valve-culture results in infective endocarditis may range from approximately 10% to 29%, attributable to contamination, biofilm formation or polymicrobial infection. In our case, management guided by the microorganism repeatedly isolated from blood cultures proved effective and aligned with the 2023 European Society of Cardiology (ESC) guidelines. The case underlines the importance of a multidisciplinary team and an integrated interpretation of microbiological, clinical and surgical data. Conclusions: Infective endocarditis with discordant isolates presents a complex diagnostic challenge. The etiological diagnosis must rely primarily on the results of blood cultures, whereas valve culture plays a complementary role&amp;amp;mdash;useful more for prognostic stratification than for initial diagnostic purposes. A multidisciplinary approach and a critical interpretation of microbiological findings are essential to optimise therapeutic management and improve patient outcomes.</p>
	]]></content:encoded>

	<dc:title>Prosthetic-Valve Endocarditis with Discordant Isolates: A Case Report and a Review of the Literature</dc:title>
			<dc:creator>Raffaele Ferri</dc:creator>
			<dc:creator>Francesco Mucedola</dc:creator>
			<dc:creator>Marcella Conserva</dc:creator>
			<dc:creator>Jacopo Vecchiet</dc:creator>
			<dc:creator>Katia Falasca</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010017</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>17</prism:startingPage>
		<prism:doi>10.3390/idr18010017</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/17</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/16">

	<title>Infectious Disease Reports, Vol. 18, Pages 16: Efficacy and Safety of Minocycline-Containing Bismuth Quadruple Therapies Versus Standard First-Line Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</title>
	<link>https://www.mdpi.com/2036-7449/18/1/16</link>
	<description>Background: Growing antibiotic resistance and the limited availability of key components in standard Helicobacter pylori treatments have driven the search for effective alternatives. Minocycline, with its broad-spectrum activity and favorable pharmacokinetics, has emerged as a promising substitute. This meta-analysis compares the safety and efficacy of minocycline-containing bismuth quadruple therapy (MBQT) to conventional first-line BQT regimens, incorporating data from the recent study by Lin et al. Methods: The inclusion criteria were randomized controlled trials (RCTs) with a target population of both treatment-na&amp;amp;iuml;ve and previously treated patients diagnosed with Helicobacter pylori (H. pylori) infection. The intervention received by eligible patients was a minocycline&amp;amp;ndash;bismuth quadruple therapy (MBQT) regimen containing bismuth, minocycline, proton pump inhibitors (PPI), and any additional antibiotic with a minimum period of 2 weeks of administration. We excluded study designs other than RCT and clinical trials that include patients without confirmed H. pylori infection, animal populations, in vitro experiments, and reports of other outcomes that did not include a minimum intervention duration of 2 weeks. A comprehensive literature search was conducted on PubMed, EMBASE, Cochrane Library, and ScienceDirect from inception to 20 May 2025. After screening via Rayyan, data were extracted on an Excel spreadsheet. Quality was assessed using the Cochrane RoB 2.0 tool. Eligible randomized controlled trials (RCTs) were included and analyzed using RevMan 5.4. Outcomes assessed were intention-to-treat and per-protocol eradication rates. Adverse effects were compared among therapies. A random-effects model was used; an I2 &amp;amp;lt; 50% and p-value &amp;amp;lt; 0.05 indicated homogeneity and significant results respectively. Results: Five RCTs with 7 interventions involving 2812 patients were included. The pooled odds ratio (OR) for MBQT in intention-to-treat (ITT) analysis was 1.25 (95% CI: 0.96&amp;amp;ndash;1.61), showing a non-significant trend. No heterogeneity was detected (I2 = 0.0%). In the modified ITT (mITT) analysis (2 studies), MBQT showed higher eradication (OR: 1.70, 95% CI: 0.00&amp;amp;ndash;1042.90), but wide CI and high heterogeneity (I2 = 70.7%) limited interpretation. All studies were included in the per-protocol (PP) analysis, which showed a statistically significant improvement with MBQT (OR: 1.67, 95% CI: 1.14&amp;amp;ndash;2.45) and low heterogeneity (I2 = 5.2%), suggesting consistent results. Although not statistically significant, MBQT was associated with a slightly lower rate of adverse events compared to standard therapy (OR: 0.81, 95% CI: 0.59&amp;amp;ndash;1.12). I2 = 50.6% showed moderate heterogeneity in safety outcomes. Discussion: the number of included RCTs was modest, with only five studies meeting eligibility criteria, and only two contributing to the modified intention-to-treat analysis. The risk-of-bias assessment showed variation in methodological quality across the included studies. Several studies exhibited high risk judgments in critical domains. particularly randomization, deviations from intervention, and selective reporting. Patients who completed the treatment benefited more from MBQT, which also had a comparable safety profile to conventional BQT regimens. In the treatment of H. pylori infection, MBQT may be considered a safe alternative for first-line treatment.</description>
	<pubDate>2026-02-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 16: Efficacy and Safety of Minocycline-Containing Bismuth Quadruple Therapies Versus Standard First-Line Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/16">doi: 10.3390/idr18010016</a></p>
	<p>Authors:
		Hakim Ullah Wazir
		Abdul Muqeet Khuram
		I M Khalid Reza
		Hafsa Ajmal
		Hafsa Parveen
		Zeeshan Ahmed
		Yousra Iftequar
		Noora Inam
		Ilyas Muhammad Sulaiman
		Nayanika Tummala
		Hafiz Muhammad Moaaz Sajid
		Anum Zia Khan
		Ussama Shafaqat
		</p>
	<p>Background: Growing antibiotic resistance and the limited availability of key components in standard Helicobacter pylori treatments have driven the search for effective alternatives. Minocycline, with its broad-spectrum activity and favorable pharmacokinetics, has emerged as a promising substitute. This meta-analysis compares the safety and efficacy of minocycline-containing bismuth quadruple therapy (MBQT) to conventional first-line BQT regimens, incorporating data from the recent study by Lin et al. Methods: The inclusion criteria were randomized controlled trials (RCTs) with a target population of both treatment-na&amp;amp;iuml;ve and previously treated patients diagnosed with Helicobacter pylori (H. pylori) infection. The intervention received by eligible patients was a minocycline&amp;amp;ndash;bismuth quadruple therapy (MBQT) regimen containing bismuth, minocycline, proton pump inhibitors (PPI), and any additional antibiotic with a minimum period of 2 weeks of administration. We excluded study designs other than RCT and clinical trials that include patients without confirmed H. pylori infection, animal populations, in vitro experiments, and reports of other outcomes that did not include a minimum intervention duration of 2 weeks. A comprehensive literature search was conducted on PubMed, EMBASE, Cochrane Library, and ScienceDirect from inception to 20 May 2025. After screening via Rayyan, data were extracted on an Excel spreadsheet. Quality was assessed using the Cochrane RoB 2.0 tool. Eligible randomized controlled trials (RCTs) were included and analyzed using RevMan 5.4. Outcomes assessed were intention-to-treat and per-protocol eradication rates. Adverse effects were compared among therapies. A random-effects model was used; an I2 &amp;amp;lt; 50% and p-value &amp;amp;lt; 0.05 indicated homogeneity and significant results respectively. Results: Five RCTs with 7 interventions involving 2812 patients were included. The pooled odds ratio (OR) for MBQT in intention-to-treat (ITT) analysis was 1.25 (95% CI: 0.96&amp;amp;ndash;1.61), showing a non-significant trend. No heterogeneity was detected (I2 = 0.0%). In the modified ITT (mITT) analysis (2 studies), MBQT showed higher eradication (OR: 1.70, 95% CI: 0.00&amp;amp;ndash;1042.90), but wide CI and high heterogeneity (I2 = 70.7%) limited interpretation. All studies were included in the per-protocol (PP) analysis, which showed a statistically significant improvement with MBQT (OR: 1.67, 95% CI: 1.14&amp;amp;ndash;2.45) and low heterogeneity (I2 = 5.2%), suggesting consistent results. Although not statistically significant, MBQT was associated with a slightly lower rate of adverse events compared to standard therapy (OR: 0.81, 95% CI: 0.59&amp;amp;ndash;1.12). I2 = 50.6% showed moderate heterogeneity in safety outcomes. Discussion: the number of included RCTs was modest, with only five studies meeting eligibility criteria, and only two contributing to the modified intention-to-treat analysis. The risk-of-bias assessment showed variation in methodological quality across the included studies. Several studies exhibited high risk judgments in critical domains. particularly randomization, deviations from intervention, and selective reporting. Patients who completed the treatment benefited more from MBQT, which also had a comparable safety profile to conventional BQT regimens. In the treatment of H. pylori infection, MBQT may be considered a safe alternative for first-line treatment.</p>
	]]></content:encoded>

	<dc:title>Efficacy and Safety of Minocycline-Containing Bismuth Quadruple Therapies Versus Standard First-Line Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis</dc:title>
			<dc:creator>Hakim Ullah Wazir</dc:creator>
			<dc:creator>Abdul Muqeet Khuram</dc:creator>
			<dc:creator>I M Khalid Reza</dc:creator>
			<dc:creator>Hafsa Ajmal</dc:creator>
			<dc:creator>Hafsa Parveen</dc:creator>
			<dc:creator>Zeeshan Ahmed</dc:creator>
			<dc:creator>Yousra Iftequar</dc:creator>
			<dc:creator>Noora Inam</dc:creator>
			<dc:creator>Ilyas Muhammad Sulaiman</dc:creator>
			<dc:creator>Nayanika Tummala</dc:creator>
			<dc:creator>Hafiz Muhammad Moaaz Sajid</dc:creator>
			<dc:creator>Anum Zia Khan</dc:creator>
			<dc:creator>Ussama Shafaqat</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010016</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-06</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-06</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Systematic Review</prism:section>
	<prism:startingPage>16</prism:startingPage>
		<prism:doi>10.3390/idr18010016</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/16</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/15">

	<title>Infectious Disease Reports, Vol. 18, Pages 15: Atypical Presentations in Melioidosis: A Case-Based Review from Endemic Regions</title>
	<link>https://www.mdpi.com/2036-7449/18/1/15</link>
	<description>Background: Melioidosis, caused by Burkholderia pseudomallei, is a severe and often underdiagnosed infection endemic to South Asia, Southeast Asia, and northern Australia. While pneumonia and sepsis are the classical presentations, the disease is increasingly recognized for its diverse and atypical clinical manifestations. Objective: The objective is to improve diagnostic accuracy and increase clinical awareness in both endemic and non-endemic settings by reviewing and classifying atypical presentations of melioidosis that have been documented in the literature. Methods: A narrative, case-based review was conducted using 238 published case reports and series from endemic and transitional regions during the period from 2000 to 2025. Cases with non-respiratory presentations or anatomical locations not commonly linked to melioidosis were classified as atypical. Clinical syndromes were used to classify the extracted cases, and common patterns in presentation, diagnosis, and outcome were examined. Results: One hundred and sixty published articles were included after a full text review. The most frequent atypical presentations included neurological involvement (e.g., brain abscess, encephalomyelitis), musculoskeletal infections (osteomyelitis, myositis), thyroid abscess, tubo-ovarian abscess, and dermatologic manifestations such as erythema nodosum. Imported and pediatric cases were also found. Numerous cases were misidentified as cancer, fungal infections, or tuberculosis. Among risk factors, diabetes mellitus was the most prevalent. Non-specific symptoms, a lack of laboratory capacity, and incorrect pathogen identification frequently resulted in delays in diagnosis. Conclusions: In endemic areas, melioidosis should be taken into account when making a differential diagnosis of a variety of clinical syndromes, especially in patients who have diabetes or have had relevant environmental exposure. Poor outcomes and diagnostic delays are greatly exacerbated by atypical presentations. Improving diagnostic capabilities and raising awareness are crucial to lessening the worldwide burden of this often ignored but potentially deadly infection.</description>
	<pubDate>2026-02-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 15: Atypical Presentations in Melioidosis: A Case-Based Review from Endemic Regions</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/15">doi: 10.3390/idr18010015</a></p>
	<p>Authors:
		Saurav Jyoti Patgiri
		Anukalpa Saikia
		Sushmita Yadav
		Md. Atique Ahmed
		Luna Adhikari
		Chimanjita Phukan
		Chiranjay Mukhopadhyay
		Harpreet Kaur
		</p>
	<p>Background: Melioidosis, caused by Burkholderia pseudomallei, is a severe and often underdiagnosed infection endemic to South Asia, Southeast Asia, and northern Australia. While pneumonia and sepsis are the classical presentations, the disease is increasingly recognized for its diverse and atypical clinical manifestations. Objective: The objective is to improve diagnostic accuracy and increase clinical awareness in both endemic and non-endemic settings by reviewing and classifying atypical presentations of melioidosis that have been documented in the literature. Methods: A narrative, case-based review was conducted using 238 published case reports and series from endemic and transitional regions during the period from 2000 to 2025. Cases with non-respiratory presentations or anatomical locations not commonly linked to melioidosis were classified as atypical. Clinical syndromes were used to classify the extracted cases, and common patterns in presentation, diagnosis, and outcome were examined. Results: One hundred and sixty published articles were included after a full text review. The most frequent atypical presentations included neurological involvement (e.g., brain abscess, encephalomyelitis), musculoskeletal infections (osteomyelitis, myositis), thyroid abscess, tubo-ovarian abscess, and dermatologic manifestations such as erythema nodosum. Imported and pediatric cases were also found. Numerous cases were misidentified as cancer, fungal infections, or tuberculosis. Among risk factors, diabetes mellitus was the most prevalent. Non-specific symptoms, a lack of laboratory capacity, and incorrect pathogen identification frequently resulted in delays in diagnosis. Conclusions: In endemic areas, melioidosis should be taken into account when making a differential diagnosis of a variety of clinical syndromes, especially in patients who have diabetes or have had relevant environmental exposure. Poor outcomes and diagnostic delays are greatly exacerbated by atypical presentations. Improving diagnostic capabilities and raising awareness are crucial to lessening the worldwide burden of this often ignored but potentially deadly infection.</p>
	]]></content:encoded>

	<dc:title>Atypical Presentations in Melioidosis: A Case-Based Review from Endemic Regions</dc:title>
			<dc:creator>Saurav Jyoti Patgiri</dc:creator>
			<dc:creator>Anukalpa Saikia</dc:creator>
			<dc:creator>Sushmita Yadav</dc:creator>
			<dc:creator>Md. Atique Ahmed</dc:creator>
			<dc:creator>Luna Adhikari</dc:creator>
			<dc:creator>Chimanjita Phukan</dc:creator>
			<dc:creator>Chiranjay Mukhopadhyay</dc:creator>
			<dc:creator>Harpreet Kaur</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010015</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-02-03</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-02-03</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>15</prism:startingPage>
		<prism:doi>10.3390/idr18010015</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/15</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/14">

	<title>Infectious Disease Reports, Vol. 18, Pages 14: Invasive Fusariosis: Unusual Cases over 10 Years in a Tertiary Care Hospital and a Review of the Literature from Saudi Arabia</title>
	<link>https://www.mdpi.com/2036-7449/18/1/14</link>
	<description>Background/Objectives:&amp;amp;nbsp;Fusarium species are recognized as difficult-to-treat opportunistic pathogens due to extensive antifungal resistance and high mortality rates. Variability in its incidence and outcomes exists across different countries and centers. Large studies on Fusarium species are lacking in Saudi Arabia, with most previous publications being case reports. We describe all cases of invasive fusariosis identified at a tertiary center during a 10-year period and review previous reports in the country. Methods: A retrospective search of hospital records and the microbiology database was conducted to identify cases of invasive fusariosis among patients admitted during 2016&amp;amp;ndash;2025 at King Abdulaziz Medical City, Jeddah, Saudi Arabia. Results: Three cases of invasive fusariosis occurring over a 10-year period were identified. All cases occurred in the last three years of the study period. The incidence during those three years was 0.4 cases per 10,000 admissions per year. Clinical manifestations were fungemia in two immunocompetent patients and ulcers progressing to osteomyelitis in an immunocompromised patient. None of the patients progressed to death within 30 days of diagnosis. Conclusions: Data on Fusarium species are scarce in Saudi Arabia. Additional studies are required to better understand differences in invasive fusariosis between countries.</description>
	<pubDate>2026-01-26</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 14: Invasive Fusariosis: Unusual Cases over 10 Years in a Tertiary Care Hospital and a Review of the Literature from Saudi Arabia</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/14">doi: 10.3390/idr18010014</a></p>
	<p>Authors:
		Hassan Almarhabi
		Abdulmajeed Sarhan
		Murad Essatari
		Hassan Huwait
		</p>
	<p>Background/Objectives:&amp;amp;nbsp;Fusarium species are recognized as difficult-to-treat opportunistic pathogens due to extensive antifungal resistance and high mortality rates. Variability in its incidence and outcomes exists across different countries and centers. Large studies on Fusarium species are lacking in Saudi Arabia, with most previous publications being case reports. We describe all cases of invasive fusariosis identified at a tertiary center during a 10-year period and review previous reports in the country. Methods: A retrospective search of hospital records and the microbiology database was conducted to identify cases of invasive fusariosis among patients admitted during 2016&amp;amp;ndash;2025 at King Abdulaziz Medical City, Jeddah, Saudi Arabia. Results: Three cases of invasive fusariosis occurring over a 10-year period were identified. All cases occurred in the last three years of the study period. The incidence during those three years was 0.4 cases per 10,000 admissions per year. Clinical manifestations were fungemia in two immunocompetent patients and ulcers progressing to osteomyelitis in an immunocompromised patient. None of the patients progressed to death within 30 days of diagnosis. Conclusions: Data on Fusarium species are scarce in Saudi Arabia. Additional studies are required to better understand differences in invasive fusariosis between countries.</p>
	]]></content:encoded>

	<dc:title>Invasive Fusariosis: Unusual Cases over 10 Years in a Tertiary Care Hospital and a Review of the Literature from Saudi Arabia</dc:title>
			<dc:creator>Hassan Almarhabi</dc:creator>
			<dc:creator>Abdulmajeed Sarhan</dc:creator>
			<dc:creator>Murad Essatari</dc:creator>
			<dc:creator>Hassan Huwait</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010014</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-26</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-26</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>14</prism:startingPage>
		<prism:doi>10.3390/idr18010014</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/14</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/13">

	<title>Infectious Disease Reports, Vol. 18, Pages 13: Demographic Factors and Trends Associated with Mortality After AIDS Diagnosis in Puerto Rico</title>
	<link>https://www.mdpi.com/2036-7449/18/1/13</link>
	<description>Background: Millions of people have died from AIDS-related illnesses since the start of the epidemic. The objective of this study is to determine the relationship between life years lost and demographic factors in the subset of individuals in Puerto Rico with advanced HIV disease, i.e., who received a diagnosis of AIDS, and to evaluate trends in poverty, age, and number of diagnoses and deaths over this timeframe. Methods: We identified 3624 individuals diagnosed with AIDS who received services under the Eligible Metropolitan Area (EMA) of San Juan, Puerto Rico, between 2000&amp;amp;ndash;2020, and correlated demographic factors with AIDS descriptive statistics using a retrospective cohort study design. We used socioeconomic characteristics to describe the population, estimated the life years lost (LYL) compared with the life expectancy of the general population of Puerto Rico at a given age as the null model, and evaluated the relationship of demographic variables with LYL, as well as trends in poverty and age/number of deaths/diagnoses over time. Results: More life years are lost with earlier AIDS onset, and there is also an association between LYL and the level of poverty, documented mode of transmission, and insurance status. LYL were higher among AIDS patients with lower income, with perinatal transmission, and among those without insurance in the age bracket of 40&amp;amp;ndash;49 years. No relationship between LYL and gender was detected. Moreover, over the years included in the timeframe of this study, certain trends emerged: we observed a greater proportion of AIDS to HIV diagnoses over time; HIV/AIDS diagnoses and deaths occurred on average at a higher age; the number of diagnoses per year initially rose over time and then declined; and the number of deaths per year as well as the poverty level in those diagnosed with HIV/AIDS increased over time. Conclusions: This study demonstrates the continued recent impact of the HIV epidemic specifically on those with advanced disease (AIDS), and further reaffirms the importance of treatment and prevention as well as demographic and social determinants of health, including age, poverty level, insurance status, and lifestyle, highlighting the disproportionate burden of HIV/AIDS among those with greater levels of poverty.</description>
	<pubDate>2026-01-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 13: Demographic Factors and Trends Associated with Mortality After AIDS Diagnosis in Puerto Rico</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/13">doi: 10.3390/idr18010013</a></p>
	<p>Authors:
		Grisel Burgos-Barreto
		Daniel Reyes
		Raymond L. Tremblay
		</p>
	<p>Background: Millions of people have died from AIDS-related illnesses since the start of the epidemic. The objective of this study is to determine the relationship between life years lost and demographic factors in the subset of individuals in Puerto Rico with advanced HIV disease, i.e., who received a diagnosis of AIDS, and to evaluate trends in poverty, age, and number of diagnoses and deaths over this timeframe. Methods: We identified 3624 individuals diagnosed with AIDS who received services under the Eligible Metropolitan Area (EMA) of San Juan, Puerto Rico, between 2000&amp;amp;ndash;2020, and correlated demographic factors with AIDS descriptive statistics using a retrospective cohort study design. We used socioeconomic characteristics to describe the population, estimated the life years lost (LYL) compared with the life expectancy of the general population of Puerto Rico at a given age as the null model, and evaluated the relationship of demographic variables with LYL, as well as trends in poverty and age/number of deaths/diagnoses over time. Results: More life years are lost with earlier AIDS onset, and there is also an association between LYL and the level of poverty, documented mode of transmission, and insurance status. LYL were higher among AIDS patients with lower income, with perinatal transmission, and among those without insurance in the age bracket of 40&amp;amp;ndash;49 years. No relationship between LYL and gender was detected. Moreover, over the years included in the timeframe of this study, certain trends emerged: we observed a greater proportion of AIDS to HIV diagnoses over time; HIV/AIDS diagnoses and deaths occurred on average at a higher age; the number of diagnoses per year initially rose over time and then declined; and the number of deaths per year as well as the poverty level in those diagnosed with HIV/AIDS increased over time. Conclusions: This study demonstrates the continued recent impact of the HIV epidemic specifically on those with advanced disease (AIDS), and further reaffirms the importance of treatment and prevention as well as demographic and social determinants of health, including age, poverty level, insurance status, and lifestyle, highlighting the disproportionate burden of HIV/AIDS among those with greater levels of poverty.</p>
	]]></content:encoded>

	<dc:title>Demographic Factors and Trends Associated with Mortality After AIDS Diagnosis in Puerto Rico</dc:title>
			<dc:creator>Grisel Burgos-Barreto</dc:creator>
			<dc:creator>Daniel Reyes</dc:creator>
			<dc:creator>Raymond L. Tremblay</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010013</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-20</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-20</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>13</prism:startingPage>
		<prism:doi>10.3390/idr18010013</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/13</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/12">

	<title>Infectious Disease Reports, Vol. 18, Pages 12: Addressing Infectious Diseases in Vulnerable Populations Under the Auspices of One Health: A Call for Action in Europe</title>
	<link>https://www.mdpi.com/2036-7449/18/1/12</link>
	<description>While infectious diseases represent a daunting challenge to public health worldwide, their impact is disproportionately felt among the most vulnerable and marginalized segments of society [...]</description>
	<pubDate>2026-01-15</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 12: Addressing Infectious Diseases in Vulnerable Populations Under the Auspices of One Health: A Call for Action in Europe</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/12">doi: 10.3390/idr18010012</a></p>
	<p>Authors:
		Botond Lakatos
		Ferenc Balázs Farkas
		Giacomo Guido
		Annalisa Saracino
		Francesco Di Gennaro
		</p>
	<p>While infectious diseases represent a daunting challenge to public health worldwide, their impact is disproportionately felt among the most vulnerable and marginalized segments of society [...]</p>
	]]></content:encoded>

	<dc:title>Addressing Infectious Diseases in Vulnerable Populations Under the Auspices of One Health: A Call for Action in Europe</dc:title>
			<dc:creator>Botond Lakatos</dc:creator>
			<dc:creator>Ferenc Balázs Farkas</dc:creator>
			<dc:creator>Giacomo Guido</dc:creator>
			<dc:creator>Annalisa Saracino</dc:creator>
			<dc:creator>Francesco Di Gennaro</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010012</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-15</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-15</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>12</prism:startingPage>
		<prism:doi>10.3390/idr18010012</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/12</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/11">

	<title>Infectious Disease Reports, Vol. 18, Pages 11: Diagnostic Accuracy of Utilizing Artificial Intelligence for Malaria Diagnostic: A Systematic Review and Meta-Analysis</title>
	<link>https://www.mdpi.com/2036-7449/18/1/11</link>
	<description>Background: Malaria remains a major public health concern around the world. Microscopic blood smear examination continues to be the gold standard for diagnosis; however, it requires high technical skills and expertise, limiting diagnostic accuracy in resource-poor settings. Artificial intelligence (AI) has emerged as a promising tool to support malaria detection. This systematic review provides an overview of the diagnostic performance of AI-based systems for malaria diagnosis in a clinical setting. Methods: This study followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and involved articles within the last 10 years that were collected from PubMed, ScienceDirect, Cochrane, EBSCO, and Wiley Online Library. Original articles that reported AI diagnostic accuracy with external validation were involved. The quality of each study was evaluated using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Results: Ten studies with 6754 patients were analyzed. Pooled results of sensitivity [87.7% (95% CI: 78.2&amp;amp;ndash;93.4)] and specificity [91.4% (95% CI: 77.3&amp;amp;ndash;97.1)] revealed how much the AI agrees with each method when that method is used as a gold standard. Additionally, AI achieved a sensitivity of 87.7% and a specificity of 91.4% compared to microscopy examination and a sensitivity of 90.7% and a specificity of 88.3% compared to polymerase chain reaction (PCR). Conclusions: AI-based systems improve malaria diagnosis by providing high accuracy, automation, and lower costs. Showing performance comparable to reference methods such as microscopy and PCR, AI is a promising complementary tool for malaria control.</description>
	<pubDate>2026-01-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 11: Diagnostic Accuracy of Utilizing Artificial Intelligence for Malaria Diagnostic: A Systematic Review and Meta-Analysis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/11">doi: 10.3390/idr18010011</a></p>
	<p>Authors:
		Icha Farihah Deniyati Faratisha
		Khadijah Cahya Yunita
		Hanifa Rizky Rahmawati
		Loeki Enggar Fitri
		Nuning Winaris
		Lailil Muflikah
		</p>
	<p>Background: Malaria remains a major public health concern around the world. Microscopic blood smear examination continues to be the gold standard for diagnosis; however, it requires high technical skills and expertise, limiting diagnostic accuracy in resource-poor settings. Artificial intelligence (AI) has emerged as a promising tool to support malaria detection. This systematic review provides an overview of the diagnostic performance of AI-based systems for malaria diagnosis in a clinical setting. Methods: This study followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and involved articles within the last 10 years that were collected from PubMed, ScienceDirect, Cochrane, EBSCO, and Wiley Online Library. Original articles that reported AI diagnostic accuracy with external validation were involved. The quality of each study was evaluated using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Results: Ten studies with 6754 patients were analyzed. Pooled results of sensitivity [87.7% (95% CI: 78.2&amp;amp;ndash;93.4)] and specificity [91.4% (95% CI: 77.3&amp;amp;ndash;97.1)] revealed how much the AI agrees with each method when that method is used as a gold standard. Additionally, AI achieved a sensitivity of 87.7% and a specificity of 91.4% compared to microscopy examination and a sensitivity of 90.7% and a specificity of 88.3% compared to polymerase chain reaction (PCR). Conclusions: AI-based systems improve malaria diagnosis by providing high accuracy, automation, and lower costs. Showing performance comparable to reference methods such as microscopy and PCR, AI is a promising complementary tool for malaria control.</p>
	]]></content:encoded>

	<dc:title>Diagnostic Accuracy of Utilizing Artificial Intelligence for Malaria Diagnostic: A Systematic Review and Meta-Analysis</dc:title>
			<dc:creator>Icha Farihah Deniyati Faratisha</dc:creator>
			<dc:creator>Khadijah Cahya Yunita</dc:creator>
			<dc:creator>Hanifa Rizky Rahmawati</dc:creator>
			<dc:creator>Loeki Enggar Fitri</dc:creator>
			<dc:creator>Nuning Winaris</dc:creator>
			<dc:creator>Lailil Muflikah</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010011</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-13</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>11</prism:startingPage>
		<prism:doi>10.3390/idr18010011</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/11</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/10">

	<title>Infectious Disease Reports, Vol. 18, Pages 10: Metabolomics in Infectious Diseases and Vaccine Response: Insights into Neglected Tropical and Non-Neglected Pathogens</title>
	<link>https://www.mdpi.com/2036-7449/18/1/10</link>
	<description>Background/objectives: Metabolomics has emerged as a powerful systems-biology tool for deciphering dynamic metabolic alterations occurring during infectious diseases and following vaccination. While genomics and proteomics provide extensive molecular and regulatory information, metabolomics uniquely reflects the biochemical phenotype associated with infection, immune activation, and immunometabolic reprogramming. The objective of this review is to provide an integrated analysis of metabolomics applications across both neglected tropical diseases (NTDs) and non-NTD pathogens, highlighting its dual role in biomarker discovery and vaccine response evaluation. Methods: A comprehensive literature-based synthesis was conducted to examine metabolomic studies in infectious diseases and vaccinology. Metabolic perturbations associated with specific pathogens, as well as vaccine-induced metabolic changes and correlates of immune responses, were systematically analyzed and compared across NTD and non-NTD contexts. Results: Distinct pathogen- and vaccine-associated metabolic signatures were identified, reflecting alterations in glycolysis, amino acid metabolism, lipid remodeling, and immunoregulatory pathways. Comparative analysis revealed both shared and disease-specific metabolic biomarkers across NTDs and non-NTD infections. Importantly, vaccine-related metabolic correlates were shown to mirror immune activation states and, in some cases, predict immunogenicity and response durability. Conclusions: This review bridges metabolomics research in infectious disease pathogenesis and vaccine immunology across the NTD and non-NTD spectrum. By integrating these domains, it introduces the concept of &amp;amp;ldquo;metabolic immuno-signatures&amp;amp;rdquo; as predictive and translational tools for evaluating vaccine efficacy and immune response outcomes.</description>
	<pubDate>2026-01-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 10: Metabolomics in Infectious Diseases and Vaccine Response: Insights into Neglected Tropical and Non-Neglected Pathogens</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/10">doi: 10.3390/idr18010010</a></p>
	<p>Authors:
		Mahbuba Rahman
		Hasbun Nahar Hera
		Urbana Islam Barsha
		</p>
	<p>Background/objectives: Metabolomics has emerged as a powerful systems-biology tool for deciphering dynamic metabolic alterations occurring during infectious diseases and following vaccination. While genomics and proteomics provide extensive molecular and regulatory information, metabolomics uniquely reflects the biochemical phenotype associated with infection, immune activation, and immunometabolic reprogramming. The objective of this review is to provide an integrated analysis of metabolomics applications across both neglected tropical diseases (NTDs) and non-NTD pathogens, highlighting its dual role in biomarker discovery and vaccine response evaluation. Methods: A comprehensive literature-based synthesis was conducted to examine metabolomic studies in infectious diseases and vaccinology. Metabolic perturbations associated with specific pathogens, as well as vaccine-induced metabolic changes and correlates of immune responses, were systematically analyzed and compared across NTD and non-NTD contexts. Results: Distinct pathogen- and vaccine-associated metabolic signatures were identified, reflecting alterations in glycolysis, amino acid metabolism, lipid remodeling, and immunoregulatory pathways. Comparative analysis revealed both shared and disease-specific metabolic biomarkers across NTDs and non-NTD infections. Importantly, vaccine-related metabolic correlates were shown to mirror immune activation states and, in some cases, predict immunogenicity and response durability. Conclusions: This review bridges metabolomics research in infectious disease pathogenesis and vaccine immunology across the NTD and non-NTD spectrum. By integrating these domains, it introduces the concept of &amp;amp;ldquo;metabolic immuno-signatures&amp;amp;rdquo; as predictive and translational tools for evaluating vaccine efficacy and immune response outcomes.</p>
	]]></content:encoded>

	<dc:title>Metabolomics in Infectious Diseases and Vaccine Response: Insights into Neglected Tropical and Non-Neglected Pathogens</dc:title>
			<dc:creator>Mahbuba Rahman</dc:creator>
			<dc:creator>Hasbun Nahar Hera</dc:creator>
			<dc:creator>Urbana Islam Barsha</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010010</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-12</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>10</prism:startingPage>
		<prism:doi>10.3390/idr18010010</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/10</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/9">

	<title>Infectious Disease Reports, Vol. 18, Pages 9: Human Immunodeficiency Virus Infection in Romania Versus Europe: An Epidemiological and Public Health Perspective, 2024 Update</title>
	<link>https://www.mdpi.com/2036-7449/18/1/9</link>
	<description>Background/Objectives: This study presents a comprehensive and updated epidemiological and public health assessment of human immunodeficiency virus (HIV) in Romania during 2022&amp;amp;ndash;2024, situated within the wider European context. Methods: For this retrospective descriptive study, we analyzed national surveillance data from the National Institute of Infectious Diseases &amp;amp;ldquo;Prof. Dr. Matei Bal&amp;amp;#537;&amp;amp;rdquo; and European Centre for Disease Prevention and Control (ECDC) reports, between 1985&amp;amp;ndash;2024, focusing especially on 2022&amp;amp;ndash;2024 period. Key indicators included incidence, mortality, transmission routes, age and gender distribution, and treatment coverage. Comparative analyses were performed between Romania and European Union (EU)/Eastern Europe data. Results: Between 1985 and 2024, Romania registered a cumulative total of 28,793 HIV cases, with 18,768 individuals living with HIV (PLHIV) as of 2024. In that year, 810 new HIV cases were diagnoses, indicating a modest uptick compared with 2022&amp;amp;ndash;2023. Heterosexual transmission continued to predominate (59.4%), followed by cases among men who have sex with men (MSM) (30.5%) and intravenous drug users (IDUs) (5.2%). Men represented more than three-quarters of all new infections. Mortality displayed considerable year-to-year variability, increasing from 125 HIV-related deaths in 2023 to 193 in 2024. Despite this, treatment coverage improved steadily, with 16,464 individuals receiving antiretroviral therapy (ART) by the end of 2024. At 2.51 cases per 100,000 population, Romania&amp;amp;rsquo;s incidence remained below the European average of 3.5 per 100,000. Nonetheless, the proportion of infections attributable to MSM transmission rose sharply&amp;amp;mdash;from 3.91% in 2007 to 32% in 2024&amp;amp;mdash;bringing Romania&amp;amp;rsquo;s epidemiological profile increasingly in line with broader trends observed in Eastern Europe. Conclusions: These findings suggest that although Romania maintains a comparatively lower HIV incidence than the European average, the evolving transmission dynamics&amp;amp;mdash;most notably the substantial increase in MSM-related cases&amp;amp;mdash;signal a shifting epidemiological landscape that warrants strengthened, population-specific prevention measures and continued investment in comprehensive treatment and monitoring frameworks.</description>
	<pubDate>2026-01-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 9: Human Immunodeficiency Virus Infection in Romania Versus Europe: An Epidemiological and Public Health Perspective, 2024 Update</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/9">doi: 10.3390/idr18010009</a></p>
	<p>Authors:
		Andreea-Iuliana Ciobanu
		Sebastian Ionescu
		Ana Maria Tudor
		Mariana Mărdărescu
		Laurențiu-Mihăiță Stratan
		Adrian Gabriel Marinescu
		Cătălin Tiliscan
		Aida-Isabela Adamescu
		Oana Ganea
		Sorin Ștefan Aramă
		Victoria Aramă
		</p>
	<p>Background/Objectives: This study presents a comprehensive and updated epidemiological and public health assessment of human immunodeficiency virus (HIV) in Romania during 2022&amp;amp;ndash;2024, situated within the wider European context. Methods: For this retrospective descriptive study, we analyzed national surveillance data from the National Institute of Infectious Diseases &amp;amp;ldquo;Prof. Dr. Matei Bal&amp;amp;#537;&amp;amp;rdquo; and European Centre for Disease Prevention and Control (ECDC) reports, between 1985&amp;amp;ndash;2024, focusing especially on 2022&amp;amp;ndash;2024 period. Key indicators included incidence, mortality, transmission routes, age and gender distribution, and treatment coverage. Comparative analyses were performed between Romania and European Union (EU)/Eastern Europe data. Results: Between 1985 and 2024, Romania registered a cumulative total of 28,793 HIV cases, with 18,768 individuals living with HIV (PLHIV) as of 2024. In that year, 810 new HIV cases were diagnoses, indicating a modest uptick compared with 2022&amp;amp;ndash;2023. Heterosexual transmission continued to predominate (59.4%), followed by cases among men who have sex with men (MSM) (30.5%) and intravenous drug users (IDUs) (5.2%). Men represented more than three-quarters of all new infections. Mortality displayed considerable year-to-year variability, increasing from 125 HIV-related deaths in 2023 to 193 in 2024. Despite this, treatment coverage improved steadily, with 16,464 individuals receiving antiretroviral therapy (ART) by the end of 2024. At 2.51 cases per 100,000 population, Romania&amp;amp;rsquo;s incidence remained below the European average of 3.5 per 100,000. Nonetheless, the proportion of infections attributable to MSM transmission rose sharply&amp;amp;mdash;from 3.91% in 2007 to 32% in 2024&amp;amp;mdash;bringing Romania&amp;amp;rsquo;s epidemiological profile increasingly in line with broader trends observed in Eastern Europe. Conclusions: These findings suggest that although Romania maintains a comparatively lower HIV incidence than the European average, the evolving transmission dynamics&amp;amp;mdash;most notably the substantial increase in MSM-related cases&amp;amp;mdash;signal a shifting epidemiological landscape that warrants strengthened, population-specific prevention measures and continued investment in comprehensive treatment and monitoring frameworks.</p>
	]]></content:encoded>

	<dc:title>Human Immunodeficiency Virus Infection in Romania Versus Europe: An Epidemiological and Public Health Perspective, 2024 Update</dc:title>
			<dc:creator>Andreea-Iuliana Ciobanu</dc:creator>
			<dc:creator>Sebastian Ionescu</dc:creator>
			<dc:creator>Ana Maria Tudor</dc:creator>
			<dc:creator>Mariana Mărdărescu</dc:creator>
			<dc:creator>Laurențiu-Mihăiță Stratan</dc:creator>
			<dc:creator>Adrian Gabriel Marinescu</dc:creator>
			<dc:creator>Cătălin Tiliscan</dc:creator>
			<dc:creator>Aida-Isabela Adamescu</dc:creator>
			<dc:creator>Oana Ganea</dc:creator>
			<dc:creator>Sorin Ștefan Aramă</dc:creator>
			<dc:creator>Victoria Aramă</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010009</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>9</prism:startingPage>
		<prism:doi>10.3390/idr18010009</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/9</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/8">

	<title>Infectious Disease Reports, Vol. 18, Pages 8: Persistence of Symptoms and Long-Term Recovery in Hospitalized COVID-19 Patients: Results from a Five-Year Follow-Up Cohort</title>
	<link>https://www.mdpi.com/2036-7449/18/1/8</link>
	<description>Background/Objectives: This study aimed to determine the prevalence of persistent symptoms and the radiological and laboratory evolution at 6 months and 5 years after discharge in patients hospitalized for SARS-CoV-2 pneumonia during the first wave of the pandemic in Spain and to estimate the healthcare impact of their follow-up. Methods: A retrospective longitudinal observational study was conducted at the &amp;amp;ldquo;Hospital Central de la Defensa&amp;amp;rdquo;. A total of 200 patients aged &amp;amp;gt;18 years with a diagnosis of SARS-CoV-2 pneumonia were screened. Clinical, radiological, and laboratory data were collected from electronic medical records. Patients with symptoms or radiological abnormalities at discharge underwent in-person evaluations, while the remainder were assessed by telephone. Results: A total of 182 patients met the inclusion and exclusion criteria. Of these, 112 were assessed in the outpatient setting; 60.7% required in-person evaluations, with normal pulmonary auscultation in 93.6%, complete radiological resolution in 85%, and normalized laboratory parameters in almost all cases. At 6 months, 26.5% presented at least one residual symptom, whereas only three patients (4.5%) reported symptoms at 5 years. No risk factors associated with symptom persistence were identified. The estimated cumulative healthcare cost was EUR 21,627.50. Conclusions: Among patients hospitalized for SARS-CoV-2 pneumonia during the first wave of the pandemic, 26.7% and 4.46% presented at least one persistent symptom at 6 months and 5 years after discharge, respectively.</description>
	<pubDate>2026-01-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 8: Persistence of Symptoms and Long-Term Recovery in Hospitalized COVID-19 Patients: Results from a Five-Year Follow-Up Cohort</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/8">doi: 10.3390/idr18010008</a></p>
	<p>Authors:
		Ana Roel Conde
		Francisco Javier Membrillo de Novales
		María Navarro Téllez
		Carlos Gutiérrez Ortega
		Miriam Estébanez Muñoz
		</p>
	<p>Background/Objectives: This study aimed to determine the prevalence of persistent symptoms and the radiological and laboratory evolution at 6 months and 5 years after discharge in patients hospitalized for SARS-CoV-2 pneumonia during the first wave of the pandemic in Spain and to estimate the healthcare impact of their follow-up. Methods: A retrospective longitudinal observational study was conducted at the &amp;amp;ldquo;Hospital Central de la Defensa&amp;amp;rdquo;. A total of 200 patients aged &amp;amp;gt;18 years with a diagnosis of SARS-CoV-2 pneumonia were screened. Clinical, radiological, and laboratory data were collected from electronic medical records. Patients with symptoms or radiological abnormalities at discharge underwent in-person evaluations, while the remainder were assessed by telephone. Results: A total of 182 patients met the inclusion and exclusion criteria. Of these, 112 were assessed in the outpatient setting; 60.7% required in-person evaluations, with normal pulmonary auscultation in 93.6%, complete radiological resolution in 85%, and normalized laboratory parameters in almost all cases. At 6 months, 26.5% presented at least one residual symptom, whereas only three patients (4.5%) reported symptoms at 5 years. No risk factors associated with symptom persistence were identified. The estimated cumulative healthcare cost was EUR 21,627.50. Conclusions: Among patients hospitalized for SARS-CoV-2 pneumonia during the first wave of the pandemic, 26.7% and 4.46% presented at least one persistent symptom at 6 months and 5 years after discharge, respectively.</p>
	]]></content:encoded>

	<dc:title>Persistence of Symptoms and Long-Term Recovery in Hospitalized COVID-19 Patients: Results from a Five-Year Follow-Up Cohort</dc:title>
			<dc:creator>Ana Roel Conde</dc:creator>
			<dc:creator>Francisco Javier Membrillo de Novales</dc:creator>
			<dc:creator>María Navarro Téllez</dc:creator>
			<dc:creator>Carlos Gutiérrez Ortega</dc:creator>
			<dc:creator>Miriam Estébanez Muñoz</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010008</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>8</prism:startingPage>
		<prism:doi>10.3390/idr18010008</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/8</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/7">

	<title>Infectious Disease Reports, Vol. 18, Pages 7: Faster than Virus: The Physics of Pandemic Prediction</title>
	<link>https://www.mdpi.com/2036-7449/18/1/7</link>
	<description>Background: Zoonotic spillover events with pandemic potential are increasingly associated with environmental change, ecosystem disruption, and intensified human&amp;amp;ndash;animal interactions. Although the specific origin and timing of future pandemics remain uncertain, there is a clear need to complement traditional preparedness strategies with approaches that support earlier anticipation and prevention. Objectives: This study aims to propose a conceptual approach to reframe pandemic preparedness toward proactive surveillance and spillover prevention. Methods: We introduce a tachyon-inspired conceptual approach, using a thought experiment based on hypothetical faster-than-light particles to illustrate anticipatory observation of pandemic emergence. The framework is informed by interdisciplinary literature on emerging infectious diseases, One Health surveillance, predictive epidemiology, and public-health preparedness. Results: The proposed approach highlights the importance of proactive, integrated surveillance systems that combine human, animal, and environmental data. Key elements include the use of advanced analytical tools such as neural networks, early characterization of population risk profiles, strengthened public-health infrastructure, coordinated governance, adaptable financial resources, and a resilient healthcare workforce. The integration of animal welfare considerations, translational research, and planetary health principles is emphasized as central to reducing spillover risk. Conclusions: Tachyon-inspired thinking offers a conceptual tool to support a shift from reactive pandemic response toward proactive anticipation and prevention. Embedding integrated surveillance and One Health principles into public-health systems may enhance early detection capacity and contribute to mitigating the impact of future pandemics.</description>
	<pubDate>2026-01-09</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 7: Faster than Virus: The Physics of Pandemic Prediction</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/7">doi: 10.3390/idr18010007</a></p>
	<p>Authors:
		Serena Vita
		Giovanni Morlino
		Alessandra D’Abramo
		Laura Scorzolini
		Gaetano Maffongelli
		Delia Goletti
		Francesco Vairo
		Enrico Girardi
		Massimo Ciccozzi
		Emanuele Nicastri
		</p>
	<p>Background: Zoonotic spillover events with pandemic potential are increasingly associated with environmental change, ecosystem disruption, and intensified human&amp;amp;ndash;animal interactions. Although the specific origin and timing of future pandemics remain uncertain, there is a clear need to complement traditional preparedness strategies with approaches that support earlier anticipation and prevention. Objectives: This study aims to propose a conceptual approach to reframe pandemic preparedness toward proactive surveillance and spillover prevention. Methods: We introduce a tachyon-inspired conceptual approach, using a thought experiment based on hypothetical faster-than-light particles to illustrate anticipatory observation of pandemic emergence. The framework is informed by interdisciplinary literature on emerging infectious diseases, One Health surveillance, predictive epidemiology, and public-health preparedness. Results: The proposed approach highlights the importance of proactive, integrated surveillance systems that combine human, animal, and environmental data. Key elements include the use of advanced analytical tools such as neural networks, early characterization of population risk profiles, strengthened public-health infrastructure, coordinated governance, adaptable financial resources, and a resilient healthcare workforce. The integration of animal welfare considerations, translational research, and planetary health principles is emphasized as central to reducing spillover risk. Conclusions: Tachyon-inspired thinking offers a conceptual tool to support a shift from reactive pandemic response toward proactive anticipation and prevention. Embedding integrated surveillance and One Health principles into public-health systems may enhance early detection capacity and contribute to mitigating the impact of future pandemics.</p>
	]]></content:encoded>

	<dc:title>Faster than Virus: The Physics of Pandemic Prediction</dc:title>
			<dc:creator>Serena Vita</dc:creator>
			<dc:creator>Giovanni Morlino</dc:creator>
			<dc:creator>Alessandra D’Abramo</dc:creator>
			<dc:creator>Laura Scorzolini</dc:creator>
			<dc:creator>Gaetano Maffongelli</dc:creator>
			<dc:creator>Delia Goletti</dc:creator>
			<dc:creator>Francesco Vairo</dc:creator>
			<dc:creator>Enrico Girardi</dc:creator>
			<dc:creator>Massimo Ciccozzi</dc:creator>
			<dc:creator>Emanuele Nicastri</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010007</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-09</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-09</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Essay</prism:section>
	<prism:startingPage>7</prism:startingPage>
		<prism:doi>10.3390/idr18010007</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/7</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/6">

	<title>Infectious Disease Reports, Vol. 18, Pages 6: Beyond the Skin: Topical Amphotericin B Nanocarriers Targeting Cutaneous Leishmaniasis with Suppression of Lymphatic Parasite Burden</title>
	<link>https://www.mdpi.com/2036-7449/18/1/6</link>
	<description>Background/Objectives: Cutaneous leishmaniasis (CL) remains a global health challenge, with treatment options often limited by drug resistance and systemic toxicity. Amphotericin B (AmB) represents a promising alternative. but intravenous administration causes severe systemic adverse effects. Despite growing interest in topical therapies, knowledge gaps remain regarding the comparative efficacy of delivery systems, including the influence of treatment timing and potential intrinsic effects. This study aimed to develop and characterize different topical AmB formulations (polymeric nanoparticles (PCL-AmB), a lipid-based (Oil_AmB) formulation, and a gel emulsion) to evaluate their in vivo efficacy against CL in a murine model, considering treatment initiation timing and potential intrinsic effects of the delivery systems. Methods: Formulations were prepared and characterized in terms of hydrodynamic size, polydispersity index, and AmB content. Antileishmanial activity was assessed in two independent in vivo experiments, with topical monotherapy administered five days per week for four weeks, starting either 10 or 30 days post-infection, representing early and established chronic stages of infection, respectively. Results: All formulations exhibited nanoscale dimensions and high homogeneity, with the lipid system demonstrating superior AmB solubilization. Both PCL-AmB and Oil_AmB reduced parasite load in the footpad, with Oil_AmB also reducing parasite load in draining lymph nodes. Conclusions: PCL-AmB and Oil_AmB reduced lesions and parasite burden in L. amazonensis-infected mice. Treatment timing was critical, with early Oil_AmB also reducing parasite loads in draining lymph nodes. These findings suggest that topical AmB formulations may provide a promising alternative for CL treatment, though further studies are required to optimize efficacy and administration schedules.</description>
	<pubDate>2026-01-06</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 6: Beyond the Skin: Topical Amphotericin B Nanocarriers Targeting Cutaneous Leishmaniasis with Suppression of Lymphatic Parasite Burden</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/6">doi: 10.3390/idr18010006</a></p>
	<p>Authors:
		Francisco Alexandrino-Júnior
		Gabriel Barcellos
		Luiz Filipe Gonçalves-Oliveira
		Luzia Monteiro de Castro Côrtes
		Franklin Souza-Silva
		Carlos Roberto Alves
		Geovane Dias-Lopes
		Juliana Figueiredo Peixoto
		Beatriz Ferreira de Carvalho Patricio
		Helvécio Vinícius Antunes Rocha
		</p>
	<p>Background/Objectives: Cutaneous leishmaniasis (CL) remains a global health challenge, with treatment options often limited by drug resistance and systemic toxicity. Amphotericin B (AmB) represents a promising alternative. but intravenous administration causes severe systemic adverse effects. Despite growing interest in topical therapies, knowledge gaps remain regarding the comparative efficacy of delivery systems, including the influence of treatment timing and potential intrinsic effects. This study aimed to develop and characterize different topical AmB formulations (polymeric nanoparticles (PCL-AmB), a lipid-based (Oil_AmB) formulation, and a gel emulsion) to evaluate their in vivo efficacy against CL in a murine model, considering treatment initiation timing and potential intrinsic effects of the delivery systems. Methods: Formulations were prepared and characterized in terms of hydrodynamic size, polydispersity index, and AmB content. Antileishmanial activity was assessed in two independent in vivo experiments, with topical monotherapy administered five days per week for four weeks, starting either 10 or 30 days post-infection, representing early and established chronic stages of infection, respectively. Results: All formulations exhibited nanoscale dimensions and high homogeneity, with the lipid system demonstrating superior AmB solubilization. Both PCL-AmB and Oil_AmB reduced parasite load in the footpad, with Oil_AmB also reducing parasite load in draining lymph nodes. Conclusions: PCL-AmB and Oil_AmB reduced lesions and parasite burden in L. amazonensis-infected mice. Treatment timing was critical, with early Oil_AmB also reducing parasite loads in draining lymph nodes. These findings suggest that topical AmB formulations may provide a promising alternative for CL treatment, though further studies are required to optimize efficacy and administration schedules.</p>
	]]></content:encoded>

	<dc:title>Beyond the Skin: Topical Amphotericin B Nanocarriers Targeting Cutaneous Leishmaniasis with Suppression of Lymphatic Parasite Burden</dc:title>
			<dc:creator>Francisco Alexandrino-Júnior</dc:creator>
			<dc:creator>Gabriel Barcellos</dc:creator>
			<dc:creator>Luiz Filipe Gonçalves-Oliveira</dc:creator>
			<dc:creator>Luzia Monteiro de Castro Côrtes</dc:creator>
			<dc:creator>Franklin Souza-Silva</dc:creator>
			<dc:creator>Carlos Roberto Alves</dc:creator>
			<dc:creator>Geovane Dias-Lopes</dc:creator>
			<dc:creator>Juliana Figueiredo Peixoto</dc:creator>
			<dc:creator>Beatriz Ferreira de Carvalho Patricio</dc:creator>
			<dc:creator>Helvécio Vinícius Antunes Rocha</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010006</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-06</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-06</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>6</prism:startingPage>
		<prism:doi>10.3390/idr18010006</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/6</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/5">

	<title>Infectious Disease Reports, Vol. 18, Pages 5: An Unusual Case of Listeria monocytogenes-Associated Rhombencephalitis Complicated by Brain Abscesses in Italy, 2024</title>
	<link>https://www.mdpi.com/2036-7449/18/1/5</link>
	<description>Background/Objectives: Listeria monocytogenes (Lm) is an extremely rare cause of brain abscesses, accounting for 1&amp;amp;ndash;10% of neurolisteriosis cases reported in the literature, associated with high mortality (approximately 23%). Data on diagnosis, management, and treatment is scarce. We report a case of listerial brain abscesses in an elderly patient in Italy who experienced progressively worsening bilateral ptosis. Methods: Diagnostic evaluation included neuroimaging, blood cultures, and microbiological investigations, followed by antimicrobial treatment according to available evidence. The isolated Lm strain underwent whole genome sequencing. Dietary history was also collected. Results: Positive early blood cultures were pivotal in identifying Lm as the aetiological agent. Neuroimaging revealed brain abscesses consistent with neurolisteriosis. The clinical course was complicated by pneumonia and opportunistic co-infecting pathogens, and despite adequate treatment according to the available literature, the outcome was fatal. Genomic characterisation revealed that the patient was infected with an strain belonged to the sequence type 206 and clonal complex 14, described as hypervirulent. The patient reported consuming several foods known to be associated with an increased risk of listeriosis. Conclusions: This case highlights the challenges involved in diagnosing and managing listerial brain abscesses, particularly in elderly patients. Even when the primary central nervous system infection is under control, the prognosis may be significantly impacted by comorbid conditions and hospital-related complications rather than the infection itself. Our findings underscore the need for improved preventive strategies and targeted risk communication regarding high-risk foods, particularly among elderly populations.</description>
	<pubDate>2026-01-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 5: An Unusual Case of Listeria monocytogenes-Associated Rhombencephalitis Complicated by Brain Abscesses in Italy, 2024</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/5">doi: 10.3390/idr18010005</a></p>
	<p>Authors:
		Maria Gori
		Giorgia Orsani
		Carlotta Ortelli
		Erika Scaltriti
		Luca Bolzoni
		Luigi Vezzosi
		Silvia Bianchi
		Clara Fappani
		Daniela Colzani
		Antonella Amendola
		Danilo Cereda
		Laura Marzorati
		Stefano Pongolini
		Elisabetta Tanzi
		</p>
	<p>Background/Objectives: Listeria monocytogenes (Lm) is an extremely rare cause of brain abscesses, accounting for 1&amp;amp;ndash;10% of neurolisteriosis cases reported in the literature, associated with high mortality (approximately 23%). Data on diagnosis, management, and treatment is scarce. We report a case of listerial brain abscesses in an elderly patient in Italy who experienced progressively worsening bilateral ptosis. Methods: Diagnostic evaluation included neuroimaging, blood cultures, and microbiological investigations, followed by antimicrobial treatment according to available evidence. The isolated Lm strain underwent whole genome sequencing. Dietary history was also collected. Results: Positive early blood cultures were pivotal in identifying Lm as the aetiological agent. Neuroimaging revealed brain abscesses consistent with neurolisteriosis. The clinical course was complicated by pneumonia and opportunistic co-infecting pathogens, and despite adequate treatment according to the available literature, the outcome was fatal. Genomic characterisation revealed that the patient was infected with an strain belonged to the sequence type 206 and clonal complex 14, described as hypervirulent. The patient reported consuming several foods known to be associated with an increased risk of listeriosis. Conclusions: This case highlights the challenges involved in diagnosing and managing listerial brain abscesses, particularly in elderly patients. Even when the primary central nervous system infection is under control, the prognosis may be significantly impacted by comorbid conditions and hospital-related complications rather than the infection itself. Our findings underscore the need for improved preventive strategies and targeted risk communication regarding high-risk foods, particularly among elderly populations.</p>
	]]></content:encoded>

	<dc:title>An Unusual Case of Listeria monocytogenes-Associated Rhombencephalitis Complicated by Brain Abscesses in Italy, 2024</dc:title>
			<dc:creator>Maria Gori</dc:creator>
			<dc:creator>Giorgia Orsani</dc:creator>
			<dc:creator>Carlotta Ortelli</dc:creator>
			<dc:creator>Erika Scaltriti</dc:creator>
			<dc:creator>Luca Bolzoni</dc:creator>
			<dc:creator>Luigi Vezzosi</dc:creator>
			<dc:creator>Silvia Bianchi</dc:creator>
			<dc:creator>Clara Fappani</dc:creator>
			<dc:creator>Daniela Colzani</dc:creator>
			<dc:creator>Antonella Amendola</dc:creator>
			<dc:creator>Danilo Cereda</dc:creator>
			<dc:creator>Laura Marzorati</dc:creator>
			<dc:creator>Stefano Pongolini</dc:creator>
			<dc:creator>Elisabetta Tanzi</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010005</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2026-01-04</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2026-01-04</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>5</prism:startingPage>
		<prism:doi>10.3390/idr18010005</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/5</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/4">

	<title>Infectious Disease Reports, Vol. 18, Pages 4: Infective Endocarditis in a Tertiary Hospital in Porto&amp;mdash;Is There Anything New?</title>
	<link>https://www.mdpi.com/2036-7449/18/1/4</link>
	<description>Background/Objectives: Infective endocarditis (IE) remains a severe and complex disease despite advances in diagnosis and treatment. The changing epidemiological profile, with an ageing population, has reshaped its presentation and management. This study describes the epidemiological, clinical and microbiological characteristics of IE at a Portuguese tertiary referral hospital prior to the establishment of a multidisciplinary Endocarditis Team. Methods: A retrospective analysis was conducted including all adult patients diagnosed with definite or possible IE according to the 2015 ESC criteria, admitted to ULS S&amp;amp;atilde;o Jo&amp;amp;atilde;o, Porto, between January 2019 and December 2023. Data were collected from electronic medical records and included demographic characteristics, comorbidities, microbiology, imaging, surgical indications and outcomes. Results: A total of 143 IE episodes were identified. Median age was 71 years, with a predominance of heterologous material-related infections (81%). Enterococcus faecalis, viridans group streptococci and coagulase-negative staphylococci were the most frequent pathogens. Surgical indication was present in 74% of cases, although surgery was not performed in 22% due to comorbidities or frailty, contributing to a high in-hospital mortality rate. Conclusions: This study provides a contemporary overview of IE in Portugal, reflecting an elderly, comorbid population and a predominance of prosthetic disease. The results highlight the need for multidisciplinary management and early surgical decisions, supporting the creation of Endocarditis Teams in tertiary centres.</description>
	<pubDate>2025-12-25</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 4: Infective Endocarditis in a Tertiary Hospital in Porto&amp;mdash;Is There Anything New?</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/4">doi: 10.3390/idr18010004</a></p>
	<p>Authors:
		Carolina Gomes
		Isabel Gomes Abreu
		Lurdes Santos
		</p>
	<p>Background/Objectives: Infective endocarditis (IE) remains a severe and complex disease despite advances in diagnosis and treatment. The changing epidemiological profile, with an ageing population, has reshaped its presentation and management. This study describes the epidemiological, clinical and microbiological characteristics of IE at a Portuguese tertiary referral hospital prior to the establishment of a multidisciplinary Endocarditis Team. Methods: A retrospective analysis was conducted including all adult patients diagnosed with definite or possible IE according to the 2015 ESC criteria, admitted to ULS S&amp;amp;atilde;o Jo&amp;amp;atilde;o, Porto, between January 2019 and December 2023. Data were collected from electronic medical records and included demographic characteristics, comorbidities, microbiology, imaging, surgical indications and outcomes. Results: A total of 143 IE episodes were identified. Median age was 71 years, with a predominance of heterologous material-related infections (81%). Enterococcus faecalis, viridans group streptococci and coagulase-negative staphylococci were the most frequent pathogens. Surgical indication was present in 74% of cases, although surgery was not performed in 22% due to comorbidities or frailty, contributing to a high in-hospital mortality rate. Conclusions: This study provides a contemporary overview of IE in Portugal, reflecting an elderly, comorbid population and a predominance of prosthetic disease. The results highlight the need for multidisciplinary management and early surgical decisions, supporting the creation of Endocarditis Teams in tertiary centres.</p>
	]]></content:encoded>

	<dc:title>Infective Endocarditis in a Tertiary Hospital in Porto&amp;amp;mdash;Is There Anything New?</dc:title>
			<dc:creator>Carolina Gomes</dc:creator>
			<dc:creator>Isabel Gomes Abreu</dc:creator>
			<dc:creator>Lurdes Santos</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010004</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-25</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-25</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4</prism:startingPage>
		<prism:doi>10.3390/idr18010004</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/4</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/3">

	<title>Infectious Disease Reports, Vol. 18, Pages 3: Raising the Bar of PK/PD Target Attainment of Beta-Lactams in Daily Clinical Practice: An Effective Strategy to Overcome Resistance Development to Novel Beta-Lactams?</title>
	<link>https://www.mdpi.com/2036-7449/18/1/3</link>
	<description>The increase of infections caused by difficult-to-treat resistant (DTR) Gram-negatives is becoming an ever-growing remarkable issue for public health [...]</description>
	<pubDate>2025-12-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 3: Raising the Bar of PK/PD Target Attainment of Beta-Lactams in Daily Clinical Practice: An Effective Strategy to Overcome Resistance Development to Novel Beta-Lactams?</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/3">doi: 10.3390/idr18010003</a></p>
	<p>Authors:
		Milo Gatti
		Federico Pea
		</p>
	<p>The increase of infections caused by difficult-to-treat resistant (DTR) Gram-negatives is becoming an ever-growing remarkable issue for public health [...]</p>
	]]></content:encoded>

	<dc:title>Raising the Bar of PK/PD Target Attainment of Beta-Lactams in Daily Clinical Practice: An Effective Strategy to Overcome Resistance Development to Novel Beta-Lactams?</dc:title>
			<dc:creator>Milo Gatti</dc:creator>
			<dc:creator>Federico Pea</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010003</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-23</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Editorial</prism:section>
	<prism:startingPage>3</prism:startingPage>
		<prism:doi>10.3390/idr18010003</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/3</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/2">

	<title>Infectious Disease Reports, Vol. 18, Pages 2: A Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses&amp;mdash;Case Report</title>
	<link>https://www.mdpi.com/2036-7449/18/1/2</link>
	<description>Invasive Mucormycosis (IM) is an extremely rare infection with a high mortality rate, caused by a group of fungi classified as Mucorales moulds. Rhizomucor pusillus is a saprophitic, thermophilic, and angioinvasive microorganism that grows and lives at about 45 &amp;amp;deg;C and is usually found in different environmental spaces such as soil, air, water, food, and other organic matter. These features predispose the infection to wide dissemination, especially in immunocompromised patients and most often in children after chemotherapy for hematological malignancies (HMs). Mucormycosis in patients with hematologic malignancies and neutropenia represents between 0.07% and 4.29% of the concomitant diseases. IM can develop into an infection in different sites, but its most common manifestation is pulmonary, followed by rhino-orbital&amp;amp;ndash;cerebral and disseminated forms. In recent years, an increased morbidity rate has been associated with the ongoing COVID-19 pandemic, as cited in the literature. There are many publications with COVID-19-associated mucormycosis (CAM) cases. The present treatment protocol includes extensive and radical surgical debridement and systemic antifungal therapy with Liposomal Amphotericin B (L-AmB), Posaconazole, and Isavuconazole, either combined or as monotherapy. Despite these new treatment modalities, the mortality rate remains over 50%. We present a rare case of a 3-year-old child with acute lymphoblastic leukemia (ALL) and systemic Rhizomucor pusillus infection, diagnosed on the occasion of lung and brain abscesses. The patient underwent lung and brain surgery and is recovering well with no further complications. The two-year follow-up period shows no signs of recurrence of the disease.</description>
	<pubDate>2025-12-23</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 2: A Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses&amp;mdash;Case Report</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/2">doi: 10.3390/idr18010002</a></p>
	<p>Authors:
		Yanko Pahnev
		Boryana Avramova
		Natalia Gabrovska
		Yolin Dontcheva
		Genoveva Tacheva
		Krasimir Minkin
		Hans Kreipe
		Nadezhda Yurukova
		Marin Penkov
		Nikola Kartulev
		Zdravka Antonova
		Velichka Oparanova
		Nadezhda Tolekova
		Petia Moutaftchieva
		Bogdan Mladenov
		Plamena Hristova
		Kaloyan Gabrovski
		Svetlana Velizarova
		Albena Spasova
		Hristo Shivachev
		</p>
	<p>Invasive Mucormycosis (IM) is an extremely rare infection with a high mortality rate, caused by a group of fungi classified as Mucorales moulds. Rhizomucor pusillus is a saprophitic, thermophilic, and angioinvasive microorganism that grows and lives at about 45 &amp;amp;deg;C and is usually found in different environmental spaces such as soil, air, water, food, and other organic matter. These features predispose the infection to wide dissemination, especially in immunocompromised patients and most often in children after chemotherapy for hematological malignancies (HMs). Mucormycosis in patients with hematologic malignancies and neutropenia represents between 0.07% and 4.29% of the concomitant diseases. IM can develop into an infection in different sites, but its most common manifestation is pulmonary, followed by rhino-orbital&amp;amp;ndash;cerebral and disseminated forms. In recent years, an increased morbidity rate has been associated with the ongoing COVID-19 pandemic, as cited in the literature. There are many publications with COVID-19-associated mucormycosis (CAM) cases. The present treatment protocol includes extensive and radical surgical debridement and systemic antifungal therapy with Liposomal Amphotericin B (L-AmB), Posaconazole, and Isavuconazole, either combined or as monotherapy. Despite these new treatment modalities, the mortality rate remains over 50%. We present a rare case of a 3-year-old child with acute lymphoblastic leukemia (ALL) and systemic Rhizomucor pusillus infection, diagnosed on the occasion of lung and brain abscesses. The patient underwent lung and brain surgery and is recovering well with no further complications. The two-year follow-up period shows no signs of recurrence of the disease.</p>
	]]></content:encoded>

	<dc:title>A Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses&amp;amp;mdash;Case Report</dc:title>
			<dc:creator>Yanko Pahnev</dc:creator>
			<dc:creator>Boryana Avramova</dc:creator>
			<dc:creator>Natalia Gabrovska</dc:creator>
			<dc:creator>Yolin Dontcheva</dc:creator>
			<dc:creator>Genoveva Tacheva</dc:creator>
			<dc:creator>Krasimir Minkin</dc:creator>
			<dc:creator>Hans Kreipe</dc:creator>
			<dc:creator>Nadezhda Yurukova</dc:creator>
			<dc:creator>Marin Penkov</dc:creator>
			<dc:creator>Nikola Kartulev</dc:creator>
			<dc:creator>Zdravka Antonova</dc:creator>
			<dc:creator>Velichka Oparanova</dc:creator>
			<dc:creator>Nadezhda Tolekova</dc:creator>
			<dc:creator>Petia Moutaftchieva</dc:creator>
			<dc:creator>Bogdan Mladenov</dc:creator>
			<dc:creator>Plamena Hristova</dc:creator>
			<dc:creator>Kaloyan Gabrovski</dc:creator>
			<dc:creator>Svetlana Velizarova</dc:creator>
			<dc:creator>Albena Spasova</dc:creator>
			<dc:creator>Hristo Shivachev</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010002</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-23</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-23</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>2</prism:startingPage>
		<prism:doi>10.3390/idr18010002</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/2</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/18/1/1">

	<title>Infectious Disease Reports, Vol. 18, Pages 1: Comparative Retrospective Evaluation of the Clinical and Mycological Efficacy of 69% Nitric Acid, 1064 nm Nd:YAG Laser, and Their Combination in the Treatment of Trichophyton rubrum Onychomycosis over a 12-Month Follow-Up</title>
	<link>https://www.mdpi.com/2036-7449/18/1/1</link>
	<description>Background: Onychomycosis is a common nail infection primarily caused by Trichophyton rubrum, posing therapeutic challenges due to poor antifungal penetration and high recurrence rates. Conventional treatments include topical and systemic antifungals, but novel approaches such as laser therapy and chemical agents like nitric acid have emerged as promising alternatives or adjuncts. However, comparative evidence regarding the clinical and mycological efficacy of these treatments remains limited. Objectives: We aimed to assess and compare the clinical and mycological efficacy of three therapeutic modalities&amp;amp;mdash;69% nitric acid, 1064 nm Nd:YAG laser, and their combination&amp;amp;mdash;in the treatment of Trichophyton rubrum onychomycosis over a 12-month follow-up period. Methods: A prospective, comparative, observational study was conducted, assigning patients with confirmed onychomycosis to one of three treatment groups: nitric acid, Nd:YAG 1064 nm laser, or combination therapy. Clinical and mycological cure rates, mean time to clinical resolution, changes in Onychomycosis Severity Index [OSI] scores, and mycological relapse rates were assessed over a 12-month follow-up. Results: All three groups demonstrated significant improvement in both clinical and mycological cure rates, with the combination therapy yielding the most favorable outcomes in terms of response speed and durability. Laser and nitric acid monotherapies were also effective, though associated with lower cure rates and longer times to resolution. The relapse rate was lowest in the combination group. Conclusions: The combination of nitric acid and Nd:YAG laser appears to be a more effective therapeutic option for Trichophyton rubrum onychomycosis, offering superior clinical and mycological outcomes compared to monotherapies, with faster resolution and lower relapse rates. These findings suggest that combination therapy may optimize the management of this challenging nail infection.</description>
	<pubDate>2025-12-20</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 18, Pages 1: Comparative Retrospective Evaluation of the Clinical and Mycological Efficacy of 69% Nitric Acid, 1064 nm Nd:YAG Laser, and Their Combination in the Treatment of Trichophyton rubrum Onychomycosis over a 12-Month Follow-Up</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/18/1/1">doi: 10.3390/idr18010001</a></p>
	<p>Authors:
		Raquel García De La Peña
		José María Juárez-Jiménez
		João Miguel Costa Martiniano
		Ana María Rayo Pérez
		</p>
	<p>Background: Onychomycosis is a common nail infection primarily caused by Trichophyton rubrum, posing therapeutic challenges due to poor antifungal penetration and high recurrence rates. Conventional treatments include topical and systemic antifungals, but novel approaches such as laser therapy and chemical agents like nitric acid have emerged as promising alternatives or adjuncts. However, comparative evidence regarding the clinical and mycological efficacy of these treatments remains limited. Objectives: We aimed to assess and compare the clinical and mycological efficacy of three therapeutic modalities&amp;amp;mdash;69% nitric acid, 1064 nm Nd:YAG laser, and their combination&amp;amp;mdash;in the treatment of Trichophyton rubrum onychomycosis over a 12-month follow-up period. Methods: A prospective, comparative, observational study was conducted, assigning patients with confirmed onychomycosis to one of three treatment groups: nitric acid, Nd:YAG 1064 nm laser, or combination therapy. Clinical and mycological cure rates, mean time to clinical resolution, changes in Onychomycosis Severity Index [OSI] scores, and mycological relapse rates were assessed over a 12-month follow-up. Results: All three groups demonstrated significant improvement in both clinical and mycological cure rates, with the combination therapy yielding the most favorable outcomes in terms of response speed and durability. Laser and nitric acid monotherapies were also effective, though associated with lower cure rates and longer times to resolution. The relapse rate was lowest in the combination group. Conclusions: The combination of nitric acid and Nd:YAG laser appears to be a more effective therapeutic option for Trichophyton rubrum onychomycosis, offering superior clinical and mycological outcomes compared to monotherapies, with faster resolution and lower relapse rates. These findings suggest that combination therapy may optimize the management of this challenging nail infection.</p>
	]]></content:encoded>

	<dc:title>Comparative Retrospective Evaluation of the Clinical and Mycological Efficacy of 69% Nitric Acid, 1064 nm Nd:YAG Laser, and Their Combination in the Treatment of Trichophyton rubrum Onychomycosis over a 12-Month Follow-Up</dc:title>
			<dc:creator>Raquel García De La Peña</dc:creator>
			<dc:creator>José María Juárez-Jiménez</dc:creator>
			<dc:creator>João Miguel Costa Martiniano</dc:creator>
			<dc:creator>Ana María Rayo Pérez</dc:creator>
		<dc:identifier>doi: 10.3390/idr18010001</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-20</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-20</prism:publicationDate>
	<prism:volume>18</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1</prism:startingPage>
		<prism:doi>10.3390/idr18010001</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/18/1/1</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/151">

	<title>Infectious Disease Reports, Vol. 17, Pages 151: Sex Differences in Outcomes of Critically Ill Adults with Respiratory Syncytial Virus Pneumonia: A Retrospective Exploratory Cohort Study</title>
	<link>https://www.mdpi.com/2036-7449/17/6/151</link>
	<description>Background: Respiratory syncytial virus (RSV) pneumonia is an underrecognized cause of critical illness in adults. However, the influence of biological sex on intensive care unit (ICU) outcomes in this population remains unclear. Due to limited case numbers and incomplete covariate data, this study was designed as exploratory and hypothesis-generating. Methods: We conducted a retrospective exploratory cohort study using the MIMIC-IV database and identified 105 adult ICU patients with laboratory-confirmed RSV pneumonia. Clinical variables included sex, age, ICU length of stay, use of mechanical ventilation, and weaning status. Exploratory multivariable logistic regression was performed to assess associations with in-hospital mortality and weaning success, acknowledging substantial missingness of comorbidity data, severity scores, and treatment variables. This limited adjustment for confounding and statistical power. Results: Overall, in-hospital mortality was 33.3%. Mortality was significantly higher among women than men (51.6% vs. 7.0%; p &amp;amp;lt; 0.001), although the absolute number of deaths in men was very small. In adjusted models, female sex (OR 14.6, 95% CI 1.58&amp;amp;ndash;135.3, p = 0.018), reflecting model instability due to sparse events, as well as longer ICU stay (OR 1.22 per day, p = 0.001) were independently associated with higher mortality. Female sex was also associated with lower odds of successful weaning (OR 0.07, 95% CI 0.01&amp;amp;ndash;0.63, p = 0.018). These effect estimates must be interpreted cautiously due to the very small number of deaths in men and the resulting wide confidence intervals. Age and ventilation duration were not significant predictors. Conclusions: In this preliminary ICU cohort, female sex and prolonged ICU stay were linked to higher mortality and lower weaning success in adults with RSV pneumonia. However, given the very small number of events&amp;amp;mdash;particularly among male patients&amp;amp;mdash;together with the modest sample size, limited covariate availability, and unstable effect estimates, the findings should be viewed as exploratory rather than confirmatory. Larger, well-powered, prospective multicenter studies are needed to validate and further characterize potential sex-related differences in outcomes of RSV-associated critical illness.</description>
	<pubDate>2025-12-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 151: Sex Differences in Outcomes of Critically Ill Adults with Respiratory Syncytial Virus Pneumonia: A Retrospective Exploratory Cohort Study</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/151">doi: 10.3390/idr17060151</a></p>
	<p>Authors:
		Josef Yayan
		Kurt Rasche
		</p>
	<p>Background: Respiratory syncytial virus (RSV) pneumonia is an underrecognized cause of critical illness in adults. However, the influence of biological sex on intensive care unit (ICU) outcomes in this population remains unclear. Due to limited case numbers and incomplete covariate data, this study was designed as exploratory and hypothesis-generating. Methods: We conducted a retrospective exploratory cohort study using the MIMIC-IV database and identified 105 adult ICU patients with laboratory-confirmed RSV pneumonia. Clinical variables included sex, age, ICU length of stay, use of mechanical ventilation, and weaning status. Exploratory multivariable logistic regression was performed to assess associations with in-hospital mortality and weaning success, acknowledging substantial missingness of comorbidity data, severity scores, and treatment variables. This limited adjustment for confounding and statistical power. Results: Overall, in-hospital mortality was 33.3%. Mortality was significantly higher among women than men (51.6% vs. 7.0%; p &amp;amp;lt; 0.001), although the absolute number of deaths in men was very small. In adjusted models, female sex (OR 14.6, 95% CI 1.58&amp;amp;ndash;135.3, p = 0.018), reflecting model instability due to sparse events, as well as longer ICU stay (OR 1.22 per day, p = 0.001) were independently associated with higher mortality. Female sex was also associated with lower odds of successful weaning (OR 0.07, 95% CI 0.01&amp;amp;ndash;0.63, p = 0.018). These effect estimates must be interpreted cautiously due to the very small number of deaths in men and the resulting wide confidence intervals. Age and ventilation duration were not significant predictors. Conclusions: In this preliminary ICU cohort, female sex and prolonged ICU stay were linked to higher mortality and lower weaning success in adults with RSV pneumonia. However, given the very small number of events&amp;amp;mdash;particularly among male patients&amp;amp;mdash;together with the modest sample size, limited covariate availability, and unstable effect estimates, the findings should be viewed as exploratory rather than confirmatory. Larger, well-powered, prospective multicenter studies are needed to validate and further characterize potential sex-related differences in outcomes of RSV-associated critical illness.</p>
	]]></content:encoded>

	<dc:title>Sex Differences in Outcomes of Critically Ill Adults with Respiratory Syncytial Virus Pneumonia: A Retrospective Exploratory Cohort Study</dc:title>
			<dc:creator>Josef Yayan</dc:creator>
			<dc:creator>Kurt Rasche</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060151</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-18</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-18</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>151</prism:startingPage>
		<prism:doi>10.3390/idr17060151</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/151</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/150">

	<title>Infectious Disease Reports, Vol. 17, Pages 150: Beyond the Spike Glycoprotein: Mutational Signatures in SARS-CoV-2 Structural Proteins</title>
	<link>https://www.mdpi.com/2036-7449/17/6/150</link>
	<description>Background: The continuous emergence of SARS-CoV-2 variants represents a major public health concern. Next-generation sequencing (NGS) enables genomic surveillance, facilitating the detection and monitoring of mutations that impact viral evolution. Methods: In this study, full-length SARS-CoV-2 genomes were analyzed between February 2022 and March 2024 as part of routine genomic surveillance conducted in Verona, Italy. Mutations in the envelope (E), membrane (M), and nucleocapsid (N) structural proteins were investigated. Only substitutions with a total prevalence of greater than 1% in the study dataset were considered. Results: A total of 178 mutations were identified across the three proteins (E: 16; M: 33; N: 129), of which 18 met the inclusion threshold (E: 3; M: 5; N: 10). Mutations were classified according to temporal dynamics as fixed, emerging, or transient. Throughout the study period, fixed mutations were consistently prevalent, emerging mutations appeared later but persisted with an ascending trend, while transient mutations displayed a single frequency peak before disappearing. Several mutations were reported with potential structural or functional relevance based on the existing literature, while others remain of unknown significance. Conclusions: The mutational patterns detected in this study broadly reflect global evolutionary trends of SARS-CoV-2. These findings emphasize the importance of continued genomic surveillance and underline the need for integrated experimental approaches to clarify the biological and epidemiological impact of poorly characterized mutations.</description>
	<pubDate>2025-12-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 150: Beyond the Spike Glycoprotein: Mutational Signatures in SARS-CoV-2 Structural Proteins</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/150">doi: 10.3390/idr17060150</a></p>
	<p>Authors:
		Emil Tonon
		Riccardo Cecchetto
		Virginia Lotti
		Anna Lagni
		Erica Diani
		Asia Palmisano
		Marco Mantoan
		Livio Montesarchio
		Francesca Palladini
		Giona Turri
		Davide Gibellini
		</p>
	<p>Background: The continuous emergence of SARS-CoV-2 variants represents a major public health concern. Next-generation sequencing (NGS) enables genomic surveillance, facilitating the detection and monitoring of mutations that impact viral evolution. Methods: In this study, full-length SARS-CoV-2 genomes were analyzed between February 2022 and March 2024 as part of routine genomic surveillance conducted in Verona, Italy. Mutations in the envelope (E), membrane (M), and nucleocapsid (N) structural proteins were investigated. Only substitutions with a total prevalence of greater than 1% in the study dataset were considered. Results: A total of 178 mutations were identified across the three proteins (E: 16; M: 33; N: 129), of which 18 met the inclusion threshold (E: 3; M: 5; N: 10). Mutations were classified according to temporal dynamics as fixed, emerging, or transient. Throughout the study period, fixed mutations were consistently prevalent, emerging mutations appeared later but persisted with an ascending trend, while transient mutations displayed a single frequency peak before disappearing. Several mutations were reported with potential structural or functional relevance based on the existing literature, while others remain of unknown significance. Conclusions: The mutational patterns detected in this study broadly reflect global evolutionary trends of SARS-CoV-2. These findings emphasize the importance of continued genomic surveillance and underline the need for integrated experimental approaches to clarify the biological and epidemiological impact of poorly characterized mutations.</p>
	]]></content:encoded>

	<dc:title>Beyond the Spike Glycoprotein: Mutational Signatures in SARS-CoV-2 Structural Proteins</dc:title>
			<dc:creator>Emil Tonon</dc:creator>
			<dc:creator>Riccardo Cecchetto</dc:creator>
			<dc:creator>Virginia Lotti</dc:creator>
			<dc:creator>Anna Lagni</dc:creator>
			<dc:creator>Erica Diani</dc:creator>
			<dc:creator>Asia Palmisano</dc:creator>
			<dc:creator>Marco Mantoan</dc:creator>
			<dc:creator>Livio Montesarchio</dc:creator>
			<dc:creator>Francesca Palladini</dc:creator>
			<dc:creator>Giona Turri</dc:creator>
			<dc:creator>Davide Gibellini</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060150</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-18</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-18</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>150</prism:startingPage>
		<prism:doi>10.3390/idr17060150</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/150</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/149">

	<title>Infectious Disease Reports, Vol. 17, Pages 149: Factors Associated with Condomless Anal Sex and Absence of Pre-Exposure Prophylaxis (PrEP) Use Among Brazilian Men Who Have Sex with Men: A Cross-Sectional Study</title>
	<link>https://www.mdpi.com/2036-7449/17/6/149</link>
	<description>Background: Men who have sex with men (MSM) in Brazil remain disproportionately affected by HIV. Combination prevention strategies, including Pre-Exposure Prophylaxis (PrEP), are critical, yet adherence remains a challenge. This study aimed to identify factors associated with the simultaneous practice of condomless anal sex and non-use of PrEP among Brazilian MSM. Methods: A national cross-sectional study was conducted in 2020 via an online questionnaire disseminated on social media and dating apps. The outcome was defined as reporting condomless anal sex and no PrEP use in the previous year. Bivariate and multivariate logistic regression analyses were performed. Results: Among 1357 MSM participants, a high proportion (69.4%) reported condomless anal sex without PrEP use. Factors significantly associated with this behavior included being younger (18&amp;amp;ndash;28 years; AOR: 2.59), identifying as homosexual (AOR: 6.04), bisexual (AOR: 5.30), or pansexual (AOR: 8.67), having a steady partner (AOR: 4.57), engaging primarily in receptive or insertive anal sex, and having a prior STI diagnosis (AOR: 1.49). Conclusions: The confluence of condomless sex and PrEP non-use reveals a significant vulnerability profile among young MSM in Brazil, even within steady relationships. These findings highlight the originality of examining this combined behavioral outcome and underscore the urgent need for targeted, culturally sensitive prevention strategies that address risk perception and enhance PrEP uptake to meet the UNAIDS 2030 goals.</description>
	<pubDate>2025-12-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 149: Factors Associated with Condomless Anal Sex and Absence of Pre-Exposure Prophylaxis (PrEP) Use Among Brazilian Men Who Have Sex with Men: A Cross-Sectional Study</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/149">doi: 10.3390/idr17060149</a></p>
	<p>Authors:
		Laelson Rochelle Milanês Sousa
		Patrícia Thais Cardoso da Silva
		Allan Araujo Rodrigues
		Márcio José dos Santos Silva
		José Carlos Vinícius Jansen de Paz
		Breno da Silva Oliveira
		Daniel de Macêdo Rocha
		Maria Wiklander
		Elucir Gir
		Renata Karina Reis
		</p>
	<p>Background: Men who have sex with men (MSM) in Brazil remain disproportionately affected by HIV. Combination prevention strategies, including Pre-Exposure Prophylaxis (PrEP), are critical, yet adherence remains a challenge. This study aimed to identify factors associated with the simultaneous practice of condomless anal sex and non-use of PrEP among Brazilian MSM. Methods: A national cross-sectional study was conducted in 2020 via an online questionnaire disseminated on social media and dating apps. The outcome was defined as reporting condomless anal sex and no PrEP use in the previous year. Bivariate and multivariate logistic regression analyses were performed. Results: Among 1357 MSM participants, a high proportion (69.4%) reported condomless anal sex without PrEP use. Factors significantly associated with this behavior included being younger (18&amp;amp;ndash;28 years; AOR: 2.59), identifying as homosexual (AOR: 6.04), bisexual (AOR: 5.30), or pansexual (AOR: 8.67), having a steady partner (AOR: 4.57), engaging primarily in receptive or insertive anal sex, and having a prior STI diagnosis (AOR: 1.49). Conclusions: The confluence of condomless sex and PrEP non-use reveals a significant vulnerability profile among young MSM in Brazil, even within steady relationships. These findings highlight the originality of examining this combined behavioral outcome and underscore the urgent need for targeted, culturally sensitive prevention strategies that address risk perception and enhance PrEP uptake to meet the UNAIDS 2030 goals.</p>
	]]></content:encoded>

	<dc:title>Factors Associated with Condomless Anal Sex and Absence of Pre-Exposure Prophylaxis (PrEP) Use Among Brazilian Men Who Have Sex with Men: A Cross-Sectional Study</dc:title>
			<dc:creator>Laelson Rochelle Milanês Sousa</dc:creator>
			<dc:creator>Patrícia Thais Cardoso da Silva</dc:creator>
			<dc:creator>Allan Araujo Rodrigues</dc:creator>
			<dc:creator>Márcio José dos Santos Silva</dc:creator>
			<dc:creator>José Carlos Vinícius Jansen de Paz</dc:creator>
			<dc:creator>Breno da Silva Oliveira</dc:creator>
			<dc:creator>Daniel de Macêdo Rocha</dc:creator>
			<dc:creator>Maria Wiklander</dc:creator>
			<dc:creator>Elucir Gir</dc:creator>
			<dc:creator>Renata Karina Reis</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060149</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-12</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>149</prism:startingPage>
		<prism:doi>10.3390/idr17060149</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/149</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/148">

	<title>Infectious Disease Reports, Vol. 17, Pages 148: The Evolution of Artificial Intelligence in Ocular Toxoplasmosis Detection: A Scoping Review on Diagnostic Models, Data Challenges, and Future Directions</title>
	<link>https://www.mdpi.com/2036-7449/17/6/148</link>
	<description>Ocular Toxoplasmosis (OT), a leading cause of infectious posterior uveitis, presents significant diagnostic challenges in atypical cases due to phenotypic overlap with other retinochoroiditides and a reliance on expert interpretation of multimodal imaging. This scoping review systematically maps the burgeoning application of artificial intelligence (AI), particularly deep learning, in automating OT diagnosis. We synthesized 22 studies to characterize the current evidence, data landscape, and clinical translation readiness. Findings reveal a field in its nascent yet rapidly accelerating phase, dominated by convolutional neural networks (CNNs) applied to fundus photography for binary classification tasks, often reporting high accuracy (87&amp;amp;ndash;99.2%). However, development is critically constrained by small, imbalanced, single-center datasets, a near-universal lack of external validation, and insufficient explainable AI (XAI), creating a significant gap between technical promise and clinical utility. While AI demonstrates strong potential to standardize diagnosis and reduce subjectivity, its path to integration is hampered by over-reliance on internal validation, the &amp;amp;ldquo;black box&amp;amp;rdquo; nature of models, and an absence of implementation strategies. Future progress hinges on collaborative multi-center data curation, mandatory external and prospective validation, the integration of XAI for transparency, and a focused shift towards developing AI tools that assist in the complex differential diagnosis of posterior uveitis, ultimately bridging the translational chasm to clinical practice.</description>
	<pubDate>2025-12-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 148: The Evolution of Artificial Intelligence in Ocular Toxoplasmosis Detection: A Scoping Review on Diagnostic Models, Data Challenges, and Future Directions</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/148">doi: 10.3390/idr17060148</a></p>
	<p>Authors:
		Dodit Suprianto
		Loeki Enggar Fitri
		Ovi Sofia
		Akhmad Sabarudin
		Wayan Firdaus Mahmudy
		Muhammad Hatta Prabowo
		Werasak Surareungchai
		</p>
	<p>Ocular Toxoplasmosis (OT), a leading cause of infectious posterior uveitis, presents significant diagnostic challenges in atypical cases due to phenotypic overlap with other retinochoroiditides and a reliance on expert interpretation of multimodal imaging. This scoping review systematically maps the burgeoning application of artificial intelligence (AI), particularly deep learning, in automating OT diagnosis. We synthesized 22 studies to characterize the current evidence, data landscape, and clinical translation readiness. Findings reveal a field in its nascent yet rapidly accelerating phase, dominated by convolutional neural networks (CNNs) applied to fundus photography for binary classification tasks, often reporting high accuracy (87&amp;amp;ndash;99.2%). However, development is critically constrained by small, imbalanced, single-center datasets, a near-universal lack of external validation, and insufficient explainable AI (XAI), creating a significant gap between technical promise and clinical utility. While AI demonstrates strong potential to standardize diagnosis and reduce subjectivity, its path to integration is hampered by over-reliance on internal validation, the &amp;amp;ldquo;black box&amp;amp;rdquo; nature of models, and an absence of implementation strategies. Future progress hinges on collaborative multi-center data curation, mandatory external and prospective validation, the integration of XAI for transparency, and a focused shift towards developing AI tools that assist in the complex differential diagnosis of posterior uveitis, ultimately bridging the translational chasm to clinical practice.</p>
	]]></content:encoded>

	<dc:title>The Evolution of Artificial Intelligence in Ocular Toxoplasmosis Detection: A Scoping Review on Diagnostic Models, Data Challenges, and Future Directions</dc:title>
			<dc:creator>Dodit Suprianto</dc:creator>
			<dc:creator>Loeki Enggar Fitri</dc:creator>
			<dc:creator>Ovi Sofia</dc:creator>
			<dc:creator>Akhmad Sabarudin</dc:creator>
			<dc:creator>Wayan Firdaus Mahmudy</dc:creator>
			<dc:creator>Muhammad Hatta Prabowo</dc:creator>
			<dc:creator>Werasak Surareungchai</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060148</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-08</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-08</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>148</prism:startingPage>
		<prism:doi>10.3390/idr17060148</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/148</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/147">

	<title>Infectious Disease Reports, Vol. 17, Pages 147: When Fever Strikes Twice: A Case Report of Streptococcus pneumoniae Myelitis with Delayed-Onset Reactive Arthritis</title>
	<link>https://www.mdpi.com/2036-7449/17/6/147</link>
	<description>Background:Streptococcus pneumoniae is a well-known pathogen responsible for respiratory and invasive diseases; however, central nervous system (CNS) involvement in the form of bacterial myelitis is exceedingly rare, particularly in immunocompetent adults. Moreover, the association between pneumococcal infections and reactive arthritis is scarcely documented. We report an unusual case of pneumococcal myelitis complicated by reactive arthritis in an elderly patient with no evident immunosuppression. Case Presentation: A 68-year-old man with a medical history of hypertension, benign prostatic hyperplasia, multiple disc herniations, and a resected pancreatic neuroendocrine tumour presented to the emergency department with acute urinary retention and fever (38.5 &amp;amp;deg;C). The neurological examination revealed lower limb weakness and decreased deep tendon reflexes. Spinal magnetic resonance demonstrated T2 hyperintense lesions suggestive of longitudinally transverse myelitis. Cerebrospinal fluid (CSF) analysis showed pleocytosis with elevated protein levels; the polymerase chain reaction (PCR) test resulted positive result for Streptococcus pneumoniae. The patient received intravenous antimicrobial and corticosteroid therapy with partial neurological improvement. Within days, he developed acute monoarthritis of the right ankle. Joint aspiration revealed sterile inflammatory fluid, negative for crystals and cultures, supporting a diagnosis of reactive arthritis. The articular symptoms resolved with the use of prednisone. An extensive immunological work-up was negative, and no other infectious or autoimmune triggers were identified. The patient underwent a structured rehabilitation program with gradual improvement in motor function over the following weeks. Conclusions: This case illustrates a rare clinical scenario of pneumococcal myelitis associated with reactive arthritis in a patient without overt immunosuppression. It highlights the importance of considering bacterial aetiologies in cases of acute transverse myelitis and the potential for unusual systemic immune responses such as reactive arthritis. Early recognition and the administration of appropriate antimicrobial and supportive therapies are crucial for improving neurological and systemic outcomes. To our knowledge, this is one of the first reported cases describing the co-occurrence of these two conditions in the context of S. pneumoniae infection.</description>
	<pubDate>2025-12-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 147: When Fever Strikes Twice: A Case Report of Streptococcus pneumoniae Myelitis with Delayed-Onset Reactive Arthritis</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/147">doi: 10.3390/idr17060147</a></p>
	<p>Authors:
		Rosario Luca Norrito
		Sergio Mastrilli
		Felice Fiorello
		Giuseppe Taormina
		Lucia Di Giorgi
		Grazia Mery Anna Ruggirello
		Carlo Domenico Maida
		Aurelio Piazza
		Fabio Cartabellotta
		</p>
	<p>Background:Streptococcus pneumoniae is a well-known pathogen responsible for respiratory and invasive diseases; however, central nervous system (CNS) involvement in the form of bacterial myelitis is exceedingly rare, particularly in immunocompetent adults. Moreover, the association between pneumococcal infections and reactive arthritis is scarcely documented. We report an unusual case of pneumococcal myelitis complicated by reactive arthritis in an elderly patient with no evident immunosuppression. Case Presentation: A 68-year-old man with a medical history of hypertension, benign prostatic hyperplasia, multiple disc herniations, and a resected pancreatic neuroendocrine tumour presented to the emergency department with acute urinary retention and fever (38.5 &amp;amp;deg;C). The neurological examination revealed lower limb weakness and decreased deep tendon reflexes. Spinal magnetic resonance demonstrated T2 hyperintense lesions suggestive of longitudinally transverse myelitis. Cerebrospinal fluid (CSF) analysis showed pleocytosis with elevated protein levels; the polymerase chain reaction (PCR) test resulted positive result for Streptococcus pneumoniae. The patient received intravenous antimicrobial and corticosteroid therapy with partial neurological improvement. Within days, he developed acute monoarthritis of the right ankle. Joint aspiration revealed sterile inflammatory fluid, negative for crystals and cultures, supporting a diagnosis of reactive arthritis. The articular symptoms resolved with the use of prednisone. An extensive immunological work-up was negative, and no other infectious or autoimmune triggers were identified. The patient underwent a structured rehabilitation program with gradual improvement in motor function over the following weeks. Conclusions: This case illustrates a rare clinical scenario of pneumococcal myelitis associated with reactive arthritis in a patient without overt immunosuppression. It highlights the importance of considering bacterial aetiologies in cases of acute transverse myelitis and the potential for unusual systemic immune responses such as reactive arthritis. Early recognition and the administration of appropriate antimicrobial and supportive therapies are crucial for improving neurological and systemic outcomes. To our knowledge, this is one of the first reported cases describing the co-occurrence of these two conditions in the context of S. pneumoniae infection.</p>
	]]></content:encoded>

	<dc:title>When Fever Strikes Twice: A Case Report of Streptococcus pneumoniae Myelitis with Delayed-Onset Reactive Arthritis</dc:title>
			<dc:creator>Rosario Luca Norrito</dc:creator>
			<dc:creator>Sergio Mastrilli</dc:creator>
			<dc:creator>Felice Fiorello</dc:creator>
			<dc:creator>Giuseppe Taormina</dc:creator>
			<dc:creator>Lucia Di Giorgi</dc:creator>
			<dc:creator>Grazia Mery Anna Ruggirello</dc:creator>
			<dc:creator>Carlo Domenico Maida</dc:creator>
			<dc:creator>Aurelio Piazza</dc:creator>
			<dc:creator>Fabio Cartabellotta</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060147</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-08</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-08</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>147</prism:startingPage>
		<prism:doi>10.3390/idr17060147</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/147</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/146">

	<title>Infectious Disease Reports, Vol. 17, Pages 146: Integration Models for Delivering COVID-19 Vaccines Through HIV Services in Low-and Middle-Income Countries: A Scoping Review</title>
	<link>https://www.mdpi.com/2036-7449/17/6/146</link>
	<description>Background: The Coronavirus Disease 2019 (COVID-19) remains a major global public health issue. People living with HIV (PLHIV) are among the vulnerable groups facing a higher risk of severe outcomes. Combining COVID-19 vaccination with HIV services can improve access and utilization of the vaccine among PLHIV although effective methods of delivery are yet to be ascertained. We conducted a scoping review to identify and describe models for delivering COVID-19 vaccines through HIV care services in low- and middle-income countries (LMICs). Methods: We used PRISMA-ScR guidelines to conduct the review. On 3rd and 4th February 2025, we searched PubMed, Web of Science, Cochrane Library, and EMBASE for studies on integrated COVID-19 vaccine delivery for PLHIV. Results: Three studies from sub-Saharan Africa reported call-back strategy, diverse partnership, and mixed service delivery models for implementing COVID-19 vaccination in HIV care services. Key strategies that were used included building capacity, generating demand, managing the supply chain, and involving stakeholders. The outcomes showed significant increases in vaccination coverage among PLHIV and reduced vaccine wastage. Conclusions: Integrating COVID-19 vaccination into HIV services is practical and effective in LMICs. It makes use of current infrastructure, partnerships, and local innovations.</description>
	<pubDate>2025-12-05</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 146: Integration Models for Delivering COVID-19 Vaccines Through HIV Services in Low-and Middle-Income Countries: A Scoping Review</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/146">doi: 10.3390/idr17060146</a></p>
	<p>Authors:
		Nyanyiwe Masingi Mbeye
		Roselyn Chipojola
		Susan Banda
		Prince Kaude
		Aaron Mdolo
		Charles Nwosisi
		Sandra Mounier-Jack
		</p>
	<p>Background: The Coronavirus Disease 2019 (COVID-19) remains a major global public health issue. People living with HIV (PLHIV) are among the vulnerable groups facing a higher risk of severe outcomes. Combining COVID-19 vaccination with HIV services can improve access and utilization of the vaccine among PLHIV although effective methods of delivery are yet to be ascertained. We conducted a scoping review to identify and describe models for delivering COVID-19 vaccines through HIV care services in low- and middle-income countries (LMICs). Methods: We used PRISMA-ScR guidelines to conduct the review. On 3rd and 4th February 2025, we searched PubMed, Web of Science, Cochrane Library, and EMBASE for studies on integrated COVID-19 vaccine delivery for PLHIV. Results: Three studies from sub-Saharan Africa reported call-back strategy, diverse partnership, and mixed service delivery models for implementing COVID-19 vaccination in HIV care services. Key strategies that were used included building capacity, generating demand, managing the supply chain, and involving stakeholders. The outcomes showed significant increases in vaccination coverage among PLHIV and reduced vaccine wastage. Conclusions: Integrating COVID-19 vaccination into HIV services is practical and effective in LMICs. It makes use of current infrastructure, partnerships, and local innovations.</p>
	]]></content:encoded>

	<dc:title>Integration Models for Delivering COVID-19 Vaccines Through HIV Services in Low-and Middle-Income Countries: A Scoping Review</dc:title>
			<dc:creator>Nyanyiwe Masingi Mbeye</dc:creator>
			<dc:creator>Roselyn Chipojola</dc:creator>
			<dc:creator>Susan Banda</dc:creator>
			<dc:creator>Prince Kaude</dc:creator>
			<dc:creator>Aaron Mdolo</dc:creator>
			<dc:creator>Charles Nwosisi</dc:creator>
			<dc:creator>Sandra Mounier-Jack</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060146</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-12-05</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-12-05</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>146</prism:startingPage>
		<prism:doi>10.3390/idr17060146</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/146</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/145">

	<title>Infectious Disease Reports, Vol. 17, Pages 145: Epidemiological Profile and Diagnostic Outcomes of Blood Donors Following Hepatitis B Screening at the Largest Blood Bank in the State of Par&amp;aacute;, Brazil</title>
	<link>https://www.mdpi.com/2036-7449/17/6/145</link>
	<description>Background/Objectives: Serological and molecular screening for Hepatitis B virus (HBV) has been essential in reducing the risk of transfusion-transmitted infection, particularly in regions of high endemicity. This retrospective study aimed to analyze the epidemiological profile and laboratory outcomes of 259 blood donors deemed ineligible after initial reactive or inconclusive screening for HBV markers. Methods: Donors were summoned for revaluation at the HEMOPA Foundation, in Bel&amp;amp;eacute;m, Par&amp;amp;aacute;, between February 2015 and July 2016. Demographic data, risk factors, and results for HBsAg, anti-HBc, anti-HBs, and HBV DNA obtained at the donation and return time points were collected. Results: The mean age was 37 &amp;amp;plusmn; 11.25 years, with a predominance of males (56.8%) and first-time donors (76%). At the return time point, 63.7% presented a profile indicative of resolved HBV infection and 3.5% of active infection, 6.6% were susceptible to HBV infection, and 1.9% presented vaccine-induced HBV immunity. Cases of Occult Hepatitis B Infection (OBI, 0.4%) and Window Period (WP, 0.4%) were also identified. Conclusions: The findings reveal a high prevalence of resolved HBV infection among ineligible donors, particularly first-time donors, and reinforce the importance of combined serological and molecular screening, as well as the need for vaccination and health education strategies for at-risk populations. As a public blood bank located in the Amazon region, we highlight that local epidemiological specificities must be considered in the formulation of public health policies that are sensitive to the regional context.</description>
	<pubDate>2025-11-28</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 145: Epidemiological Profile and Diagnostic Outcomes of Blood Donors Following Hepatitis B Screening at the Largest Blood Bank in the State of Par&amp;aacute;, Brazil</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/145">doi: 10.3390/idr17060145</a></p>
	<p>Authors:
		Núbia Caroline Costa de Almeida
		Beatriz Monteiro Rodrigues Coelho
		Camila Fonseca Barroso
		Carlos Eduardo de Melo Amaral
		Renata Bezerra Hermes de Castro
		Letícia Martins Lamarão
		Jacqueline Cortinhas Monteiro
		Lucimar Di Paula dos Santos Madeira
		Igor Brasil-Costa
		</p>
	<p>Background/Objectives: Serological and molecular screening for Hepatitis B virus (HBV) has been essential in reducing the risk of transfusion-transmitted infection, particularly in regions of high endemicity. This retrospective study aimed to analyze the epidemiological profile and laboratory outcomes of 259 blood donors deemed ineligible after initial reactive or inconclusive screening for HBV markers. Methods: Donors were summoned for revaluation at the HEMOPA Foundation, in Bel&amp;amp;eacute;m, Par&amp;amp;aacute;, between February 2015 and July 2016. Demographic data, risk factors, and results for HBsAg, anti-HBc, anti-HBs, and HBV DNA obtained at the donation and return time points were collected. Results: The mean age was 37 &amp;amp;plusmn; 11.25 years, with a predominance of males (56.8%) and first-time donors (76%). At the return time point, 63.7% presented a profile indicative of resolved HBV infection and 3.5% of active infection, 6.6% were susceptible to HBV infection, and 1.9% presented vaccine-induced HBV immunity. Cases of Occult Hepatitis B Infection (OBI, 0.4%) and Window Period (WP, 0.4%) were also identified. Conclusions: The findings reveal a high prevalence of resolved HBV infection among ineligible donors, particularly first-time donors, and reinforce the importance of combined serological and molecular screening, as well as the need for vaccination and health education strategies for at-risk populations. As a public blood bank located in the Amazon region, we highlight that local epidemiological specificities must be considered in the formulation of public health policies that are sensitive to the regional context.</p>
	]]></content:encoded>

	<dc:title>Epidemiological Profile and Diagnostic Outcomes of Blood Donors Following Hepatitis B Screening at the Largest Blood Bank in the State of Par&amp;amp;aacute;, Brazil</dc:title>
			<dc:creator>Núbia Caroline Costa de Almeida</dc:creator>
			<dc:creator>Beatriz Monteiro Rodrigues Coelho</dc:creator>
			<dc:creator>Camila Fonseca Barroso</dc:creator>
			<dc:creator>Carlos Eduardo de Melo Amaral</dc:creator>
			<dc:creator>Renata Bezerra Hermes de Castro</dc:creator>
			<dc:creator>Letícia Martins Lamarão</dc:creator>
			<dc:creator>Jacqueline Cortinhas Monteiro</dc:creator>
			<dc:creator>Lucimar Di Paula dos Santos Madeira</dc:creator>
			<dc:creator>Igor Brasil-Costa</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060145</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-28</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-28</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>145</prism:startingPage>
		<prism:doi>10.3390/idr17060145</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/145</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/144">

	<title>Infectious Disease Reports, Vol. 17, Pages 144: Repurposing Agents as Anti-Infective Therapeutics to Aid in the Treatment of Candida auris Infections</title>
	<link>https://www.mdpi.com/2036-7449/17/6/144</link>
	<description>Background: Candida auris is an emerging nosocomial fungal pathogen whose inherent multidrug resistance and ability to form biofilms make treatment extremely difficult. Given the limited number of therapeutic options available and the poor clinical outcomes associated with current therapeutics, this study evaluated the potential of repurposing existing agents to treat C. auris infections. Methods: Six clinical C. auris isolates from a single tertiary care center were tested for in vitro susceptibility to topical agents (hypochlorous acid, chlorhexidine gluconate, sodium hypochlorite) and systemic agents (N-acetylcysteine, ethylenediaminetetraacetic acid, ethyl pyruvate). Furthermore, these six isolates were allowed to form biofilms and the ability of repurposed agents to disrupt C. auris biofilms was measured. Results: All agents except N-acetylcysteine demonstrated inhibitory activity against planktonic C. auris. With respect to C. auris biofilms, these were characterized using electron microscopy and all six agents showed statistically significant (p &amp;amp;lt; 0.05) ability to disrupt biofilms over controls. Moreover, the ability to disrupt biofilms was also statistically significant (p &amp;amp;lt; 0.05) when compared to use of either normal saline or amphotericin B. Discussion: These findings support the potential clinical utility of repurposing existing agents, such as Ethyl Pyruvate or EDTA, for systemic C. auris infections, or hypochlorous acid for C. auris wound infections. Yet, further studies are needed to optimize dosing parameters and evaluate in vivo efficacy and tolerability.</description>
	<pubDate>2025-11-27</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 144: Repurposing Agents as Anti-Infective Therapeutics to Aid in the Treatment of Candida auris Infections</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/144">doi: 10.3390/idr17060144</a></p>
	<p>Authors:
		Nazary Nebeluk
		James B. Doub
		</p>
	<p>Background: Candida auris is an emerging nosocomial fungal pathogen whose inherent multidrug resistance and ability to form biofilms make treatment extremely difficult. Given the limited number of therapeutic options available and the poor clinical outcomes associated with current therapeutics, this study evaluated the potential of repurposing existing agents to treat C. auris infections. Methods: Six clinical C. auris isolates from a single tertiary care center were tested for in vitro susceptibility to topical agents (hypochlorous acid, chlorhexidine gluconate, sodium hypochlorite) and systemic agents (N-acetylcysteine, ethylenediaminetetraacetic acid, ethyl pyruvate). Furthermore, these six isolates were allowed to form biofilms and the ability of repurposed agents to disrupt C. auris biofilms was measured. Results: All agents except N-acetylcysteine demonstrated inhibitory activity against planktonic C. auris. With respect to C. auris biofilms, these were characterized using electron microscopy and all six agents showed statistically significant (p &amp;amp;lt; 0.05) ability to disrupt biofilms over controls. Moreover, the ability to disrupt biofilms was also statistically significant (p &amp;amp;lt; 0.05) when compared to use of either normal saline or amphotericin B. Discussion: These findings support the potential clinical utility of repurposing existing agents, such as Ethyl Pyruvate or EDTA, for systemic C. auris infections, or hypochlorous acid for C. auris wound infections. Yet, further studies are needed to optimize dosing parameters and evaluate in vivo efficacy and tolerability.</p>
	]]></content:encoded>

	<dc:title>Repurposing Agents as Anti-Infective Therapeutics to Aid in the Treatment of Candida auris Infections</dc:title>
			<dc:creator>Nazary Nebeluk</dc:creator>
			<dc:creator>James B. Doub</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060144</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-27</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-27</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>144</prism:startingPage>
		<prism:doi>10.3390/idr17060144</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/144</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/143">

	<title>Infectious Disease Reports, Vol. 17, Pages 143: Atypical Blistering Manifestation of Secondary Syphilis: Case Report and Review of Reported Cases</title>
	<link>https://www.mdpi.com/2036-7449/17/6/143</link>
	<description>Background/Objectives: Secondary syphilis typically presents with a non-pruritic maculopapular rash. However, vesicular and bullous manifestations are exceedingly rare in adults and may mimic autoimmune blistering diseases. The objective of this report is to describe atypical presentation of secondary syphilis with predominant vesiculobullous lesions and to emphasize the importance of including syphilis in the differential diagnosis of blistering skin diseases. Methods: We describe the case of a 46-year-old bisexual man with syphilis of unknown duration who presented with recurrent polymorphic skin eruptions, predominantly bullous and vesicular in nature. Clinical examination, serologic testing, and histopathologic evaluation were performed to establish the diagnosis. Results: Serologic tests confirmed active syphilis infection. A brief review of similar reported cases was conducted to highlight the clinical variability of vesiculobullous syphilis. Conclusions: Atypical vesiculobullous presentations of secondary syphilis pose significant diagnostic challenges and may be mistaken for autoimmune blistering disorders. Clinicians should maintain a high index of suspicion for syphilis in patients with polymorphic or blistering eruptions, particularly in those with risk factors for sexually transmitted infections. Awareness of these uncommon manifestations can facilitate timely diagnosis and appropriate treatment.</description>
	<pubDate>2025-11-18</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 143: Atypical Blistering Manifestation of Secondary Syphilis: Case Report and Review of Reported Cases</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/143">doi: 10.3390/idr17060143</a></p>
	<p>Authors:
		Agnieszka Markiewicz
		Aleksandra Skórka
		Agnieszka Owczarczyk-Saczonek
		</p>
	<p>Background/Objectives: Secondary syphilis typically presents with a non-pruritic maculopapular rash. However, vesicular and bullous manifestations are exceedingly rare in adults and may mimic autoimmune blistering diseases. The objective of this report is to describe atypical presentation of secondary syphilis with predominant vesiculobullous lesions and to emphasize the importance of including syphilis in the differential diagnosis of blistering skin diseases. Methods: We describe the case of a 46-year-old bisexual man with syphilis of unknown duration who presented with recurrent polymorphic skin eruptions, predominantly bullous and vesicular in nature. Clinical examination, serologic testing, and histopathologic evaluation were performed to establish the diagnosis. Results: Serologic tests confirmed active syphilis infection. A brief review of similar reported cases was conducted to highlight the clinical variability of vesiculobullous syphilis. Conclusions: Atypical vesiculobullous presentations of secondary syphilis pose significant diagnostic challenges and may be mistaken for autoimmune blistering disorders. Clinicians should maintain a high index of suspicion for syphilis in patients with polymorphic or blistering eruptions, particularly in those with risk factors for sexually transmitted infections. Awareness of these uncommon manifestations can facilitate timely diagnosis and appropriate treatment.</p>
	]]></content:encoded>

	<dc:title>Atypical Blistering Manifestation of Secondary Syphilis: Case Report and Review of Reported Cases</dc:title>
			<dc:creator>Agnieszka Markiewicz</dc:creator>
			<dc:creator>Aleksandra Skórka</dc:creator>
			<dc:creator>Agnieszka Owczarczyk-Saczonek</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060143</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-18</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-18</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>143</prism:startingPage>
		<prism:doi>10.3390/idr17060143</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/143</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/142">

	<title>Infectious Disease Reports, Vol. 17, Pages 142: Waning Protection Against Severe COVID-19 Following Vaccination: A Longitudinal IPTW Analysis of Emergency Department Encounters</title>
	<link>https://www.mdpi.com/2036-7449/17/6/142</link>
	<description>Background: The duration of protection that COVID-19 vaccination provides against severe outcomes remains uncertain. Accurately defining this timeframe is critical for informing effective vaccination policies and booster strategies. This investigation aimed to quantify the length and durability of vaccine-conferred protection against severe disease, delivering evidence to guide public health decision-making. Methods: We conducted a multi-site cohort study to evaluate the relationship between time since last COVID-19 vaccination and the risk of severe infection among emergency department (ED) patients with a principal diagnosis of COVID-19. Vaccination status was categorized by time since the last documented dose: unvaccinated, 0&amp;amp;ndash;6 months, 7&amp;amp;ndash;12 months, 13&amp;amp;ndash;18 months, and 19&amp;amp;ndash;24 months. The primary outcome was severe COVID-19, defined as ICU admission, mechanical ventilation, or in-hospital death. Inverse Probability of Treatment Weighting (IPTW) was used to adjust for baseline confounding based on age group, sex, race, comorbidity burden, immunocompromised status, and calendar time period (pre-2023 vs. post-2023). Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for each vaccination interval compared to unvaccinated patients. Results: Between 1 December 2021, and 20 July 2024, 42,124 ED encounters were included in the analysis. In IPTW-weighted models, vaccination within 0&amp;amp;ndash;6 months (aHR 0.73, 95% CI 0.64&amp;amp;ndash;0.83), 7&amp;amp;ndash;12 months (aHR 0.72, 95% CI 0.64&amp;amp;ndash;0.82), and 13&amp;amp;ndash;18 months (aHR 0.67, 95% CI 0.57&amp;amp;ndash;0.79) was associated with a significantly reduced risk of severe outcomes. However, no significant protection was observed at 19&amp;amp;ndash;24 months (aHR 0.95, 95% CI 0.80&amp;amp;ndash;1.14). In age-stratified analyses, protection persisted longer in individuals aged &amp;amp;ge;65 years than in those aged 50&amp;amp;ndash;64. Older age, male sex, comorbidities, and immunocompromised status were also associated with increased risk. Conclusions: COVID-19 vaccination provides sustained protection against severe outcomes for up to 18 months, after which effectiveness declines substantially. These findings support booster dose strategies based on time since last vaccination and targeted prioritization for high-risk populations.</description>
	<pubDate>2025-11-13</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 142: Waning Protection Against Severe COVID-19 Following Vaccination: A Longitudinal IPTW Analysis of Emergency Department Encounters</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/142">doi: 10.3390/idr17060142</a></p>
	<p>Authors:
		Yuying Xing
		Amit Bahl
		</p>
	<p>Background: The duration of protection that COVID-19 vaccination provides against severe outcomes remains uncertain. Accurately defining this timeframe is critical for informing effective vaccination policies and booster strategies. This investigation aimed to quantify the length and durability of vaccine-conferred protection against severe disease, delivering evidence to guide public health decision-making. Methods: We conducted a multi-site cohort study to evaluate the relationship between time since last COVID-19 vaccination and the risk of severe infection among emergency department (ED) patients with a principal diagnosis of COVID-19. Vaccination status was categorized by time since the last documented dose: unvaccinated, 0&amp;amp;ndash;6 months, 7&amp;amp;ndash;12 months, 13&amp;amp;ndash;18 months, and 19&amp;amp;ndash;24 months. The primary outcome was severe COVID-19, defined as ICU admission, mechanical ventilation, or in-hospital death. Inverse Probability of Treatment Weighting (IPTW) was used to adjust for baseline confounding based on age group, sex, race, comorbidity burden, immunocompromised status, and calendar time period (pre-2023 vs. post-2023). Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for each vaccination interval compared to unvaccinated patients. Results: Between 1 December 2021, and 20 July 2024, 42,124 ED encounters were included in the analysis. In IPTW-weighted models, vaccination within 0&amp;amp;ndash;6 months (aHR 0.73, 95% CI 0.64&amp;amp;ndash;0.83), 7&amp;amp;ndash;12 months (aHR 0.72, 95% CI 0.64&amp;amp;ndash;0.82), and 13&amp;amp;ndash;18 months (aHR 0.67, 95% CI 0.57&amp;amp;ndash;0.79) was associated with a significantly reduced risk of severe outcomes. However, no significant protection was observed at 19&amp;amp;ndash;24 months (aHR 0.95, 95% CI 0.80&amp;amp;ndash;1.14). In age-stratified analyses, protection persisted longer in individuals aged &amp;amp;ge;65 years than in those aged 50&amp;amp;ndash;64. Older age, male sex, comorbidities, and immunocompromised status were also associated with increased risk. Conclusions: COVID-19 vaccination provides sustained protection against severe outcomes for up to 18 months, after which effectiveness declines substantially. These findings support booster dose strategies based on time since last vaccination and targeted prioritization for high-risk populations.</p>
	]]></content:encoded>

	<dc:title>Waning Protection Against Severe COVID-19 Following Vaccination: A Longitudinal IPTW Analysis of Emergency Department Encounters</dc:title>
			<dc:creator>Yuying Xing</dc:creator>
			<dc:creator>Amit Bahl</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060142</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-13</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-13</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>142</prism:startingPage>
		<prism:doi>10.3390/idr17060142</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/142</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/141">

	<title>Infectious Disease Reports, Vol. 17, Pages 141: A Comparison of the Risk of Viral Load Blips in Human Immunodeficiency Virus Patients on Two-Drug Versus Three-Drug Antiretroviral Regimens</title>
	<link>https://www.mdpi.com/2036-7449/17/6/141</link>
	<description>Background/Objectives: The objective of this retrospective, multicenter cohort study was to compare the incidence of viral load blips between two-drug and three-drug antiretroviral therapy regimens in human immunodeficiency virus (HIV) patients. Methods: A total of 121 patients were included, with 44 receiving two-drug regimens (e.g., dolutegravir/lamivudine) and 77 receiving three-drug regimens (e.g., bictegravir/tenofovir alafenamide/emtricitabine) at the time of analysis. The primary outcome was the occurrence of viral blips, defined as transient HIV-RNA elevations &amp;amp;ge; 50 copies/mL; a sensitivity analysis used &amp;amp;ge;20 copies/mL. Results: Generalized estimating equation models adjusted for clinical covariates showed no significant difference in the odds of blip occurrence comparing three-drug with two-drug regimens, both for blips &amp;amp;ge; 50 (odds ratio [OR]: 2.64; 95% confidence interval [CI]: 0.91&amp;amp;ndash;7.70; p = 0.075) and &amp;amp;ge;20 (OR: 1.76; 95% CI: 0.76&amp;amp;ndash;4.08; p = 0.190). In the two- and three-drug groups, the predicted probabilities of blips were 1.4% and 3.7% (p = 0.075) for blips &amp;amp;ge; 50, and 6.9% and 11.5% (p = 0.190) for &amp;amp;ge;20, respectively. No virologic failure was observed. Conclusions: These findings suggest that two-drug regimens provide virologic control comparable to three-drug regimens and may be a viable clinical option due to fewer drug interactions, lower toxicity, and reduced cost.</description>
	<pubDate>2025-11-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 141: A Comparison of the Risk of Viral Load Blips in Human Immunodeficiency Virus Patients on Two-Drug Versus Three-Drug Antiretroviral Regimens</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/141">doi: 10.3390/idr17060141</a></p>
	<p>Authors:
		Kimihiro Yamaguchi
		Masashi Ishihara
		Yoshikazu Ikoma
		Hitomi Sugiyama
		Daichi Watanabe
		Kei Fujita
		Shin Lee
		Tetsuji Morishita
		Nobuhiro Kanemura
		Masahito Shimizu
		Hisashi Tsurumi
		</p>
	<p>Background/Objectives: The objective of this retrospective, multicenter cohort study was to compare the incidence of viral load blips between two-drug and three-drug antiretroviral therapy regimens in human immunodeficiency virus (HIV) patients. Methods: A total of 121 patients were included, with 44 receiving two-drug regimens (e.g., dolutegravir/lamivudine) and 77 receiving three-drug regimens (e.g., bictegravir/tenofovir alafenamide/emtricitabine) at the time of analysis. The primary outcome was the occurrence of viral blips, defined as transient HIV-RNA elevations &amp;amp;ge; 50 copies/mL; a sensitivity analysis used &amp;amp;ge;20 copies/mL. Results: Generalized estimating equation models adjusted for clinical covariates showed no significant difference in the odds of blip occurrence comparing three-drug with two-drug regimens, both for blips &amp;amp;ge; 50 (odds ratio [OR]: 2.64; 95% confidence interval [CI]: 0.91&amp;amp;ndash;7.70; p = 0.075) and &amp;amp;ge;20 (OR: 1.76; 95% CI: 0.76&amp;amp;ndash;4.08; p = 0.190). In the two- and three-drug groups, the predicted probabilities of blips were 1.4% and 3.7% (p = 0.075) for blips &amp;amp;ge; 50, and 6.9% and 11.5% (p = 0.190) for &amp;amp;ge;20, respectively. No virologic failure was observed. Conclusions: These findings suggest that two-drug regimens provide virologic control comparable to three-drug regimens and may be a viable clinical option due to fewer drug interactions, lower toxicity, and reduced cost.</p>
	]]></content:encoded>

	<dc:title>A Comparison of the Risk of Viral Load Blips in Human Immunodeficiency Virus Patients on Two-Drug Versus Three-Drug Antiretroviral Regimens</dc:title>
			<dc:creator>Kimihiro Yamaguchi</dc:creator>
			<dc:creator>Masashi Ishihara</dc:creator>
			<dc:creator>Yoshikazu Ikoma</dc:creator>
			<dc:creator>Hitomi Sugiyama</dc:creator>
			<dc:creator>Daichi Watanabe</dc:creator>
			<dc:creator>Kei Fujita</dc:creator>
			<dc:creator>Shin Lee</dc:creator>
			<dc:creator>Tetsuji Morishita</dc:creator>
			<dc:creator>Nobuhiro Kanemura</dc:creator>
			<dc:creator>Masahito Shimizu</dc:creator>
			<dc:creator>Hisashi Tsurumi</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060141</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-12</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>141</prism:startingPage>
		<prism:doi>10.3390/idr17060141</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/141</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/140">

	<title>Infectious Disease Reports, Vol. 17, Pages 140: A Rare Case of Disseminated Nocardia transvalensis in an Immunocompetent Host</title>
	<link>https://www.mdpi.com/2036-7449/17/6/140</link>
	<description>Background: Nocardia are a group of bacteria known to cause pulmonary, cutaneous, neurologic, or disseminated diseases, usually in immunocompromised hosts. Within the Nocardia family is Nocardia transvalensis, a rarely encountered and underreported organism in the clinical literature. Case: Here, we report the case of an immunocompetent patient presenting with lumbar pain diagnosed and treated for disseminated Nocardia transvalensis infection. Our patient underwent magnetic resonance imaging (MRI), demonstrating possible abscess and subtle osteomyelitis of the L3-L4 facet joint and transverse process; a subsequent biopsy and culture resulted in Nocardia transvalensis. Further imaging with a computed tomography (CT) scan of the head revealed a 9 mm enhancing supratentorial lesion. The patient was treated with empiric antibiotics, but this was narrowed to levofloxacin, linezolid, and trimethoprim-sulfamethoxazole after antibiotic sensitivities cropped up. Conclusions: Within this case, we extensively discuss the clinical pathogenesis of Nocardia transvalensis in an unusual host, the diagnostic approach to confirming active Nocardia infection, and the susceptibility patterns in a relatively unstudied organism.</description>
	<pubDate>2025-11-12</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 140: A Rare Case of Disseminated Nocardia transvalensis in an Immunocompetent Host</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/140">doi: 10.3390/idr17060140</a></p>
	<p>Authors:
		Branavan Ragunanthan
		Kevin Wunderly
		James Kleshinski
		Caitlyn Hollingshead
		</p>
	<p>Background: Nocardia are a group of bacteria known to cause pulmonary, cutaneous, neurologic, or disseminated diseases, usually in immunocompromised hosts. Within the Nocardia family is Nocardia transvalensis, a rarely encountered and underreported organism in the clinical literature. Case: Here, we report the case of an immunocompetent patient presenting with lumbar pain diagnosed and treated for disseminated Nocardia transvalensis infection. Our patient underwent magnetic resonance imaging (MRI), demonstrating possible abscess and subtle osteomyelitis of the L3-L4 facet joint and transverse process; a subsequent biopsy and culture resulted in Nocardia transvalensis. Further imaging with a computed tomography (CT) scan of the head revealed a 9 mm enhancing supratentorial lesion. The patient was treated with empiric antibiotics, but this was narrowed to levofloxacin, linezolid, and trimethoprim-sulfamethoxazole after antibiotic sensitivities cropped up. Conclusions: Within this case, we extensively discuss the clinical pathogenesis of Nocardia transvalensis in an unusual host, the diagnostic approach to confirming active Nocardia infection, and the susceptibility patterns in a relatively unstudied organism.</p>
	]]></content:encoded>

	<dc:title>A Rare Case of Disseminated Nocardia transvalensis in an Immunocompetent Host</dc:title>
			<dc:creator>Branavan Ragunanthan</dc:creator>
			<dc:creator>Kevin Wunderly</dc:creator>
			<dc:creator>James Kleshinski</dc:creator>
			<dc:creator>Caitlyn Hollingshead</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060140</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-12</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-12</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>140</prism:startingPage>
		<prism:doi>10.3390/idr17060140</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/140</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/139">

	<title>Infectious Disease Reports, Vol. 17, Pages 139: Epidemiological and Clinical Changes in RSV-Associated Pneumonia in Children in Mexico Before and During the COVID 19 Pandemic</title>
	<link>https://www.mdpi.com/2036-7449/17/6/139</link>
	<description>Background/Objectives: Respiratory syncytial virus (RSV) significantly affects young children. In 2020, at the beginning of the COVID-19 pandemic, widespread public health measures temporarily interrupted RSV transmission. However, by mid-2021, an atypical resurgence of RSV was observed. The objective of this study was to compare the clinical and epidemiological characteristics of RSV infections in children before and during the second half of the SARS-CoV-2 pandemic in Mexico. Methods: A comparative ambispective longitudinal epidemiological study was conducted using two distinct cohorts: one from 2010 to 2013 and another from 2021 to 2023. The study included children under five years of age diagnosed with RSV-related pneumonia. Statistical analyses included Student&amp;amp;rsquo;s t-tests, chi-square tests, and logistic regression to identify risk factors associated with severe pneumonia. Incidence density was calculated as the number of RSV-positive pneumonia cases per 10 new pneumonia admissions per month. Results: The mean age of affected children increased from 10 to 15 months. RSV activity began earlier in 2021, emerging during the summer months, and showed a higher incidence than in previous seasons. RSV type B was significantly more common during the pandemic period (58.5% vs. 3.8%), and the proportion of co-infections also increased (60% vs. 39%), indicating a change in the viral landscape. Conclusions: These findings indicate a shift in RSV seasonality toward summer and autumn, increased case incidence, and infections in older children. These observations underscore the need for ongoing surveillance to better understand evolving RSV patterns, especially in the context of complex public health scenarios like the COVID-19 pandemic.</description>
	<pubDate>2025-11-08</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 139: Epidemiological and Clinical Changes in RSV-Associated Pneumonia in Children in Mexico Before and During the COVID 19 Pandemic</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/139">doi: 10.3390/idr17060139</a></p>
	<p>Authors:
		Ilen Adriana Diaz-Torres
		Isamu Daniel Cabrera-Takane
		Fanny Yasmin Ortega-Vargas
		Aldo Agustin Herrera-González
		Miguel Leonardo Garcia-León
		Patricia Bautista-Carbajal
		Daniel E. Noyola
		Maria Susana Juárez-Tobías
		Pedro Antonio Martínez-Arce
		María del Carmen Espinosa-Sotero
		Verónica Tabla-Orozco
		Gerardo Martínez-Aguilar
		Fabian Rojas-Larios
		Rosa María Wong-Chew
		</p>
	<p>Background/Objectives: Respiratory syncytial virus (RSV) significantly affects young children. In 2020, at the beginning of the COVID-19 pandemic, widespread public health measures temporarily interrupted RSV transmission. However, by mid-2021, an atypical resurgence of RSV was observed. The objective of this study was to compare the clinical and epidemiological characteristics of RSV infections in children before and during the second half of the SARS-CoV-2 pandemic in Mexico. Methods: A comparative ambispective longitudinal epidemiological study was conducted using two distinct cohorts: one from 2010 to 2013 and another from 2021 to 2023. The study included children under five years of age diagnosed with RSV-related pneumonia. Statistical analyses included Student&amp;amp;rsquo;s t-tests, chi-square tests, and logistic regression to identify risk factors associated with severe pneumonia. Incidence density was calculated as the number of RSV-positive pneumonia cases per 10 new pneumonia admissions per month. Results: The mean age of affected children increased from 10 to 15 months. RSV activity began earlier in 2021, emerging during the summer months, and showed a higher incidence than in previous seasons. RSV type B was significantly more common during the pandemic period (58.5% vs. 3.8%), and the proportion of co-infections also increased (60% vs. 39%), indicating a change in the viral landscape. Conclusions: These findings indicate a shift in RSV seasonality toward summer and autumn, increased case incidence, and infections in older children. These observations underscore the need for ongoing surveillance to better understand evolving RSV patterns, especially in the context of complex public health scenarios like the COVID-19 pandemic.</p>
	]]></content:encoded>

	<dc:title>Epidemiological and Clinical Changes in RSV-Associated Pneumonia in Children in Mexico Before and During the COVID 19 Pandemic</dc:title>
			<dc:creator>Ilen Adriana Diaz-Torres</dc:creator>
			<dc:creator>Isamu Daniel Cabrera-Takane</dc:creator>
			<dc:creator>Fanny Yasmin Ortega-Vargas</dc:creator>
			<dc:creator>Aldo Agustin Herrera-González</dc:creator>
			<dc:creator>Miguel Leonardo Garcia-León</dc:creator>
			<dc:creator>Patricia Bautista-Carbajal</dc:creator>
			<dc:creator>Daniel E. Noyola</dc:creator>
			<dc:creator>Maria Susana Juárez-Tobías</dc:creator>
			<dc:creator>Pedro Antonio Martínez-Arce</dc:creator>
			<dc:creator>María del Carmen Espinosa-Sotero</dc:creator>
			<dc:creator>Verónica Tabla-Orozco</dc:creator>
			<dc:creator>Gerardo Martínez-Aguilar</dc:creator>
			<dc:creator>Fabian Rojas-Larios</dc:creator>
			<dc:creator>Rosa María Wong-Chew</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060139</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-08</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-08</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>139</prism:startingPage>
		<prism:doi>10.3390/idr17060139</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/139</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/138">

	<title>Infectious Disease Reports, Vol. 17, Pages 138: Impact of COVID-19 on Health-Related Quality of Life and Mental Health Among Employees in Health and Social Services&amp;mdash;A Longitudinal Study</title>
	<link>https://www.mdpi.com/2036-7449/17/6/138</link>
	<description>Background/Objectives: Healthcare and social workers were at increased risk of infection during the COVID-19 pandemic, and were therefore also at increased risk of long-term physical and mental health consequences due to infection. This study aimed to investigate the course of health-related quality of life (HRQoL) and mental health, in terms of depression and anxiety. Methods: A longitudinal study surveyed employees in health and social services diagnosed with SARS-CoV-2 in 2020 over a period of three years. Results: A total of 834 individuals participated in all four surveys. The mean age was 50.2 years (SD 5.8), with 82.3% of the participants being female. Mixed-model analyses were performed to examine the development over time. The results showed significant impairments in physical and mental HRQoL, as well as in mental health. Factors influencing physical HRQoL were gender, age, and pre-existing conditions. Pre-existing mental health conditions and self-reported health prior to infection were found to be predictors of mental HRQoL and symptoms of depression and anxiety. Those with persistent symptoms reported a significantly lower quality of life than those who had recovered. The mean physical HRQoL among participants with ongoing symptoms was 38.6, compared with 50.0 for those without symptoms, and the mean mental HRQoL was 40.4 versus 50.1 (p &amp;amp;lt; 0.001). Conclusions: These findings suggest that health-related quality of life and mental health should continue to be monitored to prevent long-term psychological distress.</description>
	<pubDate>2025-11-04</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 138: Impact of COVID-19 on Health-Related Quality of Life and Mental Health Among Employees in Health and Social Services&amp;mdash;A Longitudinal Study</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/138">doi: 10.3390/idr17060138</a></p>
	<p>Authors:
		Claudia Peters
		Madeleine Dulon
		Anja Schablon
		Jan Felix Kersten
		Albert Nienhaus
		</p>
	<p>Background/Objectives: Healthcare and social workers were at increased risk of infection during the COVID-19 pandemic, and were therefore also at increased risk of long-term physical and mental health consequences due to infection. This study aimed to investigate the course of health-related quality of life (HRQoL) and mental health, in terms of depression and anxiety. Methods: A longitudinal study surveyed employees in health and social services diagnosed with SARS-CoV-2 in 2020 over a period of three years. Results: A total of 834 individuals participated in all four surveys. The mean age was 50.2 years (SD 5.8), with 82.3% of the participants being female. Mixed-model analyses were performed to examine the development over time. The results showed significant impairments in physical and mental HRQoL, as well as in mental health. Factors influencing physical HRQoL were gender, age, and pre-existing conditions. Pre-existing mental health conditions and self-reported health prior to infection were found to be predictors of mental HRQoL and symptoms of depression and anxiety. Those with persistent symptoms reported a significantly lower quality of life than those who had recovered. The mean physical HRQoL among participants with ongoing symptoms was 38.6, compared with 50.0 for those without symptoms, and the mean mental HRQoL was 40.4 versus 50.1 (p &amp;amp;lt; 0.001). Conclusions: These findings suggest that health-related quality of life and mental health should continue to be monitored to prevent long-term psychological distress.</p>
	]]></content:encoded>

	<dc:title>Impact of COVID-19 on Health-Related Quality of Life and Mental Health Among Employees in Health and Social Services&amp;amp;mdash;A Longitudinal Study</dc:title>
			<dc:creator>Claudia Peters</dc:creator>
			<dc:creator>Madeleine Dulon</dc:creator>
			<dc:creator>Anja Schablon</dc:creator>
			<dc:creator>Jan Felix Kersten</dc:creator>
			<dc:creator>Albert Nienhaus</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060138</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-04</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-04</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>138</prism:startingPage>
		<prism:doi>10.3390/idr17060138</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/138</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/137">

	<title>Infectious Disease Reports, Vol. 17, Pages 137: Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series</title>
	<link>https://www.mdpi.com/2036-7449/17/6/137</link>
	<description>Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a genetically distinct lineage from healthcare-associated MRSA (HA-MRSA), often producing Panton-Valentine leukocidin (PVL) and causing severe skin and soft tissue infections (SSTIs) in otherwise healthy individuals. Methods: We describe five cases of PVL-positive CA-MRSA SSTIs admitted to the Infectious Diseases Unit of the University Hospital &amp;amp;ldquo;Paolo Giaccone,&amp;amp;rdquo; Palermo, Italy, between 2024 and 2025. Case inclusion followed the CDC criteria for CA-MRSA. Microbiological identification was performed using MALDI-TOF mass spectrometry, and antimicrobial susceptibility testing followed EUCAST standards. PVL gene presence was confirmed by polymerase chain reaction. Results: Clinical management included surgical drainage, systemic antibiotic therapy, and decolonization of both patients and close contacts. Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. Conclusions: PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts.</description>
	<pubDate>2025-11-03</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 137: Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/137">doi: 10.3390/idr17060137</a></p>
	<p>Authors:
		Luca Pipitò
		Chiara Vincenza Mazzola
		Giulio D’Agati
		Eleonora Bono
		Raffaella Rubino
		Silvia Bonura
		Claudia Gioè
		Teresa Fasciana
		Antonio Cascio
		</p>
	<p>Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a genetically distinct lineage from healthcare-associated MRSA (HA-MRSA), often producing Panton-Valentine leukocidin (PVL) and causing severe skin and soft tissue infections (SSTIs) in otherwise healthy individuals. Methods: We describe five cases of PVL-positive CA-MRSA SSTIs admitted to the Infectious Diseases Unit of the University Hospital &amp;amp;ldquo;Paolo Giaccone,&amp;amp;rdquo; Palermo, Italy, between 2024 and 2025. Case inclusion followed the CDC criteria for CA-MRSA. Microbiological identification was performed using MALDI-TOF mass spectrometry, and antimicrobial susceptibility testing followed EUCAST standards. PVL gene presence was confirmed by polymerase chain reaction. Results: Clinical management included surgical drainage, systemic antibiotic therapy, and decolonization of both patients and close contacts. Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. Conclusions: PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts.</p>
	]]></content:encoded>

	<dc:title>Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series</dc:title>
			<dc:creator>Luca Pipitò</dc:creator>
			<dc:creator>Chiara Vincenza Mazzola</dc:creator>
			<dc:creator>Giulio D’Agati</dc:creator>
			<dc:creator>Eleonora Bono</dc:creator>
			<dc:creator>Raffaella Rubino</dc:creator>
			<dc:creator>Silvia Bonura</dc:creator>
			<dc:creator>Claudia Gioè</dc:creator>
			<dc:creator>Teresa Fasciana</dc:creator>
			<dc:creator>Antonio Cascio</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060137</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-11-03</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-11-03</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Case Report</prism:section>
	<prism:startingPage>137</prism:startingPage>
		<prism:doi>10.3390/idr17060137</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/137</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
        <item rdf:about="https://www.mdpi.com/2036-7449/17/6/136">

	<title>Infectious Disease Reports, Vol. 17, Pages 136: A Six-Year Surveillance of Nasal Methicillin-Resistant Staphylococcus aureus Colonization on Intensive Care Unit Admission: Do We Need Screening?</title>
	<link>https://www.mdpi.com/2036-7449/17/6/136</link>
	<description>Background: Methicillin-resistant Staphylococcus aureus (MRSA) colonization is a risk factor for potential staphylococcal infection and outbreaks. Although it is recommended to obtain a swab culture to detect nasal colonization its necessity in low-prevalence countries is debated. The aim of this study was to determine the prevalence of MRSA nasal colonization, the rate of invasive infection development, and the risk factors for invasive infections in patients admitted to the intensive care unit. Materials and Methods: This retrospective study included patients who were followed up in one of the adult intensive care units at Kayseri City Training and Research Hospital between 1 January 2019 and 31 December 2024 (6 years) and from whom a culture was taken at the time of hospital admission to detect MRSA colonization in the nose. MRSA carriers were examined for the development of any invasive infection caused by MRSA within 28 days of their relevant admission. Results: Over a total period of six years, nasal swab samples were collected from 22,913 patients, and MRSA colonization was detected in 939 (4.0%). Of the patients with MRSA colonization, 32 (3.4%) were excluded from the analysis because they already had invasive MRSA infection. Additionally, 431 patients (45.8%) were excluded from the analysis because they were discharged or died within the first seven days of their admission. Consequently, invasive MRSA infection developed within 28 days in 29 of the 476 patients with MRSA colonization (6.0%). Patients who developed invasive infection had a higher rate of chronic renal failure (p &amp;amp;lt; 0.001), hemodialysis (p &amp;amp;lt; 0.001), central venous catheter (p = 0.028), staying in nursing home (p = 0.001), and a history of hospitalization within the last 90 days (p = 0.015). In the multivariable regression analysis, routine hemodialysis (OR: 5.216, p = 0.015), nursing home stay (OR: 3.668, p = 0.014), and a history of hospitalization within the last 90 days (OR: 2.458, p = 0.028) were found to be risk factors for developing invasive infection. The most common invasive infections were ventilator-associated pneumonia (n = 9), surgical site infection (n = 7), and catheter-related bloodstream infection (n = 6). All 29 strains were susceptible to vancomycin, linezolid, and daptomycin, while one strain was resistant to teicoplanin (3.5%). Conclusions: MRSA colonization has been detected in 4% of patients admitted to the intensive care unit. Screening should be performed because MRSA colonization may be a risk factor for invasive infections; however, screening all patients would be prohibitively expensive and labor-intensive. Instead, it may be more appropriate to identify risk factors and then screen select patients.</description>
	<pubDate>2025-10-24</pubDate>

	<content:encoded><![CDATA[
	<p><b>Infectious Disease Reports, Vol. 17, Pages 136: A Six-Year Surveillance of Nasal Methicillin-Resistant Staphylococcus aureus Colonization on Intensive Care Unit Admission: Do We Need Screening?</b></p>
	<p>Infectious Disease Reports <a href="https://www.mdpi.com/2036-7449/17/6/136">doi: 10.3390/idr17060136</a></p>
	<p>Authors:
		Esma Eryilmaz Eren
		Nursel Karagöz
		Esma Saatçi
		İlhami Çelik
		Emine Alp Meşe
		</p>
	<p>Background: Methicillin-resistant Staphylococcus aureus (MRSA) colonization is a risk factor for potential staphylococcal infection and outbreaks. Although it is recommended to obtain a swab culture to detect nasal colonization its necessity in low-prevalence countries is debated. The aim of this study was to determine the prevalence of MRSA nasal colonization, the rate of invasive infection development, and the risk factors for invasive infections in patients admitted to the intensive care unit. Materials and Methods: This retrospective study included patients who were followed up in one of the adult intensive care units at Kayseri City Training and Research Hospital between 1 January 2019 and 31 December 2024 (6 years) and from whom a culture was taken at the time of hospital admission to detect MRSA colonization in the nose. MRSA carriers were examined for the development of any invasive infection caused by MRSA within 28 days of their relevant admission. Results: Over a total period of six years, nasal swab samples were collected from 22,913 patients, and MRSA colonization was detected in 939 (4.0%). Of the patients with MRSA colonization, 32 (3.4%) were excluded from the analysis because they already had invasive MRSA infection. Additionally, 431 patients (45.8%) were excluded from the analysis because they were discharged or died within the first seven days of their admission. Consequently, invasive MRSA infection developed within 28 days in 29 of the 476 patients with MRSA colonization (6.0%). Patients who developed invasive infection had a higher rate of chronic renal failure (p &amp;amp;lt; 0.001), hemodialysis (p &amp;amp;lt; 0.001), central venous catheter (p = 0.028), staying in nursing home (p = 0.001), and a history of hospitalization within the last 90 days (p = 0.015). In the multivariable regression analysis, routine hemodialysis (OR: 5.216, p = 0.015), nursing home stay (OR: 3.668, p = 0.014), and a history of hospitalization within the last 90 days (OR: 2.458, p = 0.028) were found to be risk factors for developing invasive infection. The most common invasive infections were ventilator-associated pneumonia (n = 9), surgical site infection (n = 7), and catheter-related bloodstream infection (n = 6). All 29 strains were susceptible to vancomycin, linezolid, and daptomycin, while one strain was resistant to teicoplanin (3.5%). Conclusions: MRSA colonization has been detected in 4% of patients admitted to the intensive care unit. Screening should be performed because MRSA colonization may be a risk factor for invasive infections; however, screening all patients would be prohibitively expensive and labor-intensive. Instead, it may be more appropriate to identify risk factors and then screen select patients.</p>
	]]></content:encoded>

	<dc:title>A Six-Year Surveillance of Nasal Methicillin-Resistant Staphylococcus aureus Colonization on Intensive Care Unit Admission: Do We Need Screening?</dc:title>
			<dc:creator>Esma Eryilmaz Eren</dc:creator>
			<dc:creator>Nursel Karagöz</dc:creator>
			<dc:creator>Esma Saatçi</dc:creator>
			<dc:creator>İlhami Çelik</dc:creator>
			<dc:creator>Emine Alp Meşe</dc:creator>
		<dc:identifier>doi: 10.3390/idr17060136</dc:identifier>
	<dc:source>Infectious Disease Reports</dc:source>
	<dc:date>2025-10-24</dc:date>

	<prism:publicationName>Infectious Disease Reports</prism:publicationName>
	<prism:publicationDate>2025-10-24</prism:publicationDate>
	<prism:volume>17</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>136</prism:startingPage>
		<prism:doi>10.3390/idr17060136</prism:doi>
	<prism:url>https://www.mdpi.com/2036-7449/17/6/136</prism:url>
	
	<cc:license rdf:resource="CC BY 4.0"/>
</item>
    
<cc:License rdf:about="https://creativecommons.org/licenses/by/4.0/">
	<cc:permits rdf:resource="https://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="https://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
